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Abstract 
In this thesis small molecule inhibitors of MDMX-p53 interaction, and ATAD2 bromodomain 
are investigated. 
In many human cancers, the function of the tumour suppressor protein p53 is inhibited by the 
overexpression of MDM2 or MDMX. Modulation of MDM2-p53 and MDMX-p53 interactions 
is therefore an attractive strategy for anticancer drug discovery. A number of small molecule 
inhibitors of the MDM2-p53 interaction have been reported to date and several have entered 
clinical trials. Although MDM2 and MDMX have a high sequence homology, most of the small 
molecule MDM2 inhibitors show significantly lower binding affinity towards MDMX. A series 
of 2,4-aminothiazoles including compound 1 with modest inhibitory activity against the 
MDM2-p53 and MDMX-p53 interactions has been reported. The series was extended to a 
pyrrole series, which led to the discovery of compound 2 with low micromolar dual inhibition 
of MDM2/MDMX and structure-activity relationship studies were conducted. 
 
 
An ELISA was used to examine potency against MDM2-p53 and MDMX-p53. Although, the 
assay gave results in agreement with literature values for some inhibitors of the MDM2-p53 
interaction, the potencies of the published dual inhibitors RO-2443 3 and RO-5963 4 were 
around 1000-fold lower than reported. Therefore, an HTRF assay was developed, which 
provided IC50 values comparable to the reported values for inhibition of MDM2-p53 and 
MDMX-p53 by RO-5963. Co-crystallisation experiments, using three different constructs of 
MDMX, were attempted using 15 compounds.  
vi 
 
 
 
Bromodomains are protein modules that function as epigenetic readers of histone lysine 
acetylation. ATAD2, a bromodomain containing protein, is overexpressed in a wide range of 
human cancers including breast, lung, prostate, ovarian, liver, osteosarcoma and gastrointestinal 
carcinomas. Due to the polar and flexible nature of the binding surface, ATAD2 has been 
considered as a challenging target for ligand discovery. Therefore, very few potent and selective 
inhibitors of ATAD2 bromodomains have been reported to date. 
 
Extensive SAR studies around hit 5 obtained from a fragment screening led to the identification 
of a sub-millimolar inhibitor 6 of ATAD2 bromodomain. Co-crystal structures of ATAD2 were 
used to guide compound design and synthesis.  
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Chapter 1. Introduction 
1.1 Cancer  
Cancer is a genetic disease caused by alterations in the genome such as point mutations, 
deletions, duplications, chromosome rearrangements and epigenetic changes.2 The number of 
genetic alterations in a cancer can vary from tens to thousands.1 A large number of mutations 
are known as ‘passengers’ that do not confer any growth advantage. The mutations that 
contribute to cancer development are known as ‘drivers’.1, 3 A vast amount of research on the 
identification of ‘drivers’ has led to the discovery of various oncogenes and tumour suppressor 
genes.4 Oncogenes are dominant cancer genes that require only one of the two parental alleles 
present in the normal cell to be mutated, resulting in the activation of the encoded protein.5 
Tumour suppressor genes are recessive genes that require mutations in both alleles resulting in 
the inactivation of the encoded protein.5 
Cancer was first described as an evolutionary process analogous to Darwinian natural selection 
by Peter Nowell almost forty years ago.6 Genetic variations that confer growth advantage lead 
to the progression of normal cells into cancer cells.1, 6 An alternative to the Darwinian 
evolutionary model is the stem cell model, which proposes that a small population of cancer 
stem cells, irrespective of their origin, are responsible for cancer growth and progression.7-8 The 
stem cell model considers that a few sub-populations of cancer cells are tumorigenic, and 
responsible for cancer growth. The stem cell model and the evolutionary model are not mutually 
exclusive in cancers that follow stem cell model, in which stem cells can evolve by clonal 
evolution.8 Whereas, in cancers that do not follow stem cell model, the evolutionary model 
could explain the cancer growth. A better understanding of these models involved in various 
cancers will help to develop effective treatments.8 
Cancer research over the past few decades has led to the identification of a large number of 
phenotypic and genotypic variations involved in cancer. In 2000, Hanahan and Weinberg 
proposed six hallmarks of cancer that comprised of physiological changes or capabilities 
acquired during cancer development (Figure 1.1).9 In an update in 2011, two new hallmarks 
were added: the avoidance of immune destruction and the reprogramming of energy 
metabolism.10  
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Figure 1.1: Hallmarks of cancer.10 
 
1.2 Cancer Chemotherapy 
The era of chemotherapy began with the use of nitrogen mustards, including chlormethine 7, 
for the treatment of lymphomas.11 These agents act by cross-linking DNA. Several other DNA-
alkylating agents were subsequently introduced including chlorambucil 8 and 
cyclophosphamide 9. 
 
Over the next few decades, several chemotherapeutic agents including antimetabolites: 6-
mercaptopurine 10, 5-fluorouracil 11, methotrexate 12; antitumour antibiotics: doxorubicin; 
and antimitotic agents: Vinca alkaloids, taxanes were discovered.11-12 Antimetabolites mimic 
nitrogenous bases of DNA or other endogenous molecules and inhibit the synthesis of nucleic 
acids. Anti-mitotic agents act by inhibiting cell division of rapidly dividing cells. Conventional 
chemotherapy acts on the processes that contribute in the rapid division of cancer cells. 
However, many normal cells such as hair follicles, stomach epithelia, and bone-marrow cells 
are also rapidly replicating.13 Therefore, conventional chemotherapeutic agents also act on 
rapidly dividing non-cancerous cells causing serious side effects.  
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s  
With the increase in the understanding of cancer biology at a molecular level, anti-cancer drug 
discovery transitioned from classical cytotoxic agents to targeted therapy. The new targets 
specific to cancer cells such as growth factors, signalling pathways, oncogenes, tumour 
suppressor genes, cell cycle proteins, apoptosis modulators and angiogenesis promoters were 
discovered. Imatinib (Glivec) 13, a landmark anticancer drug (based on targeted therapy) is 
used for the treatment of chronic myeloid leukaemia (CML).14-15 Imatinib acts by inhibiting 
Bcr-Abl kinase which is a product of bcr-abl gene, formed by the fusion of a segment of the 
bcr gene from chromosome 22 to the part of c-abl gene on chromosome 9. Imatinib also inhibits 
c-KIT kinase and platelet derived growth factor receptor (PDGFR) kinase that are 
overexpressed in Gastrointestinal Stromal Tumour (GIST).16 Therefore, Imatinib is also used 
in the treatment of GIST. 
 
The clinical success of Imatinib was a breakthrough in the field of targeted anticancer therapy. 
To date, more than 30 small-molecules have been approved, and several are in various stages 
of clinical trials, as targeted therapy for the treatment of variety of cancers.17 
1.3 Protein-Protein Interaction 
Protein-protein interactions play an important role in most biological processes ranging from 
signal transduction to programmed cell death.18 Development of small molecules that modulate 
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protein-protein interactions involved in disease pathways has become an attractive strategy for 
drug discovery. However, there are several challenges in the discovery of small molecules that 
inhibit protein-protein interaction. 
Protein-protein interfaces are generally flat with large surface areas around 1600 (± 400) Å2 on 
each protein.19 There are numerous interactions including electrostatic, hydrophobic, hydrogen 
bonds, involved in protein-protein interaction. It is not possible to interfere with all of the 
interactions using small molecules that typically have a very small surface area (300-500 Å2) 
compared to the protein-protein interface.20 Modulation of protein-protein interactions by small 
molecules can be successful by targeting ‘hot spots’ in the protein-protein interaction.18 Hot 
spots are the regions of key interactions at the protein-protein interface that contribute to the 
large component of the binding affinity. Therefore, even a molecule with a small surface area 
that can bind at hot spots can inhibit protein-protein interactions. For example, the p53-MDM2 
interface area is approximately 1500 Å2, whereas, the MDM2 inhibitor Nutlin 3a 14 has a 
surface area of approximately 800 Å2.21-22 It is clear that Nutlin cannot cover the entire surface 
area; however, it is a strong inhibitor of the MDM2-p53 interaction, which suggests that 
interfering with all the interactions is not necessary.  
 
The other important examples of small molecule inhibitors of PPIs are inhibitors of Bcl-2 family 
proteins. These proteins play a major role in the regulation of apoptosis and are divided into 
three classes of proteins.23 
 The pro-apoptotic proteins Bax and Bak, which stimulates apoptosis. 
 The anti-apoptotic proteins Bcl-2 and Bcl-xL, which inhibit the function of Bax and 
Bak. 
 The BH3 only protein which inhibits Bcl-2 and Bcl-xL. 
The Bcl-2 and Bcl-xL proteins contain a hydrophobic groove upon which Bax, Bak and BH3 
only proteins bind.24-25 Bcl-2 and Bcl-xL are upregulated in cancer cells, and therefore, small 
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molecule inhibitors that can bind on the hydrophobic groove of the Bcl-2 and Bcl-xL proteins 
can induce apoptosis.23, 26  
To date, several small molecule inhibitors have been identified for inhibiting protein-protein 
interactions. Some of the small-molecule PPI inhibitors which are in various stages of clinical 
development are shown in Figure 1.2.20, 27 
 
 
Figure 1.2: Small molecule PPI inhibitors under clinical development.27 
Although, binding at hot spots is often sufficient for inhibiting protein-protein interactions, 
identifying a hot spot is another challenge. Binding sites that could fit small molecules are 
sometimes not visible in crystal structures due to the flexibility and adaptivity of proteins.18 
The drug leads developed by targeting the protein-protein interfaces often have high molecular 
weight and are hydrophobic. Inhibition of the protein-protein interaction is not enough for 
compound to become a drug. Small molecule PPI inhibitors should also possess drug-like 
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pharmacokinetic and pharmacodynamics properties. Therefore, besides being an attractive area 
for drug discovery, the development of small molecule inhibitors that can modulate protein-
protein interactions has several challenges.  
In this thesis, development of small molecules targeting two different protein-protein 
interactions are discussed: (a) MDMX-p53 interaction; (b) ATAD2-acetylated histone 
interaction. 
 
1.4 Stages of Drug Discovery 
The first stage in the drug discovery process involves the identification of a biological target, 
whose modulation might affect the disease progression (Figure 1.3). The target is then validated 
using data collected from bioinformatics, as well as several in vivo and in vitro experiments 
including genetically engineered knock-out animals, reducing the amount of target by short 
interfering siRNA experiments, or the target is modulated by a known small molecule or peptide 
inhibitor.28-30 
Once a biological target is validated, a full drug discovery program can be commenced. The 
first step is the identification of a chemical starting point known as a ‘hit’, which is performed 
using various techniques like high-throughput screening (HTS), fragment screening, virtual 
screening, or structure based de novo design.31-34 
In the hit to lead phase, structure-activity relationships around the hit are studied in-order to 
identify the effect of different groups in a molecule on the potency, selectivity and 
pharmacokinetic properties.34 A lead molecule, which has the potential to be developed as a 
drug is selected. In the lead optimisation stage, analogues of leads are synthesised by combining 
all of the desired properties in a molecule to achieve optimum potency, in-vivo 
pharmacokinetics, safety and pharmaceutical properties.34 Then, a candidate is selected for pre-
clinical evaluation.   
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Figure 1.3: Various stages of drug discovery. 
 
The two projects described in this thesis are in the target validation stage. The aim of the 
medicinal chemistry efforts was to develop chemical tools for use in in vitro and in vivo 
experiments to access the effect of inhibition of two protein-protein interactions: (a) MDMX-
p53; (b) ATAD2 bromodomain-acetylated histone. 
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Chapter 2. Introduction to MDMX and Reported Inhibitors 
2.1 p53, MDM2, and MDMX 
The tumour suppressor gene p53 is mutated in almost half of all human cancers.35 In cancers 
with wild-type p53, the protein levels of p53 is controlled by its negative regulators, such as 
MDM2 and MDMX.36 p53 functions as a transcription factor responsible for the regulation of 
expression of a variety of genes involved in various stages of cell growth and progression.37 
p53 is activated by DNA damage, abnormal growth signals, oncogene activation and other 
cellular stress, including hypoxia and nucleotide depletion (Figure 2.1).37-38 Following 
activation, tetrameric p53 binds to DNA,39 and mediates the transcription of genes that express 
proteins to accomplish a number of functions including cell cycle arrest, DNA repair, apoptosis 
and inhibition of angiogenesis.40 These responses either reverse potential mutagenic damage by 
cell cycle arrest and DNA repair, or signal the destruction of the damaged cells by apoptosis.37-
38, 40-41  
 
  
Figure 2.1: Upstream activators (blue) and downstream cellular effects (red) of p53.37 
 
2.1.1 Cell Cycle Arrest Mediated by p53 
During G1 to S phase transition of the cell cycle, four proteins, p16, cyclin D1, CDK4 and Rb 
(Retinoblastoma protein) play a central role.42 p16 negatively regulates cyclin D1 and CDK4 
which activate Rb (Figure 2.2).42 After being activated by cyclin D1 and CDK4, Rb protein 
releases several transcription factors responsible for the G1 to S phase transition. In most 
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cancers, one of the four genes encoding for these four proteins is mutated. In response to 
upstream stress, p53 induces transcription of the p21 gene which encodes for p21 protein. The 
p21 protein then binds to and inhibits several cyclin and CDK complexes, which inhibit 
progression of the cell cycle to S phase causing cell cycle arrest.42 The p21 protein is also 
involved in inhibiting DNA replication by binding with PCNA (Proliferating Cell Nuclear 
Antigen).42 
 
Figure 2.2: p53 mediated cell cycle arrest. 
 
2.1.2 Apoptosis Mediated by p53 
Apoptosis is a type of programmed cell death and is mediated by two main pathways, the 
intrinsic pathway and extrinsic pathway.43 The extrinsic pathway is mediated by cell surface 
receptors, whereas, the intrinsic pathway is initiated by stress signals. The p53 protein is 
involved in induction of the proteins in both pathways, predominantly the intrinsic pathway. 
BAX and BH3-only proteins are apoptosis promoters involved in the intrinsic pathway, 
whereas, Bcl2 and Bcl-xL proteins are anti-apoptotic proteins.41, 44 The p53 protein induces 
apoptosis by transcriptionally regulating the genes encoding for apoptotic and anti-apoptotic 
proteins.41 
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2.1.3 The Structure of p53 Protein 
Human p53 contains 393 amino acid residues divided into five domains (Figure 2.3):45-46 
 
Figure 2.3: Schematic representation of p53 protein domains. The black columns indicate the 
mutational hotspots.46 
 
(a) Transactivation domain: This domain is situated in the N-terminal region from residues 1 
to 62 and can be divided into sub-domains TAD 1 and TAD 2.46 The transactivation domain 
interacts with a number of regulators of p53 including MDM2 and MDMX.47  
 
(b) Proline-rich domain: As the name suggests, this domain (residues 63-94) contains repeated 
proline residues. There are five repetitive sequence PXXP (P= Proline, X= any amino 
acid).46 Although this domain is not essential for transcriptional activity, deletion from p53 
inhibits p53’s ability to reduce tumour cell growth in culture.48 
 
(c) DNA binding domain: The DNA binding domain (residues 94-292) is the central core 
domain and contains mutational hotspots. This domain binds to DNA response elements 
that contain the repetitive sequence 5’-Pu-Pu-Pu-C-(A/T)-(T/A)-G-Py-Py-Py-3’ (Pu 
represents A/G, Py represents T/C).46 p53 forms a tetramer and other domains also co-
operate in binding at these DNA response elements.39 
 
(d) Tetramerization domain: This is present in the C-terminal region, residues 325-356, and 
regulates the formation of p53 tetramer.46 
 
(e) Auto-regulatory domain: This is present in the C-terminal region, residues 356-393. This 
domain contains lysine residues that get acetylated by histone acetyltransferase 
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p300/CBP.49 Acetylation plays critical role in DNA-binding to the central core domain, and 
is also important in the transcription activity of p53.50 
 
2.2 MDM2 
MDM2, a negative regulator of p53, induces proteasomal degradation of p53 by modifying the 
carboxyl terminus via ubiquitination (Figure 2.4).51 MDM2 contains a RING (Really Interesting 
New Gene) domain52 in the C-terminal with an E3 ubiquitin ligase activity important for 
proteasomal degradation of p53. MDM2 has ubiquitin ligase activity following homo-
dimerization as well as hetero-dimerization with MDMX.53 In addition, MDM2 binds at the 
transactivation domain of p53 and inhibits its transcriptional activity.54-55 MDM2 contains 
nuclear export signal sequence that binds to p53, and exports it to the cytoplasm.56 The 
transcriptional activity of p53 can only occur inside the nucleus, therefore, p53 can no longer 
act as a transcription factor.57  
 
Figure 2.4: Regulation of p53 by MDM2 and MDMX. 
 
MDM2 is a transcriptional target of p53; therefore, p53 increases the amount of MDM2, which 
in turn degrades p53. As a result, the level of p53 decreases which reduces the production of 
MDM2 that causes an increase in p53 activity forming an auto-regulatory feedback loop.58-59 
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Inhibition of MDM2-p53 interaction is a well validated target, and several inhibitors (such as 
17, 18, 19 and 20) are currently under clinical evaluation.36, 60-61 However, these compounds do 
not inhibit MDMX-p53 interactions and therefore, fail to restore p53 activities in cancers 
overexpressing MDMX.60 
 
 
2.3 MDMX and its Role in Cancer 
In order to identify new cellular proteins that regulate p53 activity, Shvarts et al. screened a 
murine cDNA expression library with a radioactively labelled p53.62 A cDNA clone encoding 
MDMX was identified that had structural homology with MDM2. The human form, HDMX 
was identified by the same group a year later in 1997.63 
Like MDM2, MDMX also has a RING domain at its C-terminus but lacks intrinsic ubiquitin 
ligase activity. However, MDMX can mediate MDM2 ubiquitin ligase activity by hetero-
oligomerisation with MDM2.53 MDMX acts as a negative regulator of p53 primarily due to the 
inhibition of the transcriptional activity of p53.62  
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MDMX is overexpressed in 15% of human cancers.64 Elevated levels of MDMX mRNA are 
found in 65% of retinoblastoma, 65% of cutaneous melanoma, 19% of breast carcinoma, 19% 
of colon carcinoma and 18% of lung carcinoma (Table 2.1).65-67 
Table 2.1: Analysis of primary tumour samples to study MDMX overexpression.65-67 
Tumour Samples Total Analysed MDMX overexpressed 
Retinoblastoma 49 32 
Breast carcinoma 218 41 
Colon carcinoma 27 5 
Lung carcinoma 88 16 
Prostate carcinoma 25 0 
Stomach carcinoma 14 6 
Testis carcinoma 11 3 
Larynx carcinoma 13 3 
Uterus carcinoma 13 2 
Melanoma 14 2 
Sarcoma 10 0 
 
The deletion of MDMX in mice, despite having MDM2, causes embryonic lethality that can be 
rescued by loss of Trp53.68-69 This indicates that MDMX is a critical negative regulator of p53. 
The potent MDM2 inhibitor Nutlin 3 is inactive against MDMX-p53 interaction. Nutlin 3 failed 
to restore p53 activity in cancer cells overexpressing MDMX.70 A combination of Nutlin with 
MDMX-siRNA increases p53 activity which suggests that inhibition of MDMX is also an 
attractive approach for restoring p53 activity.70 It has been reported that dual inhibition of 
MDM2 and MDMX can increase the p53 activity more than the inhibitors of only MDM2-p53 
interaction in cancer cells containing wild-type p53.71-72 Therefore, in order to achieve complete 
reactivation of p53 in cancers containing wild-type p53, inhibition of both MDM2 as well as 
MDMX is essential. 
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MDMX, independent of p53 and MDM2, is responsible for influencing genomic stability.64, 73 
The overexpression of MDMX delayed DNA damage response signals and double strand DNA 
break repair.64 
 
2.4 Structure of MDMX: Comparison with MDM2 
MDMX, containing 490 amino acids is structurally similar to MDM2 with 491 amino acids 
(Figure 2.5).74 MDMX and MDM2 have a very similar N-terminal p53 binding domain with 
54% sequence homology. MDMX lacks nuclear export sequence (NES) and nuclear 
localisation signal (NLS) to travel in and out from the nucleus.75 
 
Figure 2.5: Domain structures of MDM2 and MDMX highlighting different domains. NLS: 
Nuclear Localisation Signal; NES: Nuclear Export Sequence. (Adapted from Lee et al)75 
 
N-terminal p53 binding domain of both MDM2 and MDMX have hydrophobic binding pockets 
into which the side-chains of three residues of p53; Phe19, Trp23 and Leu26 bind (Figure 
2.6A/B).21, 76 The Trp23 nitrogen forms an H-bond with Leu54 in MDM2 (Figure 2.6 C), 
whereas, with Met53 in MDMX (Figure 2.6 D). The Leu26 pocket in MDMX is smaller and 
less-defined compared to MDM2 (Figure 2.6 E/F), and it is considered as the main hurdle to 
discovering a small-molecule inhibitor of MDMX-p53 interaction.77  
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Figure 2.6: Crystal structure of p53-peptide (green) in complex with (A) MDM2,21 and (B) 
MDMX.76 The H-bond interaction between the nitrogen of Trp23 with (C) MDM2, and (D) 
MDMX. The p53 binding surface of (E) MDM2, and (F) MDMX. The surface and secondary 
structures of both MDM2 and MDMX are coloured cyan. 
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2.5 Reported Inhibitors of the MDMX-p53 Interaction 
2.5.1 Peptides and Stapled Peptides 
Using structure-based design and phage display methods several peptide and peptidomimetics 
with nanomolar inhibitory activity against MDMX-p53 interactions have been identified.78-79 
Despite having high potency against MDMX, peptides are less likely to become cancer 
therapeutics because of their instability in vivo and poor pharmacokinetic properties.80 SAH-
p53-8 is a stapled peptide with improved stability and pharmacokinetic properties (Figure 
2.7).81 SAH-p53-8 acts as a dual inhibitor of MDM2-p53 and MDMX-p53 interactions in vitro. 
S20 and P27 residues in WT-p53 were replaced with synthetic olefinic residues, which were 
stapled using olefin metathesis. SAH-p53-8 showed nanomolar inhibitory activity against both 
MDM2- and MDMX-p53 interactions. The WT-p53 and mutant SAH-p53-8F19A did not show 
any inhibition of MDMX at that dose range. However, SAH-p53-8 requires Nutlin-3a 14 for 
optimal inhibition of MDM2-p53 interactions in cells.81  
 
Figure 2.7: Composition of wild-type p53, SAH-p53-8 and SAH-p53-8F19A peptides. The 
olefinic residues used for stapling are shown by stars.81 
 
A stapled peptide ATSP-7041, which demonstrated p53 dependent tumour growth suppression 
in MDM2 or MDMX-overexpressing xenograft models was reported in 2013.72 ATSP-7041 
binds with MDM2 and MDMX with nanomolar affinities in vitro and demonstrates sub-
micromolar activities in cancer cells overexpressing MDM2 and MDMX.72 The stapled peptide 
also demonstrated favourable pharmacokinetic properties when tested in vivo in rat, mouse, and 
monkey.  
17 
 
 
Figure 2.8: Sequences of a series of stapled peptides and their potency against MDM2 and 
MDMX. R8 and S5 are the olefininc residues stapled using olefin metathesis.72 
 
The crystal structure of ATSP-7041 in complex with MDMX (15-106) showed that Phe19, 
Trp23 and Cba26 were bound on the three hydrophobic pockets of MDMX (Figure 2.9).72 The 
Tyr22 of ATSP-7041 forms a water-mediated H-bond with His68 of MDMX. The staple group 
occupies a binding pocket on the surface of MDMX formed by Lys47, Met50, Gly54, Gln55 
Ile57, and Met58. 
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Figure 2.9: Crystal structure of ATSP-7041 (green) bound to MDMX (PDB: 4N5T). The 
MDMX surface is coloured based on the charge of amino acid residues: blue: positive; red: 
negative. 
 
2.5.2 SJ-172550 
SJ-172550 21 was the first small-molecule inhibitor of MDMX discovered from the high-
throughput screening of 295,848 unique compounds.82 It increased p53 activity in MDMX-
amplified retinoblastoma cells. However, further studies on the compound showed that it forms 
a covalent adduct with cysteine residues of MDM2 and MDMX at the p53 binding domain.83  
Due to the reactivity of SJ-172550 with thiols, further development was discontinued. 
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2.5.3 Imidazole-Indoles 
Imidazole-indoles are the class of MDM2-p53 interaction inhibitors developed by Novartis.84-
85 WK298 22, an imidazole-indole is the first small-molecule whose crystal structure in 
complex with MDMX was solved (Figure 2.10).86 The chloro-indole substituent binds at the 
Trp23 pocket. The nitrogen atom of the indole forms a hydrogen bond with Met53 in MDMX. 
The chlorine atom in the indole ring induces a conformational change in key residues including 
Leu54, Met53, Leu 98 and Leu102, which helps in enlargement of the central Trp23 binding 
pocket. The phenyl ring occupies the Phe19 pocket and the chlorobenzyl group, the Leu26 
pocket in Mdmx. Although the compound was not a potent inhibitor of MDMX-p53 interaction, 
the crystal structure of WK298 bound to MDMX provided a basis for the structure based-design 
of small molecule MDMX inhibitors. 
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Figure 2.10: Crystal structure of WK298 (cyan) bound to MDMX (PDB: 3LBJ). The solvent 
accessible surface of MDMX is coloured based on the charge of the amino acid residues: 
positive: blue; negative: red. 
 
2.5.4 Pyrrolidones 
Pyrrolidones are a class of compounds identified by structure-based virtual screening.87 
Structure based design led to the identification of compounds with low nanomolar activity 
against MDM2-p53 interaction. Several compounds (such as 23 and 24) also showed low-
micromolar binding affinity for MDMX.   
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2.5.5 Indolylhydantoins 
Graves et al identified two compounds, RO-2443 (3) and RO-5963 (4), with low nanomolar 
potency against both MDM2 and MDMX.71 RO-5963 is an analogue of RO-2443 with 
improved solubility. RO-5963 restored p53 activity in MDMX overexpressing cell-lines SJSA-
X and MCF-7. However, due to poor pharmacological characteristics, the compound did not 
progress for clinical development.72 The crystal structure of RO-2443 bound to MDMX showed 
that the compound forms a dimer, and MDMX also forms a dimer (Figure 2.11). The details of 
the crystal structure are discussed in detail in Chapter 8. 
 
 
Figure 2.11: Crystal structure of RO-2443 (grey) bound to MDMX (PDB: 3U15). The two 
monomers of MDMX are coloured cyan and blue. 
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2.5.6 Nutlin-3a Derivative 
Qin et al reported a Nutlin 3a derivative 25 as a dual inhibitor of MDM2- and MDMX-p53 
interactions.88 However, the paper was retracted recently (Oct 30, 2015) due to the intellectual 
property issues.89 The compound was rationally designed using the crystal structure of Nutlin-
3a bound to MDM2. The compound demonstrated p53-dependent activity on various cell 
lines.88 After the withdrawal of RO-5963 from clinical evaluation, compound 25 is the only 
low-nanomolar inhibitor of MDMX reported to date with therapeutic potential.  
 
The docking studies of compound 25 on p53 binding surface of MDMX revealed that the 
compound mimics the binding mode of p53 occupying the three key hydrophobic pockets.88 
 
Figure 2.12: Docking of compound 25 (green) on the p53 binding surface of MDMX.88 
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2.5.7 Pyrroles 
The diaryl- and triaryl-pyrroles were identified within the group from a screening of 800 
compounds using MDM2-p53 ELISA assay.90 Compound 26 with an IC50 of 12 μM against 
MDM2-p53 was identified as a hit. Extensive SAR studies around the hit were conducted to 
identify triaryl-pyrroles 27 and 28 as the most potent compounds in the series. SAR 
investigation revealed that the barbituric acid was important for the activity. However, the 
barbituric acid substituent is considered as a promiscuous binder in screening campaigns.91 
Although, the compounds showed sub-micromolar potency against MDM2 and MDMX, the 
compounds were not selective on cancer cells with WT-p53 over cells containing mutant-p53. 
In this thesis, the structural features of the reported triaryl pyrroles were taken into consideration 
while designing compounds against MDMX-p53 interaction (discussed in detail in the next 
chapter). 
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2.6 MDMX Project Aim 
As mentioned earlier, the MDM2-p53 interaction inhibitors cannot restore p53 activities in 
cancer cells overexpressing MDMX. The aim of the project was to design and develop small-
molecule inhibitors of the MDMX-p53 interaction. The knowledge obtained from the SAR 
studies around the thiazole series and the pyrrole series (both series developed within the group) 
was utilised to design and synthesise a new set of compounds (details in next chapter).  
The other aim of the project was to synthesise the reported dual inhibitors RO-2443 3 and RO-
5963 4 to benchmark the in-house ELISA assay and develop a Homogenous Time Resolved 
FRET (HTRF) assay as an alternative assay. 
 
 
After almost 20 years since the discovery of MDMX, co-crystallisation of MDMX with small 
molecules has only been reported two times: one is with a micromolar inhibitor WK298 22;86 
and the other is with RO-2443 3,71 and the features of the co-crystal structure with RO-2443 
could not be utilised in our series of compounds because it binds via a unique dimerization 
mode as discussed earlier. The final aim of the project was to co-crystallise MDMX with small-
molecule inhibitors developed within the research group. A co-crystal structure would provide 
an insight into the binding mode of the molecules guiding the design of potent inhibitors of the 
MDMX-p53 interaction. 
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Chapter 3. Development of Inhibitors of MDMX-p53 Interaction 
3.1 Rationale 
The aminothiazole series was identified from virtual screening of a large library of 
compounds.92 SAR studies around hit 1 led to the identification of compound 29 with low-
micromolar inhibitory activity against the MDMX-p53 interaction. However, due to the 
challenging chemistry at the 5-position of thiazoles, tri-substituted thiazoles that would be 
necessary to target the three hydrophobic pockets on the binding site of MDMX could not be 
synthesised. It was decided to change the scaffold from thiazole to pyrrole because the synthesis 
of tri-substituted pyrroles had been previously achieved within the group as described below. 
 
The pyrrole scaffold had previously been used within the group for developing MDMX-p53 
interaction inhibitors.90 Tetra-substituted pyrrole 26 was identified as a hit from the screen of 
800 compounds using Enzyme-Linked Immunosorbent Assay (ELISA).90 Extensive SAR 
studies led to the identification of compound 28 that showed sub-micromolar inhibitory activity 
against MDMX-p53 interaction, but suffered from low solubility in both aqueous medium, as 
well as organic solvents. 
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It was decided to remove the barbituric acid group, which has been identified as a component 
of ‘frequent hitters’ in high-throughput screening campaigns.91 Compound 30 was designed and 
docked in the binding site of MDMX (PDB: 3DAC) using Molecular Operating Environment 
(MOE) software (Figure 3.1). The binding site was defined automatically by MOE around the 
region where p53 peptide was bound to MDMX. Ten different poses were generated by MOE 
using the default London dG and GBVI/WSA dG scoring systems,93 and the top scoring pose 
was selected. The docking study suggested that a CH2 linker provides a perfect angle for the 
phenyl ring to occupy the Phe19 pocket in the binding site of MDMX. Besides, it was identified 
later on that a CH2 linker improved the organic solubility of the compounds. The 4-chlorophenyl 
group occupied the Trp23 pocket and the phenyl ring occupied the Leu26 pocket.  
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Figure 3.1: Compound 30 (carbons: magenta) docked on the binding site of MDMX (PDB: 
3DAC) using Molecular Operating Environment (MOE) software. The binding surface is 
coloured based on the charge of the amino acid residue; positive: blue, negative: red. 
 
The docked structure of compound 30 on MDMX was superimposed on the crystal structure of 
a p53 peptide in complex with MDMX (Figure 3.2). The superimposed image suggested that 
the substituents at 1,2,5-positions of the pyrrole ring occupied the same region as the three key 
amino acids in p53 (Leu26, Trp23 and Phe19). 
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Figure 3.2: Superimposition of crystal structure of MDMX in complex with p53 peptide (PDB: 
3DAC) and docked structure of compound 30 (carbons: magenta). MDMX secondary structure 
is coloured blue; p53 peptide is coloured green; three key amino acids in p53 are coloured grey. 
 
Therefore, the first strategy was to access the three key hydrophobic pockets in the MDMX 
binding surface with aromatic substituents at 1,2, and 5-positions of pyrroles. 
 
Figure 3.3: 1,2,5-trisubstituted pyrroles to be synthesised. 
 
3.2 Synthesis of 1,2,5-trisubstituted pyrroles 
Synthesis of compound 30 started with the Grignard reaction on commercially available 
phenylacetaldehyde 31 followed by oxidation to give α,β-unsaturated ketone 32 (Scheme 3.1). 
A Stetter reaction using a thiazolium salt provided the desired diketone 34. Finally, the Paal-
Knorr pyrrole synthesis afforded pyrrole 30. 
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Scheme 3.1: Reagents and conditions: (a) vinyl magnesium chloride, THF, -78 °C, 30 min, 
then r.t., 2h, 61%; (b) DMP, DCM, 0 °C-r.t., 3.5 h, quant.; (c) 3-benzyl-5-(2-hydroxyethyl)-4-
methylthiazolium chloride, benzaldehyde, NEt3, EtOH, 80 °C, 19 h, 65%;  (d) 4-chloroaniline, 
AcOH, reflux, 1.5 h, 30%. 
 
Compounds 40, 41, and 42 were synthesized using the same route. The synthesis started with 
the oxidation of 4-chlorophenethyl alcohol 35 (Scheme 3.2). Subsequently, following the 
previously described reaction sequence, diketone 39 was obtained. Finally, the Paal-Knorr 
pyrrole synthesis afforded desired pyrroles 40, 41 and 42. The Paal-Knorr condensation 
condition used for synthesising compound 30, 40 was low yielding, therefore, microwave 
conditions  described by Minetto et al were employed.94 Diketone 39 was heated with the 
corresponding amine under microwave irradiation for 10 min to obtain desired pyrroles 41 and 
42 in good isolated yields.  
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Scheme 3.2: Reagents and conditions: (a) DMP, DCM, 0 °C, 15 min, then r.t., 1 h, 66%; (b) 
vinyl magnesium chloride, THF, -78 °C, 30 min, then r.t., 2h, 39%; (c) DMP, DCM, 0 °C, 15 
min, then r.t., 3.5 h; (d) 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride, 
benzaldehyde, NEt3, EtOH, 80 °C, 19 h, 30% over 2 steps; (e)  4-chloroaniline, AcOH, reflux, 
8 h,  31% (40); or, 4-bromoaniline or 3,4-difluoroaniline, AcOH, 170 ˚C µW, 10 min, 83% 
(41), 77% (42). 
 
Compound 46 with a 6-chloroindole at the pyrrole-N1 position was designed based on the 
published inhibitor WK-298 22, which has a 6-chloroindole group to access the Trp23 pocket 
in MDMX. The proposed synthetic route for compound 46 is shown in Scheme 3.3. The 
synthesis started with the nitration of the commercially available indole 43. There is literature 
precedent for nitration at multiple positions of indole under nitration conditions using nitric 
acid.95 Therefore, milder conditions were attempted which provided desired 3-nitroindole 44 in 
10% yield.95 The low yield was due to the difficulty in purification of the tarry crude material 
as mentioned in the literature.96 A thiol SPE cartridge was used to separate silver impurities 
generated in the reaction and the remaining material was purified by reverse phase 
chromatography which helped to increase the yield to 42%. The reduction of 3-nitroindole 44 
was attempted with various reducing agents such as Zn/acetic acid, Zn/NH4Cl in MeOH, and 
Pd/C and H2, but resulted in a complex mixture of products.  
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Scheme 3.3: Reagents and conditions: (a) AgNO3, benzoyl chloride, CH3CN, 0 °C, 30 min., 
42%. 
 
There is a literature precedent for the Paal-Knorr condensation using nitrobenzenes involving 
in-situ reduction of the nitrobenzene to anilines.97 Using the literature conditions, the Paal-
Knorr condensation using Zn/Acetic acid was attempted (Scheme 3.4) but the reaction provided 
complex mixture of products.    
 
Scheme 3.4: Reagents and conditions: (a) Zn, AcOH, 90 °C, 20 h. 
 
It was proposed that the 3-aminoindole 45, due to its electron rich nature, would be involved in 
various side reactions. Therefore, the protection of indole 43 with an electron withdrawing 
protecting group was proposed (Scheme 3.5). The Boc protection of indole 43, followed by 
nitration afforded compound 48. Subsequent reduction of compound 48 using Zn/AcOH was 
unsuccessful. Following a literature procedure by Lee et al,97 nitroindole 48 was used directly 
in the Paal-Knorr condensation using indium/acetic acid, however, a mixture of unidentified 
products was obtained. While this work was underway, it was determined that 1,2,5-
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trisubstituted pyrroles (30, 40, 41 and 42) were not potent inhibitors of MDMX-p53 interaction 
as shown in Table 3.1. Therefore, the synthesis of compound 46 was abandoned. The focus was 
shifted towards other regions of the pyrroles with modifications designed to improve the 
solubility which will be discussed in detail in the next chapter. 
 
Scheme 3.5: Reagents and conditions: (a) Boc2O, DMAP, MeCN, r.t., 2 h, 97%; (b) HNO3, 
Ac2O, -78 °C-0 °C, 17 h, 51%; (c) Zn, AcOH, r.t., 45  min. 
 
 
3.3 Biological Evaluation 
1,2,5-Trisubstituted pyrroles were tested against MDMX-p53 interaction using an Enyme-
Linked Immunosorbent Assay (ELISA). Compounds 30, 40, 41 and 42 demonstrated weak 
inhibition of the MDMX-p53 interaction (Table 3.1). The compounds were very lipophilic with 
average clogP around 9. Due to high lipophilicity, the compounds had low-solubility in assay 
buffer conditions resulting in weak inhibition of the MDMX-p53 interaction. 
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Table 3.1: Results of the ELISA for 1,2,5-trisubstituted pyrroles. 
 
Compound R1 R2 R3 
MDMX  
IC50 (μM) 
30 C6H5CH2 Ph 4-ClC6H4 >200 
40 4-ClC6H4CH2 4-FC6H4 4-ClC6H4 197 
41 4-ClC6H4CH2 4-FC6H4 4-BrC6H4 168 
42 4-ClC6H4CH2 4-FC6H4 3,4-F2C6H3 281 
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Chapter 4. Introduction of Water Solubilising Group 
4.1 Rationale 
It was postulated that 1,2,5-trisubstituted pyrroles were inactive against MDMX because of the 
poor solubility of the compounds in assay buffer conditions. Therefore, it was decided to 
introduce a water solubilising group in the molecule. The 3-position of the pyrrole was chosen 
for introducing a water solubilising group for reasons of synthetic accessibility. The water 
solubilising group in the published MDMX inhibitor RO-5963 4 was chosen and compound 51 
was designed.  
 
 
4.2 Synthesis 
The synthesis of compound 51 started with the preparation of 1,4-diketone 54 following a route 
described by Minetto et al (Scheme 4.1).94 1,4-Diketone 54 was synthesised from the 
commercially available β-keto ester 52 using Et2Zn and CH2I2, followed by oxidation. Then, 
Paal-Knorr condensation of 1,4-diketone 54 with 4-chloroaniline provided pyrrole 55 which 
was hydrolysed to compound 2. Subsequent amide coupling of the carboxylic acid 2 with the 
amine 115 produced compound 57. The synthesis of amine 115 is discussed in detail in Chapter 
7 (Scheme 7.2). Finally, the deprotection of acetal 57 using HCl provided desired target 51. 
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Scheme 4.1: Reagents and conditions: (a) 36, Et2Zn, CH2I2, DCM, 0 °C, 1.5 h; (b) PCC, DCM, 
r.t., 41 h, 33% over 2 steps; (c) 4-chloroaniline, AcOH, 170 °C µW, 10 min, 48%; (d) LiOH, 
THF, MeOH, H2O, r.t., 72 h, 91%; (e) 115, DIC, DMAP, DCM, 0 °C, 15 min, then r.t., 16 h, 
70%; (f) HCl, H2O, THF, r.t., 3h, 94%. 
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Minetto et al proposed a mechanism for the formation of diketone using Et2Zn and CH2I2 
(Scheme 4.2).94 The reaction proceeds via the formation of a cyclopropyl intermediate 59 which 
ring opens to intermediate 60. The nucleophilic attack of intermediate 60 on the aldehyde 
affords alcohol 61, which can be oxidised to give desired 1,4-deketone 62. 
 
Scheme 4.2: Proposed mechanism for the conversion of β-Keto ester to 1,4-Diketone.94, 98 
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4.3 Biological Evaluation 
MDMX inhibitory activity of compound 51 along with the intermediates obtained during the 
synthesis were determined (Table 4.1). A significant increase in potency for MDM2 and 
MDMX, at least 12-fold, was observed upon the hydrolysis of ester 55 to carboxylic acid 2. 
Amides 51 and 57 were at least 4-fold less potent than the carboxylic acid 2. Interestingly, both 
the amides were more potent against MDMX than MDM2, compound 51 was the most MDMX 
selective compound. Compound 2 was considered as the lead in the pyrrole series and SAR 
studies around the compound were carried out, discussed in detail in following chapters. 
Table 4.1: Results of the ELISA for tetra-substituted pyrroles. 
 
Compound R 
MDM2 IC50 
(μM)a 
MDMX IC50 
(μM)a 
30 H >200 197 
55 -COOMe >200 188 
2 -COOH 11b 15c 
 
57 
 
104 61 
 
51 
 
>200 40 
a Determinations (n = 1 unless otherwise stated); b n = 2; c n = 3  
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Chapter 5. SAR Studies around Compound 2 
5.1 Rationale 
The increase in potency due to a carboxylic acid at the 3-position, encouraged SAR studies 
around lead 2. Compound 63 with a barbituric acid group at the 3-position could be used for 
direct comparison with the previously described pyrrole series.90 Compound 64, with two 
carboxylic acids was designed to study the effect of an additional acid at the 4-position. To 
understand the effect of homologation of carboxylic acid compound 65 and 66 were designed. 
 
 
Introduction of a succinimide ring on the 3/4-positions could be accessible via dicarboxylic acid 
compound 67. 3,4-Pyrroledicarboximides 68 has an unsubstituted nitrogen that could be used 
as a vector to introduce various water solubilising groups. Removal of fluorine is discussed in 
detail in Chapter 6. 
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Figure 5.1: Design of 3,4-pyrroledicarboximides. 
 
It was postulated that compound 69 with a CH2 linker at the N
1-position would mimic the 
indole ring of Trp23 in p53 (Figure 5.2). 
 
Figure 5.2: Overlay of compound 69 on the side chain of Trp23 of p53. 
 
5.2 Synthesis 
5.2.1 Synthesis of Tetra-Substituted and Penta-Substituted Pyrroles 
1,4-Diketone 74 and pyrrole 75 were synthesised in bulk quantities, and used for the synthesis 
of various compounds. The synthesis started with the preparation of β-keto ester 72 using acid 
chloride 70 and Meldrum’s acid 71 (Scheme 5.1). The nucleophilic attack of the enolate of β-
keto ester 71 on compound 73 afforded desired 1,4-dikeone 74 in good isolated yield. Finally, 
the Paal-Knorr pyrrole synthesis using 4-chloroaniline provided pyrrole 75. The scheme was 
high yielding, and the purification of the products was easier compared to the previously 
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described route (Scheme 4.1). In addition, this route was versatile in terms of synthesising 
different analogues of 1,4-diketone.  
 
Scheme 5.1: Reagents and Conditions: (a) (i) pyridine, DCM, 0 °C, 1 h, then r.t., 2.5 h; (ii) 
EtOH, reflux, 2 h, then r.t., 16 h, 78% over 2 steps; (b) NaH, THF, r.t., 2.5 h. 91%; (c) 4-
chloroaniline, AcOH, 170 °C µW, 10 min, 67%. 
 
Compound 63 was synthesised following a four-step reaction sequence starting from 
intermediate 75 (Scheme 5.2). DIBAL reduction of ester 75 gave alcohol 76, and subsequent 
oxidation with Dess-Martin periodinane provided aldehyde 77. Knoevenagel condensation of 
aldehyde 77 with barbituric acid in the presence of acetic acid afforded desired pyrrole 63.  
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Scheme 5.2: Reagents and Conditions: (a) DIBAL, DCM, 0 °C, 2 h, 95%; (b) DMP, DCM, 0 
˚C-r.t., 2 h, 61%; (c) barbituric acid, AcOH, reflux, 2.5 h, 48%. 
 
Compound 69 was synthesised following a two-step reaction sequence starting from 
intermediate diketone 74 (Scheme 5.3). Paal-Knorr condensation of diketone 74 with amine 78 
afforded pyrrole 79. Subsequent hydrolysis of the ester group provided desired pyrrole 69.  
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Scheme 5.3: Reagents and Conditions: (a) AcOH, 170 °C µW, 10 min, 50%; (b) NaOH, 
THF, MeOH, H2O, 75 °C, 18 h, 70%. 
 
The synthesis of di-carboxylic acid compound 64 started with the formylation of intermediate 
75 using Vilsmeier-Haack conditions (Scheme 5.4). Pinnick oxidation of aldehyde 80 provided 
mono-carboxylic acid 81. Subsequent hydrolysis provided desired di-carboxylic acid 64. 
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Scheme 5.4: Reagents and conditions: (a) POCl3, DMF, 70 
°C, 4 h, 71%; (b) NaClO2, sulfamic 
acid, MeCN, H2O, r.t., 2 h, quant.; (c) NaOH, MeOH, H2O, reflux, 4 h, 97%. 
 
Compound 65 was synthesised by the condensation of aldehyde 77 and malonic acid using 
pyridine and piperidine (Scheme 5.5).  
 
Scheme 5.5: Reagents and Conditions: (a) malonic acid, pyridine, piperidine, reflux, 2.5 h, 
75%. 
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5.2.2 Synthesis of pyrroles with succinimide ring at the 3/4-position 
Compound 68 was synthesised following a five step reaction sequence starting from 
intermediate 82 (Scheme 5.6). Di-carboxylic acid 67 was synthesised using the previously 
described chemistry. Acetic anhydride mediated ring closure afforded compound 85. 
Nucleophilic attack of ammonia on anhydride 85 opens the ring producing an intermediate 
amide, which was converted to succinimide 68 upon thionyl chloride-mediated ring closure. 
 
Scheme 5.6: Reagents and conditions: (a) POCl3, DMF, 70 
°C, 4 h, quant.; (b) NaClO2, 
sulfamic acid, MeCN, H2O, r.t., 2 h, 62%; (c) NaOH, MeOH, H2O, reflux, 4 h, quant.; (d) Ac2O, 
reflux, 2 h, 82%; (e) (i) NH3, AcOH, 120 ˚C µW, 30 min; (ii) SOCl2, THF, r.t., 1.5 h, 62%. 
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In order to examine the versatility of the reaction scheme, compound 86 was synthesised. 
Compound 86 has a 4-chlorophenyl ring at the N1-position of the succinimide ring that could 
flip the binding mode of the molecule such that the 4-chlorophenyl ring at the N1-position the 
succinimide ring would occupy the Trp23 pocket in MDMX. 
 
 
 Compound 86 was synthesised in moderate isolated yield from anhydride 85 using 4-
chloroaniline as a nucleophile (Scheme 5.7). 
 
Scheme 5.7: Reagents and Conditions: (a) (i) 4-chloroaniline, AcOH, 120 ˚C µW, 20 min; (ii) 
SOCl2, THF, r.t., 18 h, 64%. 
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5.2.3 One-Carbon Homologation of 3-Carboxylic Acid  
A classical route for one-carbon homologation of a carboxylic acid includes the conversion of 
the carbonyl compound to nitrile, which can be hydrolysed to get the desired homologated 
carboxylic acid (Scheme 5.8).  
 
Scheme 5.8: One carbon homologation via nitrile. 
 
Synthesis of homologated carboxylic acid analogue 66 started with the reduction of ester 75 to 
alcohol 76. Conversion of alcohol 76 to nitrile 87 proved to be extremely challenging. Initial 
attempts to convert the alcohol group of 76 to a leaving group (LG) such as chloro, mesyl or 
tosyl resulted in a mixture of unidentified products.   
 
Scheme 5.9: Reagents and conditions: (a) DIBAL, DCM, 0 °C, 2 h. (95%) 
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It was proposed that in the presence of a good leaving group, the lone pair of nitrogen pushes 
the electron density, eliminates the leaving group producing a reactive electrophile, which can 
be involved in unwanted side-reactions (Scheme 5.10). 
 
Scheme 5.10: Proposed mechanism for the formation of a reactive electrophile. 
 
Simply heating alcohol 76 with various cyanide sources like Et4N
+CN-, NaCN, and TMSCN 
did not produce any reaction. Cheng et al have described the direct conversion of alcohols to 
nitriles using TMSCN and catalytic InBr3.
99 The reaction was attempted, but a complex mixture 
of products was obtained. 
Cafiero et al has reported one-carbon homologation via an aldehyde.100 One of the examples in 
the paper was aldehyde 88, which has very similar electronic character to the pyrrole scaffold. 
The oxygen lone pair in methoxy group of compound 89 can push electron density, similar to 
the nitrogen of pyrroles (Scheme 5.10). 
 
The procedure described by Cafiero et al (Scheme 5.11) was used for the synthesis of the one-
carbon homologated carboxylic acid 92.100 The aldehyde 90 was trichloromethylated to afford 
compound 91, which under sodium borohydride and diphenyldiselenide and sodium hydroxide 
provided desired acid 92 in good isolated yield. The diphenyldiselenide was important in the 
reaction. The reaction in the absence of diphenyldiselenide gave alcohol. Final compound 92 
does not contain fluorine because it was identified simultaneously that the fluorine was not 
essential for potency (discussed in detail in next chapter). 
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Scheme 5.11: Reagents and conditions: (a) (i) CHCl3, DMF, -10 ˚C, 15 min; (ii) KOH, MeOH, 
-10 ˚C, 3 h, 64%; (b) (PhSe)2, NaBH4, NaOH, EtOH, r.t., 24 h, 90%. 
 
 
5.3 Biological Evaluation 
Compounds along with the intermediates obtained during the synthesis were analysed by 
ELISA (Table 5.1). Compounds 76 and 80 without any acidic groups showed a significant loss 
in potency, suggesting that an acidic group at 3- or 4-position of pyrroles is essential for activity. 
Compound 81 with an acidic group as well as an ester group showed a reduction in potency 
against MDMX; however acidic groups at both 3- and 4-positions in compound 64 were 
tolerated. Interestingly, compound 69 with a CH2 linker at the N
1-position was at least 10-fold 
more potent against MDM2 than MDMX. A crystal structure of compound 69 in complex with 
MDMX would be beneficial to understand the selectivity observed. 
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Table 5.1: Results of the ELISA for tetra- and penta-substituted pyrrole derivatives. 
 
Compound R1 R2 R3 
MDM2 
IC50 (μM)a 
MDMX 
IC50 (μM)a 
2 COOH H 4-ClC6H4 11
b 15c 
63 
 
H 4-ClC6H4 3.5 4.5 
69 COOH H 
 
4.9 53 
80 COOEt CHO 4-ClC6H4 > 200 187 
81 COOEt COOH 4-ClC6H4 15.8 55.9 
64 COOH COOH 4-ClC6H4 8.1 13.4 
76 CH2OH H 4-ClC6H4 > 200 > 200 
a Determinations (n = 1 unless otherwise stated; b n = 2; c n = 3) 
 
Before the biological evaluation of homologated carboxylic acid compounds 65 and 92, the 
antibody used in the MDMX-ELISA was withdrawn from the market. Therefore, it was decided 
to develop an alternate Homogenous Time Resolved FRET (HTRF) assay (Chapter 8). 
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Chapter 6. SAR Studies around the Phenyl Rings at 2 and 5-Positions  
 
6.1 Rationale 
The docking studies with compound 30 suggested that there is not enough space (highlighted 
by red arrow in Figure 6.1) to accommodate any atoms in the para-position of the phenyl ring 
into the Leu26 pocket of MDMX. 
 
Figure 6.1: Compound 30 (carbons: magenta) docked on the binding site of MDMX (PDB: 
3DAC) using Molecular Operating Environment (MOE) software. The binding surface is 
coloured based on the charge of the amino acid residue; positive: blue, negative: red. The space 
between the phenyl ring and Leu26 pocket is highlighted by a red arrow. 
 
The role of the fluoro group from the para position of 2 was investigated, and compound 93 
was designed. 
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The docking studies with compound 30 also suggested that the phenyl ring in the 5-position 
was close to the oxygen of Gln68 (Figure 6.2). It was postulated that an electron donating group 
might interact with Gln68 improving the potency.  
 
Figure 6.2: Compound 30 (carbons: magenta) docked on the binding site of MDMX using 
Molecular Operating Environment (MOE) software. The secondary structure of MDMX is 
coloured green. The carbons of key amino acids in the binding site are coloured grey. The red 
arrow highlights the distance between the phenyl ring and Gln68. 
 
Compound 94 was designed replacing the chloro group with a hydroxyl group that might 
provide an H-bond interaction with Gln68. In addition, the hydroxyl group also reduced the 
lipophilicity of the molecule. 
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6.2 Synthesis 
Compound 93 was synthesised using the previously described chemistry (Scheme 6.1). β-Keto 
ester was synthesised using acid chloride 70 and Meldrum’s acid 71 (Scheme 5.1). The 
nucleophilic attack of the enolate of β-keto ester 72 on compound 95 afforded desired 1,4-
dikeone 96 in good isolated yield. The Paal-Knorr pyrrole synthesis using 4-chloroaniline 
provided pyrrole 82, which was hydrolysed to desired pyrrole 93. 
 
Scheme 6.1: Reagents and Conditions: (a) NaH, THF, r.t., 2.5 h. 79%; (b) 4-chloroaniline, 
AcOH, 170 °C µW, 10 min, 73%; (c) NaOH, MeOH, H2O, 65 ˚C, 24 h, 98%. 
 
Similarly, compound 94 was synthesised following a five step reaction sequence (Scheme 6.2). 
The synthesis started with the formation of β-keto ester 98 from the commercially available 
acid chloride 97 and Meldrum’s acid 71. Following the chemistry described before, compound 
101 was obtained. Finally, BBr3-mediated removal of methyl group from compound 101 
afforded desired target 94 in good isolated yield. 
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Scheme 6.2: Reagents and conditions: (a) (i) pyridine, DCM, 0 °C, 1 h, then r.t., 2.5 h; (ii) 
EtOH, reflux, 2 h, then r.t., 16 h, 72% over 2 steps; (b) NaH, THF, r.t., 2.5 h, 76%; (c) 4-
chloroaniline, AcOH, 170 °C µW, 10 min, 75%; (d) NaOH, MeOH, H2O, 65 ˚C, 24 h, quant.; 
(e) BBr3, DCM, 0 ˚C, 1 h, 88%. 
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6.3 Biological Evaluation 
Compound 93, retained the potency suggesting that the fluoro group at the para-position was 
not important for the inhibition of MDMX-p53 interaction.  
 
As mentioned in the last chapter, before the biological evaluation of compounds 94, the 
antibody used in the MDMX-ELISA was withdrawn from the market. Therefore, it was decided 
to develop an alternate Homogenous Time Resolved FRET (HTRF) assay (Chapter 8). 
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Chapter 7. Synthesis and Biological Evaluation of RO-2443 3 and RO-5963 
4 
 
7.1 Rationale 
During the project work, RO-2443 3 and RO-5963 4 were the only reported dual small-
molecule nanomolar inhibitors of MDM2 and MDMX. Therefore, in order to benchmark the 
biochemical assay ELISA, which was used for measuring the potency of in-house compounds, 
it was decided to synthesise RO-2443 3 and RO-5963 4.71 
 
 
7.2 Synthesis 
7.2.1 Synthesis of RO-2443 3 
The syntheses of RO-2443 3 and RO-5963 4 were not described in the paper by Graves et al.71 
Initial retrosynthestic analysis of RO-2443 3 suggested that the condensation of aldehyde 104 
and substituted-hydantoin 107 could provide the desired target (Figure 7.1). The mono-
alkylation of hydantoin 105 could be performed by K2CO3-mediated procedure reported by 
Fraile et al.101 
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Figure 7.1: Retrosynthetic analysis of RO-2443. 
 
The synthesis started with a Bartoli reaction on 1-chloro-2-methyl-3-nitrobenzene 102 to give 
indole 103. Formylation under Vilsmeier-Haack conditions afforded aldehyde 104 in good 
yield. The monoalkyaltion of hydantoin 105 was achieved by using K2CO3 as a base to afford 
compound 107. Di-alkylation was observed when NaH was used. The final condensation 
reaction with NH4OAc in acetic acid was not successful. The condensation reaction was 
attempted with various reagents and conditions (Table 7.1). The desired target 3 was obtained 
in 24% yield using NH4OAc in toluene. The best results were obtained with 3 equivalents of 
piperidine for condensation to give RO-2443 3 in 92% isolated yield. 
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Scheme 7.1: Reagent and condition: (a) vinyl magnesium bromide, THF, -40 ˚C, 1 h, 43%; (b) 
POCl3, DMF, 0 ˚C, then 70 ˚C µW, 10 min, 93%; (c) K2CO3, CH3CN, reflux, 6 h; r.t., 16 h, 
57%; (d) piperidine, 130 ˚C, 30 min, 92%. 
  
58 
 
 
Table 7.1: Various reagents and conditions used in step d of Scheme 7.1 for the condensation 
of aldehyde 104 and hydantoin 107. 
 
Reagent Solvent 
Temperature 
(ºC) 
Time Result 
NH4OAc AcOH 180 µW 30 min Complex mixture of products 
NH4OAc Toluene 200 µW 30 min 24% isolated yield 
NH4OAc DME 100 µW 30 min Complex mixture of products 
NH4OAc MeCN 100 µW 30 min Complex mixture of products 
Piperidine (excess) - Reflux 24 h Complex mixture of products 
Piperidine (3 eq) - Reflux 30 min 92 % yield 
 
 
7.2.2 X-ray structure of RO-2443 3 
A small molecule X-ray crystal structure of RO-2443 3 was obtained (Figure 7.2). The torsion 
angle between the bond formed by C8 and C9 and the bond formed by C10 and C11 is 0.4˚ 
which suggests that the indolylhyantoin moiety is planar. The crystal structure, along with NMR 
and HRMS data confirmed that the compound synthesised was RO-2443 3.  
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Figure 7.2: Crystal structure of RO-2443 3. Atoms are coloured as: carbon: grey, oxygen: red, 
nitrogen: blue, hydrogen: white; chlorine: green. 
 
7.2.3 Synthesis of RO-5963 4 
Initial retrosynthetic analysis of RO-5963 4 suggested that the nucleophilic substitution reaction 
using indolylhydantoin 118 and bromo-derivative 110 would provide the desired target (Figure 
7.3). Indolylhydantoin 118 could be prepared using the chemistry described for the synthesis 
of RO-2443 3. The bromo-compound 110 could be synthesised via the amide coupling of 
carboxylic acid 109 and 2-aminopropane-1,3-diol 112.  
 
Figure 7.3: Retrosynthetic analysis of RO-5963 4. 
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The synthesis of RO-5963 4 started with the preparation of bromo-compound 110 (Scheme 
7.2). 3,4-Difluorophenylglycine 108, was brominated via the formation of the diazonium salt, 
followed by a nucleophilic attack with bromide. The amide coupling of carboxylic acid 109 and 
2-aminopropane-1,3-diol 112 in presence of DIC and EDC was unsuccessful. Therefore, it was 
decided to protect the diol. The amine group of 2-aminopropane-1,3-diol 112 was protected as 
a trifluoroacetate 113. Subsequently, acetal protection afforded compound 114. Finally, the 
trifluoroacetyl group was removed using LiOH to liberate the free amine 115, which was used 
for amide coupling with carboxylic acid 109 to afford compound 116. 
 
Scheme 7.2: Reagents and condition: (a) HBr, KBr, NaNO2, H2O, 0 °C-r.t., 3 h, 36%; (b) THF, 
r.t., 48 h, 98%; (c) 2,2-dimethoxypropane, camphor-10-sulfonic acid, DCM, r.t., 96 h, 54%; (d) 
LiOH, THF, H2O, r.t., 1.5 h, 54%; (e) DIC, DMAP, DCM, 0 °C-r.t., 16 h, 79%. 
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Condensation of aldehyde 104 with hydantoin afforded indolylhydantoin 118 (Figure 7.3). The 
nucleophilic substitution reaction with indolylhydantoin 118 and bromo-compound 116 was 
very slow, and desired product 119 was obtained in poor yield. Acid-catalysed acetal 
deprotection afforded RO-5963 4. Although, the scheme was low yielding in a few steps, the 
reactions were reproducible and was successfully repeated by a colleague (Dr Stephanie 
Myers). 
 
Scheme 7.3: Reagents and condition: (a) hydantoin, piperidine, 130 °C, 1 h, 86%; (b) 116, 
K2CO3, DMF, r.t., 96 h, 17%; (c) HCl, THF, H2O, 0 °C-r.t., 3 h, 36%. 
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7.3 Biological Evaluation 
Upon the biochemical evaluation by ELISA, RO-2443 3 and RO-5963 4 were at least 1000 fold 
less potent compared to the HTRF values reported by Graves et al (Table 7.2).71 
Table 7.2: Comparison of the reported HTRF assay and in-house ELISA assay. 
Compounds 
Published 
HTRF IC50 (µM) 
In-house 
ELISA IC50 (µM)a 
 MDM2 MDMX MDM2 MDMX 
RO-2443 3 0.033  0.041 7c 14d 
RO-5963 4 0.019  0.024 17b 20b 
a Determinations (n = 1 unless otherwise stated);  
b n = 2; c n = 3; d n = 4 
 
Although, the potencies of RO-2443 and RO-5963 were significantly lower in NCL-ELISA, the 
cellular data were in line with the published results. RO-2443 3 and RO-5963 4 were potent in 
MDMX overexpressing cell lines JEG3 and MCF-7. Although less potent, the compounds also 
exhibited growth inhibition in MDM2 overexpressing cell line SJSA-1. Therefore, in order to 
develop an alternative assay, a structural biology placement was undertaken (Chapter 8). 
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Chapter 8. MDM2 and MDMX Structural Biology 
8.1 Aims 
Although MDM2 and MDMX have high sequence homology, most of the small molecule 
MDM2 inhibitors show significantly lower binding affinity towards MDMX.70, 102-103 An 
extensive SAR on four different series (benzenoids, thiazoles, pyrroles and isoindolinones) did 
not produce any low nanomolar inhibitors of the MDMX-p53 interaction.92, 104-105 To guide 
rational drug design, a co-crystal structure of a small molecule bound to MDMX was essential. 
To date, co-crystal structures of only two small molecules bound to MDMX have been reported. 
Compound WK298 22 with low micromolar potency against MDMX is the first small molecule 
for which a structure bound to MDMX has been reported.86 The co-crystal structure of WK-
298 22 bound to MDMX revealed many key features which are important for designing small 
molecule inhibitors of MDMX (Figure 8.1). The chloro-indole substituent binds in the Trp23 
pocket. The nitrogen atom of the indole forms a hydrogen bond with Met53 in MDMX. The 
chlorine atom in the indole ring induces a conformational change in key residues including 
Leu54, Met53, Leu98 and Leu102 which helps to enlarge the Trp23 binding pocket. The phenyl 
ring occupies the Phe19 pocket and the chlorobenzyl group occupies a Leu23 pocket. 
 
Figure 8.1: The X-ray co-crystal structure of WK-298 22 bound to MDMX. WK-298 22 is 
drawn in skeleton mode with carbon, nitrogen, oxygen and chlorine atoms coloured cyan, blue 
and red and green, respectively. The solvent accessible surface of MDMX (probe radius 1.5 Å) 
around WK-298 22 is coloured based on the atoms; carbon: grey, oxygen: red, nitrogen blue, 
sulphur: yellow. The structure is taken from PDB code: 3LBJ. 
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Compound RO-2443 3 developed by Roche is the other small molecule for which a co-crystal 
structure with MDMX has been reported and it is a potent inhibitor of MDMX with an IC50 of 
41 nM.71 The compound interacts with MDM2 and MDMX by dimerization avoiding the 
challenging Leu26 pocket in both MDM2 and MDMX (Figure 8.2). The compound contains an 
indolylhydantoin and difluorophenyl groups. The indolylhydantoin moiety occupies the Phe19 
pocket in one monomer of MDMX, and the difluorophenyl moiety occupies the Trp23 pocket 
of the other monomer of MDMX. The molecules also form aromatic stacking interactions 
between two indolylhydantoin moieties and two tyrosine residues from two MDMX monomers 
to generate a four level π-sandwich. The other key interaction is between the σ-hole of the 
chlorine substituent of one monomer of the small molecule with difluorophenyl ring of the other 
monomer of the small molecule. This interaction along with the aromatic stacking interaction 
helps in the dimerization of small molecule as well as MDMX protein. 
 
Figure 8.2: Co-crystal structure of RO-2443 3 bound to MDMX. MDMX dimers are 
represented as ribbons and coloured based on secondary structure: helices are red, beta sheets 
are cyan, turns are green, and coils are white. Two molecules of RO-2443 3 and two tyrosine 
residues from two MDMX monomers form a four level π-sandwich. The four-level sandwich 
is visible in this view holding the two MDMX molecules together. The chlorine atom is labelled 
green which forms an interaction via its σ-hole with the difluorophenyl ring of the other 
monomer of RO-2443 3. The structure is taken from PDB code: 3U15. 
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Due to the unique nature of the RO-2443 3 binding mode, the key features of the crystal 
structure could not help rational drug design of the compound series developed at Newcastle. 
Therefore, a co-crystal structure of a small molecule inhibitor developed at Newcastle bound to 
MDMX would be valuable. To attempt to achieve this aim, a 5-month placement in structural 
biology at the Northern Institute for Cancer Research was completed. 
 
 
8.2 Expression and Purification of MDM2 and MDMX 
Three different constructs of MDM2 and MDMX encoding the N-terminal p53-binding domain 
were selected for co-crystallisation trials. This selection was based on the literature data as well 
as successes in protein expression experienced in-house.71, 86, 104-106 The constructs expressed 
and purified for co-crystallisation trials are listed in Table 8.1. 
Table 8.1: Constructs of MDMX and MDM2 used for co-crystallisation trials. 
Protein Construct Amino acid range Mutations 
MDMX 1 18-111 - 
MDMX 2 22-111 - 
MDMX 3 26-111 - 
MDM2 1 17-125 K51A 
MDM2 2 17-109 E69A/K70A 
MDM2 3 17-125 E69A/K70A 
 
 
The pre-cloned DNA coding for each construct of MDMX and MDM2 were inserted into the 
pGEX-6P-1 vector and expressed in E. coli Rosetta(DE3)pLys S and BL21(DE3) pLys S 
strains, respectively. 
The pGEX-6P-1 plasmid contains several genes essential for the expression of the desired 
protein. The plasmid possesses genes encoding for ampicillin resistance, a glutathione-S-
66 
 
transferase (GST) tag, a 3C viral protease cleavage site and the lac operon (Figure 8.3). The 
expression of N-GST tagged MDM2 and MDMX was induced by the addition of IPTG 
(isopropyl β-D-1-thiogalactopyranoside). 
 
 
Figure 8.3: Map of the pGEX-6P-1 expression vector. The vector map shows the positions for 
the genes encoding ampicillin resistance (Ampr), the GST protein tag, the cleavage codon 
(PreScissionTM Protease) and the lac operon (lac 1 q).107 
 
The expressed proteins were first purified by the addition of lysozyme, DNase and RNase 
followed by sonication and centrifugation. The addition of these three enzymes and sonication 
lyses the E. coli cells and subsequent centrifugation separates insoluble cell debris from soluble 
proteins, which include MDM2 or MDMX.  To separate N-GST tagged MDMX or MDM2 
from other undesired proteins, the supernatant obtained after centrifugation was incubated with 
glutathione-agarose and washed with mHBS buffer, pH 7.4 containing glutathione. SDS-PAGE 
analysis of the soluble cell lysate and the eluate from the glutathione column (Figure 8.4, lanes 
2-7) confirmed the expression and purification of N-GST tagged MDMX or MDM2. 
Subsequent incubation with 3C protease successfully cleaved the GST tag from MDMX and 
MDM2 (Figure 8.4, lanes 8-10). 
67 
 
 
Figure 8.4: Purification of MDMX. SDS-PAGE (12% acrylamide) analysis of MDMX 
constructs 1, 2 and 3 at various stages during purification. Lanes 2-4, soluble cell lysate; lanes 
5-7, glutathione elution; lanes 8-10, proteins post 3C digestion. Molecular weight markers, lane 
1, uncleaved GST-MDMX (xkDa) is identified by a star. 
 
The protein fractions containing MDMX obtained after elution from the glutathione column 
with mHBS buffer, pH 7.4 containing glutathione were pooled and incubated with 3C protease 
to cleave the GST tag from the desired protein. The protein was purified by size exclusion 
chromatography to separate the GST tag (Figure 8.5A). SDS-PAGE analysis of selected 
fractions confirmed the purity of the protein (Figure 8.5B). The pure protein fractions were 
concentrated by ultrafiltration and stored at -80 ˚C. 
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Figure 8.5: Purification of MDMX by size-exclusion chromatography. Construct C3 
(MDMX26-111) was subjected to size-exclusion chromatography as a final purification step. The 
sample was run on a Superdex HR 16/60 column (GE Healthcare) equilibrated in mHBS buffer. 
(A) Chromatogram, (B) SDS-PAGE of selected fractions. Fractions analysed in (B) are 
identified by the black line under the chromatogram in (A).   
 
8.3 Co-Crystallisation of MDM2 and MDMX with Pyrrole Inhibitors 
Compounds for co-crystallisation trials were selected based on the LogD values (calculated 
using Stardrop and the IC50 values against MDMX measured by ELISA assay (Table 8.2). The 
compounds with LogD values greater than 4 showed visible precipitation in the presence of 
MDM2 or MDMX. Compound 68 has a logD value greater than 4 but it was selected for the 
co-crystallisation trials because of a unique molecular feature: It has a succinimide ring on the 
3rd and 4th position of the pyrrole. The nitrogen of the succinimide ring would be a good vector 
to reach other favourable interactions or to introduce any water solubilising groups. A co-crystal 
structure of compound 68 bound to MDMX would be valuable to design a series of compounds 
with a fused ring system.  
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Table 8.2: Pyrrole MDMX inhibitors selected for co-crystallisation trials. 
Compound Structure 
MDMX 
ELISA IC50 
(µM) 
LogD 
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13.4 1.6 
81 
 
56 3.2 
2 
 
15 3.3 
93 
 
7.9 3.4 
68 
 
Not tested 5.5 
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The inhibitors were incubated with the concentrated proteins in a 3:2 molar ratio at 4 ˚C 
overnight. The inhibitor-protein complexes were concentrated to between 1.5 to 18 mg/ml 
(Table 8.3). The concentrations of the protein-inhibitor complexes with MDM2 were between 
10-20 mg/ml, however, precipitation was observed with MDMX complexes at concentrations 
higher than 4-5 mg/ml. Precipitation was mostly observed with compounds 68 and 93 and as a 
result crystal trays were not set up for these inhibitors. 
Table 8.3: Protein-inhibitor concentration for co-crystallisation trials. 
Compound 
Protein-Inhibitor Concentration (mg/ml) 
MDMX constructs MDM2 Constructs 
1 2 3 1 2 3 
2 3.7 3.1 2.3 23.0 10.0 17.3 
68 3.5 - - 19.0 7.2 - 
67 2.9 2.7 2.1 19.0 4.0 15.8 
81 2.9 2.9 2.2 23.0 5.7 16.8 
93 - - - 22.0 5.5 15.0 
 
In an attempt to identify novel crystallisation conditions, MDMX-inhibitor complexes were 
screened against three commercial crystallisation screens, JCSG+ (Molecular Dimensions), 
Index (Hampton Research) and ammonium sulfate (Qiagen) and MDM2-inhibitor complexes 
were screened against JCSG+ and ammonium sulfate. 2-subwell 96-well trays were used for 
co-crystallisation trials (Figure 8.6). Screening solutions were first added to the 96 wells by 
hand. The solutions were also mixed with protein-inhibitor complexes in 1:1 and 2:1 ratios 
(protein-inhibitor complex:screen) and the mixtures dispensed into the subwells using a 
Mosquito robot.  Trays were stored at 4 ˚C in a Rikagu Minstrel tray hotel which also imaged 
the subwells at set time intervals. The images were observed for 8 weeks to monitor crystal 
formation. 
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Figure 8.6: Crystallisation of MDM2 and MDMX with small molecule inhibitors. Complexes 
of MDM2 and MDMX bound to small molecule inhibitors were screened against selected 
commercial crystallisation screens in 96 well, 2 subwell plates. (A) The MRC crystallisation 
plate. (B) Close-up to show the juxtaposition of the two subwells and the screen well. 
 
In total, 24 MDMX or MDM2-inhibitor complexes were subjected to crystallisation trials using 
three commercial screens for MDMX and two screens for MDM2. Overall, around 14,000 
different conditions were used for co-crystallisation trials of MDMX and MDM2 with pyrrole-
based inhibitors. 
 
8.4 Co-Crystallisation of MDM2 and MDMX with Autoinhibitory domains 
It was reported recently that MDMX contains an autoinhibitory sequence which interferes with 
its binding to p53.108-109 The autoinhibitory sequence is a tryptophan-rich segment within 
residues 190-210 of MDMX (190FEEWDVAGLPWWFLGNLRSNY210). The tandem 
tryptophan residues at positions 200 and 201 have been called the WW element. Bista et al 
(2013) performed isothermal titration calorimetry (ITC) experiments to measure the binding 
affinity (Kd) of MDMX with p53 in the presence or absence of the autoinhibitory sequence.
108 
Full length MDMX (1-340) with an autoinhibitory sequence bound to p53 with a measured Kd 
of 2700 nM. MDMX (1-111) without the autoinhibitory sequence was 100-fold more tightly 
bound to p53 (Kd = 30.3 nM). MDMX without residues 193-210 had binding affinity of 92.6 
nM with p53 (Table 8.4).  
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Table 8.4: Binding of different MDMX sequences to the transactivation domain of p53. The 
p53 transactivation domain is defined as residues 17-32.108 
Protein Kd (nM) 
MDMX 1-340 2700 ± 531 
MDMX 1-111 30.3 ± 3.9 
MDMX Δ193-210* 92.6 ± 11.7 
MDMX W200D/201D 385 ± 43.5 
*Residues 193-210 deleted. 
 
Based on these findings reported by Bista et al (2013), it was hypothesised that the 
autoinhibitory sequence could stabilise MDMX and help in its crystallisation. Three 
autoinhibitory sequences (AID1, AID2 and AID3,Table 8.5) of different lengths were kindly 
supplied by Astex pharmaceuticals. All three autoinhibitory sequences contain the WW element 
which was reported as the most essential sequence for binding to the N-terminal domain of 
MDMX. 
Co-crystallisation trials of AID with MDMX were set up using the JCSG+ and AmSO4 screens 
(Table 8.5). Precipitation was observed when AID1 was incubated with MDMX construct 3. 
Similarly, AID3 showed precipitation with constructs 1 and 2. 
 
Table 8.5: MDMX-AID co-crystallisation. Protein-autoinhibitory domain concentration for 
co-crystallisation trials. 
Autoinhibitory 
Domain 
Sequence 
MDMX-Peptide 
concentration (mg/ml) 
MDMX constructs 
1 2 3 
AID1 FEEWDVAGLPWWFLGN 17.7 20.2 - 
AID2 GLPWWFL 15 15 6 
AID3 FEEWDVAGLPWWFLGNLRSNY - 16 - 
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The images generated by the Rikagu Minstrel tray hotel were reviewed at irregular intervals for 
8 weeks. Unfortunately, from more than 15,000 different conditions, crystal formation was not 
observed. In most of the cases, precipitation of the protein-inhibitor complex was observed 
(Figure 8.7A). In one case, a more promising precipitation was found (Figure 8.7B). 
A B 
  
Figure 8.7: MDMX crystallisation trials. Images taken by the Rikagu Minstrel tray hotel. (A) 
MDMX C1 + 67, (B) MDMX C2 + 81.                   
 
Based on the most promising leads from the initial screen, an optimisation screen was prepared 
by altering the concentration of the Li2SO4 (0-0.3 M), PEG400 (30-100%), sodium acetate (0.1 
M) and pH (4-5.5) of the final solution. The five pyrrole-based inhibitors, AID1 and AID2 were 
used for co-crystallisation trials with MDMX constructs 1, 2 and 3 using this optimised screen. 
However, crystal formation was not observed after 6 weeks of monitoring. 
8.5 Development of Homogenous Time-Resolved FRET assay 
RO-2443 3 and RO-5963 4 are reported as dual inhibitors of MDM2 and MDMX with low 
nanomolar IC50 values against both MDM2 and MDMX.
71 However, the IC50 values generated 
using the in-house ELISA were around 500-1000 fold less than the reported IC50 values (Table 
8.6). To investigate the discrepancies in IC50 values between Roche’s homogenous time-
resolved FRET (HTRF) assay and the NCL-ELISA assay, an HTRF assay was developed. 
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Table 8.6: IC50 values of RO-2443 3 and RO-5963 4 obtained from ELISA assay and 
published HTRF values. 
Inhibitors 
Roche’s HTRF assay Newcastle ELISA assay 
MDM2 IC50  
(µM) 
MDMX IC50  
(µM) 
MDM2 IC50  
(µM) 
MDMX IC50  
(µM) 
RO-2443 0.033 0.041 6.9 13.7 
RO-5963 0.019 0.024 16 26 
 
The HTRF (Homogenous Time Resolved Fluorescence) assay relies on the Fluorescence 
Resonance Energy Transfer (FRET) from an excited donor molecule to an acceptor 
molecule.110-111 The donor molecule absorbs energy and transfers it to an acceptor. FRET 
efficiency (E) is inversely proportional to the sixth power of the distance between the donor 
and acceptor as shown in the equation below.112 E is the FRET efficiency, Ro is the Förster 
distance at which half of the energy is transferred and r is the actual distance between the donor 
and acceptor. When the donor and acceptor are not in close proximity, the FRET efficiency is 
reduced (Figure 8.8). 
E =
𝑅0
6
𝑅0
6 + r6
 
HTRF is a time resolved FRET in that there is a time delay of 50-150 µs between the excitation 
of the donor and measurement of the FRET signal.111 This time delay prevents measurement of 
any short-lived fluorescence which would otherwise interfere with measurement of the 
authentic signal. 
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Figure 8.8: Principle of FRET (Fluorescence Resonance Energy Transfer).111 
 
In the HTRF assay established at Newcastle for measuring the potency of MDMX-p53 
interaction inhibitors, GST-tagged MDMX (residues 22-111) was mixed with fluorescein-
labelled IP3 peptide (Ac-16-MPRFMDYWQGLN-27-NH2). IP3 peptide is a mutant form of 
p53 with high affinity for MDM2/MDMX.113 The fluorescein label on IP3 acts as an acceptor. 
A terbium-labelled anti-GST antibody which binds to GST-tagged MDMX was added to the 
mixture.  The terbium label acts as a donor. Upon excitation, there is a transfer of FRET from 
donor to acceptor which can be measured (Figure 8.9A).  
In the absence of an inhibitor, the donor (terbium) and the acceptor (fluorescein) are in close 
proximity. The donor terbium absorbs energy and transfers it to fluorescein. The transfer of 
energy is measured as a FRET signal. In the presence of an inhibitor, the donor and acceptor 
are separated which results in a decrease in the amount of FRET (Figure 8.9B). 
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Figure 8.9: Schematic representation of MDMX-FRET assay. (A) Without inhibitor, (B) 
With inhibitor. 
 
The ELISA was performed by Dr Yan Zhao. In the assay, biotinylated IP3 peptide was bound 
to streptavidin coated plate (Figure 8.10). MDM2 and MDMX were incubated with the 
compound being tested and added to the plate containing IP3 peptide. Then a primary mouse 
antibody that binds to MDM2 or MDMX was added. Subsequently, a secondary goat-antimouse 
antibody, conjugated to horseradish peroxidase (HRP) was bound to the primary antibody. The 
plate was analysed using a luminometer to detect signals from HRP (see chapter 16.2.1 for 
details). The data obtained from the luminometer were analysed and the IC50 values derived. 
 
There were key differences between the protocols of the ELISA and HTRF assays. The major 
difference is the length of MDMX used, and it is believed to be the major cause of discrepancies 
between the IC50s obtained from ELISA and HTRF assays. In the ELISA, full length MDMX 
was used, whereas, in the HTRF assay, the MDMX construct (residues 22-111) was used. The 
full length MDMX contains an autoinhibitory domain (described in section 8.3), which binds 
on the p53 binding domain of MDMX, thus, preventing the binding of p53 to MDMX. The 
MDMX construct used in the HTRF assay did not contain the autoinhibitory domain. The use 
of full length MDMX in HTRF assay development would require the optimisation of expression 
and purification of the desired protein, therefore, it was outside the scope of the structural 
biology placement undertaken. However, other differences in the assay protocols like the 
incubation order and times, different buffers were addressed during the HTRF assay 
development (described later in this chapter). 
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Figure 8.10: Schematic representation of ELISA. 
 
The HTRF assay development was done by Dr Judith Reeks. In a typical HTRF experiment, 
the transfer of FRET signals were measured with the decreasing concentration of inhibitors. 
The maximum value (positive control) was obtained when p53 and MDMX formed a complex 
in the absence of inhibitors. The minimum value (negative control) was obtained in the absence 
of both MDMX and inhibitor. The values were converted to % inhibition using the formula 
given below and plotted against the concentration of the inhibitor to get a dose-response curve 
and IC50 value. 
% Inhibition  =
FRET(Average of positive control) − FRET (inhibitor)
FRET(Average of positive control) − FRET(Average of negative control)
× 100 
 
 The assay had provided reasonable dose-response curves with stapled peptides and published 
small-molecule inhibitors, although the IC50 values obtained from the assay were not consistent 
(Figure 8.11A).114 RO-5963 showed greater than 50% inhibition at the lowest concentration 
used in the assay. However, the other Roche compound, RO-2443 was significantly less potent 
in our HTRF assay compared to the published data. The IC50 values from the assay were not 
reproducible, therefore, the data should not be over-interpreted. However, the discrepancies in 
the data may be due to the different constructs of MDMX used, but the construct of MDMX 
used in the assay was not disclosed by Roche. The investigation on the discrepancies observed, 
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and the development of other assay formats is currently ongoing. In favour of the assay, the 
signal to noise ratio of the assay was 25 and Z’ of the assay was 0.61. The published inhibitors 
showed dose-response relationships, and the error bars were low. However, when the Newcastle 
small molecule inhibitors were tested in this assay, the measurements had associated high error 
bars (Figure 8.11B). Following assay optimisation, the final assay concentrations were MDMX- 
3nM, IP3 peptide-125 nM, 1 nM Tb-antibody and DMSO-2%.  
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Figure 8.11: MDM2/X inhibitor evaluation by HTRF. HTRF assay results for (A) RO-2443 3, 
WK-298 22, and stapled peptides YSO1 and YSO2115, (B) Newcastle inhibitors. The assay was 
done in duplicates shown by the error bars. 
 
The assay protocol required the inhibitor samples (provided in DMSO) to be diluted into assay 
buffer so that the final concentration of DMSO was 2%. Precipitation was observed with most 
of the Newcastle inhibitors when the DMSO solution of the inhibitors were added to the assay 
buffer. This resulted in high error bars and inhibition could not be observed with any Newcastle 
inhibitors.     
 
In order to decrease precipitation of the inhibitors, the DMSO concentration was increased to 
5%. However, this increase in the concentration of DMSO, decreased the Z’ and signal to noise 
(S/N) ratio. Therefore, the assay had to be redeveloped to improve the Z’ and S/N ratio. Initially, 
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MDMX at a range of concentrations was titrated against various concentrations of IP3 peptide 
to identify conditions that yielded a robust FRET readout at the lowest concentration of 
MDMX. The lowest concentration of MDMX and p53 after which the curve starts to flatten 
was chosen. Thus MDMX concentration was selected to be 10 nM as shown in Figure 8.12. 
The concentration of IP3 peptide was selected to be 300 nM as it was the rough average of the 
Kd values obtained.  
A 
 
B 
 
Figure 8.12: Titration of IP3 against different concentration of MDMX.114 (A), Graph showing 
the FRET values at different concentration of IP3 and MDMX, (B) Table associated with the 
figure A. 
 
To determine the optimal concentration of Tb antibody, the S/N ratio was determined at various 
antibody concentrations with decreasing concentration of MDMX (Figure 8.13). At around 10 
nM MDMX, 10 nM antibody provided maximum S/N ratio. Therefore the final concentration 
of the Tb antibody was selected to be 10 nM.  
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Figure 8.13: Signal to noise ratio at different concentrations of Tb antibody and MDMX.114 
 
Based on these results, the final assay condition was changed to 10 nM MDMX, 300 nM IP3 
peptide, 5% DMSO in buffer A. After 1 h incubation of MDMX, IP3 and inhibitor, the terbium-
labelled antibody was added to a final concentration of 10 nM and the final assay volume was 
brought to 20 µl. This new protocol provided good reproducible Z’ values (0.5-0.7) and two 
inhibitors showed measurable inhibition (Figure 8.14). 
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A 
 
B 
 
Figure 8.14: HTRF results for Newcastle small molecule inhibitors. (A) Compounds without 
any significant inhibition (B) Compounds that show inhibition. 
 
The assay was repeated again with selected Newcastle inhibitors with low logD values (Table 
8.7). The compounds with low logD values showed dose-response curves. The lipophilic 
compound 305 which was the most potent isoindolinone inhibitor of MDMX-p53 interaction 
in the ELISA showed no measurable inhibition in the HTRF assay (Figure 8.15). 
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Table 8.7: List of Newcastle inhibitors with their logD values and MDMX ELISA IC50 
values. 
Compounds Structures LogD 
MDMX  IC50 
(µM) 
302 
 
2.7 29 
64 
 
1.7 13 
303 
 
1.9 110 
304 
 
2.5 
50% inhibition @ 
200 
84 
 
305 
 
6.1 6 
306 
 
2.1 Not tested 
307 
 
2.6 67 
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Figure 8.15: HTRF results for Newcastle small molecule inhibitors. 
 
Although, hydrophilic compounds provided reasonable dose-response curves, the results were 
not reproducible and the derived IC50 values did not agree with the ELISA values. There were 
some major differences between the protocols of the ELISA and HTRF assay which are 
tabulated in Table 8.8. 
 
Table 8.8: Protocol differences between the MDMX ELISA and HTRF assays. 
S. No. ELISA HTRF 
1. PBS buffer was used. Tris buffer was used. 
2. 
Inhibitors were incubated with MDMX 
for 45 min, then, p53 peptide was 
added. 
Inhibitors, MDMX and p53 peptide were 
added to the final reaction plate and 
incubated for 1 h. 
3. 
4. 
Full length MDMX was used. 
Proteins are immobilised. 
MDMX construct was used. 
Proteins are in solution. 
 
 
Following this comparative analysis, the buffer was changed to PBS and the incubation 
sequence was changed in the HTRF assay to make the two assay protocols similar. However, 
these changes did not improve the HTRF assay results (Figure 8.16). 
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Figure 8.16: HTRF assay of Newcastle small molecule inhibitors. (A) With Tris buffer, (B) 
with PBS buffer. For both conditions, the order of addition of reagents was similar to that used 
in the ELISA as described in the 2nd point of Table 8.8. 
 
The HTRF assay provided reasonable dose-response curves, with low error bars for literature 
inhibitors and peptides, but the IC50 values were inconsistent. Most of the Newcastle inhibitors 
did not return a measurable IC50 from the HTRF assay. Newcastle inhibitors provided high error 
bars and the results were not reproducible. The discrepancies in IC50 values obtained from the 
ELISA and HTRF assay may be because of the different constructs of MDMX used. The 
discrepancies in the IC50 values obtained for RO-2443 in the published HTRF assay and our 
HTRF assay might also be due to the difference in the length of MDMX used, but the MDMX 
construct was not disclosed by Roche. Further investigations on the different assay formats are 
ongoing. In order to get a good comparison between ELISA and HTRF assays, full length 
MDMX should be used in the HTRF assay. In addition, a label free assay such as Isothermal 
titration calorimetry (ITC) should be considered as an orthogonal assay. ITC does not rely on 
the fluorescence and depends on the change in enthalpy produced after the binding of the two 
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protein partners. Therefore, an assay with a different principle such as ITC might be beneficial 
to compare with the results obtained from ELISA and HTRF.  
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Chapter 9. Introduction to ATAD2 and Reported Small-Molecule 
Inhibitors 
9.1 Introduction to Epigenetics 
Every cells in an organism inherits the same genetic material, yet form structurally different 
tissues and organs with unique biological functions. This is due to the differences in the 
heritable epigenetic modifications, which include DNA methylation, histone modification and 
nucleosome positioning but do not include changes in the DNA sequence.116-118  
To understand the role of epigenetic modifications in producing different phenotypes, and its 
disease linkage, it is important to understand the architecture of chromatin formed by DNA and 
several proteins, most importantly, histones. 
 
9.1.1 Chromatin Architecture 
The diploid human genome contains approximately 6 billion base pairs of DNA packaged into 
23 pairs of chromosomes per cell.119-120 Each base pair is around 0.34 × 10-9 metre long, 
therefore, each diploid cell contains approximately 2 meters of DNA ((0.34× 10-9) × (6× 
109)).119 The histone proteins play an important role in the packaging of 2 meters of DNA into 
a small volume of cell nucleus. The dimers of four histone proteins H2A, H2B, H3 and H4 form 
an octamer which wraps approximately 147 base pairs of DNA to form nucleosomes which are 
the basic subunit of chromatin.121-123 
Nucleosomes are connected by short DNA segments known as ‘linker DNA’. The linker DNA 
is either naked or bound to histone protein H1.123 The nucleosomes assemble to form chromatin 
fibres, which are further packaged to form chromosomes (Figure 9.1).120-121 
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Figure 9.1: Packaging of DNA (adapted from Marx et al).124 
 
9.1.2 Post-Translational Modifications of Histones 
The histone proteins undergo several post translational modifications which affect DNA centred 
processes, including DNA transcription, replication and repair as well as genomic 
architecture.125 The histone post-translational modifications also known as ‘histone marks’ are 
regulated by three groups of proteins known as writers, erasers and readers (Figure 9.3).118, 126-
127 
Although, there are several post-translational modifications of histones including 
phosphorylation and ubiquitylation, the most important and the most widely studied are 
acetylation and methylation. 
 
9.1.2.1 Histone Acetylation 
Histone acetyltransferases (HATs) are the writer proteins responsible for the acetylation of 
histones. Acetylation takes place at the amino group of the lysine side chain of the histone tail 
(Figure 9.2).128-129 Acetylation neutralises the positive charge on lysine reducing the affinity of 
the histone tail for DNA, resulting in a relaxed chromatin architecture.129 Acetylation of 
histones has several effects depending on the site of acetylation. For example, acetylation of 
90 
 
H4K5 (means Histone H4, Lysine-5) and H4K12 are important for chaperone recognition 
during the formation of nucleosome core.118 Acetylation of H3K56 occurs on the histone within 
the nucleosome core and affects the interaction between histones and DNA.118, 130 
 
L-Lysine ɛ-N-acetylated lysine 
Figure 9.2: Neutralisation of the positive charge on lysine due to acetylation. 
 
Histone deacetylases (HDACs) are the eraser proteins that help to remove the acetylation mark 
from the lysine residues of histones. HDACs are well-studied targets in the field of drug 
discovery and several clinically successful inhibitors of HDACs are reported to date (Table 
9.1).131-133 
Table 9.1: Selected inhibitors of HDAC and their clinical status.133 
 
Drugs Status 
Vorinostat Approved by FDA in 2006 
Romidepsin Approved by FDA in 2009 
Panobinostat Approved by FDA in 2015 
Entinostat Phase III 
Mocetinostat Phase II 
Pracinostat Phase III 
Ricolinostat Phase II 
Resminostat Phase II 
 
9.1.2.2 Histone Methylation 
There are different types of S-adenosylmethionine (SAM)-dependent methyl transferases that 
write one, two or three methyl marks mostly on the side chains of lysine and arginine residues 
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of histones.118 Methylation on glutamine and histidine residues of histones have also been 
reported.134-135 Unlike acetylation marks, methylation does not neutralise the charge on the 
positively charged amino acids in histones. Therefore, methylation of histones does not directly 
impact on the chromatin architecture, instead, the methyl marks are recognised by several other 
proteins.136-138 
 
Figure 9.3: Representation of post-translational histone modifications.126 
 
9.2 Bromodomains 
The post-translational modifications (PTMs) of histones are recognised and regulated by the 
reader proteins.126 To date, several classes of readers have been identified with conserved 
domains that detect the modifications on histone.118, 127, 139 
One of the most important class of readers are bromodomains, which were first identified in the 
brahma gene of Drosophila melanogaster and named after it.140 Bromodomains are the class 
of evolutionary conserved protein interaction modules which recognise the ɛ-N-acetylated 
lysines.126 A total of 61 bromodomains in 46 diverse proteins have been identified in the human 
proteome. They are divided into eight structural classes (Figure 9.4).126, 141 Proteins containing 
bromodomains have been implicated in cancer, inflammation and viral diseases which make 
them one of the most studied targets currently in drug discovery.126, 142-145 
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Figure 9.4: Structure based classification of bromodomains. The eight different classes are 
represented by Roman numerals.126 
 
Bromodomains contain an acetylated lysine binding site in a conserved fold containing four α 
helices (αZ, αA, αB, αC) and two loop regions ZA and BC loops (Figure 9.5). Structural studies 
with peptides have demonstrated that the acetylated lysine residue lies in the deep hydrophobic 
pocket where it forms hydrogen bond interactions with the conserved asparagine residue. In 
addition, there are several conserved water molecules which take part in the network of 
interactions with the acetylated histone.141, 146 
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Figure 9.5: X-ray crystal structure of the first bromodomain of human BRD4 in complex with 
a diacetylated histone 4 peptide (PDB: 3UVW). (A) Helices and loops are highlighted by 
different colour codes. (B) The charged nature of the surface lining the KAc binding site is also 
coloured using electrostatic module ranging from -10 to +10 kT/e.126 
 
9.3 Bromodomain Inhibitors 
9.3.1 BET-Bromodomain Inhibitors 
To date, different classes of bromodomain inhibitors have been identified. The BET family in 
the subfamily II of the structure-based tree (Figure 9.4) is one of the most studied classes of 
bromodomains with several known potent small molecule inhibitors.127, 147 BET family 
comprises of BRD2, BRD3, BRD4 and the testes specific BRDT. BET proteins contain two 
bromodomains and an extra terminal region.141 
Although, few bromodomain inhibitors were reported in the literature,148 it was in 2010 that 
two potent and selective inhibitors of BET bromodomains (+)-JQ1 (120)149 and I-BET762 
(121)150 were disclosed, and provided the proof-of-principle that bromodomains can be 
selectively inhibited by small molecules. This sparked the field and led to the development of 
several potent and selective bromodomain inhibitors.126, 147, 151 
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(+)-JQ1 120 is the most widely studied bromodomain inhibitor which results in 179 hits in the 
scopus search field.152 The compound was developed by Filippakopoulos et al. after successful 
optimisation of a benzodiazepine core based on the several patents disclosed between 1998 and 
2006.149, 153-154 The compound was selective for BET bromodomains over other classes of 
bromodomains when studied against a panel of 46 human bromodomains.149 The first in vivo 
study that demonstrated the effect of bromodomain small-molecule inhibitors in cancer therapy 
was done with (+)-JQ1 on a mouse xenograft with NUT (Nuclear Protein in Testis) midline 
carcinoma. At minimal toxicity dose, the compound showed reduction in tumour volume and 
promoted survival (Figure 9.6).149 Similarly, other studies with different BET bromodomain 
inhibitors have shown reduction in tumour volumes in various mouse models of tumours 
including acute myeloid leukaemia, gliobastoma, melanoma and prostate cancer.155-159 
 
A 
 
B 
 
Figure 9.6: (+)-JQ1 (red line, 50 mg kg-1, daily) on NUT midline carcinoma xenograft model 
produces (A) decrease in tumour volume, (B) prolonged survival. Vehicle is shown by black 
line.149 
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9.3.2 Non-BET bromodomain Inhibitors 
After successful development of several small-molecule inhibitors of the BET bromodomains, 
drug discovery efforts were shifted towards the development of bromodomains outside the BET 
family. Structural Genomics Consortium (SGC) are aiming to develop a selective inhibitor for 
each bromodomain.160 Bromosporine 122 was developed at SGC and is a pan-bromodomain 
inhibitor that inhibits various bromodomains, including BRD2(1), BRD3(1), BRD4(1), 
BRDT(1), CECR2, TAF1(2), BRD9, and CREBBP.161 The compound can be used as a 
chemical tool for identifying the biological role of the bromodomains for which selective 
inhibitor have not been developed.   
Various selective small molecule inhibitors of non-BET bromodomains have been reported. 
SGC-CBP30 (123) for CREBBP, GSK2801 (124) for BAZ2A/B, PFI-3 (125) for SMARCA4 
and PB1 are few examples of the selective non-BET bromodomain inhibitors.162-164 
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9.4 ATAD2 and its Role in Cancer 
ATAD2 contains a double AAA+ ATPase domain165 and a bromodomain. It is also known as 
ANCAA166-169 (AAA nuclear co-regulator cancer-associated protein), and belongs to subfamily 
IV in the structure-based classification of bromodomains (Figure 9.4). ATAD2 is overexpressed 
in a wide range of human cancers including breast, lung,  prostate, ovarian, liver, osteosarcoma 
and gastrointestinal carcinomas, and it is present in low levels in normal non-tumour cells.167, 
170-171 ATAD2 was overexpressed in 23% of 172 tumour specimens analysed by Ciró et al 
(Table 9.2).171 In a separate study by Kalashnikova et al, ATAD2 was shown to be 
overexpressed in around 70% of breast tumours.166  
Table 9.2: ATAD2 expression in primary tumours.171 
Tumour No. of Samples 
Highly expressed, 
n (%) 
Breast carcinoma 25 9 (36) 
Colon carcinoma 27 10 (37) 
Lung carcinoma 22 5 (23) 
Prostate carcinoma 24 0 (0) 
Stomach carcinoma 21 9 (43) 
Uterus carcinoma 20 4 (20) 
Lymphoma 12 2 (17) 
Melanoma 11 0 (0) 
Sarcoma 10 1 (10) 
Total 172 40 (23) 
 
 
ATAD2 acts as a coactivator of various transcription factors including androgen receptor (AR), 
estrogen receptor (ER) and MYC. ATAD2 is crucial for the transcription of various androgen 
genes in prostate cancer.167 Zou et al. showed that suppression of ATAD2 expression using 
ATAD2-RNAi inhibited the proliferation of androgen-dependent and androgen-independent or 
hormone refractory prostate cells (Figure 9.7).167  
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Figure 9.7: Suppression of ATAD2 expression in (A) androgen-dependent LNCaP cell lines 
(B) androgen-independent cell lines LNCaP-C4-2B, and (C) CW22Rv1. Cells were plated in 
hormone-deprived medium for 24 h before being infected with adeno-RNAi-ANCCA 
(ATAD2-RNAi) or adeno-RNAi-GFP control, or mock-infected (for LNCaP, also act as a 
control).167 
 
Similarly, ATAD2 is also a co-activator of estrogen receptor (ER), thus it is highly expressed 
in breast cancer.168 ATAD2 is an important cofactor for MYC-dependent transcription. MYC 
is a critical regulator of cell proliferation, therefore, enhancement of MYC transcriptional 
activity by ATAD2 contributes to the development of many human cancers.171-172 Various 
knock-down studies using siRNA and shRNA technologies have confirmed the role of ATAD2 
in apoptosis, cell growth and proliferation in several cancer cell lines.170, 172 Altogether, these 
studies suggest that ATAD2 is an important target for cancer drug discovery, and a small-
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molecule inhibitor would provide an insight on the phenotypic response to the inhibition of 
ATAD2. 
 
9.5 Structure and Druggability of ATAD2 Bromodomain 
Similar to other bromodomain structures, ATAD2 has four left-handed helices (αZ, αA, αB, αC) 
and two loops (ZA and BC). The acetyllysine binding pocket is created by two helices (αB, αC), 
and ZA loop. The amino acids involved in the binding site are Val1008, Val1013, Val1018, 
Tyr1063 and Ile1074 (Figure 9.8A). 
 
A 
 
B 
 
Figure 9.8: (A) Crystal structure of ATAD2 in apo form (PDB: 3DAI). The Asn1064 is 
evolutionarily conserved and is important for the histone recognition. The other highlighted 
amino acid residues form the acetyllysine binding pocket. (B) Acetyllysine binding surface of 
ATAD2 bound to H4K5ac (4QUU). The secondary structure of ATAD2 is coloured in blue. 
The acetyllysine binding surface of ATAD2 is coloured in green. The amino acid residues are 
coloured based on atoms; carbon: grey, oxygen: red, nitrogen: blue. 
 
The crystal structure of ATAD2 bound to acetyllysine (PDB: 4QSP) shows the key hydrogen 
bond interaction that anchors the acetyllysine in the binding site (Figure 9.9).169 The oxygen 
atom of the acetyl group forms two key hydrogen bond interactions, one with the Asn1064 and 
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the other with Tyr1021 via a water molecule. ATAD2, like other bromodomains, contains 
conserved water molecules which are important in the binding of acetyllysine.141, 169, 173 
 
 
Figure 9.9: Interactions of ATAD2 with acetyllysine (PDB: 4QSP).169 A bound ethylene 
glycol molecule (highlighted in cyan), water molecules (in pink spheres), Acetyllysine 
(carbons: yellow, oxygen: red, nitrogen: blue) are shown.  
 
ATAD2 has some flexibility in its loops. Poncet-Montage et al studied the flexibility of ATAD2 
using different conditions for crystallising ATAD2 in its apo form.173 They obtained four crystal 
structures of apo-ATAD2 and compared with the published structures (PDB: 3DAI and 4QUU). 
Superimposition of the six structures demonstrates the flexibility in the ZA loop and the BC 
loop (Figure 9.10).  
 
Figure 9.10: Superimposition of the 6 crystal structures of ATAD2. Red, yellow and green 
ZA loop represents the ATAD2 states from wide-open to closed state, respectively.173 
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The acetyllysine binding site of ATAD2 is polar and shallow compared to several other 
bromodomains.169 In Figure 9.11, the acetyllysine binding pocket of the bromodomain of 
ATAD2 is compared with the bromodomain of BRD4. The ZA loop of ATAD2 which forms 
a major part of the binding site is polar, whereas, the binding site in BRD4 is mostly 
hydrophobic.  
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A 
 
 
B 
 
Figure 9.11: Comparision of the acetyllysine binding pocket of (A) ATAD2 (PDB: 4QUU) 
and, (B) BRD4 (PDB: 3UVW). The solvent accessible surface (probe radius 1.4) was 
coloured based on the charge; blue for positive charge and red for negative charge.   
 
Altogether, due to the flexibility of the ZA loop, as well as, the shallow and polar nature of the 
binding site, ATAD2 bromodomain was grouped in the list of low-druggable bromodomains.169, 
174 However, very recently a low nanomolar inhibitor of ATAD2 was reported by Bamborough 
et al. which is discussed in detail later in this chapter.175 
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9.6 Reported ATAD2 Bromodomain Inhibitors 
9.6.1 Fragments Targeting ATAD2 Bromodomains 
In 2014, Chaikuad et al used fragment based approach to identify thymine analogues (126-130) 
as a chemical starting point for the development of more potent inhibitors of ATAD2 
bromodomain-acetylated histone interaction.169 The optimisation of those fragments was 
reported as an on-going activity, and the results have not been published yet. Initial attempts to 
screen a library of acetyllysine mimetics using high-throughput screening methods revealed no 
potent hits. Therefore, co-crystallisation and NMR chemical shift perturbation experiments 
were used to identify the fragments. The binding affinities of the fragments were determined 
by the NMR chemical shift perturbation experiments where the chemical shifts of 13C-methyl-
labelled ATAD2 was monitored. The fragments showed low millimolar binding affinities for 
ATAD2 bromodomain. As reported with apo-ATAD2,173 the flexibility of the ZA loop was also 
observed in the presence of thymine based ligands.169  
 
 
 
Co-crystal structures of different thymine-based fragments bound to ATAD2 showed that the 
thymine ring formed the canonical acetyllysine mimetic H-bond with Asn1064 and the water 
mediated H-bond with Tyr1021 (Figure 9.12). 
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Figure 9.12: Crystal structure of ATAD2 bromodomain in complex with thymine 
(represented by yellow stick model).169 
Simultaneously, Harner et al. (2014) reported the results of a fragment-based screen using NMR 
against ATAD2 bromodomain.176 A total of 65 hits were identified against ATAD2 
bromodomain which were clustered into three chemical groups (Table 9.3). Cluster 1 contained 
the fragments with 5,6 and 6,6-fused ring systems that have been previously identified as 
acetyllysine mimetics. Cluster 2 contained fragments unique to ATAD2 bromodomains with 
tricyclic chemotypes. Cluster 3 also contained unique fragments with sulfur containing 
chemotypes.  
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Table 9.3: Representative ATAD2 bromodomain fragment hits identified by Harner et al.176 
Cluster 1 
Kd 
(µM) 
Cluster 2 
Kd 
(µM) 
Cluster 3 
Kd 
(µM) 
 
131 
600 
135 
350 
 
 
139 
400 
 
132 
600 
 
136 
400 
140 
450 
133 
650 
 
137 
450 
 
141 
500 
 
 
134 
650 
 
138 
600 
142 
500 
 
Three fragments from different clusters were used for co-crystallisation studies. Out of the three 
fragment, two of them displaced conserved water molecules from the KAc binding site. 
Fragment 135 displaces four conserved water molecules which may account for the higher 
binding affinity. Fragment 142 displaces one conserved water molecule and the position of the 
water is occupied by an amine substituent (Figure 9.13). 
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Figure 9.13: View of Kac binding site in presence of (A) fragment 131, (B) fragment 135, (C) 
fragment 142. Fragment 131 does not displace any conserved waters, whereas, fragment 135 
displaces four and fragment 142 displaces one conserved water.176 PDB: 4TYL, 4TZ2, and 
4TZ8, respectively. 
 
Poncet-Montage et al (2015) reported two isoxazole based compounds 143 and 144 as 
ATAD2 bromodomain binders.173 The compounds were identified from X-ray crystallography 
screen of fragments and known acetyllysine mimetic chemical scaffolds.  
None of these compounds were potent enough to be used as a chemical tool to study the 
implications ATAD2 bromodomain inhibition in cells. 
 
IC50 = 96 µM IC50 = 422 µM 
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9.6.2 Naphthyridone Series 
The first, and the only potent and selective small molecule inhibitor of the ATAD2 
bromodomain reported to date was developed very recently.175, 177 The small molecule inhibitor 
development started from a quinolone fragment 145 inspired from the dihydroquinazoline 
fragments known to bind the BET bromodomains, as seen in inhibitor PFI-1 146 and its 
quinolin-2-one analogue 147.177 
 
A crystal structure of fragment 145 bound to ATAD2 revealed that the carbonyl group mimics 
the acetyllysine binding mode. The carbonyl oxygen forms H-bond with Asn1064 and a water 
mediated H-bond with Tyr1021. The N-H forms an additional H-bond with the Asn1064. The 
methyl group points in the same pocket as occupied by the methyl group of the acetyllysine 
(Figure 9.14).  
 
Figure 9.14: Overlay of the crystal structures of ATAD2 bromodomain bound to capped 
acetylated lysine (grey, PDB: 5a5n) and fragment 145 (magenta, PDB: 5a5o). 
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A focussed set of compounds based on quinolinone core were screened against ATAD2 
bromodomain using time-resolved fluorescence resonance energy transfer (TR-FRET) assay. 
Compound 148 was considered as a ligand efficient starting point (LE = 0.3), and SAR studies 
at the C5-position resulted in the identification of a low micromolar inhibitor (149, ATAD2 
IC50 = 1.3 µM, Figure 9.15). Although, the compounds were the most potent inhibitors reported 
to date, they were not selective for ATAD2 over other BET bromodomains.177 
 
 ATAD2 IC50 = 100 µM ATAD2 IC50 = 1.3 µM 
 
Figure 9.15: Development of the first low-micromolar inhibitor of ATAD2.177 
 
To improve the selectivity and potency of the inhibitor 149, the RVF shelf of ATAD2 was 
targeted (Figure 9.16B).175 The RVF shelf is formed by three amino acids Arg1007, Val1008 
and Phe1009. It is in the same area as the WPF shelf (formed by Trp-Pro-Phe) in BET 
bromodomains. The WPF shelf has been exploited by potent BET inhibitors including (+)-JQ1 
as well as I-BET762 (Figure 9.16A). RVF shelf in ATAD2 bromodomain is shallow and polar 
compared to the WPF shelf in BET bromodomains which was used as an advantage to get 
selectivity over BET bromodomains. 
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Figure 9.16: (A) BRD4 BD1 in complex to I-BET762 (PDB: 3p5o); (B) ATAD2 
bromodomain in complex to a quinolone compound (PDB: 5a5q). The detailed interactions 
are on the left and protein surface coloured based on electrostatic charge on the right. A 
purple arrow head on (B) denotes the area of SAR investigation.175 
 
SAR studies at the 3’-position of the piperidine ring with the aim to target the RVF shelf gave 
compound 150 with desired potency and >100-fold selectivity for ATAD2 over other BET 
bromodomains (Figure 9.17). However, the compound was very hydrophilic with low cell-
permeability. Attempts to increase cell permeability by reducing the polar surface area and the 
number of H-bond acceptors and donors resulted in reduced potency and selectivity. As 
described by Bamborough et al, the further optimisation of the series to obtain a cell permeable, 
potent and selective ATAD2 small molecule inhibitor is underway and will be published in the 
near future.175 
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ATAD2 pIC50 (TR-FRET)  6.9 
BRD2-4 BD1/2 pIC50 (TR-FRET) 4.3-5.3 
Chemiluminescent nitrogen detection (CLND) solubility (µM) 179 
Artificial membrane permeability (nm/s, pH 7.4) <3 
 
Figure 9.17: Summary of properties of compound 150.175 
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Chapter 10. Development of ATAD2 Inhibitors: SAR strategies 
10.1  Fragment hits 
Seventeen fragment hits bound in the acetyllysine binding site of ATAD2, were identified at 
Astex Pharmaceuticals by X-ray crystallographic focused screening. The fragments were 
clustered into five different classes based on their structures (Figure 10.1). 
Cluster 1 (NMP-like) 
 
Cluster 2 (Triazoles) 
 
 
Cluster 3 (Acetamides) 
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Cluster 4 (Isoxazoles) 
 
Cluster 5 (Others) 
 
 
Figure 10.1: Structure-based classification of fragment hits identified at Astex 
Pharmaceuticals. 
 
The initial strategy was to grow the fragments with subtle modifications including addition of 
alkyl or aryl groups in the lipophilic region of the binding surface, or adding H-bond donors or 
acceptors near the polar region of the binding surface. The work described in this thesis includes 
the SAR studies around four fragments 5, 157, 158 and 160.   
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10.2 Preliminary SARs around Fragment 157, 158 and 160 
10.2.1 Rationale 
The crystal structure of ATAD2 in complex with fragment 158 revealed that the amide group 
mimics the acetyllysine binding mode (Figure 10.2). The oxygen atom of the amide group forms 
H-bond with Asn1064 and a water mediated H-bond with Tyr1021.  
 
Figure 10.2: Crystal structure of fragment 158 (carbons: grey) bound to ATAD2. The binding 
surface is coloured based on the charge, positive: blue and negative: red. The ZA-shelf is shown 
by dark pink coloured circle. The pink arrow denotes the area of potential SAR investigation.  
 
A shelf around the ZA loop (hereafter referred to as ZA-shelf) was identified from the crystal 
structure (Figure 10.2). Small alkyl substituents at the 3-position of fragment 158 were selected 
to exploit the ZA-shelf (Figure 10.3). 
 
Figure 10.3: 3-Substituted benzamides to be synthesised. 
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Similarly, the crystal structure of fragment 160 bound to ATAD2 showed that the oxygen of 
amide forms H-bond with Asn1064, and a water mediated H-bond with Tyr1021 (Figure 10.4). 
 
Figure 10.4: Crystal structure of fragment 160 (carbons: grey) bound to ATAD2. The binding 
surface is coloured based on the charge, positive: blue and negative: red. The ZA-shelf is shown 
by pink coloured circle. The pink arrow denotes the area of potential SAR investigation. 
 
It was postulated that substitution at the 2-position of the phenyl ring could access the ZA-shelf. 
Alkyl and alkoxy substituents were selected for preliminary investigation (Figure 10.5). 
 
Figure 10.5: 2-Substituted phenylacetamides to be synthesised. 
 
Crystal structure of triazole fragment 157 bound to ATAD2 showed that the compound adopted 
a different binding mode compared to other fragments (Figure 10.6). The H-bond with Asn1064 
and water mediated H-bond with Tyr1021 was formed with two different nitrogen atoms in the 
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triazole ring, whereas, the two H-bonds were formed with one oxygen atom in fragments 158 
and 160. 
 
Figure 10.6: Crystal structure of fragment 157 (carbons: grey) bound to ATAD2. The binding 
surface is coloured based on the charge, positive: blue and negative: red. The ZA-shelf is shown 
by pink coloured circle. The pink arrow denotes the area of potential SAR investigation. 
 
Interestingly, fragment 157 has a bromine atom on the pyridyl ring that could be utilised as a 
vector to exploit the ZA-shelf. Therefore, small alkyl substituents were selected for initial 
investigation (Figure 10.7). 
 
Figure 10.7: 5-substituted triazolopyridines to be synthesised. 
 
 
10.2.2 Synthesis  
Synthesis of compound 172 began with formylation of the commercially available phenol 167 
using magnesium chloride and paraformaldehyde (Scheme 10.1).178 Subsequent Pinnick 
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oxidation of the aldehyde 168 gave carboxylic acid 169, which was bis-methylated to obtain 
compound 170. Hydrolysis of ester 170 followed by amide coupling with methylamine 
provided the target 172 in good yield. 
 
 
Scheme 10.1: Reagents and conditions: (a) paraformaldehyde, NEt3, MgCl2, MeCN, reflux, 3 
h, 93%; (b) NaClO2, sulfamic acid, H2O, MeCN, r.t., 8 h, 88%; (c) MeI, Cs2CO3, DMF, r.t., 18 
h, 58%; (d) NaOH, H2O, MeOH, 60 ˚C, 18 h, 95%; (e) MeNH2, DIC, HATU, DMAP, THF, 
r.t., 18 h, 71%. 
 
Compounds 175 and 178 were prepared following a two-step reaction sequence (Scheme 10.2). 
Reduction of commercially available nitrophenols 173 and 176 provided the corresponding 
amines, subsequent acetylation afforded targets 175 and 178. 
 
Scheme 10.2: Reagents and conditions: (a) H2, 10% Pd/C, MeOH, r.t., 24 h; (b) Ac2O, AcOH, 
r.t., 30 min, (175, 80%; 178, 71%, over 2 steps). 
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To access triazolo[4,3-a]pyridine analogues, two different routes were employed. The first 
route involved SNAr reaction on commercially available compound 179. 2-Fluoro-5-
methylpyridine 179 was resistant to SNAr reaction with acethydrazide 180 at various conditions 
(Table 10.1).  
 
Table 10.1: Reagents and conditions used in step a  
 
Solvent Base 
Temp 
˚C 
Time 
h 
Resulta 
Ethanol None 100 3 No conversion 
Ethanol None 100 under µW 3 No conversion 
Ethanol NEt3 100 18 No conversion 
Ethanol DIPEA 100 18 No conversion 
a Observations from TLC and LCMS analyses 
 
Failure of the SNAr reaction might be due to the decrease in nucleophlicity of hydrazine in 
acethydrazide 180, caused by the electron withdrawing acetyl group. Therefore, the SNAr 
reaction was performed on commercially available compound 179 with unsubstituted hydrazine 
to get compound 183 (Scheme 10.3). Subsequent ring closure was performed in the presence 
of acetic acid and acetic anhydride, and gave target 182 in poor isolated yield.  
 
Scheme 10.3: Reagents and conditions: (a) hydrazine, EtOH, reflux, 72 h, 43%; (b) Ac2O, 
AcOH, reflux, 24 h, 16%. 
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The second route to access triazolo[4,3-a]pyridine analogues involved Suzuki-Miyaura 
coupling of compound 157 with alkyl boronic acids. Unfortunately, the coupling reaction with 
ethyl boronic acid was not successful. Further cross-coupling attempts were therefore 
performed with vinylboronic acid pinacol ester, followed by reduction (Scheme 10.4). 
However, the intermediate was found to be unstable with a noticeable colour change from beige 
to dark brown upon standing. A plausible explanation for the observed degradation is that the 
ring is very electron rich, therefore, susceptible to oxidation in presence of air. Literature 
searches of compound 186 and 187 were undertaken using Reaxys® and SciFinder® but with 
no success as the compounds had not been reported yet. Degradation of compounds with the 
triazolo[4,3-a]pyridine scaffold was also observed by our bioscientist colleague Dr Mathew 
Martin whilst performing the HTRF assay. Therefore, the series was not explored further due 
to the observed degradation of the intermediates 184 and 185. 
 
Scheme 10.4: Reagents and conditions: (a) vinylboronic acid pinacol ester, or 
isopropenylboronic acid pinacol ester, NaOH, N,N-dicyclohexylmethylamine, 
Pd(dppf)Cl2.DCM, THF, 95 ˚C, 2.5 h, (184, 51%; 185, 62%, over 2 steps);  (b) H2, 10% Pd/C, 
MeOH. 
 
10.2.3 Biological Evaluation 
A homogenous time resolved FRET assay (HTRF) was used to measure the ATAD2 inhibitory 
activity. GST-tagged ATAD2 was mixed with biotinylated acetylated ligand (Figure 10.8). 
Streptavidin labelled phycobiliprotein pigment purified from red algae (SA-XL665),111 which 
binds to the biotinylated acetylated ligand, and a terbium-labelled anti-GST antibody that binds 
to GST-tagged ATAD2 was added to the mixture.  The terbium label acts as a donor of FRET 
signal, and SA-XL665 acts as an acceptor of the FRET signal. Upon excitation, there is a 
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transfer of FRET from donor to acceptor which can be measured. In the absence of an inhibitor, 
the donor (terbium) and the acceptor (SA-XL665) are in close proximity. The donor terbium 
absorbs energy and transfers it to SA-XL665. The transfer of energy is measured as a FRET 
signal. In the presence of an inhibitor, the donor and acceptor are separated which results in a 
decrease in the amount of FRET. The experimental details of the HTRF assay are discussed in 
16.4.1. 
 
 
Figure 10.8: Schematic representation of ATAD2-HTRF assay. 
 
Compounds 172, 175, 178 and 182 did not show measurable inhibition by Homogenous Time 
Resolved FRET assay (HTRF) at 4 mM concentration. In addition, co-crystallisation 
experiments of ATAD2 with the compounds had failed. Meanwhile, Dr Duncan Miller had 
demonstrated that subtle modifications in fragment 5 improved ATAD2 inhibition and the 
compounds were successfully co-crystallised with ATAD2. Besides, fragment 5 was a novel 
scaffold which had not been reported to date for bromodomain inhibition. Therefore, most of 
the medicinal chemistry effort was focussed in SAR studies around fragment 5 which will be 
discussed in detail in following chapters.  
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Chapter 11. SAR Studies around the N1-Position of Fragment 5 
 
11.1 Rationale 
Crystal structure of fragment 5 bound to ATAD2 showed that the oxygen atom of the pyridone 
ring formed two key H-bonds, one with Asn1064 and the other water mediated H-bond with 
Tyr1021 (Figure 11.1).  
 
Figure 11.1:  Crystal structure of fragment 5 (carbons: grey) bound to ATAD2. The binding 
surface is coloured based on the charge, positive: blue and negative: red. The ZA-shelf is shown 
by the dark pink coloured circle. The pink arrow denotes the area of potential SAR 
investigation. Water molecules are shown as red spheres. 
 
The initial strategy was to explore SARs at the N1-position of the pyrrolidinone ring to access 
the ZA-shelf (Figure 11.1). A range of polar and lipophilic substituents were selected (Figure 
11.2). 
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Figure 11.2: N1-substituted targets to be synthesised. 
 
11.2 Synthesis 
The strategy was to synthesise fragment 5 in bulk quantity, and subsequent alkylation reactions 
would provide the desired targets. The synthesis started with N-Boc protection of commercially 
available 6-methoxy-4-methylpyridin-3-amine 188 to get compound 189, which was used in a 
carboxylation reaction to give compound 190 (Scheme 11.1). The ring closure was mediated 
by acetic anhydride in the presence of catalytic tetrabutylammonium acetate to give compound 
191. Subsequent bis-methylation provided compound 192. The N-Boc deprotection, as well as 
formation of pyridone was achieved in a single step by heating in the presence of MeI and 
catalytic sodium iodide to get compound 5. Formation of pyridone using MeI and sodium iodide 
is a widely used method to synthesise pyridones from 2-alkoxypyridines.179-182 Interestingly, 
when the reaction was performed in the absence of sodium iodide, quantitative yield of the 
product was obtained. 
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Scheme 11.1: Reagents and conditions: (a) Boc2O, THF, Na2CO3, THF, r.t., 42 h, 95%; (b) (i) 
s-BuLi, THF, -78 ˚C, 15 min; (ii) CO2 (dry ice), -78 ˚C to r.t., 45 min, 74%; (c) Ac2O, 
tetrabutylammonium acetate, 65 ˚C, 1 h, 81%; (d) MeI, Cs2CO3, MeCN, 60 ˚C, 3 h, 78%; (e) 
MeI, MeCN, 170 ˚C, µW, 1  h, quant. 
 
Targets 193 and 194 were synthesised following NaH-mediated alkylation reactions (Scheme 
11.2).  
 
 
Scheme 11.2: Reagents and conditions: (a) (i) NaH, DMF, r.t., 15 min; (ii) benzyl bromide or 
(2-bromoethyl)benzene, r.t., 3 h, 61%; (193), 30% (194). 
 
The isolated yields of NaH mediated alkylation reactions were low to moderate. Besides, 
isolation of the products was difficult due to close-running impurities. Therefore, in search of 
alternative alkylation conditions, the stronger base NaH was replaced by caesium carbonate. 
Caesium carbonate mediated alkylation reactions were faster, and isolation of the product easier 
(Scheme 11.3).  
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Scheme 11.3: Reagents and conditions: (a) 1-(2-chloroethyl)pyrrolidine hydrochloride or 4-(2-
chloroethyl)morpholine hydrochloride, Cs2CO3, DMF, 100 ˚C, µW, 30 min, 40% (195), 82% 
(196). 
 
Target 198 was obtained from a two-step reaction sequence. Alkylation of compound 5 with 
chloromethyl phenyl sulphide gave sulphide 197, which was subsequently oxidised using 
Oxone® to the corresponding sulfone 198 (Scheme 11.4).  
 
Scheme 11.4: Reagents and conditions: (a) chloromethyl phenyl sulphide, Cs2CO3, DMF, 100 
˚C, µW, 30 min, 75%; (b) Oxone®, MeOH, H2O, r.t., 18 h, 52%. 
 
Initial attempt to synthesise target 202 by alkylation of compound 201 using 2-bromoethan-1-
ol 199 was unsuccessful. Therefore, an alternate synthetic route was followed to prepare target 
202 (Scheme 11.5). The synthesis started with TBS protection of commercially available 
alcohol 199 to get compound 200, which was used for alkylation of compound 5 to obtain 
compound 201. Finally, TBS-deprotection provided target 202 in good yield.   
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Scheme 11.5: Reagents and conditions: (a) TBSCl, NEt3, DMAP, DCM, r.t., 18 h, quant.; (b) 
200, Cs2CO3, DMF, 100 ˚C, µW, 30 min, 55%; (c) TBAF, THF, r.t., 18 h, 90%. 
 
11.3 Biological Evaluation 
Diverse substitution at N1-position of fragment 5 did not increase the ATAD2 inhibitory 
activity. The compounds did not show ATAD2 inhibition at 2 mM concentration using the 
HTRF assay (Table 11.1).  
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Table 11.1: ATAD2 inhibitory activity of derivatives with various substituents at N1-position. 
 
Compound        R 
ATAD2 
IC50 
(µM) 
Compound R 
ATAD2 
IC50 
(µM) 
193 
 
>2000 197 
 
>2000 
194 
 
>2000 198 
 
>2000 
195 
 
>2000 202 
 
>2000 
196 
 
>2000    
 
Therefore, focus was shifted towards the substitution on the other nitrogen (N6) of the fragment 
5, and is discussed in detail in the next chapter. 
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Chapter 12. SAR Studies around the N6-Position of Fragment 5 
 
12.1 Rationale 
SAR studies conducted at the NICR by Dr Duncan Miller identified that methylation at the N1-
position of fragment 5 to obtain fragment 203 changed the binding mode of the scaffold. The 
oxygen atom of the pyridone ring in the original fragment hit 5 forms key H-bonds with 
Asn1064 and a water-mediated H-bond with Tyr1021 (carbons coloured cyan in Figure 
12.1A/B). However, upon N1-methylation, the pyridone ring in fragment 203 (carbons coloured 
green in Figure 12.1A/B) flips and points towards the ZA-shelf. Besides, the pyridone oxygen 
is involved in an additional water-mediated H-bond interaction with Asp1014 (Figure 12.1B).  
 
 
A 
 
B 
 
Figure 12.1: Overlay of the crystal structures of fragment 203 (green) bound to ATAD2 and 
the original fragment hit 5 (cyan) showing: (A) solvent accessible surface coloured based on 
charge, positive: blue, negative: red; (B) key H-bond interactions. Water molecules are shown 
as red spheres. 
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The flipped binding mode of fragment 203 encouraged us to explore SAR at the N6-position. 
Preliminary SAR studies at the N6-position proved that an increase in potency was achievable 
with the identification of compound 206, which was the most potent in-house inhibitor to date 
(Table 12.1).  
 
Table 12.1: ATAD2 inhibitory activities of N6-substituted analogues.  
Compound Structure 
ATAD2 IC50 
(µM)a 
L.E 
204 
 
3000 0.17 
205 
 
716b 0.21 
206 
 
247c  0.21 
a Determinations (n = 1 unless otherwise stated); b n = 2; c n = 4 
 
The crystal structure of compound 205 bound to ATAD2 suggested that H-bond donors or 
acceptors in the phenyl ring could interact with polar amino acids in the ZA loop including 
Arg1007 and Glu1017 (Figure 12.2).  
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A 
 
 
 
B 
 
 
Figure 12.2: Crystal structure of ATAD2 in complex with compound 205 (green) showing (A) 
solvent accessible surface coloured based on the charge, positive: blue, negative: red; (B) Key 
H-bond interactions. Water molecules are shown as red spheres. 
 
Various in-house crystal structures of ATAD2 in complex with different compounds suggested 
that the side chains of Glu1017 and Arg1008 were flexible, increasing the complexity of target 
design. SAR studies were carried out around the phenyl ring of compound 205 to obtain H-
bond interactions with the polar residues in the ZA-shelf. It was decided to introduce a range 
of substituents including H-bond donors, acceptors, lipophilic groups, and halogens at the 
ortho-, meta- or para-positions of the phenyl ring of compound 205 (Figure 12.3). 
 
 
Figure 12.3: N6-substituted analogues to be synthesised. SAR studies to be carried out around 
the phenyl ring highlighted by a green circle.  
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12.2 Synthesis 
Intermediate 192 was synthesised in large quantity (Scheme 11.1) and used for the synthesis of 
various targets. Formation of pyridone using various alkylating agents, followed by N1-
methylation gave 10 targets (Scheme 12.1).  
 
Scheme 12.1: Reagents and conditions: (a) R-Br, MeCN, 170˚C, µW, 45 min; (b) MeI, Cs2CO3, 
DMF, 100 ˚C, µW, 30 min. 
 
The isolated yields obtained in step a and b for various targets are shown in Table 12.2. The 
pyridone formation reaction (step a, Scheme 12.1) provided the desired products in high yields 
except for compound 222. The low yield for compound 222 might be due to the steric hindrance 
caused by the methyl ester in the ortho-position. The final methylation step provided the desired 
targets in moderate to good yields. 
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Table 12.2: Isolated yields of step a and step b in Scheme 12.1. 
Compound            R Step a  Step b  
208 
 
207, 63% 95% 
210 
 
209, 65% 91% 
212 
 
211, 53% 86% 
6 
 
213, 80% 90% 
215 
 
214, 82% 92% 
217 
 
216, 78% 95% 
219 
 
218, 71% 92% 
221 
 
220, 85% 92% 
223 
 
222, 22% 74% 
225 
 
224, 66% 80% 
229 
 
228, 93% 94% 
 
Nitrile 208 was hydrolysed to get compound 226. 
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Scheme 12.2:  Reagents and conditions: (a) NaOH, EtOH, H2O, 100 ˚C, 23 h, 32%.  
 
Similarly compound 227 was obtained via ester-hydrolysis of compound 225. 
 
 
Scheme 12.3: Reagents and conditions: (a) NaOH, MeOH, H2O, 70 ˚C, 2 h, 96%. 
 
 
12.3 SAR and Biological Evaluation 
A small library of compounds with different substituents on the phenyl ring were tested against 
ATAD2 (Table 12.3). Compounds 6 and 217 with a halogen at the para-position retained 
ATAD2 inhibitory activity. Compound 219 with a para-substituted trifluoromethyl group was 
also tolerated. However, compound 221 with a para-substituted methyl group showed a 
reduction in ATAD2 inhibitory activity by around 4-fold.  The para-substituted methyl sulfone 
derivative 212, which was synthesised to study the effect of an H-bond acceptor sulfone group 
in the proximity of polar amino acids in ZA-shelf, showed at least 2-fold reduction in potency. 
Substitution at the ortho-position resulted in a significant loss in ATAD2 inhibition as seen with 
compounds 208, 215, 223 and 226. Compound 227 with a methoxy group at the ortho-position 
retained some activity, probably due to the presence of the carboxylic acid at the para-position. 
Compound 229 with an additional chloro substituent at the meta-position resulted in at least 2-
fold loss in potency.   
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Table 12.3: ATAD2 inhibitory activity of N6-substituted analogues. 
 
Compound        R 
ATAD2 
IC50 
(µM)a 
Compound R 
ATAD2 
IC50 
(µM)a 
208 
 
>2000 217 
 
294b  
210 
 
1393 219 
 
354d  
212 
 
565 221 
 
815 
6 
 
209c  223 
 
>2000 
215 
 
>2000 225 
 
>2000 
229 
 
469 227 
 
734 
226 
 
>2000    
a Determinations (n = 1 unless otherwise stated); b n = 2; c n = 3; d n = 6 
 
Compound 6 with a chloro group at the para-position was the most potent inhibitor identified 
in this series. The crystal structure of compound 6 bound to ATAD2 showed that an additional 
water-mediated H-bond with the flexible side-chain of Glu1017 was formed (Figure 12.4). The 
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binding mode was very similar to the parent compound 205 where pyrrolidinone oxygen forms 
H-bond with Asn1064 and water mediated H-bond with Tyr1021. 
 
A 
 
B 
 
Figure 12.4: Crystal structure of ATAD2 in complex with compound 6 (magenta); (A) front 
view of the compound; (B) side view of the compound to highlight two water-mediated H-
bonds with Asp1014 and Glu1017. Water molecules are shown as red spheres.  
 
The crystal-structure of compound 226 showed that the ortho-substituted carboxylic acid 
twisted the phenyl ring, probably due to the intramolecular clash of the carboxylic acid with the 
pyridone oxygen atom, leading to reduced activity (Figure 12.5). In addition, the water-
mediated H-bond with Asp1014 was not observed, due to the movement of the scaffold (Figure 
12.5B). 
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A 
 
B 
 
Figure 12.5: Overlay of crystal structure of compound 6 (magenta) and 226 (green) bound to 
ATAD2; (A) front view of the compounds, (B) side view of the compounds highlighting the 
movement of compound 226 (green). 
 
As mentioned earlier the methyl sulfone substituted derivative 212 was synthesised to test the 
effect of 2 H-bond acceptors in the ZA-self. Although, the two oxygens of the sulfone group 
were in close proximity to Arg1008, H-bond interactions were not formed (Figure 12.6). The 
binding mode of compound 212 was same as that of compound 6. 
A 
 
B 
 
Figure 12.6: Crystal structure of ATAD2 in complex with compound 212 (green); (A) front 
view of the compound; (B) side view of the compound. Water molecules are shown as red 
spheres. 
Various analogues bearing amines at the para-position were synthesised by other colleagues, 
with the hypothesis that H-bond donors might interact with the flexible side chain of Glu1017 
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leading to improvement in the ATAD2 inhibition. However, the compounds did not improve 
the activity, making the para-chloro substituted derivative 6, the most potent compound to date. 
Therefore, the para-chlorobenzyl group was chosen as the optimum group to access the ZA-
shelf and focus was shifted towards SAR studies at other positions of compound 6.   
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Chapter 13. Accessing the Region Occupied by Acetylated Histone 
13.1 Rationale 
After identifying the para-chlorobenzyl as the optimum substituent at N6-position to access the 
ZA-shelf, new regions of the ATAD2 binding site were explored. A region around the BC loop 
was identified from the crystal structure of acetylated histone bound to ATAD2 (PDB: 4QUU, 
Figure 13.1). The acetylated histone occupies a region between the BC-loop and the ZA-loop. 
The lead compound 6 has two methyl groups pointing towards the same region (Figure 13.1). 
  
 
Figure 13.1:  Overlay of crystal structures of ATAD2 in complex with compound 6 (magenta) 
and acetylated histone peptide (green, PDB: 4QUU). The binding surface is coloured based on 
the charge, positive: blue and negative: red. The region of interest is highlighted by a green 
circle. 
 
It was decided to explore this region by using one of the methyl substituents as a vector for 
expansion. A series of 3-substituted pyrrolidinone derivatives were proposed (Figure 13.2).  
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Figure 13.2: 3-susbstituted pyrrolidinone derivatives to be synthesised. 
 
13.2 Synthesis  
13.2.1 Mono-alkylation at the 3-Position 
In the initial synthetic route to prepare intermediate 5 (Scheme 13.1), step d involved a bis-
methylation at the 3-position. This route had to be modified to enable a mono-alkylation in step 
d. 
 
Scheme 13.1: Reagents and conditions: (a) Boc2O, THF, Na2CO3, THF, r.t., 42 h, 95%; (b) (i) 
s-BuLi, THF, -78 ˚C, 15 min; (ii) CO2 (dry ice), -78 ˚C to r.t., 45 min, 74%; (c) Ac2O, 
tetrabutylammonium acetate, 65 ˚C, 1 h, 81%; (d) MeI, Cs2CO3, MeCN, 60 ˚C, 3 h, 78%; (e) 
MeI, MeCN, 170 ˚C, µW, 1  h, quant. 
 
The mono-alkylation would provide a versatile intermediate which could be used to introduce 
a range of substituents at the 3-position (Figure 13.3).  
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Figure 13.3: Proposed synthetic scheme to prepare a mono-alkylated intermediate. 
 
As there were no literature precedent for mono-alkylating the 3-position of our scaffold, mono-
alkylation at the 3-position of oxindoles was searched. There are numerous examples describing 
the mono-alkylation of the 3-position of oxindoles.183-186 The strategy was to deprotonate at the 
3-position and use 1 equivalent of an electrophile to obtain the mono-alkylated product. 
However, various electrophiles and bases at different temperatures did not lead to mono-
alkylated product. A significant amount of time was engaged to develop a chemistry that would 
allow mono-alkylation at the 3-position by three chemists within the group. Few examples are 
highlighted in Table 13.1. 
 
Table 13.1: Summary of different conditions used for mono-alkylation at the 3-position. 
 
Electrophiles 
RXa 
Basesa Solvent 
Temperature 
˚C 
Results 
CH3I Cs2CO3 MeCN 60  Significant bis-methylation 
CH3CH2I Cs2CO3 MeCN 60  
Complex mixture, significant bis-
ethylation 
CH3CH2I
 Cs2CO3
b MeCN r.t. 
Complex mixture, significant bis-
ethylation 
CH3CH2I LiHMDS THF -50  Starting material only 
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CH3CH2I LiHMDS THF r.t. Starting material only 
CH3I KHMDS THF r.t. 
Significant bis-methylated 
product 
 
LHMDS THF -78 to r.t. Starting material only 
 
LHMDS THF -78 ˚C to r.t. Starting material only 
a No. of equvalents used = 1; b No. of equivalents = 0.5 
 
The mono-alkylation reaction worked with very low isolated yield when LHMDS was used as 
a base and allyl bromide as an electrophile (Scheme 13.2). The product was not stable in air, 
therefore, it had to be stored under nitrogen. Although, the reaction worked, the yield was poor, 
the reaction was not reproducible, and there were at least 4 additional steps towards the desired 
targets. Moreover, the scheme would not allow further functionalisation at the 3-position, 
therefore, the scheme was discarded.   
 
Scheme 13.2: Reagents and conditions: (a) (i) LHMDS, THF, -78 ˚C, 45 min; (ii) allyl 
bromide, -78 ˚C, 2 h, then, r.t., 20 h, 26%.  
 
13.2.2 Variation at the 3-Position using Knoevenagel Condensation 
Whilst attempting various routes for mono-alkylating the 3-position, Knoevenagel 
condensation of compound 191 with acetaldehyde and formaldeyde was attempted, without any 
success. However, major breakthrough came from the Knoevenagel condensation of 
benzaldehyde with compound 191 which provided the desired compound 231 in high yield 
(Scheme 13.3). Subsequent reduction of the double bond, followed by methylation provided 
compound 235. Treatment of pyridine 235 with 4-chlorobenzyl bromide at high temperature 
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provided the target pyridone 237 in moderate yield. Similarly, compound 238 was synthesised 
via Knoevenagel condensation of compound 191 and picolinaldehyde. 
 
Scheme 13.3: Reagents and conditions: (a) benzaldehyde or picolinaldehyde, piperidine, THF, 
100 ˚C, 30 min, 88% (X = C), 50% (X = N); (b) H2, 10% Pd/C, THF, MeOH, r.t., 2 h; (c) MeI, 
Cs2CO3, DMF, 50 ˚C, 1.5 h, 55% (X = C), 56% (X = N) over 2 steps; (d) 4-chlorobenzyl 
bromide, MeCN, 170 ˚C µW, 45 min, 64% (X = C), 50% (X = N). 
 
It was decided to utilise the synthetic route via Knoevenagel condensation to synthesise more 
derivatives. The chemistry was performed with a variety of aldehydes. However, the 
condensation worked only in the absence of an enolisable proton at the α-position to the 
aldehyde carbon. Various aldehydes with different ring systems were used in the Knoevenagel 
condensation to explore SAR at the 3-position. Synthesis of compound 244 started with the 
oxidation of commercially available alcohol 239 to aldehyde 240. The Knoevenagel 
condensation of compound 191 with aldehyde 240 provided compound 241. Then, following 
the chemistry described before, target 244 was obtained. 
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Scheme 13.4: Reagents and conditions: (a) DMP, DCM, 0 ˚ C-r.t., 3 h, 78%; (b) 240, piperidine, 
THF, 100 ˚C, 30 min, 50%; (c) H2, 10% Pd/C, THF, MeOH, r.t., 2 h; (d) MeI, Cs2CO3, DMF, 
50 ˚C, 1.5 h, 42% over 2 steps; (e) 4-chlorobenzyl bromide, MeCN, 170 ˚C µW, 45 min, 83%. 
 
13.3 Biological Evaluation 
A small library of compounds were synthesised using the Knoevenagel condensation chemistry 
by three different chemists within the group. Compounds with different ring systems at 3-
position were tested against ATAD2 inhibition (Table 13.2). The compounds with 6-membered 
aromatic rings at the 3-position were not tolerated. The 5-membered thiazole ring was tolerated, 
however, thiophene ring was detrimental to the ATAD2 inhibitory activity. Compounds with 
smaller substituents 244, 247 and 251 retained activity. 
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Table 13.2: ATAD2 inhibitory activity of derivatives with various substituents at the 3-
position. 
 
Compound        R 
ATAD2 
IC50 
(µM)a 
Compound R 
ATAD2 
IC50 
(µM)a 
237 
 
>2000 248e 
 
352c 
238 
 
1284 249e 
 
1633b 
245e 
 
>2000 244 
 
214c 
246e 
 
>2000  250f 
 
1291b 
247f 
 
486b 251f 
 
319d 
a Determinations (n = 1 unless otherwise stated); b n = 2; c n = 3; d n = 4; e synthesised by Dr 
Stephen Hobson; f synthesised by Dr Duncan Miller. 
 
The crystal structure of ATAD2 in complex with compound 238 showed that the 6-membered 
aromatic ring pointed towards solvent, rather than pointing towards the area where the 
acetylated histone binds, between the ZA and BC loops (Figure 13.4). The overall binding mode 
of the molecule was similar to the lead compound 6.  
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Figure 13.4: Crystal structure of ATAD2 in complex with compound 238 (magenta); the 
solvent accessible surface is coloured based on charge positive: blue, negative: red. Water 
molecules are shown as red spheres. 
 
Similarly, the crystal structure of ATAD2 in complex with compound 244 showed that the 4-
membered oxetane ring pointed towards solvent (Figure 13.5). The oxetane derivative 244 was 
at least 5-fold more potent than the pyridyl derivative 238, suggesting that the 4-membered ring 
was tolerated in the binding site.  
 
Figure 13.5: Crystal structure of ATAD2 in complex with compound 244 (magenta); the 
solvent accessible surface is coloured based on charge positive: blue, negative: red. Water 
molecules are shown as red spheres.  
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Chapter 14. Accessing the Bidentate Interaction with Asn1064 
 
14.1 Rationale 
It has been reported that the bidentate H-bond interaction with the conserved asparagine residue 
in bromodomains provided an increase in potency.147, 187-188 The crystal structure of compound 
244 with ATAD2 revealed that the oxetane ring was in close proximity to Asn1064 (Figure 
14.1). The carbon atom at the α-position to the oxygen atom of the oxetane ring was 3.2 Å away 
from the oxygen of Asn1064. It was hypothesised that an H-bond donor in the region near 
Asn1064 would form the additional H-bond interaction with Asn1064, improving the potency 
against ATAD2.  
 
Figure 14.1: Crystal structure of compound 244 (magenta) bound to ATAD2 showing key H-
bond interaction. The distance between the oxetane ring and Asn1064 is highlighted by a double 
headed black arrow. 
 
The synthetic route used so far did not allow the introduction of desired H-bond donors 
including alcohols, amines and amides with variable linker lengths at the 3-position (Figure 
14.2).  
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Figure 14.2: Compounds that were not accessible by the previously described synthetic route. 
 
Therefore, a different strategy was taken to form the bidentate interaction with Asn1064. It was 
decided to synthesise spirocycles at the 3-position to introduce H-bond donors (Figure 14.3). 
Compound 253 with the pyrrolidine spirocycle was inspired from a natural product Horsfiline 
254, which was first isolated in 1991 from Horsfieldia superba, a tree whose extracts are used 
in local medicines in Malaysia.189  
 
Figure 14.3: Proposed pyrrolidinone targets bearing a spirocycle at the 3-position. 
 
14.2 Synthesis of Compound 252 
Synthesis of compound 252 started with bis-allylation of intermediate 191 at the 3-position 
(Scheme 14.1). Olefin metathesis of compound 255 using Grubbs catalyst 2nd generation,190-191 
gave the desired spirocyclopropene 256 in 90% isolated yield. Compound 256 was converted 
to the pyridone 257 by heating with 4-chlorobenzyl bromide at 170 ˚C under microwave 
irradiation. Subsequent methylation gave compound 258, which was subjected to osmium 
tetroxide-mediated bis-hydroxylation to get the desired target 252 in 59% yield and the 
diastereoisomer 259 in 18% yield.  
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Scheme 14.1: Reagents and conditions: (a) allyl bromide, Cs2CO3, MeCN, 40 ˚C, 2.5 h, 55%; 
(b) Grubbs catalyst 2nd generation, DCM, 80 ˚C µW, 20 min, 90%; (c) 4-chlorobenzyl bromide, 
MeCN, 170 ˚C µW, 45 min, 89%; (d) MeI, Cs2CO3, DMF, 100 ˚C µW, 30 min, 87%; (e) OsO4, 
NMO, THF, H2O, r.t., 18 h, 59% (252), 18% (259). 
 
The structures of the two diastereoisomers 252 and 259 were confirmed by NOE experiments. 
In case of compound 252, the enhancement of both H2 and H3 signals were observed (Figure 
14.4A). Enhancement of H3 proton signal suggests that the H3 protons are pointing upwards 
and the OH groups are pointing downwards. 
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Figure 14.4: NOE difference spectrometry for compound 252; (A) shows enhancement of H2 
and H3 protons on irradiation of H1-proton; (B) shows the 
1H-NMR spectrum of compound 252. 
 
In the case of compound 259, when H1 proton was irradiated, only the H2 proton signal was 
enhanced, confirming that the H3 protons face downwards (Figure 14.5). 
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Figure 14.5: NOE difference spectrometry for compound 259; (A) shows enhancement of the 
H2 protons on irradiation of the H1-proton; (B) shows the 
1H-NMR spectrum of compound 259. 
 
14.3 Synthesis of Compound 253 
The synthetic route of compound 253 was designed based on the total synthesis of Horsfiline 
reported by Fischer et al. (Scheme 14.2).192 The synthesis started with the alkylation of 
intermediate 191 using 1,2-dibromoethane to get the spirocyclopropane 260. Ring expansion 
of cyclopropane 260 using MgI2 and triazinane 261 gave spiropyrrolidine 262 in moderate yield. 
However, the pyridone formation at 170 ˚C under microwave irradiation did not work, resulting 
in a complex mixture of products.  
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Scheme 14.2: Reagents and conditions: (a) 1,2-dibromoethane, Cs2CO3, MeCN, 40 ˚C, 3.5 h, 
55%; (b) MgI2 (10 mol%), THF, 50 ˚C, 26 h, 64%; (c) 4-chlorobenzyl bromide, MeCN, 170 
˚C µW, 45 min. 
 
The synthetic route was redesigned so that the ring-expansion of spirocyclopropane could be 
perfomed at a later stage (Scheme 14.3). The spirocyclopropane 260 was converted to 
compound 265 via pyridone formation and methylation as described before. Ring expansion of 
spirocyclopropane 265 was achieved using triazinane 261 and MgI2 to get compound 271.  
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Scheme 14.3: Reagents and conditions: (a) 1,2-dibromoethane, Cs2CO3, MeCN, 40 ˚C, 3.5 h, 
55%; (b) 4-chlorobenzyl bromide, MeCN, 150 ˚C µW, 45 min, 68%; (c) MeI, Cs2CO3, DMF, 
100 ˚C µW, 30 min, 53%; (d) MgI2 (10 mol%), THF, 50 ˚C, 13 h, 90 ˚C, 20 h, 53%. 
 
Fischer et al. proposed a mechanism for the ring expansion of spirocyclopropane, involving the 
formation of an intermediate enolate 267 (Scheme 14.4).192 Nucleophilic substitution of iodine 
by the triazinane 261 forms intermediate 268, which upon fragmentation gives 269. The enolate 
attack on the iminium ion provides the target pyrolidine 270. Fischer et al. also proposed a 
different mechanism in which the triazinane 261 undergoes fragmentation to form N-
methylimine before attacking the electrophilic centre of C-I bond of the enolate 267.192 
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Scheme 14.4: Proposed mechanism of ring expansion of spirocyclopropane 266 to 
spiropyrolidine 270.192 
 
The final step to get compound 253 was N-demethylation of compound 271. However, various 
methods of N-demethylation using ACE-chloride and benzyl chloroformate did not provide the 
desired target 253. Therefore, it was decided to incorporate a different group at the pyrrolidine 
nitrogen using the spirocyclopropane ring expansion approach. A benzyl derivative 272 or an 
allyl derivative 273 (Figure 14.6) were the first choice of targets because the corresponding 
triazinanes were either commercially available or the synthesis was reported.193 
 
Figure 14.6: Compounds to be synthesised. 
 
Ring expansion of spirocyclopropane 265 using commercially available triazinane 274 
produced a mixture of unidentified products (Scheme 14.5). 
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Scheme 14.5: Reagents and conditions: (a) MgI2 (10 mol%), THF, 50 ˚C, 13 h, 90 ˚C, 20 h. 
 
Ring expansion of compound 265 with triazinane 276 provided the desired product 273 
(Scheme 14.6). The triazinane 276 was prepared using allylamine 275 and paraformaldehyde 
following a procedure described by Jasiński et al.193  
 
Scheme 14.6: Reagents and conditions: (a) paraformaldehyde, MeOH, 0 ˚C-r.t., 20 h, quant.; 
(b) MgI2 (10 mol%), THF, 90 ˚C, 20 h; (c) Pd(PPh3)4, N,N-dimethylbarbituric acid, DCM, 35 
˚C, 16 h, 22% over two steps. 
The compound 273 was not pure enough by 1H-NMR, containing unidentified impurities, and 
a very small amount (16 mg) was remaining. Therefore, the compound was taken forward 
without further purification. Removal of the N-allyl group using Pd(PPh3)4 and N,N-
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dimethylbarbituric acid following a protocol described by Garro-Helion et al (Scheme 14.6) to 
afforded desired target 253 in poor yield.194 
 
14.4 Biological Evaluation 
The ATAD2 inhibitory activity of compounds 252 and 253 along with the intermediates 
obtained during the synthesis were determined (Table 14.1). Spirocyclopropane intermediate 
265 was inactive, whereas, spirocyclopentene derivative 258 retained the potency. The bis-
hydroxylated compounds 252 and 259 showed no ATAD2 inhibitory activity. The horsfiline 
analogue 271 showed a loss in potency by at least 7 fold compared to lead compound 6. 
Removal of the N-methyl group was tolerated but did not improve the potency, although the 
desired bidentate H-bond interaction with Asn1064 was formed (Figure 14.7). Compound 253 
was tested as a racemic mixture, therefore, the correct enantiomer might provide an increase in 
potency. In conclusion, the spirocycles with H-bond donors did not improve the activity against 
ATAD2, contradicting the initial hypothesis. A crystal structure of ATAD2 in complex with 
the bis-hydroxylated derivatives 252 and 259 would be beneficial to explain the loss in activity, 
despite having H-bond donors capable of forming the bidentate interaction with Asn1064.  
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Table 14.1: ATAD2 inhibitory activity of lead compound 6 compared with analogues bearing 
a spirocycle at the 3-position. 
Compound        Structures 
ATAD2 
IC50 (µM)a 
6 
 
209b 
265 
 
>2000 
271 
 
1571b 
253 
 
234 
258 
 
339c   
259 
 
1467c 
252 
 
>2000c 
a Determinations (n = 1 unless otherwise stated); 
b n = 3; c n = 4 
 
A crystal structure of ATAD2 in complex with compound 253 was solved (Figure 14.7). The 
binding mode of compound 253 was very similar to that observed with the lead compound 6. 
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The N-H of spiropyrrolidine ring forms a H-bond with Asn1064, making the bidentate 
interaction with Asn1064. 
 
Figure 14.7: Crystal structure of ATAD2 in complex with compound 253 (magenta), showing 
the key H-bond interactions. Water molecules are shown as red spheres. The bidentate 
interaction with Asn1064 is shown as green dotted lines. 
 
 
14.5 Investigation of Scaffold Hopping Approach 
The bidentate interaction made by the spiropyrrolidine derivative 253 was not beneficial for 
increasing ATAD2 inhibition. The chemistry used so far did not allow the exploration of SAR 
at the 3-position with a range of H-bond donor substituents. Therefore, a scaffold hopping 
approach was used, changing the scaffold to oxindole, which was chosen because of its 
structural similarity to the current scaffold. In addition, the chemistry to introduce a range of 
substituents at 3-position of oxindoles has been reported.185, 195-196 Compound 277 with an 
amide at 3-position of the oxindole was modelled in the binding site of ATAD2 (Figure 14.8). 
The modelling suggested that the methylene linked amide group at 3-position would form an 
additional H-bond with Asn1064, providing the desired bidentate interaction. 
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Figure 14.8: Modelling of compound 277 (green) on the ATAD2 binding site using Accelrys 
Discovery Studio.  
 
Therefore, to examine the effect of a flexible H-bond donor, compound 277 was chosen as a 
target (Figure 14.9). Compound 278 was chosen to examine if scaffold hopping to oxindole 
retains the ATAD2 inhibition (Figure 14.9). The work load was shared with Dr Stephen 
Hobson, who undertook the synthesis of compound 278. 
 
Figure 14.9: Targets to be synthesised based on scaffold hopping approach. 
 
14.5.1 Synthesis of Compound 277 
It was decided to synthesise intermediate 282, which could be used with a range of electrophiles 
to explore the 3-position. Compound 281 was prepared following a literature procedure by 
Loreto et al.197 Synthesis of compound 281 started with the Peterson olefination of N-
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methylisatin 279 to give compound 281 (Scheme 14.7). Due to the reported instability,197 
compound 281 was reduced immediately to get intermediate 282 with a mono-methyl group at 
the 3-position. Nucleophilic attack of the enolate of compound 282 on 2-bromoacetamide gave 
the desired product in poor yield, but sufficient for co-crystallisation studies.  
 
Scheme 14.7: Reagents and conditions: (a) (trimethylsilyl)methylmagnesium chloride (1M in 
Et2O), THF, -78 ˚C to r.t, 1.5 h, 71%; (b) BF3.Et2O, DCM, -78 ˚C, 1 h; (c) H2, 10% Pd/C, 
MeOH, Et2O, r.t., 1 h, 50% over 2 steps; (d) 2-bromoacetamide, Cs2CO3, DMF, 50 ˚C, 2 h, 
12%. 
 
14.5.2 Biological Evaluation 
Compounds 277 and 278 did not show ATAD2 inhibitory activity at 4 mM concentration (Table 
14.2). The inhibitory activity of compound 277 was expected to be low because it is a very 
small fragment, and it was intended for co-crystallisation studies. Compound 278 did not 
exhibit ATAD2 inhibition. These results suggested that the pyridone-pyrrolidinone scaffold 
was important for the ATAD2 inhibition.  
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Table 14.2: ATAD2 inhibitory activity of compounds 277 and 278 compared with compound 
205. 
Compound        Structures 
ATAD2 
IC50 (µM)a 
205 
 
716b 
278c 
 
>4000 
277 
 
>4000 
a Determinations (n = 1 unless otherwise stated); 
b n = 2; c synthesised by Dr Stephen Hobson 
 
 
A crystal structure of compound 277 bound to ATAD2 was solved (Figure 14.10). The N-
methylpyrrolidinone ring mimics the acetyllysine, forming a key H-bond interaction with 
Asn1064 and a water-mediated H-bond with Tyr1021. The amide group flips away from the 
Asn1064 and did not form a H-bond interaction, contradicting the hypothesis based on 
modelling studies. Altogether, the compounds with an oxindole scaffold did not retain ATAD2 
inhibitory activity, therefore, the series was not pursued further. However, the crystal structure 
of compound 277 bound to ATAD2 was helpful to demonstrate that a flexible methylene linked 
H-bond donor amide group at the 3-position would not be beneficial to get the bidentate 
interaction with Asn1064 (Figure 14.10). 
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Figure 14.10: Crystal structure of ATAD2 in complex with compound 277 (green) showing 
the key H-bond interactions.  
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14.6 Introduction of a H-bond Donor Heterocycle at 3-Position 
The crystal structure of compound 248 bound to ATAD2 showed that the 5-membered thiazole 
ring was close to the Asn1064 (Figure 14.11). It was hypothesised that a 5-membered 
heterocycle with a H-bond donor would interact with Asn1064. 
 
Figure 14.11: Crystal structure of ATAD2 in complex with compound 248 (green) showing 
the H-bond interactions. 
 
In order to form the bidentate interaction with Asn1064, an imidazole derivative 283 was 
designed. 
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14.6.1 Synthesis  
Previous work within the research group have suggested that the Knoevenagel condensation of 
unprotected heterocycles resulted in a complex mixture of products. Therefore, it was decided 
to protect 1H-imidazole-4-carbaldehyde 284. The protecting group should withstand high 
temperatures up to 170 ˚C, mild acidic, and basic conditions. After an extensive literature 
search, N,N-dimethylsulfonic amide was selected as a protecting group as it was reported to 
withstand high temperatures, as well as, mild acidic and basic conditions.198-199 The protecting 
group could be cleaved by either strongly acidic or basic conditions. The synthesis started with 
the protection of 1H-imidazole-4-carbaldehyde 284 to get compound 285 (Scheme 14.8). 
Knoevenagel condensation of intermediate 191 and aldehyde 285 provided compound 286. 
Surprisingly, the Boc group was not cleaved, unlike previous synthetic schemes. Compound 
286 was then reduced, followed by methylation to get methoxypyridine 288. The subsequent 
pyridone formation at 170 ˚C produced a mixture of complex products.  
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Scheme 14.8: Reagents and conditions: (a) N,N-dimethylsulfamoyl chloride, NEt3, DCM, r.t., 
24 h, 85%; (b) 285, piperidine, THF, 50 ˚C, 1 h, 30%; (c) H2, 10% Pd/C, THF, MeOH, r.t., 2 h; 
(d) MeI, Cs2CO3, DMF, 50 ˚C, 1.5 h, 69% over 2 steps; (e) 4-chlorobenzyl bromide, MeCN, 
170 ˚C µW, 45 min. 
 
Concurrently, the synthesis of pyrrole derivative 296 was also undertaken, based on the same 
rationale as the imidazole derivative 283. Synthesis of compound 296 started with a SEM-
protection of 1H-pyrrole-2-carbaldehyde 291 to get compound 292 (Scheme 14.9). The 
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reduction of compound 293, followed by bis-methylation gave compound 295. The pyridone 
formation did not work as observed with the imidazole derivative 288 in Scheme 14.8.  
 
 
Scheme 14.9: Reagents and conditions: (a) (i) NaH, THF, 0 ˚C, 30 min; (ii) SEMCl, r.t., 2.5 h, 
85%; (b) 292, piperidine, THF, 60 ˚C, 1 h, 79%; (c) H2, 10% Pd/C, THF, MeOH, r.t., 2 h; (d) 
MeI, Cs2CO3, DMF, r.t., 1 h, 67% over 2 steps; (e) 4-chlorobenzyl bromide, MeCN, 170 ˚C 
µW, 45 min. 
 
The pyridone formation reaction was performed at a very high temperature under microwave. 
Therefore, various milder conditions were attempted for the pyridone formation, however, a 
complex mixture of products were obtained in each case (Table 14.3). 
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Table 14.3: Reagents and conditions attempted for pyridone formation. 
 
Entry Reagents and conditions Results 
1 4M HCl, Dioxane, 80 ˚C, 18 h Complex mixture of products 
2 BBr3, DCM, -78 ˚C, 2 h Complex mixture of products 
3 TMSI, MeCN, r.t., 1 h Complex mixture of products 
 
Due to the failure of several attempts of pyridone formation, it was decided to submit pyridine 
298 for biological evaluation. The pyridine 298 would provide an answer to the design question, 
that is, whether an H-bond donor heterocycle would form an H-bond with Asn1064. The 
pyridine 298 was synthesised by TBAF-mediated removal of the SEM group from compound 
295 (Scheme 14.10).  
 
 
Scheme 14.10: Reagents and conditions: (a) TBAF, THF, 50 ˚C, 48 h, 51%. 
 
 
14.6.2 Biological Evaluation 
As expected, compound 298 did not show any ATAD2 inhibition at 2 mM in HTRF assay. A 
crystal structure of the compound bound to ATAD2 would be beneficial to understand if the 
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bidentate interaction with Asn1064 was achievable with H-bond donor heterocycles at 3-
position. However, several attempts of co-crystallisation of the compound with ATAD2 have 
failed.  
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Chapter 15. Conclusion and Future Directions 
15.1 MDMX 
Based on the docking and modelling studies, a substituted-pyrrole series was identified. 
Introduction of an acidic group led to the identification of lead compound 2. 
 
 
A novel route to the synthesis of RO-2443 3 and RO-5963 4 was identified. The compounds 
were used to validate the in-house biochemical assay ELISA. There were at least 1000 fold 
discrepancies between the IC50 values obtained from in-house ELISA and the published HTRF 
assay. Therefore, a structural biology placement was undertaken. 
 
An HTRF assay was developed, which provided reasonable dose-response curves for published 
small molecules as well as peptides. The Newcastle small molecule inhibitors with logD < 3 
yielded reasonable dose-response curves, but the lipophilic compounds with logD > 3 were 
completely inactive in the HTRF assay. The HTRF assay results for Newcastle small molecule 
inhibitors were not in line with the values obtained from the ELISA. The MDMX construct 
used in the HTRF assay does not include an autoinhibitory sequence. In contrast, a full length 
MDMX construct that includes the autoinhibitory sequence was used in the ELISA. This 
difference might be a major factor responsible for the discrepancies between the results 
obtained from the ELISA and HTRF assays. Therefore, development of HTRF assay with a 
full-length MDMX would be of interest. 
Several MDMX and MDM2 constructs were expressed and purified. Co-crystallisation trials of 
MDM2 and MDMX with both small molecule inhibitors and autoinhibitory domains were 
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attempted.  Around 20,000 different conditions were screened for co-crystallisation studies with 
MDMX but without any success. Future work will include the identification of a MDMX 
surface-entropy reduction mutant that could enhance crystallogenesis and might be used for the 
co-crystallisation of MDMX with small molecules, as reported for MDM2.200  
 
15.2 ATAD2 
The ATAD2 project is in the hit to lead phase. Subtle modifications were undertaken around 
the fragment hits, obtained from Astex pharmaceuticals, with the aim to improve the ATAD2 
inhibitory activity. Extensive SARs around fragment 5 led to the identification of compound 6.  
 
 
The SAR studies presented in this thesis have shown that substitution at ortho- or meta-position 
of the phenyl ring reduced the ATAD2 inhibition. SAR studies with different linkers between 
the phenyl ring and the N6-position would be of interest. 
 
Based on the crystal structure of compound 6 bound to ATAD2, extensive SARs at the 3-
position were performed. Chemistry to allow variations at the 3-position was challenging. The 
synthetic route involving a Knoevenagel condensation allowed rapid exploration of SARs 
around the 3-position. Compounds with methylene-linked 6-membered ring at the 3-position 
showed significant reduction in ATAD2 inhibition. Interestingly, methylene linked small sized 
rings, such as 244, retained the potency. 
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In an attempt to form a bidentate interaction with Asn1064, several strategies were employed, 
including introduction of H-bond donor spirocycles, and flexible H-bond donor amides or 
heterocycles at the 3-position. Compound 253, which was submitted as a racemic mixture, 
formed the desired bidentate interaction with Asn1064, and retained potency against ATAD2. 
The crystal structure of compound 253 bound to ATAD2 suggests that the substitution at the 2-
position of the spiropyrrolidine ring would access the small RVF shelf, which was explored by 
Bamborough et al. to develop a potent ATAD2 inhibitor.175 Therefore, SAR studies around 
spirocyles at the 3-position might provide the desired bidentate interaction, as well as access to 
the RVF shelf (Figure 15.1).175 
 
Figure 15.1: Possible future SAR studies around the spiropyrrolidine at the 3-position of 
compound 253 to access the RVF shelf. 
 
Thus, the work presented in this thesis has enhanced our understanding of the binding site of 
ATAD2 bromodomain. Fragment based drug discovery and structure based drug design led to 
the identification of sub-millimolar inhibitors of ATAD2. The key SAR studies are summarised 
in Figure 15.2. 
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Figure 15.2: Summary of SARs around the pyridone-pyrrolidinone series. 
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Chapter 16. Experimental 
 
16.1 Summary of Generic Reactions, Analytical and Chromatographic 
Conditions 
16.1.1 Solvents and Reagents 
All chemicals and reagents were purchased from Sigma Aldrich, Acros, Alfa Aesar, Apollo 
Scientific, Fisher Scientific, Fluorochem, Tokyo Chemical Industry or Strem Chemicals. The 
chemicals were of the highest available purity. Anhydrous solvents were stored in Aldrich 
Sure/Seal bottles and stored under an atmosphere of nitrogen. Petrol refers to the fraction with 
a boiling point between 40 and 60 oC.  
 
16.1.2  Chromatography 
Thin layer chromatography utilised to monitor reaction progress was conducted on plates pre-
coated with silica gel (Merck 60F254) or NH2F254S. The eluent was as stated (where this consisted 
of more than one solvent, the ratio is stated as volume:volume) and visualisation was either by 
short wave (254 nm) ultraviolet light, or by treatment with the visualisation reagent stated 
followed by heating. ‘Flash’ medium pressure liquid chromatography (MPLC) was carried out 
either on a Biotage SP4 automated purification system or a Varian 971-FP automated 
purification system, using pre-packed Varian or Grace silica or amino-bonded silica cartridges. 
Compounds were first loaded onto Biotage Isolute HM-N. 
 
16.1.3 Microwave Reactions 
All reactions carried out in a microwave were performed in a Biotage Initiator with Sixty robot. 
 
16.1.4 Analytical Techniques 
Melting points were determined using a VWR Stuart SMP40 apparatus and are uncorrected. 
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1H, 13C, 19F and 2D nuclear magnetic resonance (NMR) spectra were obtained as either CDCl3, 
CD3OD or DMSO-d6 solutions and recorded at 500 MHz, 125 MHz, 470 MHz and 76 MHz 
respectively, on a Bruker Avance III 500 spectrometer. Chemical shifts are quoted in parts per 
million (δ) referenced to the appropriate deuterated solvent employed. Multiplicities are 
indicated by s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad), ap 
(apparent) or combinations thereof. Coupling constant values are given in Hz. Homonuclear and 
heteronuclear two dimensional NMR experiments were used where appropriate to facilitate 
assignment of chemical shifts. 
LC-MS was carried out on a Waters Acquity UPLC system with PDA and ELSD employing 
positive or negative electrospray modes as appropriate to the individual compound. High 
resolution mass spectrometry was performed by the EPSRC UK National Mass Spectrometry 
Facility, University of Wales Swansea, Singleton Park, Swansea, SA2 8PP. 
FTIR spectra were recorded on either a Bio-Rad FTS 3000MX diamond ATR or an Agilent 
Cary 630 FTIR as a neat sample. 
UV spectra were obtained using a U-2001 Hitachi Spectrophotometer with the sample dissolved 
in ethanol. 
Data were compared with literature data for compounds which had been previously reported. 
 
16.2 Synthesis of MDMX Inhibitors-Experimental Procedures 
16.2.1 MDMX Biology Procedures 
ELISA 
To evaluate IC50 values of compounds, ELISA assay was undertaken by Dr Yan Zhao at the 
Northern Institute for Cancer Research (details taken from Hardcastle et al).201 The 96-well 
black and white high binding luminometry isoplates (Wallac, Cat N0 140-155) were coated by 
overnight incubation at 35 °C with 200 µL per well of 5 µg mL-1 streptavidin (Chemicon 
International) in coating buffer (0.1 M Na2HPO4‚2H2O; 0.1 M citric acid; pH 5.0). The plates 
were washed five times in 1× dissociation enhanced lanthanide fluorescence immunoassay 
(DELFIA) buffer (Wallac) and then incubated for 3 h at room temperature with saturation buffer 
(0.3 M D-sorbitol; 50 mM Tris; 150 mM NaCl; 0.1% BSA; 0.05% sodium azide; pH 7.0) to 
block nonspecific protein binding sites on the plate. After removal of the buffer from the plates, 
they were allowed to dry in a sterile laminar air flow hood at room temperature before 
incubation for 1 h at 4 °C with 200 µL per well of 100 µg mL-1 biotinylated IP3 peptide (b-
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IP3: Ac-Met-Pro-Arg-Phe19-Met-Asp-Tyr-Trp-Glu-Gly-Leu26- Asn-NH2)17 dissolved in 
0.05% DMSO-PBS, pH 7.4 buffer. After washing the wells three times with PBS, the plates 
were ready to use for MDM2 binding.  
For initial testing, the compounds and controls were plated out in triplicate into clear 96-well 
plates (Nunc) in 10-µL aliquots to give final concentrations of 500 µM, 100 µM, and 20 µM in 
the assay. Control samples consisted of 5% DMSO carrier alone as a negative control and 100 
nM active peptide (AP-B: Ac-Phe19-MetAib-Pmp-6-Cl-Trp-Glu-Ac3-Leu26-NH2) as a 
positive control peptide antagonist of the MDM2-p53 interaction (IC50 ) 5 nM).18 Compounds 
and controls aliquoted in 96-well plates were preincubated at 20 °C for 20 min with 190 µL 
aliquots of optimized concentrations of in vitro translated MDM2, before transfer of the 
MDM2-compound mixture to the b-IP3 streptavidin plates, and incubation at 4 °C for 90 min. 
After washing three times with PBS to remove unbound MDM2, each well was incubated at 20 
°C for 1 h with a TBS-Tween (50 mM Tris pH 7.5; 150 mM NaCl; 0.05% Tween 20 nonionic 
detergent) buffered solution of primary mouse monoclonal anti-MDM2 antibody (Ab-5, 
Calbiochem, used at a 1/200 dilution), then washed three times with TBS-Tween before 
incubation for 45 min at 20 °C with a goat-anti-mouse horseradish peroxidase (HRP) 
conjugated secondary antibody (Dako, used at 1/2000). The unbound secondary antibody was 
removed by washing three times with TBS-Tween. The bound HRP activity was measured by 
enhanced chemiluminescence (ECL, Amersham Biosciences) using the oxidation of the 
diacylhydrazide substrate, luminol, to generate a quantifiable light signal. The luminol substrate 
together with enhancer was automatically injected into each well and the relative luminescence 
units (RLU) measured over a 30 s interval using a Berthold MicroLumat-Plus LB 96 V 
microplate luminometer. The percentage MDM2 inhibition at a given concentration is 
calculated as the (RLU detected in the compound treated sample ÷ RLU of DMSO controls) × 
100. The IC50 was calculated using a plot of % MDM2 inhibition versus concentration and is 
the average of three independent experiments.  
The same procedure was used for measuring MDMX inhibition. 
 
16.2.2 Synthesis of MDMX Inhibitors: General Procedures 
Except where water was included in the reaction mixture, all reactions were carried out under 
strict anhydrous conditions with glassware oven-dried and cooled under nitrogen. Temperatures 
quoted refer to bath temperatures. 
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General Procedure A: Grignard reaction 
The relevant aldehyde (1 eq.) was dissolved in THF (1.2 mL/mmol) and cooled to -78 °C. A 
1.6 M solution of vinylmagnesium chloride in THF (5 eq.) was added dropwise and the reaction 
mixture was stirred at -78 °C for 30 min and at r.t. until the starting material was completely 
consumed. The reaction was quenched with saturated aqueous NH4Cl (20 mL), and extracted 
with ethyl acetate (3 × 20 mL). The organic layers were combined, washed with brine, dried 
over MgSO4, and the solvent removed in vacuo. 
 
General procedure B: Synthesis of β-keto ester 
A solution of Meldrum’s acid (1 eq.) in DCM (1.15 mL/mmol) was cooled to O ˚ C and pyridine 
(2 eq.) was added dropwise followed by addition of the relevant acid chloride (1 eq.). The 
reaction mixture was stirred at 0 ˚C for 1 h and at r.t. for 2.5 h. The reaction mixture was poured 
into a mixture of ice and 2 M HCl (10 mL) and extracted with DCM (3 × 50 mL). The organic 
layers were combined, washed with brine (20 mL) and water (20 mL), dried over MgSO4 and 
evaporated in vacuo to get an orange solid. The residue was suspended in ethanol, refluxed for 
2 h and stirred at r.t. for 16 h. The mixture was cooled and the solvent was removed in vacuo.  
 
General Procedure C: Synthesis of 1, 4-diketone 
To a solution of the relevant β-keto ester (1 eq.) in THF (0.6 ml/mmol) was added NaH (60% 
in mineral oil, 1.3 eq) and stirred for 20 min at 0 °C. A solution of the relevant 2-bromo-
acetophenone (1.1 eq.) in THF (0.5 mL/mmol) was added dropwise and the mixture was stirred 
at r.t. for 2.5 h. The reaction was quenched with water (20 mL) and extracted with EtOAc (3 × 
30 mL). The organic layers were combined, dried over MgSO4 and the solvent removed in 
vacuo.  
 
General Procedure D: Paal-Knorr pyrrole synthesis 
A mixture of the relevant 1,4-diketone (1 eq.), the relevant amine (5 eq.) and acetic acid (3 
mL/mmol) was heated under microwave irradiation to 170 °C for 10 min. The reaction was 
allowed to cool, neutralised with saturated aqueous NaHCO3 and extracted with EtOAc (3 × 30 
ml). The organic layers were combined, washed with brine, dried over MgSO4 and the solvent 
removed in vacuo.  
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General Procedure E: Hydrolysis of esters 
To a solution of the relevant ester (1 eq.), in MeOH:water (2:1) was added NaOH (30-50 eq.) 
and the mixture was stirred at 65 ˚C for 18 h. MeOH was added to the resulting suspension and 
stirred at 65 ˚C for 6 h. The reaction mixture was cooled and solvents removed in vacuo. The 
residue was dissolved in water (20 mL), acidified with 2M HCl and extracted with EtOAc (3 × 
20 mL). The organic layers were combined, dried over MgSO4 and the solvent removed in 
vacuo. 
 
General procedure F: DIBAL reduction of esters to alcohols 
The relevant pyrrole-ester (1 eq.) was dissolved in THF (1.6 mL/mmol) and cooled to 0 °C. 1M 
DIBAL in cyclohexane (2.5 eq.) was added dropwise and stirred at 0 °C until the starting 
material was completely consumed. The reaction mixture was warmed to r.t., MeOH (1.8 
mL/mmol) was added and stirred for 10 min. A saturated aqueous solution of Rochelle’s salt (6 
mL/mmol) was added and stirred for 10 min. Water (20 mL), brine (10 mL) and EtOAc (30 
mL) were added and the resulting mixture was stirred for 30 min. The aqueous layer was 
extracted with EtOAc (3 × 30 mL), organic layers were combined, dried over MgSO4 and the 
solvent removed in vacuo. 
 
General Procedure G: Oxidation of alcohols to aldehydes using Dess-Martin 
periodinane 
The relevant alcohol (1 eq.) was dissolved in DCM (4 mL/mmol) and cooled to 0 ˚C. Dess-
Martin periodinane (1.7 eq.) in DCM (6 mL/mmol) was added dropwise and the resulting 
mixture was stirred at 0 °C for 15 minutes, followed by stirring at r.t. until the starting material 
was completely consumed. Saturated aqueous NaHCO3 (20 mL) and saturated aqueous 
Na2S2O3 (25 mL) were added and stirred vigorously for 20 min. The aqueous layer was 
extracted with DCM (4 × 30 mL), dried over MgSO4, and the solvent removed in vacuo. 
 
General procedure H: Formylation of pyrroles 
The relevant pyrrole (1 eq.) was dissolved in DMF (5 mL/mmol) and cooled to 0 ˚C. 
Phosphorous oxychloride (5 eq.) was added dropwise, warmed to 70 ˚C and stirred until the 
starting material was completely consumed. NaOH (1M in H2O, 10 ml) and ice cubes were 
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added to the reaction mixture and heated at 100 ˚C for 45 min. The reaction mixture was cooled 
to r.t. and extracted with EtOAc (3 × 30 mL). The organic layers were combined, washed with 
brine, dried over MgSO4 and the solvent removed in vacuo. 
 
General procedure I: Pinnick Oxidation 
To a solution of the relevant pyrrole (1 eq.) in MeCN (11.8 mL/mmol), was added a solution of 
sodium chlorite (1.4 eq.) in water (1.12 mL/mmol of sodium chlorite). A solution of sulfamic 
acid (1.4 eq.) in water (1.12 mL/mmol of sodium chlorite) was added dropwise and the mixture 
was stirred at r.t. until the starting material was consumed. The solvent was removed in vacuo 
and water (30 mL) was added to the residue. The aqueous layer was extracted with EtOAc (3 × 
30 mL), dried over MgSO4 and the solvent removed in vacuo. 
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16.2.3 MDMX Inhibitors: Synthetic Procedures 
 
1-Phenylbut-3-en-2-ol (32)202 
 
Prepared according to general procedure A using phenylacetaldehyde (1.4 mL, 12.48 mmol), 
1.6 M solution of vinylmagnesium chloride in THF (11.7 mL, 18.72 mmol) and THF (15 mL). 
Purification by MPLC on SiO2 (Petrol:EtOAc, 0-17%) gave a yellow liquid (1.12 g, 61%). Rf = 
0.39 (15% EtOAc/Petrol); IR νmax/cm-1 3279 (OH), 3045, 2921, 2868; 1H NMR (500 MHz, 
CDCl3) δH 1.64 (1H, brs, OH), 2.81 (1H, dd, J = 13.6 and 8.0 Hz, ArCH2), 2.88 (1H, dd, J = 
13.6 and 5.4 Hz, 2 × ArCH2), 4.33-4.37 (1H, m, CHOH), 5.15 (1H, app dt, J = 10.5 and 1.4  
Hz, CH=CHcisH), 5.27 (1H, app dt, J = 17.2 and 1.4 Hz, CH=CHtransH), 5.95 (1H, ddd, J = 17.2, 
10.5, 5.8 Hz, CH=CH2), 7.24-7.27 (3H, m, 3 × ArH), 7.32-7.35 (2H, m, 2 × ArH); 
13C NMR 
(125 MHz, CDCl3) δC 43.8 (ArCH2), 73.6 (CHOH), 114.9 (CH=CH2), 126.5 (CH-Ar) , 128.4 
(2 × CH-Ar), 129.5 (2 × CH-Ar), 137.7 (C-Ar), 140.1 (CH=CH2). LRMS (ES
+) m/z 131.2 [(M-
H2O)+H]
+. 
 
1-Phenylbut-3-en-2-one (33)203 
 
Prepared according to general procedure G using compound 32 (698 mg, 4.71 mmol) in DCM 
(17 ml) and Dess-Martin periodinane (3.99 g, 9.42 mmol) in DCM (25 mL). The product was 
used for next step without further purification (685 mg, quant.). Rf = 0.67 (15% EtOAc/Petrol); 
λmax (EtOH)/nm 210, 256; IR νmax/cm-1 1670 (C=O); 1H NMR (500 MHz, CDCl3) δH 3.87 (2H, 
s, 2 × ArCH2), 5.82 (1H, dd, J = 10.3 and 1.2 Hz, CH=CHcisH), 6.30 (1H, dd, J = 17.5 and 1.2 
Hz, CH=CHtransH), 6.40 (1H, dd, J = 17.5 and 10.3 Hz, CH=CH2), 7.20-7.22 (2H, m, 2 × ArH), 
7.24-7.27 (1H, m, ArH), 7.31-7.35 (2H, m, 2 × ArH); 13C NMR (125 MHz, CDCl3) δC (125 
MHz, CDCl3) δ 47.2 (ArCH2), 127.0 (CH-Ar), 128.8 (2 × CH-Ar), 129.1 (CH=CH2), 129.4 (2 
× CH-Ar), 134.1 (C-Ar), 135.6 (CH=CH2), 197.7 (C=O). 
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1,5-Diphenylpentane-1,4-dione (34) 
 
Benzaldehyde (0.14 ml, 1.4 mmol)  was dissolved in ethanol (0.8 mL), triethylamine (0.4 mL, 
2.8 mmol), compound 33 (225 mg, 1.5 mmol), and 3-benzyl-5-(2-hydroxyethyl)-4-
methylthiazolium chloride (94 mg, 0.35 mmol) were added and stirred at 80 °C for 19 h. The 
solvent was evaporated in vacuo and the residue was treated with 2M HCl (10 mL). The aqueous 
layer was extracted with DCM (3 × 20 ml). The organic layers were combined, washed with 
saturated aqueous NaHCO3, dried over MgSO4 and evaporated in vacuo. Purification by MPLC 
on SiO2 (DCM:MeOH, 0-1%) gave a pale brown viscous liquid (230 mg, 65%). Rf = 0.40 (20% 
EtOAc/Petrol); λmax (EtOH)/nm 240; IR νmax/cm-1 1709 (C=O), 1686 (C=O); 1H NMR (500 
MHz, CDCl3) δH 2.89 (2H, t, J = 6.3 Hz, 2 × CH2CO), 3.26 (2H, t, J = 6.3 Hz, 2 × CH2CO), 
3.82 (2H, s, 2 × ArCH2), 7.24-7.28 (3H, m, 3 × ArH), 7.32- 7.35 (2H, m, 2 × ArH), 7.43-7.46 
(2H, m, 2 × ArH) 7.52-7.57 (1H, m, ArH), 7.95-7.97 (2H, m, 2 × ArH); 13C NMR (125 MHz, 
CDCl3) δC 32.5 (CH2CO), 35.6 (CH2CO), 50.2 (ArCH2), 127.1 (CH-Ar), 128.1 (2 × CH-Ar), 
128.6 (2 × CH-Ar), 128.7 (2 × CH-Ar), 129.5 (2 × CH-Ar), 133.2 (C-Ar), 134.3 (C-Ar), 136.6 
(C-Ar), 198.5 (C=O), 207.1 (C=O). LRMS (ES+) m/z 253.3 [M+H]+. 
 
2-Benzyl-1-(4-chlorophenyl)-5-phenyl-1H-pyrrole (30) 
 
A mixture of compound 34 (70 mg, 0.28 mmol), 4-chloroaniline (40 mg, 0.31 mmol) and acetic 
acid (2 mL) was refluxed for 1.5 h. After cooling to r.t., water (20 mL) was added and the 
mixture was neutralised with 1N NaOH. The aqueous layer was extracted with DCM (3 × 20 
mL), the organic layers were combined, washed with water (30 mL), dried over MgSO4 and 
evaporated in vacuo. Purification by MPLC on SiO2 (Petrol:EtOAc, 0-20%) gave a white solid 
(29 mg, 30%). Rf = 0.83 (20% EtOAc/Petrol); m.p. 165 °C; λmax (EtOH)/nm 286; IR νmax/cm-1 
3065, 2922, 2658, 1489.; 1H NMR (500 MHz, CDCl3) δH 3.73 (2H, s, 2 × CH2), 6.00 (1H, d, J 
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= 3.5 Hz, Pyrrole-H), 6.30 (1H, d, J = 3.5 Hz, Pyrrole-H), 6.87-6.89 (2H, m, 2 × ArH), 6.93-
6.97 (4H, m, 4 × ArH), 7.00-7.03 (1H, m, ArH), 7.05-7.09 (3H, m, 3 × ArH),  7.11-7.18 (4H, 
m, 4 × ArH).; 13C NMR (125 MHz, CDCl3) δC 33.6 (ArCH2), 109.0 (2 × CH-Pyrrole), 126.0 
(C-Ar), 126.1 (C-Ar), 127.9 (2 × C-Ar), 128.1 (2 × C-Ar), 128.3 (2 × C-Ar), 128.6 (2 × C-Ar), 
129.1 (2 × C-Ar), 130.0 (2 × C-Ar), 133.0 (C-Ar), 133.4 (C-Ar), 134.8 (C-Ar), 134.8 (C-Ar), 
137.7 (C-Ar), 139.4 (C-Ar); LRMS (ES+) m/z 344.3 [M(35Cl)+H]+, 346.4 [M(37Cl)+H]+. 
 
2-(4-Chlorophenyl)acetaldehyde (36) 
 
Prepared according to general procedure G using 2-(4-chlorophenyl) ethanol (244 mg, 1.56 
mmol) in DCM (5 mL) and Dess-Martin periodinane (1 g, 2.35 mmol) in DCM (8 mL). 
Purification by MPLC on SiO2 (Petrol:EtOAc, 0-20%) gave a colourless liquid (160 mg, 66%). 
Rf = 0.70 (15% EtOAc/Petrol); IR νmax/cm-1 3030, 2925, 1701 (C=O); 1H NMR (500 MHz, 
CDCl3) δH 3.68 (2H, d, J = 2.1 Hz, 2 × ArCH2), 7.14-7.16 (2H, m, 2 × ArH), 7.33-7.35 (2H, m, 
2 × ArH), 9.74 (t, J = 2.1 Hz, CHO); 13C NMR (125 MHz, CDCl3) δC 49.8 (CH2), 129.1 (2 × 
CH-Ar), 130.3 (C-Ar), 130.9 (2 × CH-Ar), 133.5 (C-Ar), 198.6 (C=O). 
 
1-(4-Chlorophenyl)but-3-en-2-ol (37) 
 
Prepared according to general procedure A using compound 36, 1.6 M solution of 
vinylmagnesium chloride in THF (9.5 mL, 15.16 mmol) and THF (15 mL). Purification by 
MPLC on SiO2 (Petrol:EtOAc, 0-20%) gave a colourless liquid (535 mg, 39%). Rf = 0.38 (15% 
EtOAc/Petrol); λmax (EtOH)/nm 221, IR νmax/cm-1 3368 (OH), 3081, 2921, 2854, 1490; 1H 
NMR (500 MHz, CDCl3) δH 2.76 (1H, dd, J = 13.6, 7.6 Hz, ArCH2), 2.82 (1H, dd, J = 13.6, 5.2 
Hz, ArCH2), 4.29-4.33 (1H, m, CHOH), 5.12 (1H, dt, J = 10.4 and 1.2 Hz, CH=CHcisH), 5.22 
(1H, dt, J = 17.2 and 1.2 Hz, CH=CHtransH), 5.89 (1H, ddd, J = 17.2, 10.4, 5.9 Hz, CH=CH2), 
7.14-7.14 (2H, m, 2 × ArH), 7.25-7.28 (2H, m, 2 × ArH); 13C NMR (125 MHz, CDCl3) δC 43.0 
(ArCH2), 73.5 (CHOH), 115.3 (CH=CH2), 128.6 (2 × CH-Ar), 130.9 (2 × CH-Ar), 132.4 (C-
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Ar), 136.3 (C-Ar), 139.9 (CH=CH2). LRMS (ES
+) m/z 165.2 [(M(35Cl)-H2O)+H]
+, 167.2 
[(M(37Cl)-H2O)+H]
+. 
 
1-(4-Chlorophenyl)but-3-en-2-one (38)204  
 
Prepared according to general procedure G using compound 37 (100 mg, 0.547 mmol) in DCM 
(2 mL) and Dess-Martin periodinane (348 mg, 0.82 mmol) in DCM (4 mL). Purification (SP4, 
silica, EtOAc/Petrol, 0-10%) gave a colourless liquid; Rf = 0.70 (EtOAc/Petrol, 15%); λmax 
(EtOH)/nm 218; IR νmax/cm-1 3035, 2921, 1690 (C=O stretch); 1H NMR (500 MHz, CDCl3) δ 
3.85 (2H, s, 2×ArCH2), 5.86 (1H, dd, J = 10.3, 1.2 Hz, CH=CHcisH), 6.30 (1H, dd, J = 17.5, 1.2 
Hz, CH=CHtransH), 6.40 (1H, dd, J = 17.5 and 10.3 Hz, CH=CH2), 7.12-7.14 (2H, m, 2 × ArH), 
7.28-7.31 (2H, m, 2 × ArH). 
 
5-(4-Chlorophenyl)-1-(4-fluorophenyl)pentane-1,4-dione (39) 
 
To a solution of 4-fluorobenzaldehyde (0.06 ml, 0.497 mmol) in ethanol (0.3 mL), was added 
triethylamine (0.14 mL, 0.25 mmol), compound 38 (crude product), and 3-benzyl-5-(2-
hydroxyethyl)-4-methylthiazolium chloride (33 mg, 0.124 mmol) and stirred at 80 °C for 19 h. 
The solvent was evaporated in vacuo and the residue was treated with 2 M HCl (10 mL). The 
aqueous layer was extracted with DCM (3 × 20 mL), organic layers were combined, washed 
with saturated aqueous NaHCO3, dried over MgSO4 and evaporated in vacuo. Purification by 
MPLC on SiO2 (Petrol:DCM, 0-80%) gave a colourless viscous liquid (50 mg, 30% in 2 steps). 
Rf = 0.42 (20% EtOAc/Petrol); λmax (EtOH)/nm 240; IR νmax/cm-1 3078, 2909, 1710 (C=O), 
1689 (C=O); 1H NMR (500 MHz, CDCl3) δH 2.88 (2H, t, J = 6.1 Hz, CH2CO), 3.23 (2H, t, J = 
6.1 Hz, CH2CO), 3.80 (2H, s, ArCH2), 7.09-7.14 (2H, m, 2 × ArH), 7.15- 7.18 (2H, m, 2 × 
ArH), 7.29-7.31 (2H, m, 2 × ArH), 7.96-8.00 (2H, m, 2 × ArH); 13C NMR (125 MHz, CDCl3) 
δC 32.5 (CH2CO), 35.8 (CH2CO), 49.3 (ArCH2), 115.7 (2C, d, J =21.5 Hz, 2 × ArCHCF), 128.8 
(2 × CH-Ar), 130.7 (2C, d, J = 9.3 Hz, 2 × ArCHCHCF), 130.9 (2 × CH-Ar), 132.6 (C-Ar), 
133.0 (d, J = 2.9 Hz, ArCCHCHCF), 133.1 (C-Ar), 165.8 (d, J = 254.9 Hz, ArCF), 196.8 (C=O), 
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206.4 (C=O); 19F NMR (470 MHz; CDCl3) δ -105.0; HRMS calcd for C17H15ClFO2 
[M(35Cl)+H]+ 305.0720, found 305.0721. 
 
2-(4-Chlorobenzyl)-1-(4-Chlorophenyl)-5-(4-fluorophenyl)-1H-pyrrole (40) 
 
A mixture of compound 39 (35 mg, 0.115 mmol), 4-chloroaniline (15 mg, 0.115 mmol) and 
acetic acid (0.9 ml) were refluxed for 8 h. After cooling to r.t., water (20 mL) was added and 
the mixture was neutralised with 1M NaOH. The aqueous layer was extracted with DCM (3 × 
20 mL), the organic layers were combined, washed with water (30 mL), dried over MgSO4 and 
evaporated in vacuo. Purification by MPLC on SiO2 (Petrol:DCM, 0-15%) gave a white solid 
(14 mg, 31%) Rf = 0.56 (10% EtOAc/Petrol); m.p. 110-112 °C; λmax (EtOH)/nm 247; IR 
νmax/cm-1 2924, 2251, 1493; 1H NMR (500 MHz, CDCl3) δH 3.68 (2H, s, CH2), 5.99 (1H, d, J = 
3.5 Hz, Pyrrole-H), 6.24  (1H, d, J = 3.5 Hz, Pyrrole-H), 6.75-6.79 (2H, m, 2 × ArH), 6.83-6.85 
(4H, m, 4 × ArH), 6.90-6.93 (2H, m, 2 × ArH), 7.08-7.11 (2H, m, 2 × ArH), 7.16-7.18 (2H, m, 
2 × ArH). 13C NMR (125 MHz, CDCl3) δC 33.0 (CH2), 108.9 (CH-Pyrrole), 109.1 (CH-Pyrrole), 
115.1 (2C, d, J =21.5 Hz, 2 × ArCHCF), 128.4 (2 × CH-Ar), 129.1 (d, J = 3.2 Hz, 
ArCCHCHCF) 129.2 (2 × CH-Ar), 129.6 (2C, d, J = 7.8 Hz, 2 × ArCHCHCF), 129.9 (2 × CH-
Ar), 129.9 (2 × CH-Ar), 131.9 (C-Ar), 133.7 (C-Ar), 133.9 (C-Ar), 134.0 (C-Ar), 137.4 (C-Ar), 
137.8 (C-Ar), 161.4 (d, J = 246.0 Hz, ArCF). 19F NMR (470 MHz; CDCl3) δF -116.0; HRMS 
calcd for C23H17Cl2FN [M(
35Cl2)+H]
+ 396.0526, found 396.0523. 
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1-(4-Bromophenyl)-2-(4-chlorobenzyl)-5-(4-fluorophenyl)-1H-pyrrole (41) 
 
Prepared according to general procedure D using compound 39 (50 mg, 0.164 mmol), 4-
bromoaniline (141 mg, 0.82 mmol) and acetic acid (0.5 mL). Purification by MPLC on SiO2 
(Petrol:EtOAc, 0-20%) gave a white solid (60 mg, 83%) Rf = 0.56 (EtOAc/Petrol, 10%); m.p. 
123-125 °C; λmax (EtOH)/nm 248; IR νmax/cm-1 3053, 2847, 2285, 1590, 1485; 1H NMR (500 
MHz, CDCl3) δH 3.68 (2H, s, CH2), 5.98 (1H, d, J = 3.5 Hz, Pyrrole-H), 6.24  (1H, d, J = 3.5 
Hz, Pyrrole-H), 6.75-6.79 (4H, m, 4 × ArH), 6.84-6.86 (2H, m, 2 × ArH), 6.90-6.93 (2H, m, 2 
× ArH), 7.09-7.11 (2H, m, 2 × ArH), 7.32-7.35 (2H, m, 2 × ArH); 13C NMR (125 MHz, CDCl3) 
δC 33.0 (CH2), 108.9 (CH-Pyrrole), 109.1 (CH-Pyrrole), 115.1 (2C, d, J = 21.5 Hz, 2 × 
ArCHCF), 121.7 (C-Ar), 128.4 (2 × CH-Ar), 129.1 (d, J = 3.2 Hz, ArCCHCHCF) 129.6 (2C, 
d, J = 7.9 Hz, 2 × ArCHCHCF), 129.9 (2 × CH-Ar), 130.3 (2 × CH-Ar), 132.0 (C-Ar), 132.7 
(C-Ar), 133.9 (C-Ar), 134.0 (C-Ar), 137.4 (C-Ar), 137.8 (C-Ar), 137.9 (C-Ar), 161.4 (d, J = 
246.1 Hz, ArCF); 19F NMR (470 MHz; CDCl3) δF -116.0; HRMS calcd for C23H16BrClFN 
[M(79Br35Cl)+H]+ 440.0025, found 440.0023. 
 
2-(4-Chlorobenzyl)-1-(3,4-difluorophenyl)-5-(4-fluorophenyl)-1H-pyrrole (42) 
 
Prepared according to general procedure D using compound 39 (23 mg, 0.075 mmol), 3,4-
difluoroaniline (0.04 ml, 0.375 mmol) and acetic acid (0.23 mL). Purification by MPLC on 
SiO2 (Petrol:EtOAc, 0-20%) gave a white solid (60 mg, 77%). Rf = 0.52 (10% EtOAc/Petrol); 
m.p. 118-120 °C; λmax (EtOH)/nm 277; IR νmax/cm-1 2912, 2088, 1519; 1H NMR (500 MHz, 
CDCl3) δH 3.69 (2H, s, CH2), 5.99 (1H, d, J = 3.5 Hz, Pyrrole-H), 6.23  (1H, d, J = 3.5 Hz, 
181 
 
Pyrrole-H), 6.63-6.66 (1H, m, ArH ), 6.73-6.76 (1H, m, ArH), 6.77-6.80 (2H, m, 2 × ArH), 
6.83-6.85 (2H, m, 2 × ArH), 6.90-6.93 (2H, m, 2 × ArH), 6.98 (1H, q, J = 18.4, 8.7 Hz, ArH), 
7.11 (2H, d, J = 8.3 Hz, 2 × ArH); 13C NMR (125 MHz, CDCl3) δC 33.0 (CH2), 109.0 (CH-
Pyrrole), 109.3 (CH-Pyrrole), 115.2 (2C, d, J = 21.5 Hz, 2 × ArCHCF), 117.4 (d, J = 18.2 Hz, 
ArCHCFCF), 118.1 (d, J = 18.0 Hz, ArCHCFCF), 125.1 (dd, J = 6.1, 3.3 Hz, ArCHCHCFCF), 
128.5 (2 × CH-Ar), 128.9 (d, J=3. 3 Hz, ArCCHCHCF), 129.6 (2C, d, J = 7.9 Hz, 2 × 
ArCHCHCF), 129.8 (2 × CH-Ar), 132.1 (C-Ar), 134.0 (C-Ar), 134.2 (C-Ar), 135.2 (dd, J = 7.4, 
3.4 Hz, ArCCHCFCF), 137.6 (C-Ar), 149.8 (dd, J = 250.4, 12.5 Hz, ArCF), 149.9 (dd, J = 
246.4 Hz, ArCF), 161.5 (dd, J = 246.4 Hz, ArCF). 19F NMR (470 MHz; CDCl3) δF -137.2 (d, J 
= 20.8 Hz), -134 (d, J = 20.8 Hz), -115.7; HRMS calcd for C23H16ClF3N [M(
35Cl)+H]+ 
398.0920, found 398.0918. 
 
6-Chloro-3-nitro-1H-indole (44) 
 
6-chloroindole (305 mg, 2.01 mmol) and silver nitrate (362 mg, 2.13 mmol) were suspended in 
MeCN (1.9 mL) and cooled to 0 ˚C. Benzoyl chloride (0.25 mL, 2.13 mmol) was added 
dropwise and the mixture was stirred at 0 ˚C for 30 min. The reaction mixture was treated with 
MeOH (5 mL) and filtered through PL-thiol cartridge. The filtrate was evaporated in vacuo and 
the residue was purified by MPLC (H2O:MeOH, reversed phase with 0.1% HCOOH modifier, 
0-85%) to get a yellow solid (165 mg, 42%). Rf = 0.46 (40% EtOAc/Petrol); m.p. 234-236 °C; 
IR νmax/cm-13191, 3144, 1456, 1368, 1199; 1H NMR (500 MHz, DMSO-d6) δH 7.37 (1H, dd, J 
= 8.5  and 1.8 Hz, H5), 7.61 (1H, d, J = 1.8 Hz, H7),  8.05 (1H, d, J = 8.5 Hz, H4),  8.67 (1H, s, 
H2), 12.74 (1H, br s, NH); 13C NMR (125 MHz, DMSO-d6): δC 113.6 (CH7), 119.1 (C-Ar), 
121.3 (CH4), 124.5 (CH5), 128.9 (C-Ar), 129.2 (C-Ar), 131.9 (CH2), 135.9 (C-Ar). LRMS (ES-
) m/z 195.1 [M(35Cl)-H]-, 197.1 [M(37Cl)-H]-. 
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tert-Butyl 6-chloro-1H-indole-1-carboxylate (47) 
 
6-chloroindole (1 g, 6.59 mmol) and DMAP (402 mg, 3.29 mmol) were dissolved in MeCN (5 
mL). A solution of di-tert-butyl dicarbonate (2.27 mL, 9.88 mmol) in MeCN (15 mL) was added 
dropwise and the mixture was stirred at r.t. for 2 h. The solvent was evaporated in vacuo to get 
brown coloured liquid. Purification by MPLC on SiO2 (Petrol:EtOAc, 0-15%) gave a colourless 
liquid (1.6 g, 97%). Rf = 0.50 (20% EtOAc/Petrol); 
1H NMR (500 MHz, CDCl3) δH 1.67 (9H, 
s, 3 × CH3), 6.52 (1H, d, J = 3.3 Hz, H
3), 7.19 (1H, dd, J = 8.3 and 1.9 Hz, H5), 7.44 (1H, d, J 
= 8.3 Hz, H4),  7.56 (1H, d, J = 3.3 Hz, H2),  8.19 (1H, s, H7); 13C NMR (125 MHz, CDCl3) δC 
28.2 (CH3), 84.2 (C-CH3), 107.0 (CH
3), 115.5 (CH7), 121.6 (CH4), 123.2 (CH5), 126.4 (CH2), 
129.0 (C-Ar), 130.2 (C-Ar), 135.6 (C-Ar), 149.4 (C=O). LRMS (ES+) m/z 252.3 [(M(35Cl)+H]+, 
254.4 [(M(37Cl)+H]+. 
 
tert-Butyl 6-chloro-3-nitro-1H-indole-1-carboxylate (48) 
 
Acetyl nitrate was generated by the dropwise addition of fuming HNO3 (0.15 mL, 3.57 mmol) 
to Ac2O (2.4 mL) at 0 °C followed by standing at r.t. for 5 min and was used immediately. 
Compound 47 (300 mg, 1.19 mmol) was dissolved in Ac2O (6 mL) and cooled to -78 °C and a 
solution of the acetyl nitrate was added dropwise. The mixture was warmed to 0 °C and stirred 
for 17 h. The reaction mixture was neutralised with saturated aqueous NaHCO3 and stirred for 
20 min. The aqueous layer was extracted with EtOAc (4 × 50 mL), the organic layers were 
combined, dried over MgSO4 and the solvent was removed in vacuo. Purification by MPLC on 
SiO2 (Petrol:EtOAc, 0-6%) gave a pale yellow solid (180 mg, 51%). Rf = 0.50 (5% 
EtOAc/Petrol); λmax (EtOH)/nm 319, 250; IR νmax/cm-13148, 3114, 2974,2928, 1747 (C=O), 
1542, 1493, 1326; 1H NMR (500 MHz, CDCl3) δH 1.70 (9H, s, 3×CH3), 7.42 (1H, dd, J = 8.6 
and 1.8 Hz, H5), 8.17 (1H, d, J = 8.6 Hz, H4),  8.28 (1H, d, J = 1.8 Hz, H7),  8.49 (1H, s, H2); 
13C NMR (125 MHz, CDCl3): δC 28.0 (3 × CH3), 87.3 (C-CH3), 115.9 (CH7), 120.0 (C-Ar), 
121.6 (CH4), 126.2 (CH5), 128.1 (CH2), 132.3 (C-Ar), 132.9 (C-Ar), 134.6 (C-Ar), 147.8 (C-
Ar); HRMS calcd for C13H14ClN2O4 [M(
35Cl)+H]+ 297.0637, found 297.0638. 
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Methyl 4-(4-chlorophenyl)-2-(2-(4-fluorophenyl)-2-oxoethyl)-3-oxobutanoate (54) 
 
1M Diethylzinc in hexane (15 mL, 14.76 mmol) was dissolved in DCM (28 mL) and cooled to 
0 °C. Diiodomethane (1.2 mL, 14.76 mmol) was added dropwise, and the mixture was stirred 
for 30 min. After the formation of a white precipitate, methyl 4-fluorobenzoyl acetate (0.57 mL, 
3.6 mmol) was added dropwise, and the reaction mixture was stirred for 30 min. Compound 36 
(736 mg, 5 mmol) was added and the mixture was stirred at 0 °C for 1.5 h. Silica gel (10 g) was 
added and the mixture was stirred at r.t. for 30 min. The mixture was filtered and the solvent 
was evaporated in vacuo. The residue was dissolved in DCM (8 mL), PCC (853 mg, 3.96 mmol) 
was added, and the mixture was stirred at r.t. for 17 h. Then, additional PCC (776 mg, 3.6 mmol) 
was added and the reaction mixture was stirred at r.t. for 24 h. The mixture was passed through 
a short path of silica gel and eluted with DCM and concentrated in vacuo. Purification by MPLC 
on SiO2 (Petrol:EtOAc, 0-20%) followed by another purification by MPLC (H2O:MeOH, 
reversed phase with 0.1% HCOOH modifier, 0-100%) gave a pale yellow viscous liquid (436 
mg, 33%). Rf = 0.36 (25% EtOAc/Petrol); λmax (EtOH)/nm 244, 225; IR νmax/cm-1 3070, 2954, 
2920, 1742 (C=O), 1719 (C=O), 1680 (C=O); 1H NMR (500 MHz, CDCl3) δH 3.51 (1H, dd, J 
= 18.3 and 4.8 Hz, 1 × CH2), 3.70-3.75 (1H, m, peaks coincided with OMe singlet, 1 × CH2), 
3.75 (3H, s, CH3), 4.05 (1H, d, J = 16.9 Hz, ArCH2), 4.10 (1H, d, J = 16.9 Hz, ArCH2), 4.30 
(2H, dd, J = 8.9 and 4.8 Hz, CHCOOMe), 7.11-7.19 (4H, m, 4 × ArH), 7.29-7.31 (2H, m, 2 × 
ArH), 7.97-8.00 (2H, m, 2 × ArH); 13C NMR (125 MHz, CDCl3) δC 37.7 (CH2), 49.1 (ArCH2), 
52.4 (CHCOOMe), 52.9 (COOCH3), 115.9 (2C, d, J = 22.0 Hz, 2 × ArCHCF), 128.7 (2 × CH-
Ar),  130.9 (2C, d, J = 9.4 Hz, 2 × ArCHCHCF), 131.2 (2 × CH-Ar), 131.9 (C-Ar), 132.4 (d, J 
= 2.9 Hz, ArCCHCHCF), 133.1 (C-Ar), 166.1 (d, J = 255.5 Hz, ArCF), 169.1 (C=O), 195.5 
(C=O), 201.7 (C=O);  19F NMR (470 MHz; CDCl3) δF -104.1; HRMS calcd for  C19H17ClFO4 
[M(35Cl)+H]+ 363.0794, found 363.0787. 
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Methyl 2-(4-chlorobenzyl)-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1H-pyrrole-3-
carboxylate (55) 
 
Prepared according to general procedure D using compound 54 (200 mg, 0.55 mmol), 4-
chloroaniline (350 mg, 2.75 mmol) and acetic acid (1.6 ml). Purification by MPLC on SiO2 
(Petrol:EtOAc, 0-20%) gave a white solid (121 mg, 48%). Rf = 0.56 (10% EtOAc/Petrol); m.p. 
124-126 °C; λmax (EtOH)/nm 263; IR νmax/cm-1 3068, 2946, 1700 (C=O); 1H NMR (500 MHz, 
CDCl3) δH 3.84 (3H, s, COOCH3), 4.23 (2H, s, 2 × CH2), 6.78-6.87 (7H, m, 7 × ArH), 6.96-
6.99 (2H, d, 2 × ArH), 7.11-7.13 (2H, m, 2 × ArH), 7.23-7.25 (2H, m, 2 × ArH); 13C NMR (125 
MHz, CDCl3) δC 30.8 (CH2), 51.2 (COOCH3), 110.3 (CH-Pyrrole), 113.8 (C-Ar), 115.3 (2C, d, 
J = 21.6 Hz, 2 × ArCHCF), 127.9 (d, J = 3.3 Hz, ArCCHCHCF), 128.4 (2 × CH-Ar), 129.4 (2 
× CH-Ar), 129.5 (2 × CH-Ar), 130.0 (2 × CH-Ar), 130.1 (2C, d, J=8.05 Hz, 2 × ArCHCHCF), 
131.9 (C-Ar), 133.8 (C-Ar), 134.7 (C-Ar), 136.0 (C-Ar), 137.4 (C-Ar), 139.0 (C-Ar), 161.8 (d, 
J = 247.5 Hz, ArCF), 165.5 (COOMe). 19F NMR (470 MHz; CDCl3) δF -114.5; HRMS calcd 
for C25H19Cl2FNO2 [M(
35Cl2)+H]
+ 454.0771, found 454.0763. 
 
2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1H-pyrrole-3-carboxylic acid 
(2) 
 
Compound 55 (70 mg, 0.15 mmol) was dissolved in THF (1 mL), 4 M LiOH in H2O 
monohydrate (1 mL), and the mixture was stirred at r.t. for 15 h. To the resulting suspension, 
MeOH (1 mL) was added and the mixture was stirred at r.t. for 72 h. Then, the reaction mixture 
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was neutralised with 2 M HCl and extracted with EtOAc (3 × 20 mL). The organic layers were 
combined, dried over MgSO4, and evaporated in vacuo. Purification by MPLC on SiO2 
(Petrol:EtOAc, 0-20%) gave a white solid (60 mg, 91%). The reaction repeated with 50 mg of 
the ester starting material to have enough material for the next step. Rf = 0.62 (2% 
MeOH/DCM); m.p. 184-186 °C; λmax (EtOH)/nm 255; IR νmax/cm-1 2300-3100 (very broad, O-
H overlap with C-H), 1669 (C=O); 1H NMR (500 MHz, CDCl3) δH 4.24 (2H, s, CH2), 6.79-
6.88 (7H, m, 7 × ArH), 6.97-7.00 (2H, m, 2 × ArH), 7.12 (2H, d, J = 7.9 Hz, 2 × ArH), 7.25 
(2H, d, coincided with CDCl3 peak, 2 × ArH); 
13C NMR (125 MHz, CDCl3) δC 30.8 (CH2), 
110.8 (Pyrrole-CH), 115.3 (2C, d, J = 21.6 Hz, 2 × ArCHCF), 127.7 (d, J = 3.4 Hz, 
ArCCHCHCF), 128.4 (2 × CH-Ar), 129.4 (2 × CH-Ar), 129.5 (2 × CH-Ar), 130.0 (2 × CH-Ar), 
130.1 (2C, d, J = 8.1 Hz, 2 × ArCHCHCF), 131.9 (C-Ar), 134.2 (C-Ar), 134.8 (C-Ar), 135.9 
(C-Ar), 137.1 (C-Ar), 140.1 (C-Ar), 161.9 (d, J = 247.5 Hz, ArCF), 170.0 (COOH). 19F NMR 
(470 MHz; CDCl3) δF -114.3; HRMS calcd for C24H17Cl2FNO2 [M(35Cl2)+H]+ 440.0615, found 
440.0610. 
 
2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-N-(2,2-dimethyl-1,3-dioxan-5-yl)-5-(4-
fluorophenyl)-1H-pyrrole-3-carboxamide (57) 
 
Compound 2 (98 mg, 0.22 mmol), amine 115 (34 mg, 0.26 mmol) and DMAP (2.5 mg, 0.02 
mmol) were dissolved in DCM (2 mL) and the reaction mixture was stirred at 0 °C for 5 min. 
DIC (0.04 ml, 0.26 mmol) was added and the resulting solution was stirred at 0 °C for 15 min 
and at r.t. for 16 h. The reaction mixture was quenched with water (10 mL) and extracted with 
DCM (3 × 20 mL). The organic layers were combined, dried over MgSO4, and concentrated in 
vacuo. Purification by MPLC on SiO2 (Petrol:EtOAc, 0-50%) gave a white solid (85 mg, 70%). 
Rf = 0.17 (33% EtOAc/Petrol); m.p. 152-154°C; λmax (EtOH)/nm 240; IR νmax/cm-1 3302 (NH), 
2968, 2939, 2876, 1616 (C=O); 1H NMR (500 MHz, CDCl3) δH 1.43 (3H, s, CH3), 1.51 (3H, s, 
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CH3), 3.82 (2H, d, J = 11.3 Hz, CH2OC), 4.05-4.08 (1H, m, CONHCHCH2), 4.20 4.25 (2H, d, 
J = 11.3 Hz, CH2OC), 4.25 (2H, s, 2 × CH2), 6.56 (1H, s, pyrrole-H), 6.80-6.89 (7H, m, 6 × 
ArH, 1 × CONH), 6.98-7.01 (2H, m, 2 × ArH), 7.10-7.11 (2H, m, 2 × ArH), 7.23-7.24 (2H, m, 
2 × ArH); 13C NMR (125 MHz, CDCl3) δC 18.5 (CH3), 29.1 (CH3), 30.7 (Ar-CH2), 43.3 
(CONHCHCH2), 64.0 (2C, 2 × CH2OC), 98.6 (C(CH3)2), 107.3 (CH-Pyrrole), 115.3 (2C, d, J 
= 21.6 Hz, 2 × ArCHCF), 116.8 (C-Ar), 127.9 (d, J = 3.3 Hz, ArCCHCHCF), 128.3 (2 × CH-
Ar), 129.3 (2 × CH-Ar), 129.6 (2 × CH-Ar), 130.0 (2 × CH-Ar), 130.1 (2C, d, J = 8.1 Hz, 2 × 
ArCHCHCF), 131.8 (C-Ar), 133.7 (C-Ar), 134.5 (C-Ar), 136.1 (C-Ar), 137.1 (C-Ar), 137.8 (C-
Ar), 161.9 (d, J = 247.6 Hz, ArCF), 164.7 (COONH); 19F NMR (470 MHz; CDCl3) δF -114.5; 
HRMS calcd for C30H26Cl2FN2O3 [M(
35Cl2)-H]
- 551.1310, found 551.1297. 
 
2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-N-(1,3-dihydroxypropan-2-yl)-5-(4-
fluorophenyl)-1H-pyrrole-3-carboxamide (58) 
 
Compound 57 (60 mg, 0.108 mmol) was dissolved in THF (1.7 mL) and 2 M HCl (0.57 mL) 
was added dropwise and stirred at r.t. for 3 h. 2 M HCl (0.29 mL) was added again and the 
reaction was stirred for 15 min. The solvent was evaporated in vacuo and the residue was 
neutralised with 1 M NaOH and extracted with EtOAc (3 × 20 mL). The organic layers were 
combined, washed with H2O, dried over MgSO4 and evaporated in vacuo to get a white solid 
(52 mg, 94%). Rf = 0.34 (5% MeOH/DCM); m.p. 210-212 °C; λmax (EtOH)/nm 239; IR νmax/cm-
1 3344 (broad, Amide N-H and O-Hs overlapped), 2922, 2852, 1600 (C=O stretch); 1H NMR 
(500 MHz, DMSO-d6) δH 3.52 (4H, t, J = 5.7 Hz, 2 × CH2OC), 3.93-3.99 (1H, m, 
CONHCHCH2),  4.29 (2H, s, 2 × ArCH2), 4.65 (2H, t, J = 5.7 Hz, 2 × CH2OH), 6.78-6.80 (2H, 
m, 2 × ArH), 6.99 (1H, s, Pyrrole-H,), 7.01-7.03 (2H, m, 2 × ArH), 7.07 (4H, d, J = 7.2 Hz, 4 
× ArH), 7.15-7.17 (2H, m, 2 × ArH), 7.46 (1H, d, J = 8.5 Hz, CONH); 13C NMR (125 MHz, 
DMSO-d6) δC 29.6 (CH2), 52.9 (CONHCHCH2), 60.5 (2C, 2 × CH2OC), 108.4 (CH-Pyrrole), 
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115.2 (2C, d, J = 21.6 Hz, 2 × ArCHCF), 116.7 (C-Ar), 127.8 (2 × CH-Ar), 128.4 (d, J = 3.3 
Hz, ArCCHCHCF), 129.2 (2 × CH-Ar), 129.7 (2 × CH-Ar), 129.8 (2C, d, J = 8.1 Hz, 2 × 
ArCHCHCF), 130.3 (C-Ar), 130.5 (2 × CH-Ar), 132.2 (C-Ar), 133.0 (C-Ar), 136.1 (C-Ar), 
136.5 (C-Ar), 138.3 (C-Ar), 160.9 (d, J = 244.7 Hz, ArCF), 164.3 (CONH). 19F NMR (470 
MHz; DMSO-d6) δF -115.2; HRMS calcd for C27H22Cl2FN2O3 [M(35Cl2)-H]- 511.0997, found 
511.0981. 
 
Ethyl 4-(4-chlorophenyl)-3-oxobutanoate (72) 
 
Prepared according to general procedure B using Meldrum’s acid (1 g, 6.94 mmol), DCM (6 
mL), pyridine (1.1 mL), 4-chlorophenylacetyl chloride (1 mL, 6.94 mmol) and ethanol (22 ml). 
Purification by MPLC on SiO2 (Petrol:EtOAc, 0-20%) gave a colourless liquid (1.3 g, 78%). 
1H NMR (500 MHz, CDCl3) δH 1.26 (3H, t, J = 7.2 Hz, COOCH2CH3), 3.45 (2H, s, CH2), 3.81 
(2H, s, CH2), 4.17 (2H, q, J = 7.2 Hz, COOCH2CH3),  7.12-7.14 (2H, m, 2 × ArH), 7.30-7.32 
(2H, m, 2 × ArH)  13C NMR (125 MHz, CDCl3) δC 14.1 (COOCH2CH3), 48.5 (CH2), 49.0 
(CH2), 61.6 (COOCH2CH3), 129.0 (2 × CH-Ar), 131.0 (2 × CH-Ar), 131.6 (C-Ar), 133.4 (C-
Ar), 167.0 (C=O), 199.9 (C=O).205 
 
Ethyl 4-(4-chlorophenyl)-2-(2-(4-fluorophenyl)-2-oxoethyl)-3-oxobutanoate (74) 
 
Prepared according to general procedure C using compound 72 (500 mg, 2.07 mmol) and NaH 
(60% in mineral oil, 107.6 mg, 2.69 mmol) in THF (1.3 ml) and 2-bromo-4’-
fluoroacetophenone (492 mg, 2.27 mmol) in THF (1 ml). Purification by MPLC on SiO2 
(Petrol:EtOAc, 0-20%) gave a colourless viscous liquid which solidifies upon standing (709 
mg, 91%). Rf = 0.43 (20% EtOAc/Petrol); λmax (EtOH)/nm 244, 225; IR νmax/cm-13072, 2954, 
1740 (C=O), 1718 (C=O), 1680 (C=O); 1H NMR (500 MHz, CDCl3) δH 1.28 (3H, t, J = 7.1 Hz, 
COOCH2CH3),  3.50 (1H, dd, J = 18.3 and 4.8 Hz, 1 × CH2), 3.72 (1H, dd, J = 18.3 and 9.0 Hz, 
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1 × CH2), 4.08 (1H, d, J = 17.1 Hz, ArCH2), 4.11 (1H, d, J = 17.1 Hz, ArCH2), 4.20 (2H, q, J 
= 7.1 Hz, COOCH2CH3), 4.29 (2H, dd, J = 9.0 and 4.8 Hz, CHCOOEt), 7.11-7.18 (4H, m, 4 × 
ArH), 7.29-7.31 (2H, m, 2 × ArH), 7.97-8.00 (2H, m, 2 × ArH); 13C NMR (125 MHz, CDCl3) 
δC 14.1 (COOCH2CH3), 37.7 (CH2), 49.2 (ArCH2), 52.6 (CHCOOMe), 62.0 (COOCH2CH3), 
115.8 (2C, d, J = 22.0 Hz, 2 × ArCHCF), 128.7 (2 × CH-Ar),  130.9 (2C, d, J = 9.4 Hz, 2 × 
ArCHCHCF), 131.2 (2 × CH-Ar), 132.0 (C-Ar), 132.4 (d, J = 3.0 Hz, ArCCHCHCF), 133.1 
(C-Ar), 166.0 (d, J = 255.5 Hz, ArCF), 168.6 (C=O), 195.6 (C=O), 201.9 (C=O);  19F NMR 
(470 MHz; CDCl3) δF -104.2. 
 
Ethyl 2-(4-chlorobenzyl)-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1H-pyrrole-3-
carboxylate (75) 
 
Prepared according to general procedure D using 74 (350 mg, 0.93 mmol), 4-chloroaniline (593 
mg, 4.65 mmol) and acetic acid (2.8 mL). Purification by MPLC on SiO2 (Petrol:EtOAc, 0-
10%) gave a white solid (290 mg, 67%). The reaction was repeated to get enough material for 
next steps. Rf = 0.45 (10% EtOAc/Petrol); m.p. 132-134 °C; IR νmax/cm-1 2985, 2927, 1702 
(C=O); 1H NMR (500 MHz, CDCl3) δH 1.25 (3H, t, J = 7.1 Hz, COOCH2CH3), 4.15 (2H, s, Ar-
CH2), 4.24 (2H, q, J = 7.1 Hz, COOCH2CH3), 6.72-6.80 (6H, m, 6 × ArH), 6.90-6.93 (2H, m, 
2 × ArH), 7.04-7.06 (2H, m, 2 × ArH), 7.15-7.18 (2H, m, 2 × ArH); 19F NMR (470 MHz, 
CDCl3) δF -114.61; HRMS calcd for C26H21Cl2NO2F [M(35Cl2)+H]+ 468.0928, found 468.0915. 
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(2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1H-pyrrol-3-yl)methanol (76) 
 
Prepared according to general procedure F using compound 75 (300 mg, 0.64 mmol), THF (1 
mL), 1 M DIBAL in cyclohexane (1.53 mL, 1.53 mmol) and MeOH (1 mL). Purification by 
MPLC on SiO2 (Petrol:EtOAc, 0-50%) gave a white solid (259 mg, 95%). Rf = 0.20 (25% 
EtOAc/Petrol); m.p. 124-126 °C; λmax (EtOH)/nm 277; IR νmax/cm-1 3279 (O-H), 3045, 2921, 
2868, 1525, 1488.; 1H NMR (500 MHz, CDCl3) δH 1.46 (1H, s, OH), 3.86 (2H, s, Ar-CH2), 4.63 
(2H, s, CH2OH), 6.44 (1H, s, Pyrrole-H), 6.80-6.86 (6H, m, 6 × ArH), 6.96-6.99 (2H, m, 2 × 
ArH), 7.13-7.14 (2H, m, 2 × ArH), 7.20-7.21 (2H, m, 2 × ArH); 13C NMR (125 MHz, CDCl3) 
δC 30.1 (Ar-CH2), 57.9 (CH2OH), 109.6 (CH-Pyrrole), 115.2 (2C, d, J = 21.5 Hz, 2 × ArCHCF), 
121.9 (C-Ar), 128.5 (2 × CH-Ar), 128.7 (d, J = 3.3 Hz, ArCCHCHCF), 129.2 (2 × CH-Ar), 
129.3 (2 × CH-Ar), 129.7 (2C, d, J = 7.9 Hz, 2 × ArCHCHCF), 130.0 (2 × CH-Ar),  131.0 (C-
Ar), 131.9 (C-Ar), 133.6 (C-Ar), 133.9 (C-Ar), 137.1 (C-Ar), 138.0 (C-Ar), 161.5 (d, J = 246.6 
Hz, ArCF). 19F NMR (470 MHz; CDCl3) δF -115.6; HRMS calcd for C24H19Cl2FNO 
[M(35Cl2)+H]
+ 426.0822, found 426.0817. 
 
2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1H-pyrrole-3-carbaldehyde 
(77) 
 
Prepared according to general procedure G using compound 76 (135 mg, 0.316 mmol) in DCM 
(3 ml) and Dess-Martin periodinane (268 mg, 0.632 mmol) in DCM (4 mL). Purification by 
MPLC on SiO2 (Petrol:EtOAc, 0-50%) gave an off-white viscous liquid (82 mg, 61%). Rf = 
0.35 (20% EtOAc/Petrol); λmax (EtOH)/nm 247; IR νmax/cm-1 3057, 2922, 2852, 2731, 1664 
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(C=O); 1H NMR (500 MHz, CDCl3) δH 4.17 (2H, s, Ar-CH2), 6.78-6.89 (7H, m, 7 × ArH), 
6.98-7.01 (2H, m, 2 × ArH), 7.14-7.15 (2H, m, 2 × ArH), 7.27-7.28 (1H, m, ArH), 10.01 (1H, 
s, CHO); 13C NMR (125 MHz, CDCl3) δC 30.3 (Ar-CH2), 109.3 (CH-Pyrrole), 115.4 (2C, d, J 
= 21.6 Hz, 2 × ArCHCF), 123.5 (C-Ar), 127.4 (d, J = 3.2 Hz, ArCCHCHCF), 128.7 (2 × CH-
Ar), 129.4 (2 × CH-Ar), 129.5 (2 × CH-Ar), 129.8 (2 × CH-Ar), 130.2 (2C, d, J = 8.1 Hz, 2 × 
ArCHCHCF), 132.4 (C-Ar), 135.0 (C-Ar), 135.4 (C-Ar), 135.4 (C-Ar), 136.5 (C-Ar), 140.2 (C-
Ar), 162.0 (d, J = 248.3 Hz, ArCF), 186.0 (C=O). 19F NMR (470 MHz; CDCl3) δF -113.9. 
HRMS calcd for C24H17Cl2FNO [M(
35Cl2)+H]
+ 424.0666, found 426.0660. 
 
5-((2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1H-pyrrol-3-
yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-trione (63) 
 
A mixture of compound 77 (48 mg, 0.11 mmol), barbituric acid (15 mg, 0.12 mmol) and acetic 
acid (1.2 mL) was refluxed for 2.5 h. The product precipitates on cooling which was filtered 
and washed with EtOAc to get yellow solid (28 mg, 48%). Rf = 0.33 (2% MeOH/DCM); m.p. 
276 °C (degraded); λmax (EtOH)/nm 398; IR νmax/cm-1 3198, 3054, 2924, 2848, 1737(C=O), 
1690 (C=O), 1652(C=O); 1H NMR (500 MHz, DMSO-d6) δH 4.17 (2H, s, ArCH2), 6.84-6.85 
(2H, m, 2 × ArH), 7.10-7.16 (4H, m, 4 × ArH), 7.19-7.20 (2H, m, 2 × ArH), 7.24-7.26 (2H, m, 
2 × ArH), 7.45-7.47 (2H, m, 2 × ArH), 7.95 (1H, s, Pyrrole-H), 8.35 (1H, s, HC=C(CO)2), 11.05 
(1H, s, NH), 11.15 (1H, s, NH).; 13C NMR (125 MHz, DMSO-d6) δC 29.4 (ArCH2), 110.8 (C-
Ar), 113.1 (CH-Pyrrole),  115.4 (2C, d, J = 21.7 Hz, 2 × ArCHCF), 118.2 (C-Ar), 128.5 (2 × 
CH-Ar), 129.4 (2 × CH-Ar), 129.6 (2 × CH-Ar), 130.1 (2 × CH-Ar), 130.5 (2C, d, J = 8.2 Hz, 
2 × ArCHCHCF), 131.1 (C-Ar), 133.7 (C-Ar), 135.2 (C-Ar), 135.5 (C-Ar), 136.8 (C-Ar), 145.8 
(C-Ar), 146.5 (C-Ar), 150.3 (C-Ar), 160.4 (C=O), 161.4 (d, J = 240.7 Hz, ArCF), 162.5 (C=O), 
164.4 (C=O). 19F NMR (470 MHz; DMSO-d6) δF -114.0; HRMS calcd for C28H19Cl2FN3O3 
[M(35Cl2)+H]
+ 534.0782, found 534.0776. 
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1,2-Bis(4-chlorobenzyl)-5-(4-fluorophenyl)-1H-pyrrole-3-carboxylic acid (69) 
 
A mixture of 79 (38 mg, 0.078 mmol), NaOH (75 mg, 1.75 mmol), MeOH (3.5 mL) and water 
(1.5 mL) was heated at 75 °C for 18 h. The solvent was evaporated in vacuo and the remaining 
residue was acidified with 1 M HCl. The aqueous layer was extracted with EtOAc (3 × 30 mL). 
The organic layers were combined, dried over MgSO4 and evaporated in vacuo. Purification by 
MPLC on SiO2 (DCM:MeOH, 0-2%) gave a white solid (25 mg, 70%).  Rf = 0.56 (2% 
MeOH/DCM); m.p. 215-217 °C; λmax (EtOH)/nm 398; IR νmax/cm-1 2922, 2851, 2765, 2668, 
2596, 1665 (C=O); 1H NMR (500 MHz, DMSO-d6) δH 4.29 (2H, s, ArCH2), 5.06 (2H, s, 
ArCH2-N), 6.59 (1H, s, Pyrrole-H), 6.64-6.66 (2H, m, 2 × ArH), 7.06-7.07 (2H, m, 2 × ArH), 
7.14-7.18 (2H, m, 2 × ArH), 7.20-7.22 (4H, m, 4 × ArH), 7.28-7.31 (2H, m, 2 × ArH), 12.10 
(1H, br s, COOH); 13C NMR (125 MHz, DMSO-d6) δC 29.5 (ArCH2), 46.5 (ArCH2-N), 110.5 
(CH-Pyrrole),  113.6 (C-Ar), 115.5 (2C, d, J = 21.4 Hz, 2 × ArCHCF), 127.2 (2 × CH-Ar), 
128.2 (2 × CH-Ar), 128.3  (d, J = 4.1 Hz,  ArCCHCHCF), 128.4 (2 × CH-Ar), 129.8 (2 × CH-
Ar), 130.7 (C-Ar), 130.9 (2C, d, J = 8.2 Hz, 2 × ArCHCHCF), 131.5 (C-Ar), 132.8 (C-Ar), 
136.4 (C-Ar), 137.3 (C-Ar), 137.6 (C-Ar), 161.6 (d, J = 245.4 Hz, ArCF), 165.9 (COOH). 19F 
NMR (470 MHz; DMSO-d6) δF -113.3; HRMS calcd for C25H19Cl2FNO2 [M(35Cl2)+H]+ 
454.0771, found 454.0772. 
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Ethyl 2-(4-chlorobenzyl)-1-(4-chlorophenyl)-5-(4-fluorophenyl)-4-formyl-1H-pyrrole-3-
carboxylate (80) 
 
Prepared according to general procedure H using 75 (100 mg, 0.213 mmol), DMF (3 mL) 
phosphorus oxychloride (0.06 mL, 0.639 mmol) heated under microwave irradiation to 70 °C 
for 4 h. Purification by MPLC on SiO2 (Petrol:EtOAc, 0-20%) gave a white solid (75 mg, 71%). 
Rf = 0.22 (20% EtOAc/Petrol); m.p. 132-134 °C; λmax (EtOH)/nm 228; IR νmax/cm-1 3050, 2962, 
2849, 1679 (C=O); 1H NMR (500 MHz, CDCl3) δH 1.34 (3H, t, J = 7.1 Hz, COOCH2CH3), 4.14 
(2H, s, ArCH2), 4.38 (2H, q, J = 7.1 Hz, COOCH2CH3), 6.68-6.70 (2H, m, 2 × ArH), 6.77-6.79 
(2H, m, 2 × ArH), 6.88-6.91 (2H, m, 2 × ArH), 7.06-7.09 (2H, m, 2 × ArH), 7.13-7.14 (2H, m, 
2 × ArH), 7.17-7.19 (2H, m, 2 × ArH), 10.31 (1H, s, CHO); 13C NMR (125 MHz, CDCl3) δC 
14.3 (COOCH2CH3), 30.9 (ArCH2), 60.9 (COOCH2CH3), 114.3 (C-Ar), 115.2 (2C, d, J = 21.7 
Hz, 2 × ArCHCF), 121.4 (C-Ar), 128.5 (2 × CH-Ar), 129.4 (2 × CH-Ar), 129.5 (2 × CH-Ar), 
129.9 (2 × CH-Ar), 132.3 (C-Ar), 132.8 (2C, d, J = 8.4 Hz, 2 × ArCHCHCF), 134.3 (C-Ar), 
135.3 (C-Ar), 136.3 (C-Ar), 138.8 (C-Ar), 139.1 (C-Ar), 164.7 (C=O), 187.7 (C=O), 
ArCCHCHCF and ArCF was not seen. 19F NMR (470 MHz; CDCl3) δF -111.52; HRMS calcd 
for C27H21Cl2FNO3 [M(
35Cl2)+H]
+ 496.0877, found 496.0878. 
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5-(4-Chlorobenzyl)-1-(4-chlorophenyl)-4-(ethoxycarbonyl)-2-(4-fluorophenyl)-1H-
pyrrole-3-carboxylic acid (81) 
 
Prepared according to general procedure I using 80 (65 mg, 0.131 mmol), MeCN (2 mL), a 
solution of sodium chlorite (17 mg, 0.183 mmol) in H2O (0.2 mL), a solution of sulfamic acid 
(18 mg, 0.183 mmol) in H2O (0.2 mL). EtOAc extraction gave an off-white solid (68 mg, 
quant.) which did not require further purification; Rf = 0.56 (2% MeOH/DCM); m.p. 172-174 
°C; λmax (EtOH)/nm 223; IR νmax/cm-1 2919, 2850, 2639, 1680 (broad, 2×C=O overlapped); 1H 
NMR (500 MHz, DMSO-d6) δH 1.18 (3H, t, J = 7.1 Hz, COOCH2CH3), 4.05 (2H, s, ArCH2), 
4.18 (2H, q, J = 7.1 Hz, COOCH2CH3), 6.81-6.83 (2H, m, 2 × ArH), 7.03-7.09 (4H, m, 4 × 
ArH), 7.18-7.22 (4H, m, 4 × ArH), 7.33-7.35 (2H, m, 2 × ArH), 12.39 (1H, s, COOH); 13C 
NMR (125 MHz, DMSO-d6) δC 13.9 (COOCH2CH3), 29.9 (ArCH2), 59.9 (COOCH2CH3), 
113.0 (C-Ar), 114.7 (2C, d, J = 21.6 Hz, 2 × ArCHCF), 116.6 (C-Ar), 126.4  (d, J = 3.3 Hz,  
ArCCHCHCF), 128.1 (2 × CH-Ar), 129.0 (2 × CH-Ar), 129.6 (2 × CH-Ar), 130.7 (C-Ar), 130.7 
(2 × CH-Ar), 132.8 (2C, d, J = 8.4 Hz, 2 × ArCHCHCF), 133.5 (C-Ar), 133.9 (C-Ar), 134.9 
(C-Ar), 136.1 (C-Ar), 137.0 (C-Ar), 161.6 (d, J = 245.4 Hz, ArCF), 164.2 (C=O), 165.8 (C=O); 
19F NMR (470 MHz; DMSO-d6) δF -113.3; HRMS calcd for C27H21Cl2FNO4 [M(35Cl2)+H]+ 
512.0826, found 512.0820. 
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2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1H-pyrrole-3,4-dicarboxylic 
acid (64) 
 
A mixture of 81 (55 mg, 0.107 mmol), NaOH (185 mg, 4.625 mmol), MeOH (3 mL), water 
(1.5 mL) was refluxed for 4 h. The solvent was evaporated in vacuo and the remaining residue 
was acidified with 2 M HCl. The aqueous layer was extracted with EtOAc (3 × 20 mL). The 
organic layers were combined, dried over MgSO4 and evaporated in vacuo to obtain an off-
white solid (50 mg, 97%) which did not require further purification. Rf = 0.47 (7.5% 
DCM/MeOH); m.p. 143-145 °C; λmax (EtOH)/nm 224; IR νmax/cm-1 3506, 3048, 2919, 2849, 
1687 (C=O), 1607 (C=O); 1H NMR (500 MHz, DMSO-d6) δH 4.16 (2H, s, 2 × ArCH2), 6.81-
6.83 (2H, m, 2 × ArH), 7.03-7.06 (4H, m, 4 × ArH), 7.19-7.21 (4H, m, 4 × ArH), 7.31-7.33 
(2H, m, 2 × ArH), 13.2 (1H, br s, COOH), other COOH could not be seen.; 13C NMR (125 
MHz, DMSO-d6) δC 30.0 (ArCH2),  114.5 (2C, d, J = 21.4 Hz, 2 × ArCHCF), 115.7 (2 × CH-
Ar), 127.1  (d, J = 4.0 Hz, ArCCHCHCF), 128.0 (2 × CH-Ar), 129.9 (2 × CH-Ar), 129.6 (2 × 
CH-Ar), 130.6 (C-Ar), 130.7 (2 × CH-Ar), 132.8 (2C, d, J = 8.3 Hz, 2 × ArCHCHCF), 133.4 
(C-Ar), 134.9 (C-Ar), 135.5 (C-Ar), 137.3 (C-Ar), 137.5 (C-Ar), 161.6 (d, J = 245.7 Hz, ArCF), 
165.7 (COOH), 166.8 (COOH); 19F NMR (470 MHz; DMSO-d6) δF -113.5; HRMS calcd for 
C25H17Cl2FNO4  [M(
35Cl2)+H]
+ 484.0507, found 484.0508. 
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(E)-3-(2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1H-pyrrol-3-yl)acrylic 
acid (65) 
 
A mixture of aldehyde 77 (70 mg, 0.16 mmol), malonic acid (26 mg, 0.247 mmol), piperidine 
(1 drop), and pyridine (0.5 mL) was refluxed for 2.5 h. The reaction was acidified to PH 2 with 
2M HCl and extracted with EtOAc (3 × 25 mL). The organic layers were combined, dried over 
MgSO4, and evaporated in vacuo. Purification by MPLC on SiO2 (DCM:MeOH, 0-10%) gave 
a yellow solid (58 mg, 71%); Rf = 0.24 (2% MeOH/DCM); m.p. 242-244 °C; λmax (EtOH)/nm 
264; IR νmax/cm-1 3061, 2920, 2851, 1674 (C=O); 1H NMR (500 MHz, DMSO-d6) δH 4.01 (2H, 
s, CH2), 6.24 (1H, d, J = 15.5 Hz, alkene-H), 6.79-6.81 (2H, m, 2 × ArH), 6.91 (1H, s, Pyrrole-
H), 7.06-7.13 (6H, m, 6 × ArH), 7.23-7.24 (2H, m, 2 × ArH), 7.40-7.41 (2H, m, 2 × ArH), 7.59 
(1H, d, J = 15.5 Hz, alkene-H).; 13C NMR (125 MHz, DMSO-d6) δC 28.9 (ArCH2), 107.0 
(Pyrrole-CH), 114.9 (Alkene-CH), 115.2 (2C, d, J = 21.4 Hz, 2 × ArCHCF), 118.6 (C-Ar), 
128.2 (d, J = 3.5 Hz, ArCCHCHCF), 128.3 (2 × CH-Ar), 129.2 (2 × CH-Ar), 129.4 (2 × CH-
Ar), 130.0 (2C, d, J = 8.1 Hz, 2 × ArCHCHCF), 130.3 (2 × CH-Ar), 130.7 (C-Ar), 133.0 (C-
Ar), 134.6 (C-Ar), 135.8 (C-Ar), 136.2 (C-Ar), 136.5 (C-Ar), 137.7 (Alkene-CH), 161.1 (d, J 
= 244.6 Hz, ArCF), 168.2 (COOH);  19F NMR (470 MHz; DMSO-d6) δF -115.0; LRMS (ES+) 
m/z 466.3 [M(35Cl2)+H]
+, 468.3 [M(35Cl 37Cl)+H]+. 
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Ethyl 4-(4-chlorophenyl)-3-oxo-2-(2-oxo-2-phenylethyl)butanoate, (96) 
 
Prepared according to general procedure C using compound 72 (2.01 g, 8.35 mmol) and NaH 
(60% in mineral oil, 433 mg, 10.85 mmol) in THF (6 mL) followed by addition of 2-bromo-1-
phenylethan-1-one (1.83 mg, 9.18 mmol) in THF (4 mL). The residue was purified by MPLC 
on SiO2 (Petrol:EtOAc, 0-20%)  to give a white solid (2.36 g, 79%). Rf = 0.22 (10% 
EtOAc/Petrol); m.p. 68-70 °C;  λmax (EtOH)/nm 241.8, 225.6; IR νmax/cm-1 3064, 3036, 2973, 
2928, 2898, 1711 (C=O stretch), 1684 (C=O); 1H NMR (500 MHz, CDCl3) δH 1.28 (3H, t, J = 
7.1 Hz, COOCH2CH3),  3.55 (1H, dd, J = 18.4, 4.8 Hz, 1 × CH2), 3.76 (1H, dd, J = 18.4, 9.1 
Hz, 1 × CH2), 4.07 (1H, d, J = 17.1 Hz, ArCH2), 4.12 (1H, d, J = 17.1 Hz, ArCH2), 4.20 (2H, 
q, J = 7.1 Hz, COOCH2CH3), 4.29 (1H, dd, J = 9.1 and 4.8 Hz, CHCOOEt), 7.18-7.20 (2H, m, 
2 × ArH), 7.29-7.31 (2H, m, 2 × ArH), 7.45-7.48 (2H, m, 2 × ArH), 7.56-7.59 (1H, m, 1 × ArH), 
7.95-7.97 (2H, m, 2 × ArH); 13C NMR (125 MHz, CDCl3) δC 14.1 (COOCH2CH3), 37.8 (CH2), 
49.2 (ArCH2), 52.6 (CHCOOEt), 62.0 (COOCH2CH3), 128.2 (2 × C-Ar), 128.7 (2 × C-Ar), 
128.7 (2 × C-Ar), 131.3 (2 × C-Ar), 132.0 (C-Ar), 133.1 (C-Ar), 133.6 (C-Ar), 135.9 (C-Ar), 
168.7 (C=O), 197.2 (C=O), 202.0 (C=O); HRMS calcd for C20H18ClO4 [M(
35Cl2)-H]
- 357.0899, 
found 357.0890. 
 
Ethyl 2-(4-chlorobenzyl)-1-(4-chlorophenyl)-5-phenyl-1H-pyrrole-3-carboxylate (82) 
 
Prepared according to general procedure D using compound 96 (1.4 g, 3.90 mmol), 4-
chloroaniline (2.5 g, 19.5 mmol) and acetic acid (11 mL). Purification by MPLC on SiO2 
(Petrol:EtOAc, 0-10%) gave a white solid (1.28 g, 73%). Rf = 0.52 (10% EtOAc/Petrol); m.p. 
127-129 °C; IR νmax/cm-1 2985, 2927, 2657, 1702 (C=O); 1H NMR (500 MHz, CDCl3) δH 1.33 
197 
 
(3H, t, J = 7.1 Hz, COOCH2CH3), 4.23 (2H, s, 2 × ArCH2), 4.31 (2H, q, J = 7.1 Hz, 
COOCH2CH3), 6.80-6.86 (5H, m, 5 × ArH), 7.01-7.04 (2H, m, 2 × ArH), 7.11-7.18 (5H, m, 5 
× ArH), 7.22-7.26 (2H, m, 2 × ArH); 13C NMR (125 MHz, CDCl3) δC 14.5 (COOCH2CH3), 
30.8 (ArCH2), 59.8 (COOCH2CH3), 110.5 (C-Ar), 114.3 (C-Ar), 127.0 (C-Ar), 128.2 (2 × C-
Ar), 128.3 (2 × C-Ar), 128.3 (2 × C-Ar), 129.3 (2 × C-Ar), 129.5 (2 × C-Ar), 130.0 (2 × C-Ar), 
131.8 (C-Ar), 131.8 (C-Ar), 134.5 (C-Ar), 134.8 (C-Ar), 136.3 (C-Ar), 137.5 (C-Ar), 138.8 (C-
Ar), 165.1 (C=O); HRMS calcd for C26H22Cl2NO2 [M(
35Cl2)+H]
+ 450.1022, found 450.1012. 
 
2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-5-phenyl-1H-pyrrole-3-carboxylic acid (93) 
 
Prepared according to general procedure E using compound 82 (45 mg, 0.099 mmol), NaOH 
(143 mg, 3.56 mmol) in MeOH (2 ml)  and water (1.5 ml) followed by addition of more MeOH 
(1 ml) after 18 h. Compound 93 was obtained as a white solid (41 mg, 98%) which did not 
require further purification. Rf = 0.55 (2% MeOH/DCM); m.p. 217-219 °C; λmax (EtOH)/nm 
264.6; IR νmax/cm-1 3300-2200 (broad COOH peak), 2936, 2851, 2591, 1665 (C=O); 1H NMR 
(500 MHz, DMSO-d6) δH 4.24 (2H, s, 2 × ArCH2), 6.76 (1H, s, Pyrrole-H), 6.79 (2H, d, J = 8.5 
Hz, 2 × ArH), 7.04-7.07 (4H, m, 4 × ArH), 7.13-7.21 (5H, m, 5 × ArH), 7.40 (2H, d, J = 8.5 
Hz, 2 × ArH), 12.15 (1H, s, COOH); 13C NMR (125 MHz, DMSO-d6) δC 29.8 (ArCH2), 110.3 
(C-Ar), 114.0 (C-Ar), 126.9 (C-Ar), 128.0 (2 × C-Ar), 128.1 (2 × C-Ar), 128.2 (2 × C-Ar), 
129.2 (2 × C-Ar), 129.5 (2 × C-Ar), 130.5 (2×C-Ar), 131.5 (C-Ar), 133.2 (C-Ar), 133.9 (C-Ar), 
136.1 (C-Ar), 137.7 (C-Ar), 138.5 (C-Ar), 165.8 (C=O); LRMS (ES+) m/z 422.2 [M(35Cl2)+H]
+, 
424.2 [M(35Cl 37Cl)+H]+. 
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Ethyl 4-(4-methoxyphenyl)-3-oxobutanoate (98) 
 
Prepared according to the procedure B using Meldrum’s acid (1 g, 6.93 mmol), 4-
methoxyphenylacetyl chloride (0.93 mL, 6.06 mmol), pyridine (1.1 ml, 13.21mmol), DCM (6 
mL), EtOH (21 mL). Purification by MPLC on SiO2 (Petrol:EtOAc, 0-20%) gave a yellow oil 
(1.03 g, 72%). 1H NMR (500 MHz, CDCl3) δH 1.25 (3H, t, J = 7.2 Hz, COOCH2CH3), 3.45 
(2H, s, CH2), 3.75 (2H, s, CH2Ar), 3.79 (3H, s, OCH3), 4.16 (2H, q, J = 7.2 Hz, COOCH2CH3),  
6.86-6.88 (2H, m, 2 × ArH), 7.11-7.13 (2H, m, 2 × ArH);  13C NMR (125 MHz, CDCl3) δC 14.1 
(COOCH2CH3), 48.2 (CH2), 49.2 (CH2Ar), 55.3 (OCH3), 61.4 (COOCH2CH3), 114.3 (2 × CH-
Ar), 125.2 (C-Ar), 130.6 (2 × CH-Ar), 131.6 (C-Ar), 158.9 (C-Ar), 167.2 (C=O), 201.0 
(C=O).205 
 
Ethyl 4-(4-methoxyphenyl)-3-oxo-2-(2-oxo-2-phenylethyl)butanoate (99) 
 
Prepared according to general procedure C using compound 98 (629 mg, 2.66 mmol) and NaH 
(60% in mineral oil, 138 mg, 3.45 mmol) in THF (1.7 mL) followed by addition of 2-bromo-1-
phenylethan-1-one (582 mg, 2.92 mmol) in THF (1.3 mL). The residue was purified by MPLC 
on SiO2 (Petrol:EtOAc, 0-20%)  to give a yellow oil (715 mg, 76%). Rf = 0.33 (20% 
EtOAc/Petrol); λmax (EtOH)/nm 241.2; IR νmax/cm-1 2979, 2836, 1738 (C=O stretch), 1715 
(C=O), 1681 (C=O); 1H NMR (500 MHz, CDCl3) δH 1.28 (3H, t, J = 7.1 Hz, COOCH2CH3),  
3.54 (1H, dd, J = 18.3 and 5.5 Hz, 1 × CH2), 3.69 (1H, dd, J = 18.3 and 8.5 Hz, 1 × CH2), 3.79 
(3H, s, OCH3), 4.00 (1H, d, J = 16.6 Hz, ArCH2), 4.04 (1H, d, J = 16.6 Hz, ArCH2), 4.19 (2H, 
q, J = 7.1 Hz, COOCH2CH3), 4.31 (1H, dd, J = 8.5 and 5.5 Hz, CHCOOEt), 6.86-6.88 (2H, m, 
2 × ArH), 7.16-7.18 (2H, m, 2 × ArH), 7.44-7.47 (2H, m, 2 × ArH), 7.55-7.59 (1H, m, 1 × ArH), 
7.95-7.97 (2H, m, 2 × ArH); 13C NMR (125 MHz, CDCl3) δC 14.1 (COOCH2CH3), 37.8 (CH2), 
49.0 (ArCH2), 52.5 (CHCOOEt), 55.3 (CH3), 61.8 (COOCH2CH3), 114.1 (2 × C-Ar), 125.6 (C-
Ar), 128.2 (2 × C-Ar), 128.7 (2 × C-Ar), 130.9 (2 × C-Ar), 133.5 (C-Ar), 136.1 (C-Ar), 158.7 
(C-Ar), 168.9 (C=O), 197.2 (C=O), 202.6 (C=O); HRMS calcd for C21H23O5 [M+H]
+ 355.1540, 
found 355.1536. 
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Ethyl 1-(4-chlorophenyl)-2-(4-methoxybenzyl)-5-phenyl-1H-pyrrole-3-carboxylate (100) 
 
Prepared according to general procedure D using compound 99 (319 mg, 0.90 mmol), 4-
chloroaniline (574 mg, 4.50 mmol) and acetic acid (2.7 mL). Purification by MPLC on SiO2 
(Petrol:EtOAc, 0-15%) gave a white solid (300 mg, 75%). Rf = 0.56 (20% EtOAc/Petrol); λmax 
(EtOH)/nm 274.8, 224.0; IR νmax/cm-1 3110, 2996, 2936, 1701 (C=O); 1H NMR (500 MHz, 
CDCl3) δH 1.33 (3H, t, J = 7.1 Hz, COOCH2CH3), 3.74 (3H, s, OCH3), 4.20 (2H, s, 2 × ArCH2), 
4.32 (2H, q, J = 7.1 Hz, COOCH2CH3), 6.68-6.71 (2H, m, 2 × ArH), 6.77-6.79 (2H, m, 2 × 
ArH), 6.84-6.86 (3H, m, 3 × ArH), 7.01-7.03 (2H, m, 2 × ArH), 7.13-7.17 (3H, m, 3 × ArH), 
7.21-7.23 (2H, m, 2 × ArH); 13C NMR (125 MHz, CDCl3) δC 14.5 (COOCH2CH3), 30.6 
(ArCH2), 55.2 (OCH3), 59.8 (COOCH2CH3), 110.5 (C-Ar), 113.6 (C-Ar), 114.0 (C-Ar), 126.8 
(2 × C-Ar), 128.2 (2 × C-Ar), 128.3 (2 × C-Ar), 129.1 (2 × C-Ar), 129.1 (2 × C-Ar), 130.1 (2 × 
C-Ar), 131.1 (C-Ar), 131.9 (C-Ar), 134.3 (C-Ar), 134.5 (C-Ar), 136.5 (C-Ar), 136.5 (C-Ar), 
140.0 (C-Ar), 157.9 (C-Ar), 165.3 (C=O); HRMS calcd for C27H25ClNO3 [M(
35Cl2)+H]
+ 
446.1517, found 446.1511. 
 
1-(4-Chlorophenyl)-2-(4-methoxybenzyl)-5-phenyl-1H-pyrrole-3-carboxylic acid (101) 
 
Prepared according to general procedure E using compound 100 (31 mg, 0.069 mmol), NaOH 
(140 mg, 3.5 mmol) in MeOH (3 ml)  and water (1.5 ml) followed by addition of more MeOH 
(1 ml) after 18 h. Purification by MPLC on SiO2 (Petrol:EtOAc, 0-100%) gave a white solid 
(28 mg, quant.). Rf = 0.40 (2% MeOH/DCM); m.p. 214-216 °C; λmax (EtOH)/nm 275.4; IR 
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νmax/cm-1 3005, 2996, 2922, 2828, 2576, 1654 (C=O); 1H NMR (500 MHz, DMSO-d6) δH 3.66 
(3H, s, OCH3), 4.19 (2H, s, 2 × ArCH2), 6.67-6.71 (4H, m, 4 × ArH), 6.74 (1H, s, 1 × ArH), 
7.01-7.06 (4H, m, 4 × ArH), 7.14-7.22 (3H, m, 3 × ArH), 7.40-7.42 (2H, m, 2 × ArH), 12.13 
(1H, br s, COOH); 13C NMR (125 MHz, DMSO-d6) δC 29.5 (ArCH2), 54.9 (OCH3), 110.3 (C-
Ar), 113.5 (C-Ar), 113.8 (C-Ar), 126.8 (2 × C-Ar), 127.9 (2 × C-Ar), 128.2 (2 × C-Ar), 128.7 
(2 × C-Ar), 129.1 (2 × C-Ar), 130.5 (2 × C-Ar), 130.5 (C-Ar), 131.6 (C-Ar), 133.0 (C-Ar), 
133.6 (C-Ar), 136.2 (C-Ar), 139.6 (C-Ar), 157.4 (C-Ar), 165.9 (C=O); LRMS (ES-) m/z 416.2 
[M(35Cl)-H]-, 418.3 [M(37Cl)-H]-. 
 
1-(4-Chlorophenyl)-2-(4-hydroxybenzyl)-5-phenyl-1H-pyrrole-3-carboxylic acid (94) 
 
Compound 101 (20 mg, 0.048 mmol) was dissolved in DCM (2 mL) and cooled to O ˚C. Boron 
tribromide (1 M in DCM, 70 µL, 0.072 mmol) was added dropwise and the reaction mixture 
was stirred at O ˚C for 1 h. The mixture was quenched with water (20 mL) and extracted with 
EtOAc (3×30 mL). The organic layers were combined, washed with brine, dried over MgSO4 
and the solvent removed in vacuo. Purification by MPLC (H2O:MeOH, reversed phase with 
0.1% HCOOH modifier, 30-100%) gave a white solid (17 mg, 88%). Rf = 0.52 (8% 
MeOH/DCM); m.p. 230°C (degraded); IR νmax/cm-1 3567 (OH), 3328-2325 (COOH), 3025, 
2923, 2854, 1665 (C=O); 1H NMR (500 MHz, DMSO-d6) δH 4.19 (2H, s, 2 × ArCH2), 6.48-
6.49 (2H, m, 2 × ArH), 6.54-6.56 (2H, m, 2 × ArH), 6.70 (1H, s, Pyrrole-H), 6.99-7.02 (4H, m, 
4 × ArH), 7.10-7.13 (1H, m, 1 × ArH), 7.16-7.19 (2H, m, 2 × ArH), 7.37-7.39 (2H, m, 2 × 
ArH); 13C NMR was not be obtained; LRMS (ES-) m/z 402.2 [M(35Cl)-H]-, 404.2 [M(37Cl)-H]-
. 
 
 
 
201 
 
Ethyl 2-(4-chlorobenzyl)-1-(4-chlorophenyl)-4-formyl-5-phenyl-1H-pyrrole-3-
carboxylate (83) 
 
Prepared according to general procedure H using compound 82 (940 mg, 2.08), phosphorous 
oxychloride (0.97 mL, 10.4 mmol) and DMF (10.5 mL). Purification by MPLC on SiO2 
(Petrol:EtOAc, 0-30%) gave a white solid (980 mg, quant.). Rf = 0.38 (20% EtOAc/Petrol); m.p. 
162-165 °C; IR νmax/cm-1 3060, 2972, 2928, 2846, 2767, 1697 (C=O), 1665 (C=O); 1H NMR 
(500 MHz, DMSO-d6) δH 1.22 (3H, t, J = 7.1 Hz, COOCH2CH3), 4.11 (2H, s, 2 × ArCH2), 4.26 
(2H, q, J = 7.1 Hz, COOCH2CH3), 6.85-6.87 (2H, m, 2 × ArH), 7.09-7.11 (2H, m, 2 × ArH), 
7.20-7.26 (7H, m, 7 × ArH), 7.33-7.35 (2H, m, 2 × ArH) 10.11 (1H, s, CHO); 13C NMR (125 
MHz, DMSO-d6) δC 14.5 (COOCH2CH3), 30.6 (ArCH2), 60.7 (COOCH2CH3), 113.8 (C-Ar), 
121.2 (C-Ar), 128.2 (2×C-Ar), 128.6 (2×C-Ar), 129.0 (C-Ar), 129.4 (2×C-Ar), 129.7 (C-Ar), 
130.1 (2×C-Ar), 131.2 (2×C-Ar), 131.3 (C-Ar), 131.5 (2×C-Ar), 134.2 (C-Ar), 134.9 (C-Ar), 
137.3 (C-Ar), 138.5 (C-Ar), 140.6 (C-Ar), 164.7 (C=O) 187.1 (C=O); HRMS calcd for 
C27H22Cl2NO3 [M(
35Cl2)+H]
+ 478.0971, found 478.0967. 
 
5-(4-Chlorobenzyl)-1-(4-chlorophenyl)-4-(ethoxycarbonyl)-2-phenyl-1H-pyrrole-3-
carboxylic acid (84) 
 
Prepared according to general procedure I using compound 83 (1.21 g, 2.52 mmol) in MeCN 
(30 ml), sodium chlorite (320 mg, 3.54 mmol) in water (4 mL), sulfamic acid (344 mg, 3.54 
mmol) in water (4 ml). Purification by MPLC on SiO2 (DCM:MeOH, 0-5%) gave a white solid 
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(780 mg, 62%). Rf = 0.44 (2% MeOH/DCM); m.p. 210-212 °C; λmax (EtOH)/nm 398; IR 
νmax/cm-1 3031, 2984, 2921, 2903, 2628, 1709 (C=O), 1683 (C=O); 1H NMR (500 MHz, 
DMSO-d6) δH 1.20 (3H, t, J = 7.1 Hz, COOCH2CH3), 4.08 (2H, s, 2 × ArCH2), 4.19 (2H, q, J 
= 7.1 Hz, COOCH2CH3), 6.82-6.84 (2H, m, 2 × ArH), 7.06-7.08 (2H, m, 2 × ArH), 7.14-7.16 
(2H, m, 2 × ArH), 7.19-7.21 (4H, m, 4 × ArH), 7.33-7.34 (2H, m, 2 × ArH), 12.39 (1H, s, 
COOH); 13C NMR (125 MHz, DMSO-d6) δC 14.4 (COOCH2CH3), 30.4 (ArCH2), 60.4 
(COOCH2CH3), 113.4 (C-Ar), 117.2 (C-Ar), 128.2 (2 × C-Ar), 128.4 (C-Ar), 128.6 (2 × C-Ar), 
129.4 (2 × C-Ar), 130.1 (2 × C-Ar), 130.5 (C-Ar), 130.9 (2 × C-Ar), 131.2 (C-Ar), 131.2 (2 × 
C-Ar), 133.9 (C-Ar), 135.1 (C-Ar), 135.5 (C-Ar), 136.7 (C-Ar), 137.6 (C-Ar), 164.6 (C=O), 
166.5 (C=O); HRMS calcd for C27H22Cl2NO4 [M(
35Cl2)+H]
+ 494.0920, found 494.0908. 
 
2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-5-phenyl-1H-pyrrole-3,4-dicarboxylic acid (67) 
 
Compound 84 (735 mg, 1.48 mmol) was dissolved in MeOH (5 mL) and THF (5 mL) and 2 M 
NaOH (5 mL) was added. The reaction mixture was stirred at 80 ˚C for 3 h. After cooling to 
r.t., the solvent was removed in vacuo, residue was acidified with 2 M HCl and extracted with 
EtOAc (3×30 mL). The organic layers were combined, dried over MgSO4 and the solvent 
removed in vacuo. Purification by MPLC on SiO2 (DCM:MeOH, 0-20%) gave a beige solid 
(690 mg, quant.). Rf = 0.13 (8% MeOH/DCM); m.p. 184-188 °C; λmax (EtOH)/nm 270.0, 224.4; 
IR νmax/cm-1 3031, 2984, 2921, 2903, 2767, 1709 (C=O), 1683 (C=O); 1H NMR (500 MHz, 
DMSO-d6) δH 4.21 (2H, s, 2 × ArCH2), 6.82 (2H, d, J = 8.4 Hz, 2 × ArH), 7.01 (2H, d, J = 8.4 
Hz, 2 × ArH), 7.12-7.18 (5H, m, 5 × ArH), 7.20 (2H, d, J = 8.4 Hz, 4 × ArH), 7.30 (2H, d, J = 
8.4 Hz, 2 × ArH); 13C NMR (125 MHz, DMSO-d6) δC 30.5 (ArCH2), 114.4 (C-Ar), 116.4 (C-
Ar), 127.9 (2 × C-Ar), 128.1 (C-Ar), 128.5 (2 × C-Ar), 129.2 (2 × C-Ar), 130.1 (2 × C-Ar), 
130.9 (C-Ar), 131.1 (2 × C-Ar), 131.3 (2 × C-Ar), 131.6 (C-Ar), 133.7 (C-Ar), 135.7 (C-Ar), 
137.2 (C-Ar), 137.9 (C-Ar), 138.1 (C-Ar), 166.5 (C=O), 167.3 (C=O); HRMS calcd for 
C25H18Cl2NO4 [M(
35Cl2)+H]
+ 466.0607, found 466.0598. 
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4-(4-Chlorobenzyl)-5-(4-chlorophenyl)-6-phenyl-1H-furo[3,4-c]pyrrole-1,3(5H)-dione 
(85) 
 
Compound 67 (520 mg, 1.11 mmol) was dissolved in acetic anhydride (8 mL) and refluxed for 
2 h. After cooling to r.t., acetic anhydride was removed by filtration. The residue was washed 
with water (3×20mL) and petrol (3×20mL) and dried in vacuum oven at 40 ˚C to get an off-
white solid (410 mg, 82%). Rf = 0.42 (20% EtOAc/Petrol); m.p. 233-235 °C; λmax (EtOH)/nm 
275.4; IR νmax/cm-1 3092, 2649, 2376, 1816 (C=O), 1756 (C=O); 1H NMR (500 MHz, DMSO-
d6) δH 4.02 (2H, s, 2 × ArCH2), 6.96 (2H, d, J = 8.3 Hz,  2 × ArH), 7.25-7.27 (4H, m, 4 × ArH), 
7.30-7.34 (5H, m, 5 × ArH), 7.53 (2H, d, J = 8.3 Hz,  2 × ArH); 13C NMR (125 MHz, DMSO-
d6) δC 31.0 (ArCH2), 116.1 (C-Ar), 117.3 (C-Ar), 127.7 (C-Ar), 128.9 (2 × C-Ar), 129.0 (2 × 
C-Ar), 129.6 (2 × C-Ar), 129.9 (C-Ar), 130.2 (2 × C-Ar), 130.6 (2 × C-Ar), 130.8 (2 × C-Ar), 
131.9 (C-Ar), 134.9 (C-Ar), 135.1 (C-Ar), 135.3 (C-Ar), 135.7 (C-Ar), 136.0 (C-Ar), 159.6 
(C=O), 159.7 (C=O); HRMS calcd for C25H16Cl2NO3 [M(
35Cl2)+H]
+ 448.0502, found 
448.0496. 
 
4-(4-Chlorobenzyl)-5-(4-chlorophenyl)-6-phenylpyrrolo[3,4-c]pyrrole-1,3(2H,5H)-dione 
(68) 
 
Compound 85 (65 mg, 0.14 mmol) was suspended in acetic acid (1 mL) and 0.5 M NH3 in 
dioxane (4.2 mL, 2.1 mmol) was added. The mixture was heated at 120 ˚C under microwave 
irradiation for 30 min. After cooling to r.t., the solvent was removed in vacuo. The residue was 
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suspended in THF (3 mL) and thionyl chloride was added (70 µL). The resulting solution was 
stirred at r.t. for 1.5 h and refluxed for 1.5 h. After cooling to r.t., the solvent was removed in 
vacuo. The residue was purified by MPLC on SiO2 (Petrol:EtOAc, 0-50%) to give a beige solid 
(39 mg, 62%). Rf = 0.52 (2% MeOH/DCM); m.p. 274-276 °C; λmax (EtOH)/nm 322.8; IR 
νmax/cm-1 3191 (NH), 3061, 2922, 2851, 2753, 1742 (C=O), 1701 (C=O); 1H NMR (500 MHz, 
DMSO-d6) δH 3.97 (2H, s, 2 × ArCH2), 6.88-6.90 (2H, m, 2 × ArH), 7.22-7.29 (9H, m, 9 × 
ArH), 7.48-7.50 (2H, m, 2 × ArH), 10.59 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) δC 30.6 
(ArCH2), 107.5 (C-Ar), 118.5 (C-Ar), 119.7 (C-Ar), 128.7 (2 × C-Ar), 128.8 (2 × C-Ar), 129.1 
(C-Ar), 129.5 (2 × C-Ar), 130.0 (2 × C-Ar), 130.4 (2 × C-Ar), 131.0 (2 × C-Ar), 131.6 (C-Ar), 
132.6 (C-Ar), 132.8 (C-Ar), 134.5 (C-Ar), 135.5 (C-Ar), 136.6 (C-Ar), 165.5 (C=O), 165.9 
(C=O); HRMS calcd for C25H17Cl2N2O2 [M(
35Cl2)+H]
+ 447.0662, found 447.0655. 
 
4-(4-Chlorobenzyl)-2,5-bis(4-chlorophenyl)-6-phenylpyrrolo[3,4-c]pyrrole-1,3(2H,5H)-
dione (86) 
 
Compound 85 (65 mg, 0.14 mmol) and 4-chloroaniline (90 mg, 0.70 mmol) were suspended in 
acetic acid (1.5 mL). The mixture was heated at 120 ˚ C under microwave irradiation for 20 min. 
After cooling to r.t., the solvent was removed in vacuo. The residue was purified by MPLC on 
SiO2 (DCM:MeOH, 0-10%) to give an off-white solid. The product was suspended in THF (5 
mL) and thionyl chloride was added (200 µL). The resulting solution was stirred at r.t. for 18 
h. After cooling to r.t., the solvent was removed in vacuo. The residue was purified by MPLC 
on SiO2 (DCM:MeOH, 0-10%) to give a beige solid (52 mg, 64%). Rf = 0.52 (20% 
EtOAc/Petrol); m.p. 256 °C (degraded); λmax (EtOH)/nm 246.8; IR νmax/cm-1 3055, 2922, 2850, 
1752 (C=O), 1700 (C=O); 1H NMR (500 MHz, DMSO-d6) δH 4.05 (2H, s, 2 × ArCH2), 6.94-
6.96 (2H, m, 2 × ArH), 7.24-7.27 (4H, m, 4 × ArH), 7.30 (5H, s, 5 × ArH), 7.44-7.46 (2H, m, 
2 × ArH), 7.51-7.53 (2H, m, 2 × ArH), 7.57-7.59 (2H, m, 2 × ArH); 13C NMR (125 MHz, 
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DMSO-d6) δC 30.8 (ArCH2), 116.9 (C-Ar), 118.1 (C-Ar), 128.5 (C-Ar), 128.8 (2 × C-Ar), 128.8 
(2 × C-Ar), 129.2 (2 × C-Ar), 129.4 (C-Ar), 129.6 (2×C-Ar), 129.7 (2×C-Ar), 130.1 (2 × C-
Ar), 130.6 (2 × C-Ar), 131.0 (2 × C-Ar), 131.7 (C-Ar), 132.1 (C-Ar), 132.5 (C-Ar), 133.9 (C-
Ar), 134.2 (C-Ar), 134.7 (C-Ar), 135.3 (C-Ar), 136.3 (C-Ar), 163.0 (C=O), 163.3 (C=O); 
HRMS calcd for C31H20Cl3N2O2 [M(
35Cl3)+H]
+ 557.0585, found 557.0585. 
 
(2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-5-phenyl-1H-pyrrol-3-yl)methanol (308) 
 
Prepared according to general procedure F using compound 82 (1.2 g, 2.66 mmol), 1 M DIBAL 
in THF (6.7 mL, 6.70 mmol) and THF (5 mL). Purification by MPLC on SiO2 (Petrol:EtOAc, 
0-30%) gave an off-white solid (1.06 g, 97%). Rf = 0.25 (25% EtOAc/Petrol); m.p. 137-140 °C; 
λmax (EtOH)/nm 283.4; IR νmax/cm-1 3319 (OH), 3089, 2918, 2877, 2224; 1H NMR (500 MHz, 
DMSO-d6) δH 3.88 (2H, s, ArCH2), 4.44 (2H, d, J = 5.3 Hz, ArCH2OH), 4.84 (1H, t, J = 5.3 
Hz, OH),  6.44 (1H, s, Pyrrole-H), 6.83-6.86 (2H, m, 2 × ArH), 6.95-6.98 (2H, m, 2 × ArH),  
6.99-7.01 (2H, m, 2 × ArH), 7.07-7.11 (1H, m, 1 × ArH), 7.15-7.19 (4H, m, 4 × ArH), 7.34-
7.37 (2H, m, 2 × ArH); 13C NMR (125 MHz, DMSO-d6) δC 29.8 (ArCH2), 56.4 (CH2OH), 110.6 
(C-Ar), 123.5 (C-Ar), 126.5 (C-Ar), 127.8 (2 × C-Ar), 128.4 (2 × C-Ar), 128.7 (2 × C-Ar), 
129.5 (2 × C-Ar), 130.2 (2 × C-Ar), 130.8 (C-Ar), 130.9 (2×C-Ar), 130.9 (C-Ar), 132.7 (C-Ar), 
133.0 (C-Ar), 133.4 (C-Ar), 137.9 (C-Ar), 139.0 (C-Ar). 
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2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-5-phenyl-1H-pyrrole-3-carbaldehyde (90) 
 
Prepared according to general procedure G using compound 308 (1.05 g, 2.57 mmol) in DCM 
(10 mL) and Dess-Martin periodinane (1.85 g, 4.37 mmol) in DCM (15 mL). Purification by 
MPLC on SiO2 (Petrol:EtOAc, 0-30%) gave an off-white viscous liquid (680 mg, 65%). Rf = 
0.50 (25% EtOAc/Petrol); m.p. 132-135 °C; λmax (EtOH)/nm 250.8; IR νmax/cm-1 3066, 2985, 
2920, 2819, 2714, 1662 (C=O); 1H NMR (500 MHz, CDCl3) δH 4.18 (2H, s, 2 × ArCH2), 6.79-
6.80 (2H, m, 2 × ArH), 6.84-6.86 (3H, m, 3 × ArH), 7.01-7.03 (2H, m, 2 × ArH), 7.14-7.16 
(2H, m, 2 × ArH), 7.17-7.19 (3H, m, 3 × ArH), 7.25-7.27 (2H, m, 2 × ArH), 10.01 (1H, s, 
CHO); 13C NMR (125 MHz, CDCl3) δC 30.3 (ArCH2), 109.4 (C-Ar), 123.5 (C-Ar), 127.4 (C-
Ar), 128.3 (2 × C-Ar), 128.4 (2 × C-Ar), 128.6 (2 × C-Ar), 129.4 (2 × C-Ar), 129.4 (2 × C-Ar), 
129.8 (2 × C-Ar), 131.3 (C-Ar), 132.4 (C-Ar), 134.9 (C-Ar), 135.6 (C-Ar), 136.5 (C-Ar), 136.6 
(C-Ar), 140.2 (C-Ar), 186.1 (C=O); LRMS (ES+) m/z 406.2 [M(35Cl2)+H]
+, 408.2 [M(35Cl 
37Cl)+H]+. 
 
2,2,2-Trichloro-1-(2-(4-chlorobenzyl)-1-(4-chlorophenyl)-5-phenyl-1H-pyrrol-3-yl)ethan-
1-ol (91) 
 
Compound 90 (400 mg, 0.98 mmol) was dissolved in DMF (0.6 mL) and cooled to -10 ˚C. 
CHCl3 (190 µL, 2.35 mmol) was added dropwise and the mixture was stirred at -10 ˚C for 15 
min. KOH (44 mg, 0.78 mmol) in MeOH (0.12 mL) was added and the mixture was stirred at  
-10 ˚C for 3 h. The reaction was quenched with 1 M HCl (2 mL) and toluene (2 mL) and stirred 
at -10 ˚C for 1 h. After warming to r.t., the aqueous layer was extracted with EtOAc (3×30 mL). 
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The organic layers were combined, dried over MgSO4 and the solvent removed in vacuo. 
Purification by MPLC on SiO2 (Petrol:EtOAc, 0-20%) gave an off-white solid (330 mg, 64%). 
Rf = 0.44 (20% EtOAc/Petrol); m.p. 84-87 °C; λmax (EtOH)/nm 277.6; IR νmax/cm-1 3550, 3035, 
2920, 2850, 2656; 1H NMR (500 MHz, CDCl3) δH 3.88 (1H, d, J = 17.1 Hz, ArCH2), 4.07 (1H, 
d, J = 17.1 Hz, ArCH2), 5.20 (1H, s, CHOH), 6.69 (1H, br s, 1 × ArH), 6.75 (1H, s, 1 × ArH), 
6.81-6.83 (2H, m, 2 × ArH), 6.98-7.05 (3H, m, 3 × ArH), 7.10-7.17 (6H, m, 6 × ArH), 7.24 
(1H, br s, 1 × ArH); 13C NMR (125 MHz, CDCl3) δC 30.6 (ArCH2), 79.6 (CHOH), 104.0 (C-
Ar), 108.0 (C-Ar), 117.5 (C-Ar), 126.6 (2 × C-Ar), 128.1 (2 × C-Ar), 128.5 (2 × C-Ar), 129.1 
(2 × C-Ar), 129.3 (2 × C-Ar), 130.0 (2 × C-Ar), 132.0 (C-Ar), 132.1 (C-Ar), 133.0 (C-Ar), 
134.0 (C-Ar), 135.0 (C-Ar), 137.0 (C-Ar), 137.2 (C-Ar); LRMS (ES+) m/z 524.0 
[M(35Cl5)+H]
+, 526.1 [M(35Cl4
37Cl)+H]+, 528.1 [M(35Cl3
37Cl2)+H]
+. 
 
2-(2-(4-Chlorobenzyl)-1-(4-chlorophenyl)-5-phenyl-1H-pyrrol-3-yl)acetic acid (92) 
 
Diphenyl diselenide (76 mg, 0.24 mmol) was dissolved in ethanol (1 mL) and NaBH4 (18 mg, 
0.48 mmol) was added and the mixture was stirred at r.t. for 30 min. Compound 91 (122 mg, 
0.23 mmol) was added, followed by the addition of NaOH (55 mg, 1.38 mmol) and the mixture 
was stirred at r.t. for 24 h. After cooling to r.t., the solvent was removed in vacuo. EtOAc (5 
mL) and H2O (5 mL) was added to the residue and acidified to pH 1 with 1 M HCl. The aqueous 
layer was extracted with EtOAc (3×30 mL). The organic layers were combined, dried over 
MgSO4 and the solvent removed in vacuo. Purification by MPLC on SiO2 (DCM:MeOH, 0-
5%) gave a beige solid (90 mg, 90%). Rf = 0.47 (5% MeOH/DCM); m.p. 145-148 °C; λmax 
(EtOH)/nm 252.8; IR νmax/cm-1 3067, 2919, 2850, 2727, 2621, 1696 (C=O); 1H NMR (500 
MHz, DMSO-d6) δH 3.44 (2H, s, CH2COOH), 3.86 (2H, s, 2 × ArCH2), 6.38 (1H, s, Pyrrole-
H), 6.82-6.84 (2H, m, 2 × ArH), 6.98-7.02 (4H, m, 4 × ArH), 7.08-7.11 (1H, m, 1 × ArH), 7.16-
7.19 (4H, m, 4 × ArH), 7.32-7.36 (2H, m, 2 × ArH), 12.22 (1H, s, COOH); 13C NMR (125 
MHz, DMSO-d6) δC 29.7 (ArCH2), 32.5 (CH2COOH), 111.3 (C-Ar), 115.8 (C-Ar), 126.5 (C-
Ar), 127.8 (2 × C-Ar), 128.4 (2 × C-Ar), 128.7 (2 × C-Ar), 129.4 (2 × C-Ar), 130.1 (2 × C-Ar), 
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130.8 (2 × C-Ar), 130.8 (C-Ar), 131.3 (C-Ar), 132.7 (C-Ar), 132.9 (C-Ar), 133.5 (C-Ar), 138.0 
(C-Ar), 138.8 (C-Ar), 173.5 (C=O); HRMS calcd for C25H20Cl2NO2 [M(
35Cl2)+H]
+ 436.0866, 
found 436.0857. 
 
16.2.4 Synthesis of RO-2443 (3) and RO-5963 (4) 
 
6-chloro-7-methyl-1H-indole (103) 
 
2-Chloro-6-nitrotoluene (618 mg, 3.6 mmol) was dissolved in THF (25 mL) and cooled to -40 
°C. 1 M vinylmagnesium bromide in THF (10.8 mL, 10.8 mmol) was added dropwise and the 
reaction mixture was stirred at -40 °C for 1 h. Saturated aqueous NH4Cl (30 mL) was added 
and the aqueous layer was extracted with ethyl acetate (3 × 20 mL). The organic layers were 
combined, dried over MgSO4, and evaporated in vacuo. Purification by MPLC on SiO2 
(Petrol:EtOAc, 0-20%) gave a dark brown viscous liquid (260 mg, 43%). Rf = 0.33 (20% 
EtOAc:Petrol); m.p. 116-119 °C. UV λmax (EtOH)/nm 271, 220; IR νmax/cm-1 3413 (NH), 1732, 
1606; 1H NMR (500 MHz; CDCl3) δH 2.45 (3H, s, CH3), 6.46 (1H, dd, J = 2.2 and 3.1 Hz, ArH), 
7.05 (1H, d, J = 8.4 Hz, ArH), 7.13 (1H, dd, J = 2.2 and 3.1 Hz, ArH), 7.33 (1H, d, J = 8.4 Hz, 
ArH), 8.01 (1H, br s, NH); 13C NMR(125 MHz; CDCl3) δC 13.9 (CH3), 103.4 (CH-Ar), 118.1 
(C-Ar), 118.9 (CH-Ar), 121.3 (CH-Ar), 124.5 (CH-Ar), 126.0 (C-Ar), 127.5 (C-Ar), 136.0 (C-
Ar).  
 
6-Chloro-7-methyl-1H-indole-3-carbaldehyde (104) 
 
Prepared according to general procedure H using compound 103 (160 mg, 0.96 mmol), DMF 
(12 mL) and phosphorus oxychloride (0.25 mL, 2.89 mmol) heated under microwave irradiation 
at 70 °C for 10 min. EtOAc extraction gave a light brown solid (175 mg, 93%) which did not 
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require further purification, Rf = 0.35 (2% MeOH/DCM); m.p. 239-241 °C; λmax (EtOH)/nm 
263; IR νmax/cm-1 1632 (C=O). 1H NMR (500 MHz; DMSO-d6) δH 2.54 (3H, s, CH3), 7.26 (1H, 
d, J = 8.5 Hz, ArH), 7.91 (1H, d, J = 8.5 Hz, ArH), 8.36 (1H, s, 1×ArH), 9.94 (1H, s, CHO), 
12.33 (1H, br s, NH). 13C NMR (125 MHz; DMSO-d6) δC 14.0 (CH3), 118.4 (C-Ar), 119.3 (C-
Ar), 119.8 (CH-Ar), 122.7 (CH-Ar), 123.1 (C-Ar), 127.8 (C-Ar), 137.1 (CH-Ar), 138.9 (C-Ar), 
185.1 (C=O). HRMS calcd for C10H7ClNO [M(
35Cl)-H]- 192.0222, 192.0213. 
 
3-(3,4-difluorobenzyl)imidazolidine-2,4-dione (107) 
 
Hydantoin (500 mg, 5 mmol), 3,4-difluorobenzyl bromide (0.64 mL, 5 mmol) and K2CO3 (700 
mg, 5mmol) were suspended in acetonitrile (12 mL). The reaction mixture was refluxed for 6 
hours and stirred at 50 ° C for 16 h. The reaction was cooled to r.t, quenched with ice and 
extracted with EtOAc (3×25 mL). The organic layers were combined, washed with brine, dried 
over MgSO4 and evaporated in vacuo. Purification by MPLC on SiO2 (Petrol:EtOAc, 0-20%) 
gave a white solid (643 mg, 57%). Rf = 0.37 (2% MeOH/DCM); m.p. 134-137 °C; λmax 
(EtOH)/nm 339, 268, 263; IR νmax/cm-1 3259 (NH), 1771 (C=O), 1712 (C=O); 1H NMR (500 
MHz, CDCl3) δH 3.92 (2H, s, CH2), 4.54 (2H, s, CH2), 6.15 (1H, br s, NH), 7.00-7.08 (2H, m, 
2 × Ar-H), 7.15-7.20 (1H, m, Ar-H); 13C NMR (125 MHz, CDCl3) δC  41.3 (CH2), 46.5 (CH2), 
117.5 (d, J = 17.3, CH-Ar), 118.0 (d, J = 17.9, CH-Ar), 125.0 (dd, J = 3.7 and 6.2 Hz, CH-Ar), 
150.2 (dd, J = 12.7 and 249.3 Hz, ArCF), 150.2 (dd, J = 12.7 and 248.8 Hz, ArCF), 157.7 
(C=O), 170.7 (C=O). 19F NMR (470 MHz; CDCl3) δF -138.5 (d, J = 21.0 Hz), -136.9 (d, J =21.0 
Hz). LRMS (ES+) m/z 227.2 [M + H]+. 
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(Z)-5-((6-chloro-7-methyl-1H-indol-3-yl)methylene)-3-(3,4-difluorobenzyl)imidazolidine-
2,4-dione (3) 
 
A mixture of compound 104 (50 mg, 0.26 mmol), 107 (68 mg, 0.30 mmol) and piperidine (0.08 
mL) was heated at 130 °C for 30 min. The reaction mixture was cooled to 60 °C, water (2 mL) 
was added and the mixture was stirred for 1 hour and additional water (20 mL) was added, 
extracted with ethyl acetate (2 × 25 mL). The organic layers were combined, dried over MgSO4 
and evaporated in vacuo to get a yellow solid (96 mg, 92 %). Rf = 0.39 (4% MeOH/DCM); m.p. 
278-280 °C (decomposed); λmax (EtOH)/nm 368, 230. IR ν max/cm-1 3475 (NH), 3216, 3151, 
3054, 1743 (C=O), 1699 (C=O). 1H NMR (500 MHz, THF-d8) δH 2.52 (3H, s, CH3), 4.67 (2H, 
s, benzyl-CH2), 6.92 (1H, s, CH=Hydantoin), 7.14 (1H, d, J = 8.5 Hz, Indole-H), 7.16-7.22 (2H, 
m, 2 × Phenyl-H), 7.31-7.35 (1H, m, Phenyl-H), 7.59 (1H, d, J = 8.5, indole-H), 7.82 (1H, d, J 
= 2.4 Hz, Indole-H2), 9.27 (1H, br s, NH), 10.97 (1H, s, NH). 
13C NMR (125 MHz, THF-d8) δC 
13.9 (CH3), 40.4 (d, J = 0.9 Hz, Benzyl-CH2), 103.5 (CH=Hydantoin), 111.2 (C-CO), 117.8 
(CH-Indole), 118.0 (d, J = 17.6, Phenyl-CHCF), 118.4 (d, J = 17.6, Phenyl-CHCF), 119.7 (C-
Ar), 122.5 (CH-Indole), 124.6 (C-Ar), 125.9 (dd, J = 3.6 and 6.5 Hz, Phenyl-CH), 126.8 (C-
Ar), 126.9 (CH-Indole), 128.9 (C-Ar), 135.7 (dd, J = 3.9, 5.5 Hz, C-Ar), 137.4 (C-Ar), 150.8 
(dd, J = 30.8 and 247.2 Hz, ArCF), 150.9 (dd, J = 31.2 and 247.2 Hz, ArCF), 155.2 (C=O), 
164.3 (C=O). 19F NMR (470 MHz; THF-d8) δF -141.4 (d, J = 22.5 Hz), -139.4 (d, J = 20.7 Hz). 
HRMS calcd for C20H13ClF2N3O2 [M(
35Cl)-H] – 400.0670, found 400.0655. 
 
(Z)-5-((6-chloro-7-methyl-1H-indol-3-yl)methylene)imidazolidine-2,4-dione (118) 
 
A mixture of compound 104 (100 mg, 0.52 mmol), hydantoin (47 mg, 0.47 mmol) and 
piperidine (0.16 mL) was heated at 130 °C for 1 h. The reaction mixture was cooled to 60 °C, 
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water (2 mL) was added and the mixture was stirred for 1 hour and additional water (20 mL) 
was added, extracted with ethyl acetate (2×25 mL). The organic layers were combined, dried 
over MgSO4 and evaporated in vacuo. Purification by MPLC on SiO2 (DCM:MeOH, 0-10%) 
gave a yellow solid (112 mg, 86 %). Rf = 0.29 (4% MeOH/DCM); m.p. 330-331 °C 
(decomposed); λmax (EtOH)/nm 362, 267, 231; IR νmax/cm-1 3047 (N-H), 3193, 2980, 2919, 
1745 (C=O), 1703 (C=O). 1H NMR (500 MHz, DMSO-d6) δH 2.52 (3H, s, CH3), 6.70 (1H, s, 
CH=CCO), 7.14 (1H, d, J = 8.4 Hz, indole-H), 7.62 (1H, d, J = 8.4 Hz, indole-H), 8.16 (1H, d, 
J = 2.1 Hz, indole-H2), 10.17 (1H, s, NH), 11.00 (1H, br s, NH), 11.94 (1H, s, NH). 
13C NMR 
(125 MHz, DMSO-d6) δC 13.9 (CH3), 101.1 (CH=CCO), 109.0 (indole-C), 116.8 (indole-CH), 
119.0 (indole-C), 121.1 (indole-CH), 124.1, 125.5, 126.8 (indole-C), 127.2 (indole-CH), 135.9 
(indole-C), 155.2 (C=O), 165.2 (C=O). HRMS calcd for C13H9ClN3O2 [M(35Cl)-H] – 274.0389, 
found 274.0382. 
 
2-Bromo-2-(3,4-difluorophenyl)acetic acid (109) 
 
2-amino-2-(3,4-difluorophenyl)acetic acid (580 mg, 3.10 mmol) was added into a solution of 
48% hydrobromic acid (2.8 mL, 24.8 mmol), KBr (1.48 g, 12.4 mmol) and water (6 mL). The 
mixture was stirred at 0°C for 15 min, then, a solution of NaNO2 (684 mg, 9.92 mmol) in water 
(4 mL) was added dropwise and the mixture was stirred at r.t. for 3 hours. The aqueous layer 
was extracted with DCM (3×30 ml). The organic layers were combined, washed with water (30 
mL), brine (20 mL), dried over MgSO4, and evaporated in vacuo. Purification by MPLC on 
SiO2 (Petrol:EtOAc, 0-100%, 0.5% Acetic acid) gave a white solid (281 mg, 36%). Rf = 0.66 
(50% EtOAc/Petrol, 5 % AcOH); m.p. 89-90 °C; λmax (EtOH)/nm 398; IR ν max/cm-1 3060, 
2920, 2669, 1728 (C=O); 1H NMR (500 MHz, CDCl3) δH 5.22 (1H, s, benzyl-CH), 7.06-
7.11(1H, m, Ar-H), 7.14-7.21 (1H, m, Ar-H), 7.37-7.41(1H, m, Ar-H), 8.87 (1H, br s, COOH). 
13C NMR (125 MHz, CDCl3) δC 44.0 (benzyl-CH), 117.6 (d, J = 17.7 Hz, ArCH), 118.3 (d, J 
= 18.6 Hz, ArCH), 125.1 (dd, J = 3.7 and 6.6 Hz, ArC6H), 131.8 (dd, J = 4.0, 5.8 Hz, ArC1), 
150.3 (dd, J = 11.6 and 249.0 Hz, ArCF), 151.0 (dd, J = 6.2 and 246.0 Hz, ArCF), 173.0 
(COOH). 19F NMR (470 MHz; CDCl3) δF -135.5 (d, J = 20.9 Hz), -131.5 (d, J =20.9 Hz). 
LRMS (ES-) m/z 205.0 [(M(79Br)-COOH)-H]-, 207.0 [(M(81Br)-COOH)-H]-. 
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N-(1,3-dihydroxypropan-2-yl)-2,2,2-trifluoroacetamide (113) 
 
A mixture of 2-aminopropane-1,3-diol (562 mg, 6.17 mmol), ethyl trifluoroacetate (6 mL) and 
THF (2 mL) was stirred at r.t. for 48 h. The solvent was evaporated in vacuo and the residue 
was purified by filtering through silica to get a white solid (1.12 g, 98 %). Rf = 0.57 (10% 
MeOH/DCM); m.p. 61-62 °C; IR ν max/cm-1 3289 (O-H), 1703 (C=O); 1H NMR (500 MHz, 
CD3OD) δH 3.52 (2H, dd, J = 6.2 and 11.3 Hz, CH2), 3.58 (2H, dd, J = 5.4 and 11.3 Hz, CH2), 
3.91 (1H, m, NHCH); 13C NMR (125 MHz, CD3OD) δC 55.6 (NHCH), 61.5 (CH2), 117.5 (d, J 
= 286.7 Hz, CF3), 159.2 (d, J = 36.8 Hz, C=O). 
19F NMR (470 MHz, CD3OD) δF -77.2 (s). 
 
N-(2,2-dimethyl-1,3-dioxan-5-yl)-2,2,2-trifluoroacetamide (114) 
 
Compound 113 (721 mg, 3.9 mmol) was dissolved in DCM (7 mL), camphor-10-sulfonic acid 
(91 mg, 0.39 mmol) and 2,2-dimethoxypropane (3.84 mL, 31.2 mmol) were added, 
respectively. The reaction mixture was stirred at r.t. for 96 h. Saturated aqueous NaHCO3 (20 
mL) was added and stirred for 1 h. The aqueous layer was extracted with DCM (3×40 mL). The 
organic layers were combined, dried over MgSO4, and evaporated in vacuo. Purification by 
MPLC on SiO2 (DCM:MeOH, 0-5%) gave a white solid (475 mg, 54%). Rf = 0.81 (2% 
MeOH/DCM); m.p. 73-75 °C; IR ν max/cm-1 3283 (N-H), 1716 (C=O), 1550 (N-H); 1H NMR 
(500 MHz, CD3OD) δH 1.32 (3H, s, CH3), 1.33 (1H, s, CH3), 3.68 (2H, dd, J = 5.6 and 12.1 Hz, 
CH2), 3.76-3.79 (1H, m, NHCH), 3.95 (2H, dd, J = 3.8 and 12.1 Hz, CH2); 
13C NMR (125 MHz, 
CD3OD) δC 23.1 (CH3), 24.8 (CH3), 46.0 (NHCH), 62.8 (2×CH2), 99.7 (CH2OC(CH3)2), (d, J 
= 286.5 Hz, CF3), 158.9 (d, J = 37.3 Hz, C=O). 
19F NMR (470 MHz, CD3OD) δF -77.1 (s).  
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2,2-Dimethyl-1,3-dioxan-5-amine (115) 
 
Compound 114 (500 mg, 2.2 mmol) was dissolved in THF (10 mL) and water (10 mL), LiOH 
monohydrate (184 mg, 4.4 mmol) was added and stirred at r.t. for 1.5 h. The solvent was 
evaporated in vauo, the remaining residue was dissolved in water (20 mL) and extracted with 
DCM (5 × 15 mL). The organic layers were combined, dried over MgSO4, and concentrated in 
vacuo to get a colourless liquid (157 mg, 54%) which was used for the next step without further 
purification. Rf = 0.18 (2% MeOH/DCM); IR νmax/cm-1 3350 (NH2 stretch), 2980, 2930; 1H 
NMR (500 MHz, CDCl3) δH 1.42 (3H, s, CH3), 1.54 (2H, br s, 2×NH2), 2.84(1H, br s, 
CH(CH2)2), 3.56 (2H, dd, J = 11.8 and 5.6 Hz, CH2O), 4.01 (2H, dd, J = 11.8 and 3.5 Hz, 
CH2O). 
 
2-Bromo-2-(3,4-difluorophenyl)-N-(2,2-dimethyl-1,3-dioxan-5-yl)acetamide (116) 
 
Compound 109 (130 mg, 0.517 mmol), 115 (68 mg, 0.517) and DMAP (6.3 mg, 0.05 mmol) 
were dissolved in DCM (2.6 mL) and the reaction mixture was stirred at 0 °C for 20 min. DIC 
(0.09 mL, 0.56 mmol) was added and the solution was stirred at 0 °C for 3 h and at r.t. for 13 
h. The reaction mixture was quenched with water (10 mL) and extracted with DCM (3 × 20 
mL). The organic layers were combined, dried over MgSO4, and concentrated in vacuo. 
Purification by MPLC on SiO2 (Petrol:EtOAc, 0-90%) gave a white solid (149 mg, 79%). Rf = 
0.45 (50% EtOAc/Petrol); m.p. 145-147 °C; λmax (EtOH)/nm 398; IR νmax/cm-1 3279 (O-H 
stretch), 3045, 2921, 2868, 1525, 1488.; 1H NMR (500 MHz, CDCl3) δH 1.44 (3H, s, CH3), 1.50 
(3H, s, CH3),  3.72-3.77(2H, m, CH2O), 3.82-3.86 (1H, m, NHCH), 4.15 (2H, dd, J = 12.3, 2.0 
Hz, CH2O), 7.12-7.17 (1H, m, ArH), 7.20-7.23 (1H, m, ArH), 7.33-7.37 (1H, m, ArH), 7.51 
(1H, br d, J = 7.7 Hz, NH); 13C NMR (125 MHz, CDCl3) δC 18.3 (CH3 ), 29.1 (CH3 ), 44.8 
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(NHCH), 49.1 (d, J = 1.5 Hz, benzyl-CH), 63.2 (CH2O), 63.2 (CH2O), 98.9 (C(CH3)2), 117.8 
(2C, dd, J = 17.9, 9.6 Hz, ArC2 and ArC5), 124.8 (dd, J = 6.6, 3.6 Hz, ArC6), 134 (2C, dd, J = 
5.8, 4.1 Hz, C1), 166.0 (C=O), ArC3 and ArC4 could not be seen. 19F NMR (470 MHz; CDCl3) 
δF -135.3 (d, J = 22.1 Hz), -134.8 (d, J = 22.1 Hz); LRMS (ES-) m/z 362.2 [M(79Br)-H]-, 364.2 
[M(81Br)-H]-. 
 
(Z)-2-(4-((6-chloro-7-methyl-1H-indol-3-yl)methylene)-2,5-dioxoimidazolidin-1-yl)-2-
(3,4-difluorophenyl)-N-(2,2-dimethyl-1,3-dioxan-5-yl)acetamide (119) 
 
Compound 118 (54 mg, 0.19 mmol) was dissolved in DMF (0.7 mL) and cooled to 0 °C. K2CO3 
(26 mg, 0.28 mmol) was added and stirred for 20 min. Compound 116 (70 mg, 0.19 mmol) was 
added and the reaction mixture was stirred at 0 °C for 30 min at r.t. for 48 h. The reaction did 
not go into completion (as monitored by TLC), therefore, K2CO3 (10 mg, 0.07 mmol) was added 
and the reaction mixture was stirred at r.t. for 48 h. The reaction was poured into ice and 
extracted with EtOAc (3 × 15 ml). The organic layers were combined, dried over MgSO4 and 
evaporated in vacuo. Purification by MPLC on SiO2 (DCM:MeOH, 0-5%) gave a yellow solid 
(18 mg, 17%). Rf = 0.55 (8% MeOH/DCM); m.p. 250 °C (degradation); λmax (EtOH)/nm 371; 
IR νmax/cm-1 3048, 2945, 1742 (C=O), 1698 (C=O), 1638 (C=O); 1H NMR (500 MHz, THF-d8) 
δH 1.16 (3H, s, CH3), 1.25 (3H, s, CH3),  2.41 (3H, s, CH3), 3.50-3.60 (2H, m, CH2O), 3.75-
3.78 (1H, m, NHCH(CH2OH)2), 3.86-3.91 (2H, m, CH2O), 5.75 (1H, s, benzyl-CH), 6.81 (1H, 
s, Indole-CH-hydantoin), 7.03 (1H, d, J = 8.5 Hz, ArH), 7.11-7.16 (1H, m, ArH), 7.20 (1H, d, 
J = 7.9, CONH), 7.26-7.28 (1H, m, ArH), 7.46-7.75 (2H, m, 2×ArH), 7.73 (1H, d, J = 2.5 Hz,  
ArH), 9.33 (1H, br s, Hydantoin-NH), 10.94 (1H, br s, Indole-NH); 13C NMR could not be 
obtained . 19F NMR (470 MHz; THF-d8) δF -140 (d, J = 21.8 Hz), -139.4 (d, J = 21.8 Hz); 
HRMS calcd for C27H26ClF2N4O5 [M(35Cl)+H]+ 559.1554, found 559.1540. 
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(Z)-2-(4-((6-chloro-7-methyl-1H-indol-3-yl)methylene)-2,5-dioxoimidazolidin-1-yl)-2-
(3,4-difluorophenyl)-N-(1,3-dihydroxypropan-2-yl)acetamide (4) 
 
Compound 119 (18 mg, 0.032 mmol) was dissolved in THF (0.5 mL), 0.2 M HCl (0.17 mL) 
was added dropwise and stirred at 0 °C for 1 h and at r.t. for 2 h. The solvent was evaporated 
in vacuo and the remaining residue was neutralised with saturated aqueous NaHCO3 and 
extracted with EtOAc (3 × 20 mL), dried over MgSO4 and evaporated in vacuo. Purification by 
semi-preparative HPLC (C-18 silica, MeCN/formic acid aq., 65%) gave a yellow solid (6 mg, 
36%). Rf = 0.36 (8% MeOH/DCM); m.p. 210 °C (degradation); λmax (EtOH)/nm 371; IR 
νmax/cm-1 3281 (O-H stretch), 2954, 1746 (C=O), 1700 (C=O), 1644 (C=O); 1H NMR (500 
MHz, THF-d8) δH 2.41 (3H, s, CH3), 3.43-3.52 (4H, m, 2×CH2OH), 3.63 (1H, br s, OH), 3.72 
(1H, br s, OH), 3.76-3.82 (1H, m, NHCH(CH2OH)2), 5.72 (1H, s, Benzyl-CH), 6.81 (1H, s, 
Indole-CHCCO), 6.89 (1H, d, J = 7.8 Hz, CONH), 7.02 (1H, d, J = 8.5, ArH), 7.07-7.13 (1H, 
m, ArH), 7.22-7.25 (1H, m, ArH), 7.43-7.48 (2H, m, 2 × ArH), 7.73 (1H, d, J = 2.5 Hz,  ArH), 
9.33 (1H, br s, Hydantoin-NH), 10.91 (1H, br s, Indole-NH). 13C NMR (125 MHz, THF-d8) δC 
12.9 (CH3), 54.0 (CH(CH2OH)2), 56.7 (BenzylCH), 60.8 (CH(CH2OH)2), 103.1 (Indole-
CHCCO), 110.2, 116.7 (ArCH, multiplicity not clear), 116.8 (Indole-CH), 118.8 (ArC), 118.9 
(d, J = 18.4 Hz, ArCH), 121.5 (Indole-CH), 123.2 (ArC),118.7 (ArC), 121.5 (ArCH), 123.6 
(ArC), 124.9 (dd, J = 3.6, 6.5 Hz, ArCH), 125.8 (ArC), 126.1 (ArC), 126.5 (ArCH, multiplicity 
not clear), 137.2 (ArC), 154.0 (CO), 163.3 (CO), 165.9 (CO). The expected dd of 2×CF were 
not seen due to the dilute NMR sample. 19F NMR (470 MHz; THF-d8) δF -140 (d, J = 21.8 Hz), 
-139.4 (d, J = 21.8 Hz); HRMS calcd for C24H21ClF2N4O5 [M(35Cl)+H]+ 519.1241, found 
559.1226. 
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16.3 MDMX Structural biology experimental 
 
16.3.1 General procedures 
 
16.3.1.1 Media supplementation 
All cultures were supplemented with an antibiotic, according to the antibiotic selectivity of the 
pGEX-6P-1 vector and E. coli strain used during recombinant protein expression. During IPTG-
based induction of protein expression, the lactose analogue IPTG was added to the culture to 
induce protein expression. Appropriate amounts of IPTG (200 mM) and ampicillin (50 mg/mL) 
were dissolved in sterile 18.2 MΩ/cm H2O, before storing at -20 °C until required. 
Chloramphenicol (34 mg/mL) was dissolved in 100% ethanol and stored at -20 °C. 
 
16.3.1.2 mHBS buffer 
To prepare the mHBS buffer, 20 mL of aq. NaCl (5 M), 5 mL of aq. DTT (1 M) and 20 mL of 
aq. HEPES (1 mM, pH 7.4) were used in 1 L of solution and the pH was brought to 7.4 by 
addition of aq. NaOH (10 M). The buffer was filtered and degassed before use and, if required, 
stored at 4 °C for no longer than one week. 
 
16.3.1.3 Glutathione elution buffer 
To prepare the glutathione elution buffer, glutathione (0.123g) was dissolved in mHBS (20 mL) 
and the pH was brought to 7.4 by addition of aq. NaOH (10 M). The buffer was stored at 4 °C 
and used immediately after preparation. 
 
16.3.1.4 Polyacrylamide gel electrophoresis 
SDS-PAGE was used for protein identification and semi-quantitative analysis. Pre-cast 12-well 
acrylamide gels (RunBlue; 12% for GST-MDMX/GST-MDM2 and 16% for MDMX/MDM2) 
were used with SDS run buffer (RunBlue). Samples were mixed with SDS loading buffer 
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(RunBlue) and denatured at 100 °C for 5 min before being loaded onto the gel. PageRuler pre-
stained protein ladder (10-170 kDa, Thermo Scientific) was used. Electrophoresis was carried 
out at 180 V and gels were stained with InstantBlue™ protein stain. 
 
16.3.2 Expression from MDMX and MDM2 gene constructs 
 
1.1.1.1 Transformation of competent RosettaTM BL21(DE3) pLysS E. coli 
Recombinant MDMX pGEX-6P-1 expression vector plasmid were transformed into competent 
RosettaTM (DE3)pLys S (Novagen), whilst recombinant MDM2 pGEX-6P-1 expression vector 
plasmid were transformed into competent BL21(DE3) pLys S E. coli (Novagen). Competent 
cells were mixed with 1 µL of plasmid and incubated on ice for 30 min. The cells were 
transferred to a water bath at 42 °C for 30 sec, before incubating on ice for 2 min. The cells 
were recovered through aseptic addition of 200 µL super optimal broth with catabolite 
repression (SOC) medium and incubated at 37 °C, 200 rpm for 1 h. The recovered cells were 
aseptically plated onto LB-agar plates supplemented with ampicillin and chloramphenicol and 
incubated overnight at 37 °C to allow growth of transformed bacterial colonies. 
 
1.1.1.2 Recombinant MDMX expression following IPTG induction 
Transformed RosettaTM BL21(DE3) pLysS E. coli colonies were used to inoculate starter 
cultures containing 10 mL of Terrific Broth (TB), supplemented with ampicillin (20 µL) and 
chloramphenicol (10 µL). The starter cultures were incubated overnight at 37 °C, 200 rpm 
before aseptic transfer of a 1% (v/v) inoculum into an appropriate volume of expression media, 
supplemented with antibiotics. The culture was incubated at 37 °C, 160 rpm and the optical 
density (OD) of the culture was monitored by spectrometry during growth. Once an OD600 nm 
of 0.6-1.0 was reached, 200 mM IPTG (1 mL) was added to the culture to induce protein 
expression. The culture was incubated at 20 °C, 160 rpm overnight. 
 
1.1.1.3 Recombinant MDM2 expression following IPTG induction 
BL21 (DE3) E. coli glycerol stocks for  MDM217−125
K51A  and MDM217−125
E69K70A were prepared 
previously by Judith Reeks and stored at -80 °C. A glycerol stock of BL21 (DE3) pLysS E. coli 
for MDM217−108
E69K70A was prepared and stored similarly. Transformed BL21 E. coli cells were 
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inoculated in starter cultures containing 10 mL of LB, supplemented with ampicillin (20 µL) 
(BL21 (DE3)) or ampicillin (20 µL) and chloramphenicol (10 µL) (BL21 (DE3) pLysS). The 
starter cultures were incubated overnight at 37 °C, 200 rpm, before aseptic transfer of a 1% 
(v/v) inoculum into an appropriate volume of expression media, supplemented with 
chloramphenicol (1 mL) and/or ampicillin (1 mL). The culture was incubated at 37 °C, 160 
rpm, whilst the optical density of the culture was monitored during growth. Once an OD600 nm 
of 0.6-1.0 was reached, 200 mM IPTG (1 mL) was added to the culture to induce protein 
expression. The culture was incubated at 20 °C, 160 rpm overnight. 
 
1.1.1.4 Cell harvesting 
Following culture, the E. coli cells were harvested by centrifugation (5000  g, 15 min, 4°C) to 
give a pellet which was resuspended in mHBS supplemented with a protease inhibitor tablet 
(Roche; 1 tablet/40 mL), flash-frozen in dry ice and stored at -20 °C until further use. 
 
16.3.3 Protein purification 
The resuspended cell pellets were thawed under running water and lysozyme (400 µL of 25 
mg/mL stock), RNAase A (200 µL of 10 mg/mL stock), DNAase I (200 µL of 2 mg/mL stock) 
and MgCl2 (100 µL of 2 M stock) were added before sonication (30% amplitude; 20 sec on/40 
sec off intervals for 15 min) whilst on ice. The lysed cells were centrifuged (45,000 × g, 60 min, 
4°C) and the supernatant (cell-free extract, CFE) was decanted from the pellet and retained. 
Diluted CFE samples were heated at 100 °C for 5 min and then analyzed by SDS-PAGE to 
establish whether the target protein had been overexpressed. 
The supernatant was incubated overnight at 4 °C with glutathione Sepharose 4B resin (GE 
Healthcare, bed volume 2 mL). The mixture was loaded by gravity flow into a column and 
washed twice with mHBS (15 mL). The GST-MDMX (or GST-MDM2) was eluted with a fresh 
solution of glutathione in mHBS (20 mL). 3C protease (50:1 protein:3C protease by weight) 
was added to cleave MDMX or MDM2 from the GST tag and the mixture was incubated 
overnight at 4 °C. The desired protein was separated from the GST tag using gel filtration 
chromatography (Äkta Superdex 75 26/60, isocratic flow of mHBS, Äkta FPLC 
Chromatographic system, UV absorbance 280 nm). 
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The protein concentration was measured using a UV-vis spectrophotometer NanoDrop 2000 
(Thermo Scientific). 
 
16.3.4 Protein preparation for crystallography 
 
The purified protein was incubated overnight at 4 °C with a 1.5× molar excess of inhibitor (20 
mM stock in DMSO). Protein mixtures were concentrated using Amicon® Ultra-15 (Millipore) 
centrifugal filter devices (5000 × g, 4 °C) to a concentration between 1 and 20 mg/mL. 
Crystallization trays were set up in 2-subwell 96-well plates by pipetting commercial screens 
(JCSG+ from Molecular Dimensions, Index (Hampton Research), and AmSO4 Suite from 
Qiagen) from deep well blocks prior to protein addition. Protein mixture and precipitant were 
mixed in the subwells by a Mosquito® robot (100 + 100 nL, 200 + 100 nL, precipitant:protein) 
using the sitting drop method. Plates were sealed and stored in the Minstrel (Rigaku) automated 
high-throughput monitoring system at 4 °C for up to five weeks. Crystals were transferred into 
a solution of 70% precipitant, 30% ethylene glycol, flash cooled in liquid nitrogen and shipped 
to Diamond Light Source (Oxford, UK) for data collection. 
 
16.3.5 HTRF assay 
 
The experimental detail described below is the final optimized procedure. 
The inhibitor solutions (20 mM solution in DMSO) were dispensed in an Echo qualified 384-
well low dead volume microplate source plate using a multi-channel pipette. Buffer A (50 mM 
Tris at pH 7.4, 100 mM NaCl, 100 μg/mL BSA, 1 mM DTT) and buffer B (50 mM Tris at pH 
7.4, 100 mM NaCl, 100 μg/mL BSA) were prepared fresh. The inhibitors were dispensed into 
a 384-well black low-binding round bottom assay plate (Corning) using a Echo® Liquid Handler 
550 (Labcyte), starting at 500 μM inhibitor (final assay concentration) and decreasing over a 
semi-log scale. Each well was backfilled with DMSO to a final volume of 250 nL and each 
condition was in duplicate.  
IP3 peptide (300 µM in DMSO) was diluted in buffer A supplemented with 4.2 % DMSO to 
obtain a 500 nM solution and was added to all the wells on the assay plate (6 µL). GST-
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MDMX22-111 (107 µM stock) was diluted with buffer A, first to 1.07 µM and subsequently to 
25 nM and was added to the plate (4 µL). Positive (peptide, MDMX and DMSO; no inhibitor) 
and negative (peptide, buffer A and DMSO; no protein or inhibitor) controls were included. 
The plate was incubated on a shaking platform for 1 h. The final concentrations were as follows: 
10 nM GST-MDMX, 300 nM IP3 peptide, 5 % DMSO. A solution of Tb-anti-GST-antibody 
(3.3 µM stock) was prepared in buffer B (20 nM) and added to each well (10 µL) of the assay 
plate followed by 45 min incubation on the shaker. The plate was read using PHERAstar FS 
(BMG Labtech) microplate reader. 
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16.4 Synthesis of ATAD2 Inhibitors-Experimental Procedures 
 
16.4.1 ATAD2 Biology Procedures 
 
HTRF assay protocol 
The ATAD2 bromodomain 981-1108 was expressed with an N-terminal GST fusion from the 
pGEX-6P-1 plasmid. The plasmids were transformed into BL21 (DE3) pLysS Escherichia coli 
(Novagen) and then the cells grown in luria bertani (LB) media at 37 ˚C until an OD600 of 0.6 
was reached. The temperature was reduced to 20 ˚C and expression induced using 0.2 mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG). The cells were harvested after overnight 
incubation and resuspended in buffer A (20 mM HEPES pH 7.4, 100 mM NaCl, 5 mM 
Dithiothreitol (DTT)). The cells were lysed by sonication and the lysate cleared by 
centrifugation (50,000 x g, 4 ˚C, 1 hr). The protein was passed over 5ml of glutathione 
Sepharose 4B resin (GE Healthcare) at 4 ˚C. The resin was then washed with buffer A and the 
protein eluted with buffer A supplemented with 10 mM glutathione. The protein was then 
applied to a Superdex 200 26/60 gel filtration column (GE Healthcare) equilibrated in buffer 
A. 
 
Compounds (dissolved to 100 mM in DMSO) were dispensed into black 384 well assay plates 
(Corning) over a final concentration range of 2000, 1350, 900, 600, 425, 300, 200, 100, 50, and 
25 μM using an Echo 550 (Labcyte). Each well was backfilled to a final volume of 200 nl (for 
the MDM2 assay), resulting in final DMSO concentrations of 2 %. 5 μl of GST-ATAD2 was 
added to each well and incubated for 30mins resulting in a final concentration of 5 nM. 5μl of 
biotinylated-histone H4 peptide (SGRG-K(Ac)-GG-K(Ac)-GLG-K(Ac)-GGA-K(Ac)-
RHRKVGG-K(Biotin)) was then added to each well at a final concentration of 500nM. Both 
GST-ATAD2 and peptide were diluted in buffer B (50 mM Tris pH 7.5, 100 nM NaCl, 1 mM 
DTT, 100 μg/ml bovine serum albumin (BSA)). The plate was then incubated at room 
temperature for 30mins and then 5 μl LanthaScreen® Tb-anti-GST Antibody (Life 
Technologies) at final concentration of 5 nM was added to each well and incubated for an 
additional 30mins. 5 μl of streptavidin-XLL65 (Cisbio Assay) at a final concentration of 62.5 
μM was added to each assay well. Both dyes were diluted in buffer C (50 mM Tris pH 7.5, 100 
nM NaCl, 100 μg/ml BSA). The plate was incubated at room temperature for a further 30mins 
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and then read using a PheraStar FS (BMG Labtech). The data were analysed using Graphpad 
Prism. 
 
16.4.2 Synthesis of ATAD2 Inhibitors: General Procedures 
 
General Procedure A: Substitution at N1 
The relevant compound (1 eq.) and Cs2CO3 (3 eq.) were suspended in DMF. The relevant alkyl 
halide (2.5 eq.) was added and stirred at 100 ˚C under microwave irradiation for 30 min. The 
reaction was quenched with water (20 mL) and the aqueous layer was extracted with EtOAc 
(3×25 mL). The organic layers were combined, dried over MgSO4 and the solvent removed in 
vacuo. 
 
General Procedure B: Pyridone formation 
The relevant pyridine (1 eq.) and alkyl halide (2 eq.) were dissolved in MeCN and the mixture 
was stirred at 170 ˚C under microwave irradiation for 1 h. The solvent was removed in vacuo 
and the residue was purified by MPLC. 
 
General Procedure C: Knoevenagel condensation 
The relevant compound (1 eq.) was dissolved in THF, the relevant aldehyde (1.1 eq.) and 
piperidine (1.5-3.1 eq.) were added. The reaction mixture was stirred at 100 ˚ C until the starting 
material was completely consumed. The solvent was removed in vacuo and the residue was 
purified by MPLC. 
 
General Procedure D: Reduction of an alkene and subsequent methylation 
Step A: The relevant Knoevenagel product (1 eq.) was dissolved in THF and MeOH. 10% Pd/C 
was added and an atmosphere of hydrogen. The mixture was stirred at r.t. until the starting 
material was completely consumed. The mixture was filtered through a Celite plug using MeOH 
(3 × 20 mL). The solvent was removed in vacuo and the crude was taken forward without 
further purification.  
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Step B: The crude was dissolved in DMF, Cs2CO3 (2-2.5 eq.) and MeI (1.8-2.1 eq.) were added 
and the mixture was stirred at 60 ˚C for 1 h. The reaction was quenched with water (20 mL) 
and the aqueous layer was extracted with EtOAc (3×25 mL). The organic layers were combined, 
dried over MgSO4 and the solvent removed in vacuo. 
 
General Procedure E: Synthesis of spiro-pyrrolidine derivatives 
The relevant spirocyclopropane (1 eq.) and MgI2 (0.1 eq.) were suspended in THF (1 mL). The 
relevant triazinane (1.5 eq.-3 eq.) was added and the reaction mixture was stirred at 90 ˚C until 
the SM was completely consumed. After cooling to r.t., solvent was removed in vacuo and the 
residue was purified by MPLC. 
 
16.4.3 ATAD2 Inhibitors: Synthetic Procedures 
 
4-Bromo-2-hydroxy-3-methylbenzaldehyde (168) 
 
3-Bromo-2-methylphenol (500 mg, 2.67 mmol) was dissolved in MeCN (3.5 mL), MgCl2 (381 
mg, 4.00 mmol) and triethylamine (1.4 mL, 10.01 mmol) were added, respectively. To the 
solution, paraformaldehyde was added portion wise and the mixture was refluxed for 3 h. After 
cooling the reaction mixture to r.t., 5% HCl (6 mL) and Et2O (10 mL) were added and stirred 
for 10 min. The aqueous layer was extracted with Et2O (3×40 mL). The organic layers were 
combined, dried over MgSO4 and the solvent removed in vacuo to get a light brown solid (535 
mg, 93%) which did not require further purification. Rf = 0.76 (25% EtOAc/Petrol); m.p. 40-42 
°C; λmax (EtOH)/nm 330.2, 270.6; IR νmax/cm-1 3099 (OH), 3019, 2872, 1635 (C=O); 1H NMR 
(500 MHz, DMSO-d6) δH 2.34 (3H, s, CH3), 7.22 (1H, d, J = 8.4 Hz, Ar-H), 7.25 (1H, d, J = 
8.4 Hz, Ar-H), 9.83 (1H, s, OH), 11.55 (1H, s, CHO); 13C NMR (125 MHz, CDCl3) δC 14.8 
(CH3), 119.0 (C-Ar), 123.9 (CH-Ar), 127.5 (C-Ar), 131.4 (CH-Ar), 134.7 (C-Ar), 160.2 (C-
Ar), 196.1 (CHO). 
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4-Bromo-2-hydroxy-3-methylbenzoic acid (169) 
 
Compound 168 (480 mg, 2.23 mmol) was dissolved in MeCN (20 mL). A solution of sodium 
chlorite (344 mg, 3.80 mmol) in water (4 mL) and a solution of sulfamic acid (369 mg, 3.80 
mmol) in water (4 mL) were added dropwise, respectively and the mixture was stirred at r.t. for 
8 h. The solvent was evaporated in vacuo, water (30 mL) was added and the aqueous layer was 
extracted with EtOAc (3×30 mL). The organic layers were combined, dried over MgSO4 and 
the solvent removed in vacuo. Purification by MPLC on SiO2 (DCM:MeOH, 0-20%) gave a 
beige solid (450 mg, 88%). Rf = 0.39 (20% MeOH/DCM); m.p. 206-209 °C; λmax (EtOH)/nm 
307.0, 248.4; 1H NMR (500 MHz, DMSO-d6) δH 2.27 (3H, s, CH3), 7.17 (1H, d, J = 8.5 Hz, 
Ar-H), 7.57 (1H, d, J = 8.5 Hz, Ar-H), COOH and OH could not be seen; 13C NMR (125 MHz, 
DMSO-d6) δC 15.6 (CH3), 112.1 (C-Ar), 123.0 (CH-Ar), 126.1 (C-Ar), 128.9 (CH-Ar), 131.6 
(C-Ar), 160.5 (C-Ar), 172.6 (COOH); LRMS (ES-) m/z 229.0 [(M(79Br)-H]-, 231.0 [(M(81Br)-
H]-. 
 
Methyl 4-bromo-2-methoxy-3-methylbenzoate (170) 
 
Compound 169 (190 mg, 0.83 mmol) was dissolved in DMF (6 mL), MeI (0.13 mL, 2.15 mmol) 
was added and stirred at r.t. for 18 h. Water (30 mL) was added and the aqueous layer was 
extracted with EtOAc (3×30 mL). The organic layers were combined, dried over MgSO4 and 
the solvent removed in vacuo. Purification by MPLC on SiO2 (DCM:MeOH, 0-7%) gave a light 
yellow oil (125 mg, 58%). Rf = 0.76 (5% MeOH/DCM); 
1H NMR (500 MHz, CDCl3) δH 2.39 
(3H, s, CH3), 3.82 (3H, s, OCH3), 3.90 (3H, s, COOCH3), 7.37 (1H, d, J = 8.4 Hz, Ar-H), 7.52 
(1H, dd, J = 8.4 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δC 16.2 (CH3), 52.3 (COOCH3), 62.0 
(OCH3), 123.8 (C-Ar), 127.9 (CH-Ar), 129.4 (CH-Ar), 130.5 (C-Ar), 133.5 (C-Ar), 158.9 (C-
Ar), 166.2 (C=O); LRMS (ES+) m/z 259.1 [(M(79Br)+H]+, 261.1 [(M(81Br)+H]+. 
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4-bromo-2-methoxy-3-methylbenzoic acid (171) 
 
Compound 170 (110 mg, 0.42 mmol) was dissolved in MeOH (4 mL) and 1 M NaOH in water 
(4 mL) was added and the mixture was stirred at 60 ˚C for 18 h. The solvent was evaporated in 
vacuo, water (30 mL) was added and the solution was acidified with 1 M HCl. The aqueous 
layer was extracted with EtOAc (3×30 mL). The organic layers were combined, dried over 
MgSO4 and the solvent removed in vacuo to get a beige solid (97 mg, 95%). Rf = 0.26 (5% 
MeOH/DCM); m.p. 135-138 °C; 1H NMR (500 MHz, DMSO-d6) δH 2.32 (3H, s, CH3), 3.75 
(3H, s, OCH3), 7.45 (1H, d, J = 8.4 Hz, Ar-H), 7.48 (1H, d, J = 8.4 Hz, Ar-H), 13.09 (1H, br s, 
COOH); 13C NMR (125 MHz, DMSO-d6) δC 16.4 (CH3), 62.2 (OCH3), 125.9 (C-Ar), 128.1 
(CH-Ar), 129.1 (C-Ar), 129.8 (C-Ar), 133.0 (C-Ar), 158.5 (C-Ar), 167.2 (COOH); HRMS 
calcd for C9H10BrO3 [M(
79Br)+H]+ 244.9808, found 244.9812. 
 
4-Bromo-2-methoxy-N,3-dimethylbenzamide (172) 
 
Compound 171 (60 mg, 0.24 mmol), DIC (40 μL, 0.28 mmol) and DMAP (2.9 mg, 0.024 mmol) 
were dissolved in THF (2.5 mL). A 2 M solution of methylamine in THF (0.4 mL, 0.80 mmol) 
was added and the reaction mixture was stirred at r.t. for 18 h. The carboxylic acid (93% by 
LC-MS) was still remaining, therefore, HATU (182 mg, 0.48 mmol) was added and the mixture 
was stirred at 60 ˚C for 4 h and at r.t. for 18 h. Water (30 mL) was added and the aqueous layer 
was extracted with EtOAc (3×20 mL). The organic layers were combined, dried over MgSO4 
and the solvent removed in vacuo. Purification by MPLC on SiO2 (DCM:MeOH, 0-5%) gave a 
white solid (50 mg, 71%). Rf = 0.71 (5% MeOH/DCM); m.p. 86-89 °C; λmax (EtOH)/nm 242.4; 
IR νmax/cm-1 3346 (NH), 2965, 2935, 2865, 1635 (C=O); 1H NMR (500 MHz, CDCl3) δH 2.39 
(3H, s, CH3), 3.02 (3H, d, J = 4.8 Hz, NHCH3), 3.75 (3H, s, OCH3), 7.43 (1H, d, J = 8.5 Hz, 
Ar-H), 7.66 (1H, br s, NH), 7.78 (1H, d, J = 8.5 Hz, Ar-H); 13C NMR (125 MHz, CDCl3) δC 
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16.2 (CH3), 26.7 (NHCH3), 61.8 (OCH3), 125.8 (C-Ar), 128.9 (CH-Ar), 129.3 (C-Ar), 129.8 
(CH-Ar), 132.0 (C-Ar), 156.8 (C-Ar), 166.6 (C=O); HRMS calcd for C10H13BrNO2 [M(
79Br)-
H]- 258.0124, found 258.0126. 
 
N-(4-hydroxy-2-methylphenyl)acetamide (175) 
 
3-Methyl-4-nitrophenol (500 mg, 3.26 mmol) was dissolved in methanol (50 mL) and reduced 
using an H-Cube continuous flow rector (Thalesnano Inc.) with a Pd/C CatCart (r.t., 1 mL/min). 
The solvent was removed in vacuo after 24 h and the residue was dissolved in AcOH (25 mL) 
and acetic anhydride (0.5 mL) and the mixture was stirred at r.t. for 30 min. The solvent was 
evaporated in vacuo and the residue was purified by MPLC on SiO2 (DCM:MeOH, 0-15%) to 
gave a brown solid (428 mg, 80%). Rf = 0.21 (5% MeOH/DCM); m.p. 85-90 °C; λmax 
(EtOH)/nm 229.8; IR νmax/cm-1 3239-3181 (NH and OH), 3059, 2922, 2817, 1623 (C=O); 1H 
NMR (500 MHz, DMSO-d6) δH 1.99 (3H, s, COCH3), 2.08 (3H, s, CH3), 6.53 (1H, dd, J = 8.5 
and 2.6 Hz, Ar-H), 6.59 (1H, d, J = 2.6 Hz, Ar-H), 7.02 (1H, d, J = 8.5 Hz, Ar-H), 9.07 (1H, s, 
NH), 9.17 (1H, s, OH); 13C NMR (125 MHz, DMSO-d6) δC 18.4 (CH3), 23.4 (COCH3), 113.0 
(CH-Ar), 117.0 (CH-Ar), 127.5 (CH-Ar), 128.4 (C-Ar), 134.4 (C-Ar), 155.3 (C-Ar), 168.6 
(COCH3); HRMS calcd for C9H12NO2 [M+H]
+ 166.0863, found 166.0857. 
 
N-(4-hydroxy-2-methoxyphenyl)acetamide (178) 
 
3-Methoxy-4-nitrophenol (200 mg, 1.28 mmol) was dissolved in methanol (18 mL) and reduced 
using an H-Cube® continuous flow rector (Thalesnano Inc.) with a Pd/C CatCart (r.t., 1 
mL/min). The solvent was removed in vacuo after 24 h and the residue was dissolved in AcOH 
(9 mL) and acetic anhydride (0.18 mL) and the mixture was stirred at r.t. for 30 min. The solvent 
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was evaporated in vacuo and the residue was purified by MPLC on SiO2 (DCM:MeOH, 0-15%) 
which gave a brown solid (155 mg, 73%). Rf = 0.31 (5% MeOH/DCM); λmax (EtOH)/nm 285.4, 
250.4; IR νmax/cm-1 3265 (OH), 2936, 2844, 1597 (C=O); 1H NMR (500 MHz, DMSO-d6) δH 
1.99 (3H, s, COCH3), 3.74 (3H, s, OCH3), 6.28 (1H, dd, J = 8.5 and 2.5 Hz, Ar-H), 6.42 (1H, 
d, J = 2.5 Hz, Ar-H), 7.46 (1H, d, J = 8.5 Hz, Ar-H), 8.87 (1H, s, NH), 9.27 (1H, s, OH); 13C 
NMR (125 MHz, DMSO-d6) δC 23.9 (COCH3), 55.8 (OCH3), 99.7 (CH-Ar), 106.5 (CH-Ar), 
119.2 (C-Ar), 124.9 (CH-Ar), 152.2 (C-Ar), 155.4 (C-Ar), 168.4 (COCH3); HRMS calcd for 
C9H12NO3 [M+H]
+ 182.0812, found 182.0808. 
 
2-Hydrazinyl-5-methylpyridine (183) 
 
2-Fluoro-5-methylpyridine (500 mg, 4.50 mmol) was dissolved in Ethanol (10 mL), hydrazine 
hydrate (2.2 mL, 45 mmol) was added and the reaction mixture was refluxed for 24 h. Strarting 
material was still remaining, therefore, hydrazine hydrate (2.2 mL, 45 mmol) was added and 
the mixture was refluxed for 48 h. The solvent was removed in-vacuo and the residue was 
purified by MPLC on SiO2 (DCM:MeOH, 0-5%) which gave a beige solid (240 mg, 43%); 
1H 
NMR (500 MHz, DMSO-d6) δH 2.11 (3H, s, CH3), 4.04 (2H, br s, NH2),  6.63 (1H, d, J = 8.5 
Hz, Ar-H), 7.11 (1H, br s, NH), 7.29 (1H, dd, J = 8.5 and 2.3 Hz, Ar-H), 7.81-7.83 (1H, m, Ar-
H); 13C NMR (125 MHz, DMSO-d6) δC 17.5 (CH3), 106.7 (CH-Ar), 121.3 (C-Ar), 138.2 (CH-
Ar), 147.1 (CH-Ar), 160.8 (C-Ar). 
 
3,6-Dimethyl-[1,2,4]triazolo[4,3-a]pyridine (182) 
 
Compound 183 (235 mg, 1.59 mmol) was dissolved in acetic acid (5 mL) and acetic anhydride 
(5 mL). The solution was refluxed for 48 h. After cooling to r.t., the solvent was removed in 
vacuo and the residue was purified by MPLC on SiO2 (DCM:MeOH, 0-7%). The purification 
was repeated to get a white solid (45 mg, 16%). Rf = 0.35 (5% MeOH/DCM); λmax (EtOH)/nm 
289.0, 212.0; IR νmax/cm-1 3033, 2925, 2868; 1H NMR (500 MHz, DMSO-d6) δH 2.30 (3H, d, J 
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= 0.9 Hz, CH3-Pyridine), 2.64 (3H, s, CH3-Triazole), 7.20 (1H, dd, J = 9.3 and 1.3 Hz, Ar-H), 
7.62 (1H, d, J = 9.3 Hz, Ar-H), 8.15-8.18 (1H, m, Ar-H); 13C NMR (125 MHz, DMSO-d6) δC 
10.2 (CH3-Triazole), 17.9 (CH3-Pyridine), 114.9 (CH-Ar), 121.1 (CH-Ar), 122.9 (C-Ar), 130.7 
(CH-Ar), 143.4 (C-Ar), 148.8 (C-Ar); HRMS calcd for C8H10N3 [M+H]
+ 148.0869, found 
148.0869. 
 
3-Methyl-6-(prop-1-en-2-yl)-[1,2,4]triazolo[4,3-a]pyridine (185) 
 
6-Bromo-3-methyl-[1,2,4]triazolo[4,3-a]pyridine (100 mg, 0.47 mmol), isopropenylboronic 
acid pinacol ester (0.13 mL, 0.71 mmol), NaOH (19 mg, 0.47 mmol), N,N-
dicyclohexylmethylamine (0.1 mL, 0.47 mmol) were suspended in THF (2.6 mL). The reaction 
mixture was sparged for 30 min with nitrogen, [1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (38 
mg, 0.047 mmol) was added and the suspension was sparged with nitrogen for a further 15 min. 
The reaction mixture was heated at 95 ˚C for 2.5 h, cooled to r.t, and filtered through a pad of 
Celite using MeOH. The solvent was removed in vacuo and the residue was purified by MPLC 
on SiO2 (DCM:MeOH, 0-15%) which gave a white solid (50 mg, 62%). Rf = 0.36 (5% 
MeOH/DCM); λmax (EtOH)/nm 282.6, 238.6; IR νmax/cm-1 2921, 2852, 2640; 1H NMR (500 
MHz, DMSO-d6) δH 2.18 (3H, s, CH3), 2.71 (3H, s, CH3-Triazole), 5.25 (1H, s, 1×C=CH2), 
5.63 (1H, s, 1×C=CH2), 7.64 (1H, dd, J = 9.7 and 1.6 Hz, 1×Ar-H), 7.68 (1H, dd, J = 9.7 and 
1.0 Hz, 1×Ar-H), 8.23 (1H, ap s, Ar-H); 13C NMR (125 MHz, DMSO-d6) δC 10.3 (CH3-
Triazole), 21.4 (CH3), 115.0 (CH-Ar), 115.0 (C=CH2), 120.4 (CH-Ar), 126.2 (CH-Ar), 126.3 
(C-Ar), 138.9 (C=CH2), 144.7 (C-Ar), 148.8 (C-Ar); LRMS (ES
+) m/z 174.2 [(M+H]+. 
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3-Methyl-6-vinyl-[1,2,4]triazolo[4,3-a]pyridine (184) 
 
6-Bromo-3-methyl-[1,2,4]triazolo[4,3-a]pyridine (100 mg, 0.47 mmol), vinylboronic acid 
pinacol ester (0.12 mL, 0.71 mmol), NaOH ( 19 mg, 0.47 mmol), N,N-
dicyclohexylmethylamine (0.1 mL, 0.47 mmol) were suspended in THF (3 mL). The reaction 
mixture was sparged for 30 min with nitrogen, [1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane (38 
mg, 0.047 mmol) was added and the suspension was sparged with nitrogen for a further 15 min. 
The reaction mixture was heated at 95 ˚C for 2.5 h, cooled to r.t, and filtered through a pad of 
celite using MeOH. The solvent was removed in vacuo and the residue was purified by MPLC 
on SiO2 (DCM:MeOH, 0-10%) followed by another purification by MPLC (H2O:MeCN, 
reversed phase with 0.1% HCOOH modifier, 0-80%) to give a beige solid (38 mg, 51%). Rf = 
0.27 (5% MeOH/DCM); 1H NMR (500 MHz, DMSO-d6) δH 2.67 (3H, s, CH3-Triazole), 5.40 
(1H, br d, J = 10.9 Hz, 1×CH=CH2), 5.96 (1H, br d, J = 17.5 Hz, 1×CH=CH2), 6.77 (1H, dd, 
17.5 and 10.9 Hz, CH=CH2), 7.66 (1H, dd, J = 9.5 and 1.4 Hz, Ar-H), 7.70 (1H, d, J = 9.5 Hz, 
Ar-H), 8.40 (1H, s, Ar-H); 13C NMR (125 MHz, DMSO-d6) δC 10.2 (CH3-Triazole), 115.5 (CH-
Ar), 116.3 (CH=CH2), 122.6 (CH-Ar), 123.9 (C-Ar), 124.9 (CH-Ar), 132.6 (CH=CH2), 144.5 
(C-Ar), 149.1 (C-Ar); LRMS (ES+) m/z 160.2 [(M+H]+. 
 
2-(5-((Tert-butoxycarbonyl)amino)-2-methoxypyridin-4-yl)acetic acid (190) 
 
Compound 189 (4 g, 16.78 mmol) was dissolved in THF (71 mL) and cooled to -78 ˚C. 1.4 M 
sec-BuLi in cyclohexane (36 mL, 50.34 mmol) was added dropwise and the reaction mixture 
was stirred at -78 ˚C for 15 min. 5-6 Pellets of dry ice were added and the reaction mixture was 
cooled to r.t. over a period of 45 min. The reaction was quenched with water (50 mL) and 
saturated NaHCO3 (50 mL). The aqueous layer was extracted with EtOAc (2 × 100 mL). The 
aqueous layer was collected and acidified with 2 M HCl, stirred for 15 min and extracted with 
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EtOAc (2 × 100 mL). The organic layers were combined, dried over MgSO4 and the solvent 
removed in vacuo to get an off-white solid (3.5 g, 74%). Rf = 0.42 (20% MeOH/DCM); m.p. 
116.120 °C; λmax (EtOH)/nm 284.2, 234.6; IR νmax/cm-1 3309, (NH), 2981, 2939, 2872, 2782, 
1690 (C=O); 1H NMR (500 MHz, DMSO-d6) δH 1.43 (9H, s, C(CH3)3), 3.58 (2H, s, 
CH2COOH), 3.82 (3H, s, OCH3), 6.74 (1H, s, 1×Pyridine-H), 7.97 (1H, s, 1×Pyridine-H), 8.62 
(1H, br s, NH), 12.44 (1H, br s, COOH); 13C NMR (125 MHz, DMSO-d6) δC 28.6 (C(CH3)3), 
36.9 (CH2CO), 53.7 (OCH3), 79.4 (C(CH3)3), 111.9 (CH-Pyridine), 128.4 (C-Pyridine), 143.7 
(CH-Pyridine), 144.4 (C-Pyridine),  154.5 (COOtBu), 161.6 (Pyridine-C-OMe), 171.6 
(COOH); HRMS calcd for C13H19N2O5 [M+H]
+ 283.1288, found 283.1288. 
 
Tert-butyl 5-methoxy-2-oxo-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate (191) 
 
Compound 190 (1.47 g, 5.20 mmol), tetrabutylammonium acetate (50 mg, 0.16 mmol) were 
dissolved in acetic anhydride (27 mL) and the mixture was stirred at 65 ˚C for 1 h. The solvent 
was removed in vacuo, water (30 mL) was added and the aqueous layer was extracted with 
DCM (3×40 mL). The organic layers were combined, washed with NaHCO3 (3×30 mL), dried 
over MgSO4 and evaporated in vacuo. Purification by MPLC on SiO2 (DCM:MeOH, 0-5%) 
gave a white solid (1.11 g, 81%). Rf = 0.71 (5% MeOH/DCM); m.p. 161-163 °C; λmax 
(EtOH)/nm 338.2, 230.0; IR νmax/cm-1 3309, (NH), 2981, 2939, 2872, 2782, 1690 (C=O), 1628 
(C=O); 1H NMR (500 MHz, DMSO-d6) δH 1.57 (9H, s, C(CH3)3), 3.76 (2H, d, J = 1.0 Hz, 
CH2CO), 3.83 (3H, s, OCH3), 6.82 (1H, m, 1×Pyridine-H), 8.37 (1H, s, 1×Pyridine-H); 
13C 
NMR (125 MHz, DMSO-d6) δC 28.1 (C(CH3)3), 36.6 (CH2CO), 53.8 (OCH3), 84.2 (C(CH3)3), 
106.9 (CH-Pyridine), 131.1 (CH-Pyridine), 133.4 (C-Pyridine),  138.4 (C-Pyridine),  148.9 
(COOtBu), 160.3 (Pyridine-C-OMe), 171.7 (C=O Pyrrolidinone); HRMS calcd for C13H17N2O4 
[M+H]+ 265.1183, found 265.1187. 
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Tert-butyl 5-methoxy-3,3-dimethyl-2-oxo-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine-1-
carboxylate (192) 
 
Compound 191 (1.10 g, 4.16 mmol) and Cs2CO3 (3 g, 9.15 mmol) were suspended in MeCN 
(29 mL). MeI (0.65 mL, 10.4 mmol) was added and stirred at 60 ˚ C for 3 h. The insoluble solids 
were removed by filtration using EtOAc and the filtrate was evaporated in vacuo. The residue 
was purified by MPLC on SiO2 (Petrol:EtOAc, 0-20%) to get a white solid (945 mg, 78%). Rf 
= 0.77 (5% MeOH/DCM); m.p. 175-178 °C; λmax (EtOH)/nm 295.0, 233.0; IR νmax/cm-1 2983, 
2936, 1785 (C=O), 1630 (C=O); 1H NMR (500 MHz, CDCl3) δH 1.41 (6H, s, 2×CH3), 1.65 (9H, 
s, C(CH3)3), 3.92 (3H, s, OCH3), 6.62 (1H, d, J = 0.6 Hz, 1×Pyridine-H), 8.54 (1H, d, J = 0.6 
Hz, 1×Pyridine-H); 13C NMR (125 MHz, CDCl3) δC 24.8 (2×CH3), 28.1 (C(CH3)3), 44.7 
(C(CH3)2), 53.7 (OCH3), 84.8 (C(CH3)3), 104.8 (CH-Pyridine), 130.2 (C-Pyridine), 132.1 (CH-
Pyridine), 147.3 (C-Pyridine),  148.9 (COOtBu), 161.1 (Pyridine-C-OMe), 178.4 (C=O 
pyrrolidinone); HRMS calcd for  C15H21N2O4 [M+H]
+ 293.1496, found 293.1497. 
 
3,3,6-Trimethyl-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-dione (5) 
 
Compound 192 (630 mg, 2.15 mmol) was dissolved in MeCN (15 mL) and MeI (0.33 mL, 5.37 
mmol) was added. The mixture was stirred at 170 ˚C under microwave irradiation for 1 h. The 
solvent was removed in vacuo and the residue was purified by MPLC on SiO2 (DCM:MeOH, 
0-10%) to get a white solid (148 mg, quant.). Rf = 0.15 (5% MeOH/DCM); m.p. 162-163°C; 
λmax (EtOH)/nm 336.2, 255.2, 218.6; IR νmax/cm-1 3455 (NH), 3081, 3019, 2960, 2926, 2705, 
2663, 1705 (C=O), 1589 (C=O); 1H NMR (500 MHz, DMSO-d6) δH 1.24 (6H, s, 2×CH3), 3.36 
(3H, s, OCH3), 6.48 (1H, s, 1×Pyridone-H), 7.14 (1H, s, 1×Pyridone-H), 10.25 (1H, s, NH); 
13C 
NMR (125 MHz, DMSO-d6) δC 24.0 (2×CH3), 37.1 (C(CH3)2), 44.0 (NCH3), 114.1 (CH-
Pyridone), 116.9 (CH-Pyridone), 123.4 (C-Pyridone), 153.8 (C-Pyridone),  161.0 (C=O 
pyridone), 180.2 (C=O pyrrolidinone); HRMS calcd for  C10H13N2O2 [M+H]
+ 193.0972, found 
193.0968. 
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1-Benzyl-3,3,6-trimethyl-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-dione (193) 
 
Compound 5 (50 mg, 0.26 mmol) was dissolved in DMF (3 mL). NaH (60% in mineral oil, 31 
mg, 0.78 mmol) was added portion wise and the mixture was stirred at r.t. for 15 min. Benzyl 
bromide (62 µL, 0.52 mmol) was added and the reaction was stirred at r.t. for 3 h. The reaction 
was quenched with water (20 mL) and the aqueous layer was extracted with EtOAc (3 × 20 
mL). The organic layers were combined, dried over MgSO4, the solvent removed in vacuo and 
the residue was purified by MPLC on SiO2 (DCM:MeOH, 0-5%) to get a beige solid (45 mg, 
61%). Rf = 0.35 (5% MeOH/DCM); m.p. 122-124°C; λmax (EtOH)/nm 257.8, 236.8; IR νmax/cm-
1 3090, 3056, 2972, 2924, 2852, 1703 (C=O), 1593 (C=O); 1H NMR (500 MHz, DMSO-d6) δH 
1.32 (6H, s, 2×CH3), 3.32 (3H, s, N-CH3), 4.75 (2H, s, CH2Ph), 6.57 (1H, s, 1×Pyridone-H), 
7.28-7.37 (6H, m, 6×ArH); 13C NMR (125 MHz, DMSO-d6) δC 24.2 (2×CH3), 37.3 (N-CH3), 
43.2 (CH2-phenyl), 43.9 (C(CH3)2), 114.2 (CH-Pyridone), 117.2 (CH-Pyridone), 124.3 (C-Ar), 
127.6 (2×C-Ar), 127.9 (C-Ar), 129.2 (2×C-Ar), 136.3 (C-Ar), 152.2 (C-Ar), 161.2 (C=O 
pyridone), 178.3 (C=O pyrrolidinone); HRMS calcd for  C17H19N2O2 [M+H]
+ 283.1441, found 
283.1440. 
 
3,3,6-Trimethyl-1-phenethyl-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-dione (194) 
 
Compound 5 (50 mg, 0.26 mmol) was dissolved in DMF (3 mL). NaH (60% in mineral oil, 31 
mg, 0.78 mmol) was added portion wise and the mixture was stirred at r.t. for 15 min. (2-
bromoethyl)benzene (90 µL, 0.65 mmol) was added and the reaction was stirred at r.t. for 3 h. 
The reaction was quenched with water (20 mL) and the aqueous layer was extracted with EtOAc 
(3 × 20 mL). The organic layers were combined, dried over MgSO4, the solvent removed in 
vacuo and the residue was purified by MPLC on SiO2 (DCM:MeOH, 0-5%) to get a beige solid 
(23 mg, 30%). Rf = 0.36 (5% MeOH/DCM); λmax (EtOH)/nm 337.0, 258.2; IR νmax/cm-1  3059, 
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2967, 2926, 2866, 1706 (C=O), 1590 (C=O); 1H NMR (500 MHz, CDCl3) δH 1.28 (6H, s, 
2×CH3), 2.94 (2H, t, J = 6.9 Hz, CH2CH2Ph), 3.39 (3H, s, N-CH3), 3.82 (2H, t, J = 6.9 Hz, 
CH2CH2Ph), 6.26 (1H, s, 1×Pyridone-H), 6.44 (1H, s, 1×Pyridone-H), 7.15-7.17 (2H, m, 
2×ArH), 7.22-7.29 (3H, m, 3×ArH); 13C NMR (125 MHz, CDCl3) δC 24.0 (2×CH3), 33.7 
(CH2CH2Ph), 37.6 (N-CH3), 42.0 (CH2CH2Ph), 43.8 (C(CH3)2), 114.6 (CH-Pyridone), 114.7 
(CH-Pyridone), 125.6 (C-Ar), 126.9 (C-Ar), 128.7 (2×C-Ar), 129.0 (2×C-Ar), 138.2 (C-Ar), 
152.2 (C-Ar), 161.7 (C=O pyridone), 178.3 (C=O pyrrolidinone); HRMS calcd for C18H21N2O2 
[M+H]+ 297.1598, 297.1597. 
 
1-(2-((Tert-butyldimethylsilyl)oxy)ethyl)-3,3,6-trimethyl-1,6-dihydro-2H-pyrrolo[2,3-
c]pyridine-2,5(3H)-dione (201) 
 
Prepared according to general procedure A using compound 5 (100 mg, 0.52 mmol), Cs2CO3 
(508 mg, 1.56 mmol), compound 200 (311 mg, 1.30 mmol) and DMF (4.5 mL). Purification by 
MPLC on SiO2 (DCM:MeOH, 0-5%) gave an orange viscous liquid (120 mg, 55%). Rf = 0.20 
(5% MeOH/DCM); λmax (EtOH)/nm 336.2, 257.6, 219.8; IR νmax/cm-1  2929, 2855, 1703 (C=O), 
1589 (C=O); 1H NMR (500 MHz, DMSO-d6) δH 0.00 (6H, s, 2×CH3 of TBDMS), 0.82 (9H, s, 
C(CH3)3 of TBDMS), 1.30 (6H, s, 2×CH3), 3.42 (3H, s, N-CH3), 3.71 (2H, t, J = 5.3 Hz, 
CH2CH2OTBDMS), 3.83 (2H, t, J = 5.3 Hz, CH2CH2OTBDMS), 6.56 (1H, s, 1×Pyridone-H), 
7.48 (1H, s, 1×Pyridone-H); 13C NMR (125 MHz, DMSO-d6) δC -5.1 (2×CH3 of TBDMS), 18.2 
(C(CH3)3 of TBDMS), 24.2 (2×CH3), 26.0 (C(CH3)3 of TBDMS), 37.2 (N-CH3), 42.6 
(CH2CH2OTBDMS), 43.7 (C(CH3)2), 60.0 (CH2CH2OTBDMS) 113.7 (CH-Pyridone), 117.6 
(CH-Pyridone), 125.1 (C-Pyridone), 152.2 (C-Pyridone), 161.1 (C=O pyridone), 178.1 (C=O 
pyrrolidinone); HRMS calcd for  C18H31N2O3Si [M+H]
+ 351.2098, found 351.2100. 
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1-(2-Hydroxyethyl)-3,3,6-trimethyl-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-
dione (202) 
 
Compound 201 (98 mg, 0.28 mmol) was dissolved in THF (2.5 mL). 1 M TBAF in THF (2.5 
mL) was added and the reaction mixture was stirred at r.t. for 18 h. The solvent was removed 
in vacuo and the residue was purified by MPLC on SiO2 (DCM:MeOH, 0-20%) to get a white 
solid (56 mg, 90%). Rf = 0.30 (15% MeOH/DCM); m.p. 140-142°C; λmax (EtOH)/nm 238.0, 
258.6; IR νmax/cm-1  3271 (OH), 3043, 2973, 2932, 2870, 1708, (C=O), 1571 (C=O); 1H NMR 
(500 MHz, DMSO-d6) δH 1.26 (6H, s, 2×CH3), 3.39 (3H, s, CH3), 3.57-3.60 (4H, m, CH2), 4.82 
(1H, t, J = 5.4 Hz, OH), 6.52 (1H, s, 1×Pyridone-H), 7.44 (1H, s, 1×Pyridone-H).; 13C NMR 
(125 MHz, DMSO-d6) δC 24.2 (2×CH3), 37.3 (N-CH3), 42.9 (CH2CH2N), 43.7 (C(CH3)2), 58.0 
(CH2CH2O), 113.7 (CH-Pyridone), 117.3 (CH-Pyridone), 125.2 (C-Pyridone), 152.4 (C-
Pyridone), 161.1 (C=O pyridone), 178.2 (C=O pyrrolidinone); HRMS calcd for C12H17N2O3 
[M+H]+ 237.1234, found 237.1232. 
 
3,3,6-Trimethyl-1-((phenylthio)methyl)-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-
dione (197) 
 
Prepared according to general procedure A using compound 5 (50 mg, 0.26 mmol), Cs2CO3 
(254 mg, 0.78 mmol), chloromethyl phenyl sulphide (0.09 mL, 0.65 mmol) and DMF (2 mL). 
Purification by MPLC on SiO2 (DCM:MeOH, 0-5%) gave a white solid (61 mg, 75%). Rf = 
0.35 (5% MeOH/DCM); m.p. 55-57 °C; λmax (EtOH)/nm 335.2, 252.4; IR νmax/cm-1  3422, 3055, 
2968, 2927, 2866, 1712 (C=O), 1586 (C=O); 1H NMR (500 MHz, DMSO-d6) δH 1.09 (6H, s, 
2×CH3), 3.39 (3H, s, CH3), 5.06 (2H, s, CH2), 6.51 (1H, s, 1×Pyridone-H), 7.27-7.30 (3H, m, 
3×ArH), 7.40-7.42 (2H, m, 2×ArH), 7.44 (1H, s, 1×Pyridone-H); 13C NMR (125 MHz, DMSO-
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d6) δC 24.0 (2×CH3), 37.4 (N-CH3), 43.8 (C(CH3)2), 44.3 (NCH2S), 113.8 (CH-Pyridone), 118.8 
(CH-Pyridone), 122.4 (C-Ar), 128.5 (C-Ar), 129.5 (2×C-Ar), 132.2 (C-Ar), 133.4 (2×C-Ar), 
151.8 (C-Ar), 161.2 (C=O pyridone), 177.7 (C=O pyrrolidinone); HRMS calcd for 
C17H18N2O2S [M+H]
+ 315.1162, found 315.1164. 
 
3,3,6-Trimethyl-1-((phenylsulfonyl)methyl)-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-
2,5(3H)-dione (198) 
 
Compound 197 (35 mg, 0.11 mmol) was dissolved in MeOH (1 mL) and a solution of oxone 
(101 mg, 0.33 mL) in water (1 mL) was added. The reaction mixture was stirred at r.t. for 18 h. 
The solvent was removed in-vacuo, water (20 mL) was added and the aqueous layer was 
extracted with EtOAc (3 × 20 mL). The organic layers were combined, dried over MgSO4, and 
the solvent removed in vacuo to get a white solid (20 mg, 52%). Rf = 0.35 (5% MeOH/DCM); 
m.p. 185-188 °C; λmax (EtOH)/nm 334.4, 256.0; IR νmax/cm-1  3053, 2970, 2920, 2865, 1718, 
(C=O), 1581 (C=O), 1309 (SO), 1134 (SO); 1H NMR (500 MHz, DMSO-d6) δH  1.12 (6H, s, 
2×CH3), 3.33 (3H, s, CH3), 5.27 (2H, s, CH2), 6.53 (1H, s, 1×Pyridone-H), 7.37 (1H, s, 
1×Pyridone-H), 7.60-7.63 (2H, m, 2×ArH), 7.74-7.78 (1H, m, 1×ArH), 7.82-7.84 (2H, m, 
2×ArH); 13C NMR (125 MHz, DMSO-d6) δC 24.0 (2×CH3), 37.5 (N-CH3), 43.6 (C(CH3)2), 61.0 
(NCH2SO2), 113.8 (CH-Pyridone), 119.2 (CH-Pyridone), 122.5 (C-Ar), 129.3 (2×C-Ar), 130.0 
(2×C-Ar), 135.1 (C-Ar), 137.5 (C-Ar), 151.3 (C-Ar), 161.1 (C=O pyridone), 177.5 (C=O 
pyrrolidinone); HRMS calcd for C17H19N2O4S [M - H]
- 347.1060, found 347.1056. 
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3,3,6-Trimethyl-1-(2-morpholinoethyl)-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-
dione (196) 
 
Prepared according to general procedure A using compound 5 (43 mg, 0.22 mmol), Cs2CO3 
(287 mg, 0.88 mmol), 4-(2-chloroethyl)morpholine hydrochloride (102 mg, 0.55 mmol) and 
DMF (2.5 mL). The product is insoluble in EtOAc, therefore aqueous layer was collected and 
the solvent removed in vacuo. The residue was purified by MPLC (H2O:MeCN, reversed phase 
with 0.1% HCOOH modifier, 0-50%) to get a white solid (55 mg, 82%). Rf = 0.15 (5% 
MeOH/DCM); m.p. 172-174°C; λmax (EtOH)/nm 336.8, 258.2, 220.6; IR νmax/cm-1  3034, 2939, 
2852, 2811, 1712 (C=O), 1590 (C=O); 1H NMR (500 MHz, CD3OD) δH 1.27 (6H, s, 2×CH3), 
2.41 (4H, br s, 4×Morpholine-H), 2.52 (2H, t, J = 6.4 Hz, 2×CON-CH2CH2), 3.46 (3H, s, CH3), 
3.51 (4H, br t, J = 4.5 Hz, 4×Morpholine-H), 3.70 (2H, t, J = 6.4 Hz, 2×CON-CH2), 6.47 (1H, 
s, 1×Pyridone-H), 7.34 (1H, s, 1×Pyridone-H); 13C NMR (125 MHz, CD3OD) δC 22.8 (2×CH3), 
36.8 (CON-CH2), 36.9 (N-CH3), 44.0 (C(CH3)2), 53.2 (2×CH2-Morpholine), 53.9 (CON-
CH2CH2), 66.6 (2×CH2-Morpholine), 113.0 (CH-Pyridone), 116.8 (CH-Pyridone), 126.1 (C-
Pyridone), 153.5 (C-Pyridone), 162.5 (C=O pyridone), 179.4 (C=O pyrrolidinone); HRMS 
calcd for C16H24N3O3 [M+H]
+ 306.1812, found 306.1812. 
 
3,3,6-Trimethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-
2,5(3H)-dione (195) 
 
Prepared according to general procedure A using compound 5 (43 mg, 0.22 mmol), Cs2CO3 
(287 mg, 0.88 mmol), 1-(2-chloroethyl)pyrrolidine hydrochloride (94 mg, 0.55 mmol) and 
DMF (2.5 mL). The product is insoluble in EtOAc, therefore aqueous layer was collected and 
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the solvent removed in vacuo. The residue was purified by MPLC (H2O:MeCN, reversed phase 
with 0.1% HCOOH modifier, 0-50%) to get a white solid (25 mg, 40%). Rf = 0.15 (5% 
MeOH/DCM); λmax (EtOH)/nm 336.0, 257.8, 220.0; IR νmax/cm-1  3029, 2962, 2923, 2787, 1712 
(C=O), 1587 (C=O); 1H NMR (500 MHz, CD3OD) δH 1.26 (6H, s, 2×CH3), 1.69-1.72 (4H, m, 
4×Pyrrolidine-H), 2.51-2.54 (4H, m, 4×Pyrrolidine-H), 2.65 (2H, t, J = 6.9 Hz, 2×CON-
CH2CH2), 3.47 (3H, s, CH3), , 3.70 (2H, t, J = 6.9 Hz, 2×CON-CH2), 6.47 (1H, s, 1×Pyridone-
H), 7.32 (1H, s, 1×Pyridone-H); 13C NMR (125 MHz, CD3OD) δC  22.7 (2×CH3), 22.9 (2×CH2-
Pyrrolidine), 36.9 (N-CH3), 38.9 (CON-CH2), 44.1 (C(CH3)2), 51.6 (CON-CH2CH2), 53.7 (2× 
CH2-Pyrrolidine), 113.1 (CH-Pyridone), 116.6 (CH-Pyridone), 126.2 (C-Pyridone), 153.5 (C-
Pyridone), 162.5 (C=O pyridone), 179.2 (C=O pyrrolidine); HRMS calcd for C16H24N3O2 
[M+H]+ 290.1863, found 290.1865. 
 
2-((3,3-Dimethyl-2,5-dioxo-1,2,3,5-tetrahydro-6H-pyrrolo[2,3-c]pyridin-6-
yl)methyl)benzonitrile (207) 
 
Prepared according to general procedure B using compound 192 (120 mg, 0.411 mmol), 2-
(bromomethyl)benzonitrile (162 mg, 0.824 mmol) and MeCN (3.8 mL). Purification by MPLC 
on SiO2 (DCM:MeOH, 0-7%) gave a white solid (75 mg, 63%). Rf = 0.32 (5% MeOH/DCM); 
m.p. 315 °C (degraded); λmax (EtOH)/nm 339.2, 224.0; IR νmax/cm-1  3069, 3019, 2972, 2726, 
2224 (CN), 1708 (C=O), 1588 (C=O); 1H NMR (500 MHz, DMSO-d6) δH  1.27 (6H, s, 2×CH3), 
5.24 (2H, s, CH2), 6.58 (1H, s, 1×Pyridone-H), 7.12 (1H, d, J = 7.8 Hz, ArH), 7.27 (1H, s, 
1×Pyridone-H), 7.48 (1H, t, J = 7.6 Hz, ArH), 7.67 (1H, td, J = 7.8 and 1.1 Hz, ArH),  7.88 
(1H, dd, J = 7.7 and 1.1 Hz, ArH), 10.33 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) δC 24.0 
(2×CH3), 44.1 (C(CH3)2), 50.4 (NCH2Ar), 110.9 (C-Ar), 114.8 (CH-Pyridone), 116.2 (CH-
Pyridone), 117.7 (CN), 124.1 (C-Ar), 127.8 (C-Ar), 128.5 (C-Ar), 133.5 (C-Ar), 134.1 (C-Ar), 
141.5 (C-Ar), 154.7 (C-Ar), 160.7 (C=O pyridone), 180.1 (C=O pyrrolidinone); HRMS calcd 
for C17H16N3O2 [M+H]
+ 294.1237, found 224.1240. 
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2-((1,3,3-Trimethyl-2,5-dioxo-1,2,3,5-tetrahydro-6H-pyrrolo[2,3-c]pyridin-6-
yl)methyl)benzonitrile (208) 
 
Prepared according to general procedure A using compound 207 (50 mg, 0.17 mmol), Cs2CO3 
(166 mg, 0.51 mmol), MeI (30 μL, 0.43 mmol) and DMF (1.5 mL). Purification by MPLC on 
SiO2 (DCM:MeOH, 0-5%) gave a white solid (50 mg, 96%). Rf = 0.42 (5% MeOH/DCM); m.p. 
195-197 °C; λmax (EtOH)/nm 258.4, 225.6; IR νmax/cm-1  3054, 2973, 2924, 2221 (CN), 1703 
(C=O), 1599 (C=O); 1H NMR (500 MHz, CD3OD) δH  1.28 (6H, s, 2×CH3), 3.03 (3H, s, N-
CH3), 5.28 (2H, s, CH2), 6.51 (1H, s, 1×Pyridone-H), 7.17 (1H, d, J = 7.9 Hz, Ar-H), 7.35-7.38 
(2H, m, Ar-H + Pyridone-H), 7.52 (1H, td, J = 7.7, 1.2 Hz, Ar-H), 7.67 (1H, dd, J = 7.7, 1.0 
Hz, Ar-H); 13C NMR (125 MHz, CD3OD) δC 22.6 (2×CH3), 25.4 (N-CH3), 44.2 (C(CH3)2), 51.2 
(NCH2Ar), 111.2 (C-Ar), 113.7 (CH-Pyridone), 115.7 (CH-Pyridone), 116.9 (CN), 127.5 (C-
Ar), 127.7 (C-Ar), 128.1 (C-Ar), 132.9 (C-Ar), 133.1 (C-Ar), 139.9 (C-Ar), 154.0 (C-Ar), 162.2 
(C=O pyridone), 179.0 (C=O pyrrolidine); HRMS calcd for C18H18N3O2 [M+H]
+ 308.1394, 
found 308.1396.  
 
3-((3,3-Dimethyl-2,5-dioxo-1,2,3,5-tetrahydro-6H-pyrrolo[2,3-c]pyridin-6-
yl)methyl)benzonitrile (209) 
 
Prepared according to general procedure B using compound 192 (100 mg, 0.342 mmol), 3-
(bromomethyl)benzonitrile (134 mg, 0.684 mmol) and MeCN (2.5 mL). Purification by MPLC 
on SiO2 (DCM:MeOH, 0-7%) gave a white solid (65 mg, 65%). Rf = 0.32 (5% MeOH/DCM); 
m.p. 310 °C (degraded); λmax (EtOH)/nm 338.4, 255.8, 223.0; IR νmax/cm-1  3059, 2964, 2925, 
2723, 2227 (CN), 1709 (C=O), 1584 (C=O); 1H NMR (500 MHz, DMSO-d6) δH  1.25 (6H, s, 
2×CH3), 5.09 (2H, s, CH2), 6.56 (1H, s, 1×Pyridone-H), 7.29 (1H, s, 1×Pyridone-H), 7.55-7.58 
(1H, m, ArH), 7.62-7.65 (1H, m, ArH),  7.76-7.79 (2H, m, ArH), 10.31 (1H, s, NH); 13C NMR 
(125 MHz, DMSO-d6) δC 24.0 (2×CH3), 44.1 (C(CH3)2), 50.9 (NCH2Ar), 111.8 (C-Ar) 114.8 
(CH-Pyridone), 115.8 (CH-Pyridone), 119.1 (CN), 124.1 (C-Ar), 130.3 (C-Ar), 131.8 (C-Ar), 
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131.9 (C-Ar), 133.2 (C-Ar), 139.8 (C-Ar), 154.4 (C-Ar), 160.7 (C=O pyridone), 180.2 (C=O 
pyrrolidinone); HRMS calcd for  C17H16N3O2 [M+H]
+ 294.1237, found 294.1242. 
 
3-((1,3,3-trimethyl-2,5-dioxo-1,2,3,5-tetrahydro-6H-pyrrolo[2,3-c]pyridin-6-
yl)methyl)benzonitrile (210) 
 
Prepared according to general procedure A using compound 209 (40 mg, 0.136 mmol), Cs2CO3 
(133 mg, 0.408 mmol), MeI (21 μL, 0.34 mmol) and DMF (1.5 mL). Purification by MPLC on 
SiO2 (DCM:MeOH, 0-5%) gave a white solid (38 mg, 91%). Rf = 0.40 (5% MeOH/DCM); m.p. 
170-172 °C; λmax (EtOH)/nm 338.4, 259.4, 225.4; IR νmax/cm-1  3033, 2926, 2864, 2229 (CN), 
1713 (C=O), 1579 (C=O); 1H NMR (500 MHz, CD3OD) δH  1.26 (6H, s, 2×CH3), 3.03 (3H, s, 
N-CH3), 5.11 (2H, s, CH2), 6.51 (1H, s, 1×Pyridone-H), 7.38 (1H, s, Ar-H), 7.43 (1H, app t, J 
= 7.8 Hz, Ar-H), 7.55-7.58 (2H, m, 2×Ar-H), 7.63-7.65 (1H, m, Ar-H); 13C NMR (125 MHz, 
CD3OD) δC 22.6 (2×CH3), 25.5 (N-CH3), 44.2 (C(CH3)2), 51.8 (NCH2Ar), 112.4 (C-Ar), 113.7 
(CH-Pyridone), 115.2 (CH-Pyridone), 118.0 (CN), 127.7 (C-Ar), 129.5 (C-Ar), 131.2 (C-Ar), 
131.3 (C-Ar), 132.3 (C-Ar), 138.5 (C-Ar), 153.8 (C-Ar), 162.1 (C=O pyridone), 179.0 (C=O 
pyrrolidinone); HRMS calcd for  C18H18N3O2 [M+H]
+ 308.1394, found 308.1393.  
 
3,3-Dimethyl-6-(4-(methylsulfonyl)benzyl)-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-
2,5(3H)-dione (211) 
 
Prepared according to general procedure B using compound 192 (87 mg, 0.298 mmol), 1-
(bromomethyl)-4-(methylsulfonyl)benzene (148 mg, 0.596 mmol) and MeCN (2.5 mL). 
Purification by MPLC on SiO2 (DCM:MeOH, 0-7%) gave a white solid (55 mg, 53%). Rf = 
0.27 (5% MeOH/DCM); m.p. 320 °C (degraded); λmax (EtOH)/nm 339.4, 255.6, 223.2; IR 
νmax/cm-1  3083, 3008, 2973, 2926, 2731, 1717 (C=O), 1549, 1306 (SO), 1146 (SO); 1H NMR 
(500 MHz, DMSO-d6) δH  1.26 (6H, s, 2×CH3), 3.20 (1H, s, SO2CH3), 5.16 (2H, s, CH2), 6.58 
(1H, s, 1×Pyridone-H), 7.28 (1H, s, 1×Pyridone-H), 7.52-7.54 (2H, m, 2×Ar-H), 7.89-7.91 (2H, 
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m, 2×Ar-H), 10.31 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) δC 24.0 (2×CH3), 44.0 
(SO2CH3), 44.1 (C(CH3)2), 51.2 (NCH2Ar), 114.8 (CH-Pyridone), 115.9 (CH-Pyridone), 124.0 
(C-Ar), 127.8 (2×C-Ar), 128.9 (2×C-Ar), 140.3 (C-Ar), 144.1 (C-Ar), 154.4 (C-Ar), 160.7 
(C=O pyridone), 180.2 (C=O pyrrolidinone); HRMS calcd for  C17H19N2O4S [M+H]
+ 347.1060, 
found 347.1062. 
 
1,3,3-Trimethyl-6-(4-(methylsulfonyl)benzyl)-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-
2,5(3H)-dione (212) 
 
Prepared according to general procedure A using compound 211 (36 mg, 0.104 mmol), Cs2CO3 
(102 mg, 0.312 mmol), MeI (16 μL, 0.260 mmol) and DMF (1 mL). Purification by MPLC on 
SiO2 (DCM:MeOH, 0-5%) gave a white solid (32 mg, 86%). Rf = 0.35 (5% MeOH/DCM); m.p. 
95-97 °C; λmax (EtOH)/nm 338.8, 259.2, 224.6; IR νmax/cm-1  3050, 2969, 2927, 1709 (C=O), 
1587 (C=O), 1300 (SO), 1145 (SO); 1H NMR (500 MHz, CD3OD) δH  1.27 (6H, s, 2×CH3), 
2.99 (1H, s, SO2CH3), 3.03 (1H, s, N-CH3) 5.19 (2H, s, CH2), 6.52 (1H, s, 1×Pyridone-H), 7.37 
(1H, s, 1×Pyridone-H), 7.46-7.48 (2H, m, 2×Ar-H), 7.82-7.84 (2H, m, 2×Ar-H); 13C NMR (125 
MHz, CD3OD) δC 22.6 (2×CH3), 25.5 (N-CH3), 42.9 (SO2CH3), 44.2 (C(CH3)2), 52.0 
(NCH2Ar), 113.7 (CH-Pyridone), 115.3 (CH-Pyridone), 127.5 (2×C-Ar), 127.7 (C-Ar), 128.3 
(2×C-Ar), 140.1 (C-Ar), 143.1 (C-Ar), 153.9 (C-Ar), 162.1 (C=O pyridone), 179.0 (C=O 
pyrrolidinone); HRMS calcd for C18H21N2O4S [M+H]
+ 361.1217, found 361.1215. 
 
Methyl 2-((3,3-dimethyl-2,5-dioxo-1,2,3,5-tetrahydro-6H-pyrrolo[2,3-c]pyridin-6-
yl)methyl)benzoate (222) 
 
Prepared according to general procedure B using compound 192 (150 mg, 0.513 mmol), methyl 
2-(bromomethyl)benzoate (235 mg, 1.02 mmol) and MeCN (4 mL). Purification by MPLC on 
SiO2 (DCM:MeOH, 0-7%) gave a white solid (36 mg, 22%). Rf = 0.32 (5% MeOH/DCM); m.p. 
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284-286 °C; λmax (EtOH)/nm 337.4, 256.4, 223.4; IR νmax/cm-1  3085, 3015, 2964, 2783, 2739, 
1711 (C=O), 1546 (C=O); 1H NMR (500 MHz, DMSO-d6) δH  1.28 (6H, s, 2×CH3), 3.88 (3H, 
s, COOCH3), 5.38 (2H, s, CH2), 6.58 (1H, s, 1×Pyridone-H), 6.90 (1H, d, J = 7.5 Hz, Ar-H), 
7.18 (1H, s, 1×Pyridone-H), 7.42 (1H, td, J = 7.6, 0.8 Hz, ArH), 7.55 (1H, td, J = 7.6 and 1.4 
Hz, ArH),  7.93 (1H, dd, J = 7.8 and 1.2 Hz, ArH), 10.28 (1H, s, NH); 13C NMR (125 MHz, 
DMSO-d6) δC 24.1 (2×CH3), 44.1 (C(CH3)2), 50.3 (NCH2Ar), 52.7 (COOCH3), 114.8 (CH-
Pyridone), 116.1 (CH-Pyridone), 124.0 (C-Ar), 127.4 (C-Ar), 127.7 (C-Ar), 129.0 (C-Ar), 
130.8 (C-Ar), 133.2 (C-Ar), 139.2 (C-Ar), 154.4 (C-Ar), 160.8 (C=O pyridone), 167.4 
(COOCH3), 180.2 (C=O pyrrolidinone); HRMS calcd for  C18H19N2O4 [M+H]
+ 327.1339, 
found 327.1341. 
 
Methyl 2-((1,3,3-trimethyl-2,5-dioxo-1,2,3,5-tetrahydro-6H-pyrrolo[2,3-c]pyridin-6-
yl)methyl)benzoate (223) 
 
Prepared according to general procedure A using compound 222 (25 mg, 0.07 mmol), Cs2CO3 
(75 mg, 0.23 mmol), MeI (12 μL, 0.19 mmol) and DMF (3 mL). Purification by MPLC on SiO2 
(DCM:MeOH, 0-5%) gave a white solid (19 mg, 74%). Rf = 0.40 (5% MeOH/DCM); λmax 
(EtOH)/nm 337.0, 226.0; IR νmax/cm-1  3062, 2968, 2924, 2863, 1716 (C=O), 1591 (C=O); 1H 
NMR (500 MHz, CD3OD) δH  1.29 (6H, s, 2×CH3), 3.00 (1H, s, N-CH3), 3.84 (3H, s, COOCH3), 
5.49 (2H, s, CH2), 6.54 (1H, s, 1×Pyridone-H), 6.88 (1H, d, J = 7.8 Hz, Ar-H), 7.28-7.31 (2H, 
m, 1×Ar-H + 1×Pyridone-H), 7.42 (1H, td, J = 7.6, 0.8 Hz, Ar-H), 7.92 (1H, dd, J = 7.8 and 1.2 
Hz, Ar-H); 13C NMR (125 MHz, CD3OD) δC 22.7 (2×CH3), 25.4 (N-CH3), 44.2 (C(CH3)2), 51.2 
(NCH2Ar), 51.3 (COOCH3), 113.6 (CH-Pyridone), 115.7 (CH-Pyridone), 126.8 (C-Ar), 127.2 
(C-Ar), 127.6 (C-Ar), 128.7 (C-Ar), 130.6 (C-Ar), 132.5 (C-Ar), 138.0 (C-Ar), 153.7 (C-Ar), 
162.4 (C=O pyridone), 167.4 (COOCH3), 179.1 (C=O pyrrolidinone); HRMS calcd for 
C19H20N2O4 [M+H]
+ 341.1496, found 341.1497. 
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6-(4-Chlorobenzyl)-3,3-dimethyl-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-dione 
(213) 
 
Prepared according to general procedure B using compound 192 (75 mg, 0.25 mmol), 4-
chlorobenzyl bromide (105 mg, 0.51 mmol) and MeCN (2 mL). Purification by MPLC on SiO2 
(DCM:MeOH, 0-7%) gave a white solid (62 mg, 80%). Rf = 0.30 (5% MeOH/DCM); m.p. 255-
257 °C; λmax (EtOH)/nm 338.8, 256.6, 221.4; IR νmax/cm-1  3071, 3022, 2967, 2930, 2864, 2734, 
1711 (C=O), 1559 (C=O); 1H NMR (500 MHz, DMSO-d6) δH  1.24 (6H, s, 2×CH3), 5.04 (2H, 
s, CH2), 6.55 (1H, s, 1×Pyridone-H), 7.22 (1H, d, J = 0.4 Hz, 1×Pyridone-H), 7.32-7.34 (2H, 
m, 2×Ar-H), 7.40-7.42 (2H, m, 2×Ar-H), 10.27 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) 
δC 24.0 (2×CH3), 44.0 (C(CH3)2), 50.7 (NCH2Ar), 114.8 (CH-Pyridone), 115.7 (CH-Pyridone), 
123.9 (C-Ar), 129.0 (2×C-Ar), 130.2 (2×C-Ar), 132.6 (C-Ar), 137.3 (C-Ar), 154.2 (C-Ar), 
160.6 (C=O pyridone), 180.2 (C=O pyrrolidinone); HRMS calcd for C16H16ClN2O2 [M(
35Cl 
)+H]+ 303.0895, found 303.0901. 
 
6-(4-Chlorobenzyl)-1,3,3-trimethyl-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-dione 
(6) 
 
Prepared according to general procedure A using compound 213 (34 mg, 0.11 mmol), Cs2CO3 
(110 mg, 0.33 mmol), MeI (17 μL, 0.28 mmol) and DMF (1.2 mL). Purification by MPLC on 
SiO2 (DCM:MeOH, 0-5%) gave a white solid (32 mg, 90%). Rf = 0.37 (5% MeOH/DCM); m.p. 
181-183 °C; λmax (EtOH)/nm 338.4, 259.4, 221.2; IR νmax/cm-1  3061, 3018, 2973, 2927, 2864, 
1713 (C=O), 1597 (C=O); 1H NMR (500 MHz, CD3OD) δH  1.26 (6H, s, 2×CH3), 3.01 (1H, s, 
N-CH3), 5.06 (2H, s, CH2), 6.50 (1H, s, 1×Pyridone-H), 7.24 (4H, s, 4×Ar-H) 7.31 (1H, s, 
1×Pyridone-H); 13C NMR (125 MHz, CD3OD) δC 22.6 (2×CH3), 25.4 (N-CH3), 44.1 (C(CH3)2), 
51.6 (NCH2Ar), 113.6 (CH-Pyridone), 115.1 (CH-Pyridone), 127.6 (C-Ar), 128.4 (2×C-Ar), 
129.2 (2×C-Ar), 133.4 (C-Ar), 135.6 (C-Ar), 153.5 (C-Ar), 162.1 (C=O pyridone), 179.0 (C=O 
pyrrolidinone); HRMS calcd for C17H18ClN2O2 [M(
35Cl)+H]+ 317.1051, found 317.1056. 
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2-((1,3,3-Trimethyl-2,5-dioxo-1,2,3,5-tetrahydro-6H-pyrrolo[2,3-c]pyridin-6-
yl)methyl)benzoic acid (226) 
 
Compound 208 (32 mg, 0.10 mmol) was dissolved in ethanol (4 mL), 1 M NaOH in water (2 
mL) was added and the mixture was stirred at 80 ˚C for 16 h. The reaction did not go into 
completion, therefore, 1 M NaOH (1 mL) was added and the reaction mixture was stirred at 
100 ˚C for 7 h. Ethanol was evaporated in vacuo and the residue was acidified to pH 1 using 1 
M HCl. The aqueous layer was extracted with EtOAc (4×20 mL), the organic layers were 
combined, dried over MgSO4 and the solvent removed in vacuo (11 mg, 32%). Rf = 0.29 (5% 
MeOH/DCM); m.p. 268 °C (degraded); λmax (EtOH)/nm 339.0, 258.8; IR νmax/cm-1  3071-2180 
(broad spectrum), 2919, 2851, 1713 (C=O), 1545 (C=O); 1H NMR (500 MHz, CD3OD) δH  1.29 
(6H, s, 2×CH3), 2.99 (1H, s, N-CH3), 5.52 (2H, s, CH2), 6.54 (1H, s, 1×Pyridone-H), 6.88 (1H, 
d, J = 7.8 Hz, Ar-H), 7.26-7.29 (1H, m, 1×Ar-H), 7.31 (1H, s, 1×Pyridone-H), 7.37 (1H, td, J 
= 7.8 and 1.3 Hz, Ar-H), 7.93 (1H, dd, J = 7.8 and 1.0 Hz, Ar-H); 13C NMR (125 MHz, CD3OD) 
δC 22.7 (2×CH3), 25.4 (N-CH3), 44.2 (C(CH3)2), 51.1 (NCH2Ar), 113.6 (CH-Pyridone), 115.8 
(CH-Pyridone), 126.9 (C-Ar), 127.1 (C-Ar), 127.6 (C-Ar), 130.8 (C-Ar), 132.0 (C-Ar), 135.8 
(C-Ar), 137.7 (C-Ar), 153.6 (C-Ar), 162.4 (C=O pyridone), 169.4 (COOCH3), 179.1 (C=O 
pyrrolidinone); HRMS calcd for C18H19N2O4 [M+H]
+ 327.1339, found 327.1343. 
 
Methyl 4-((3,3-dimethyl-2,5-dioxo-1,2,3,5-tetrahydro-6H-pyrrolo[2,3-c]pyridin-6-
yl)methyl)-3-methoxybenzoate (224) 
 
Prepared according to general procedure B using compound 192 (115 mg, 0.39 mmol), methyl 
4-(bromomethyl)-3-methoxybenzoate (168 mg, 0.65 mmol) and MeCN (2.5 mL). Purification 
by MPLC on SiO2 (DCM:MeOH, 0-7%) gave a white solid (92 mg, 66%). Rf = 0.31 (5% 
MeOH/DCM); m.p. 308-310 °C; λmax (EtOH)/nm 247.0, 211.2; IR νmax/cm-1  3076, 3004, 2964, 
2735, 1715 (C=O), 1556 (C=O); 1H NMR (500 MHz, DMSO-d6) δH  1.27 (6H, s, 2×CH3), 3.85 
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(3H, s, COOCH3), 3.92 (3H, s, OCH3), 5.04 (2H, s, CH2), 6.56 (1H, s, 1×Pyridone-H), 6.98 
(1H, d, J = 8.0 Hz, Ar-H), 7.15 (1H, s, 1×Pyridone-H), 7.52-7.54 (2H, m, 2×Ar-H), 10.23 (1H, 
s, NH); 13C NMR (125 MHz, DMSO-d6) δC 24.0 (2×CH3), 44.1 (C(CH3)2), 47.4 (NCH2Ar), 
52.7 (COOCH3), 56.2 (OCH3), 111.1 (C-Ar), 114.7 (CH-Pyridone), 116.3 (CH-Pyridone), 
122.0 (C-Ar), 123.8 (C-Ar), 128.3 (C-Ar), 130.4 (C-Ar), 131.3 (C-Ar), 154.3 (C-Ar), 157.1 (C-
Ar), 160.7 (C=O pyridone), 166.4 (COOCH3), 180.1 (C=O pyrrolidinone); HRMS calcd for  
C19H21N2O5 [M+H]
+ 357.1445, found 357.1448. 
 
Methyl 3-methoxy-4-((1,3,3-trimethyl-2,5-dioxo-1,2,3,5-tetrahydro-6H-pyrrolo[2,3-
c]pyridin-6-yl)methyl)benzoate (225) 
 
Prepared according to general procedure A using compound 224 (66 mg, 0.18 mmol), Cs2CO3 
(180 mg, 0.55 mmol), MeI (28 μL, 0.46 mmol) and DMF (1.5 mL). Purification by MPLC on 
SiO2 (DCM:MeOH, 0-5%) gave a white solid (55 mg, 80%). Rf = 0.36 (5% MeOH/DCM); m.p. 
195-198°C; λmax (EtOH)/nm 247.4, 212.0; IR νmax/cm-1  2963, 2933, 1715 (C=O), 1606 (C=O); 
1H NMR (500 MHz, DMSO-d6) δH  1.29 (6H, s, 2×CH3), 3.01 (N-CH3) 3.85 (3H, s, COOCH3), 
3.94 (3H, s, OCH3), 5.05 (2H, s, CH2), 6.62 (1H, s, 1×Pyridone-H), 6.91-6.92 (1H, m, Ar-H), 
7.44 (1H, s, 1×Pyridone-H), 7.52-7.54 (2H, m, 2×Ar-H); 13C NMR (125 MHz, DMSO-d6) δC 
24.1 (2×CH3), 26.7 (N-CH3), 43.9 (C(CH3)2), 47.8 (NCH2Ar), 52.7 (COOCH3), 56.2 (OCH3), 
111.0 (C-Ar), 114.5 (CH-Pyridone), 116.3 (CH-Pyridone), 122.0 (C-Ar), 126.1 (C-Ar), 127.8 
(C-Ar), 130.3 (C-Ar), 131.1 (C-Ar), 152.8 (C-Ar), 157.0 (C-Ar), 161.0 (C=O pyridone), 166.4 
(COOCH3), 177.9 (C=O pyrrolidinone); HRMS calcd for C20H23N2O5 [M+H]
+ 371.1601, found 
371.1600. 
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3-Methoxy-4-((1,3,3-trimethyl-2,5-dioxo-1,2,3,5-tetrahydro-6H-pyrrolo[2,3-
c]245yridine-6-yl)methyl)benzoic acid (227) 
 
Compound 225 (26 mg, 0.07 mmol) was dissolved in MeOH (1.5 mL), 1 M NaOH (1.5 mL) 
was added and the reaction mixture was stirred at 70 ˚C for 2 h. The solvent was removed in 
vacuo and water (2 mL) was added to the residue and the mixture was acidified to pH 1 with 1 
M HCl. The aqueous layer was extracted with EtOAc (4×20 mL), the organic layers were 
combined, dried over MgSO4 and the solvent removed in vacuo (24 mg, 96%). Rf = 0.56 (15% 
MeOH/DCM); m.p. 246-248 °C; λmax (EtOH)/nm 236.8, 209.6; IR νmax/cm-1  3049-2200 (broad 
stretch), 1707 (C=O), 1688 (C=O), 1581 (C=O); 1H NMR (500 MHz, DMSO-d6) δH  1.29 (6H, 
s, 2×CH3), 3.01 (N-CH3), 3.93 (3H, s, OCH3), 5.04 (2H, s, CH2), 6.62 (1H, s, 1×Pyridone-H), 
6.90 (1H, d, J = 7.8 Hz, Ar-H), 7.43 (1H, s, 1×Pyridone-H), 7.49-7.52 (2H, m, 2×Ar-H), 13.03 
(1H, s, COOH); 13C NMR (125 MHz, DMSO-d6) δC 24.1 (2×CH3), 26.7 (N-CH3), 43.9 
(C(CH3)2), 47.8 (NCH2Ar), 56.1 (OCH3), 111.2 (C-Ar), 114.5 (CH-Pyridone), 116.3 (CH-
Pyridone), 122.1 (C-Ar), 126.1 (C-Ar), 127.7 (C-Ar), 130.6 (C-Ar), 131.6 (C-Ar), 152.7 (C-
Ar), 156.9 (C-Ar), 161.0 (C=O pyridone), 167.5 (COOH), 177.9 (C=O pyrrolidinone); HRMS 
calcd for  C19H21N2O5 [M+H]
+ 357.1445, found 357.1449. 
 
6-(2,6-dichlorobenzyl)-3,3-dimethyl-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-
dione (214) 
 
Prepared according to general procedure B using compound 192 (76 mg, 0.26 mmol), 2-
(bromomethyl)-1,3-dichlorobenzene (187 mg, 0.78 mmol) and MeCN (2.5 mL). Purification 
by MPLC on SiO2 (DCM:MeOH, 0-7%) gave a white solid (72 mg, 82%). Rf = 0.32 (5% 
MeOH/DCM); m.p. 310 °C (degraded); λmax (EtOH)/nm 338.6, 256.6; IR νmax/cm-1  3078, 3012, 
2962, 2924, 2735, 1712 (C=O), 1550 (C=O); 1H NMR (500 MHz, DMSO-d6) δH  1.24 (6H, s, 
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2×CH3), 5.25 (2H, s, CH2), 6.50 (1H, d, J = 0.5 Hz, 1×Pyridone-H), 6.57 (1H, d, J = 0.5 Hz, 
1×Pyridone-H), 7.49 (1H, dd, J = 7.5 and 8.5 Hz, 1×Ar-H), 7.61 (2H, ap d, J = 8.1 Hz, 2×Ar-
H), 9.87 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) δC 24.0 (2×CH3), 44.1 (C(CH3)2), 46.3 
(NCH2Ar), 112.8 (CH-Pyridone), 114.6 (CH-Pyridone), 124.0 (C-Ar), 129.6 (2×C-Ar), 131.9 
(2×C-Ar), 136.6 (2×C-Ar), 153.7 (C-Ar), 160.5 (C=O pyridone), 179.8 (C=O pyrrolidinone); 
HRMS calcd for  C16H15Cl2N2O2 [M(
35Cl2)+H]
+ 337.0505, found 337.0509. 
 
6-(2,6-dichlorobenzyl)-1,3,3-trimethyl-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-
dione (215) 
 
Prepared according to general procedure A using compound 214 (50 mg, 0.148 mmol), Cs2CO3 
(145 mg, 0.44 mmol), MeI (23 μL, 0.37 mmol) and DMF (1.5 mL). Purification by MPLC on 
SiO2 (DCM:MeOH, 0-5%) gave a white solid (48 mg, 92%). Rf = 0.37 (5% MeOH/DCM); m.p. 
153-155°C; λmax (EtOH)/nm 338.0, 258.8; IR νmax/cm-1  3027, 2970, 2926, 2867, 1711 (C=O), 
1578 (C=O); 1H NMR (500 MHz, CD3OD) δH  1.25 (6H, s, 2×CH3), 5.36 (2H, s, CH2), 6.50 
(1H, s, 1×Pyridone-H), 6.64 (1H, s, 1×Pyridone-H), 7.29-7.32 (1H, m, Ar-H), 7.40-7.42 (2H, 
m, 2×Ar-H); 13C NMR (125 MHz, CD3OD) δC 22.6 (2×CH3), 25.2 (N-CH3), 44.0 (C(CH3)2), 
47.1 (NCH2Ar), 112.6 (CH-Pyridone), 113.5 (CH-Pyridone), 127.4 (C-Ar), 128.8 (2×C-Ar), 
130.9 (C-Ar), 130.9 (C-Ar), 136.7 (2×C-Ar), 153.1 (C-Ar), 162.1 (C=O pyridone), 178.9 (C=O 
pyrrolidinone); HRMS calcd for C17H17Cl2N2O2 [M(
35Cl2)+H]
+ 351.0662, found 351.0665. 
 
6-(4-Bromobenzyl)-3,3-dimethyl-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-dione 
(216) 
 
Prepared according to general procedure B using compound 192 (80 mg, 0.27 mmol), 1-bromo-
4-(bromomethyl)benzene (135 mg, 0.54 mmol) and MeCN (2 mL). Purification by MPLC on 
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SiO2 (DCM:MeOH, 0-7%) gave a white solid (73 mg, 78%). Rf = 0.32 (5% MeOH/DCM); m.p. 
269-271 °C; λmax (EtOH)/nm 339.4, 259.4, 221.6; IR νmax/cm-1  3025, 2965, 2928, 2860, 2734, 
1705 (C=O), 1545 (C=O); 1H NMR (500 MHz, DMSO-d6) δH  1.24 (6H, s, 2×CH3), 5.02 (2H, 
s, CH2), 6.55 (1H, s, 1×Pyridone-H), 7.22 (1H, s, 1×Pyridone-H), 7.26-7.28 (2H, m, 2×Ar-H), 
7.53-7.55 (2H, m, 2×Ar-H), 10.27 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) δC 24.0 
(2×CH3), 44.0 (C(CH3)2), 50.7 (NCH2Ar), 114.8 (CH-Pyridone), 115.7 (CH-Pyridone), 121.1 
(C-Ar), 123.9 (C-Ar), 130.5 (2×C-Ar), 131.9 (2×C-Ar), 137.7 (C-Ar), 154.2 (C-Ar), 160.6 
(C=O pyridone), 180.2 (C=O pyrrolidinone); HRMS calcd for C16H16BrN2O2 [M(
79Br )+H]+ 
347.0390, found 347.0390. 
 
6-(4-bromobenzyl)-1,3,3-trimethyl-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-dione 
(217) 
 
Prepared according to general procedure A using compound 216 (50 mg, 0.14 mmol), Cs2CO3 
(137 mg, 0.42 mmol), MeI (22 μL, 0.35 mmol) and DMF (1.4 mL). Purification by MPLC on 
SiO2 (DCM:MeOH, 0-5%) gave a white solid (48 mg, 95%). Rf = 0.40 (5% MeOH/DCM); m.p. 
198-200 °C; λmax (EtOH)/nm 338.2, 259.4, 222.4; IR νmax/cm-1  3063, 3019, 2977, 2933, 2870, 
1715 (C=O), 1598 (C=O); 1H NMR (500 MHz, CD3OD) δH  1.26 (6H, s, 2×CH3), 3.01 (1H, s, 
N-CH3), 5.04 (2H, s, CH2), 6.50 (1H, s, 1×Pyridone-H), 7.16-7.18 (2H, m, 2×Ar-H), 7.31 (1H, 
s, 1×Pyridone-H), 7.38-7.40 (2H, m, 2×Ar-H); 13C NMR (125 MHz, CD3OD) δC 22.6 (2×CH3), 
25.4 (N-CH3), 44.1 (C(CH3)2), 51.7 (NCH2Ar), 113.6 (CH-Pyridone), 115.1 (CH-Pyridone), 
121.3 (C-Ar), 127.6 (C-Ar), 129.5 (2×C-Ar), 131.4 (2×C-Ar), 136.0 (C-Ar), 153.5 (C-Ar), 
162.1 (C=O pyridone), 179.0 (C=O pyrrolidinone); HRMS calcd for C17H17BrN2O2 
[M(79Br)+H]+ 361.0546, found 361.0544. 
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3,3-Dimethyl-6-(4-(trifluoromethyl)benzyl)-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-
2,5(3H)-dione (218) 
 
Prepared according to general procedure B using compound 192 (80 mg, 0.27 mmol), 1-
(bromomethyl)-4-(trifluoromethyl)benzene (129 mg, 0.54 mmol) and MeCN (2 mL). 
Purification by MPLC on SiO2 (DCM:MeOH, 0-7%) gave a white solid (67 mg, 71%). Rf = 
0.30 (5% MeOH/DCM); m.p. 275-277 °C; λmax (EtOH)/nm 338.0, 257.0, 217.4; IR νmax/cm-1  
3073, 3008, 2973, 2932, 2867, 2735, 1716 (C=O), 1562 (C=O); 1H NMR (500 MHz, DMSO-
d6) δH  1.25 (6H, s, 2×CH3), 5.13 (2H, s, CH2), 6.57 (1H, s, 1×Pyridone-H), 7.26 (1H, s, 
1×Pyridone-H), 7.49 (2H, d, J = 8.1 Hz, 2×Ar-H), 7.72 (2H, d, J = 8.1 Hz, 2×Ar-H); 13C NMR 
(125 MHz, DMSO-d6) δC 24.0 (2×CH3), 44.1 (C(CH3)2), 51.1 (NCH2Ar), 114.8 (CH-Pyridone), 
115.9 (CH-Pyridone), 124.0 (C-Ar), 124.7 (CF3, q, J = 127.9 Hz), 125.9 (2×CF3CCH-Ar, q, J 
= 3.6 Hz), 128.4 (CF3C-Ar, q, J = 31.9 Hz), 128.8 (2×CF3CCHCH-Ar), 143.0 (2×C-Ar), 154.4 
(C-Ar), 160.7 (C=O pyridone), 180.2 (C=O pyrrolidinone); 19F NMR (470 MHz, DMSO-d6) δ 
-60.92 (3F, s, CF3); HRMS calcd for C17H16F3N2O2 [M+H]
+ 337.1158, found 337.1155. 
 
1,3,3-Trimethyl-6-(4-(trifluoromethyl)benzyl)-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-
2,5(3H)-dione (219) 
 
Prepared according to general procedure A using compound 218 (42 mg, 0.13 mmol), Cs2CO3 
(122 mg, 0.38 mmol), MeI (20 μL, 0.31 mmol) and DMF (1.2 mL). Purification by MPLC on 
SiO2 (DCM:MeOH, 0-5%) gave a white solid (40 mg, 92%). Rf = 0.40 (5% MeOH/DCM); m.p. 
172-174 °C; λmax (EtOH)/nm 338.8, 258.8, 218.8; IR νmax/cm-1  3035, 2970, 2928, 2865, 1706 
(C=O), 1580 (C=O); 1H NMR (500 MHz, CD3OD) δH  1.27 (6H, s, 2×CH3), 3.02 (1H, s, N-
CH3), 5.16 (2H, s, CH2), 6.52 (1H, s, 1×Pyridone-H), 7.33 (1H, s, 1×Pyridone-H), 7.41 (2H, d, 
J = 8.1 Hz, 2×Ar-H), 7.54 (2H, d, J = 8.1 Hz, 2×Ar-H); 13C NMR (125 MHz, CD3OD) δC 22.6 
(2×CH3), 25.4 (N-CH3), 44.1 (C(CH3)2), 51.9 (NCH2Ar), 113.7 (CH-Pyridone), 115.2 (CH-
Pyridone), 125.2 (2×CF3CCH-Ar, q, J = 3.6 Hz), 127.6 (C-Ar), 127.9 (2×CF3CCHCH-Ar), 
129.6 (CF3C-Ar, q, J = 32.2 Hz), 141.2 (C-Ar), 153.7 (C-Ar), 162.2 (C=O pyridone), 179.0 
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(C=O pyrrolidinone), CF3 quartet was not observed; 
19F NMR (470 MHz, CD3OD) δ -64.10 
(3F, s, CF3); HRMS calcd for C18H18F3N2O2 [M+H]
+ 551.1310, found 551.1297. 
 
3,3-Dimethyl-6-(4-methylbenzyl)-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-dione 
(220) 
 
Prepared according to general procedure B using compound 192 (80 mg, 0.27 mmol), 1-
(bromomethyl)-4-methylbenzene (75 mg, 0.54 mmol) and MeCN (2.7 mL). Purification by 
MPLC on SiO2 (DCM:MeOH, 0-7%) gave a white solid (66 mg, 85%). Rf = 0.30 (5% 
MeOH/DCM); m.p. 252-254 °C; λmax (EtOH)/nm 339.4, 256.8, 217.6; IR νmax/cm-1  3021, 2968, 
2922, 2863, 2736, 1719 (C=O), 1586 (C=O); 1H NMR (500 MHz, DMSO-d6) δH  1.24 (6H, s, 
2×CH3), 2.27 (3H, s, CH3-Ar), 5.00 (2H, s, CH2), 6.53 (1H, s, 1×Pyridone-H), 7.12-7.15 (2H, 
m, 2×Ar-H + 1×Pyridone-H), 7.20-7.22 (2H, m, 2×Ar-H), 10.18 (1H, s, NH); 13C NMR (125 
MHz, DMSO-d6) δC 21.2 (CH3-Ar), 24.0 (2×CH3), 44.0 (C(CH3)2), 50.8 (NCH2Ar), 114.7 (CH-
Pyridone), 115.6 (CH-Pyridone), 123.7 (C-Ar), 128.4 (2×C-Ar), 129.6 (2×C-Ar), 135.3 (C-Ar), 
137.2 (C-Ar), 153.9 (C-Ar), 160.6 (C=O pyridone), 180.2 (C=O pyrrolidinone); HRMS calcd 
for C17H19N2O2 [M+H]
+ 283.1441, found 283.1440. 
 
1,3,3-Trimethyl-6-(4-methylbenzyl)-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-
dione (221) 
 
Prepared according to general procedure A using compound 220 (50 mg, 0.18 mmol), Cs2CO3 
(173 mg, 0.53 mmol), MeI (22 μL, 0.35 mmol) and DMF (1.7 mL). Purification by MPLC on 
SiO2 (DCM:MeOH, 0-5%) gave a white solid (48 mg, 92%). Rf = 0.42 (5% MeOH/DCM); m.p. 
180-182 °C; λmax (EtOH)/nm 337.8, 256.0, 218.2; IR νmax/cm-1  3056, 2973, 2928, 2865, 1713 
(C=O), 1601 (C=O); 1H NMR (500 MHz, CD3OD) δH  1.25 (6H, s, 2×CH3), 2.20 (3H, s, CH3-
Ar), 3.00 (1H, s, N-CH3), 5.04 (2H, s, CH2), 6.49 (1H, d, J = 0.3 Hz, 1×Pyridone-H), 7.04-7.06 
(2H, m, 2×Ar-H), 7.12-7.14 (2H, m, 2×Ar-H), 7.24 (1H, d, J = 0.3 Hz, 1×Pyridone-H); 13C 
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NMR (125 MHz, CD3OD) δC 21.1 (CH3-Ar), 24.1 (2×CH3), 26.8 (N-CH3), 45.5 (C(CH3)2), 53.3 
(NCH2Ar), 115.0 (CH-Pyridone), 116.6 (CH-Pyridone), 128.9 (C-Ar), 129.0 (2×C-Ar), 130.4 
(2×C-Ar), 135.2 (C-Ar), 138.9 (C-Ar), 154.7 (C-Ar), 163.6 (C=O pyridone), 180.5 (C=O 
pyrrolidinone); HRMS calcd for C18H21N2O2 [M+H]
+ 297.1598, found 297.1596. 
 
6-(3,4-Dichlorobenzyl)-3,3-dimethyl-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-
dione (228) 
 
Prepared according to general procedure B using compound 192 (80 mg, 0.27 mmol), 4-
(bromomethyl)-1,2-dichlorobenzene (132 mg, 0.54 mmol) and MeCN (2 mL). Purification by 
MPLC on SiO2 (DCM:MeOH, 0-7%) gave a white solid (85 mg, 93%). Rf = 0.39 (5% 
MeOH/DCM); m.p. 248-250 °C; λmax (EtOH)/nm 339.0, 256.8, 220.0; IR νmax/cm-1  2961, 2870, 
2789, 2729, 1703 (C=O), 1546 (C=O); 1H NMR (500 MHz, DMSO-d6) δH  1.25 (6H, s, 2×CH3), 
5.04 (2H, s, CH2), 6.55 (1H, s, 1×Pyridone-H), 7.27 (1H, s, 1×Pyridone-H), 7.30 (1H, dd, J = 
8.2 and 2.0 Hz, 1×Ar-H), 7.60-7.63 (2H, m, 2×Ar-H), 10.27 (1H, s, NH); 13C NMR (125 MHz, 
DMSO-d6) δC 24.0 (2×CH3), 44.0 (C(CH3)2), 50.4 (NCH2Ar), 114.8 (CH-Pyridone), 115.7 (CH-
Pyridone), 124.1 (C-Ar), 128.8 (C-Ar), 130.5 (C-Ar), 131.3 (C-Ar), 131.4 (C-Ar), 139.4 (2×C-
Ar), 154.4 (C-Ar), 160.6 (C=O pyridone), 180.2 (C=O pyrrolidinone); HRMS calcd for  
C16H15Cl2N2O2 [M(
35Cl2)+H]
+ 337.0505, found 337.0505. 
 
6-(3,4-Dichlorobenzyl)-1,3,3-trimethyl-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-2,5(3H)-
dione (229) 
 
Prepared according to general procedure A using compound 228 (50 mg, 0.15 mmol), Cs2CO3 
(145 mg, 0.44 mmol), MeI (23 μL, 0.37 mmol) and DMF (1.5 mL). Purification by MPLC on 
SiO2 (DCM:MeOH, 0-5%) gave a white solid (49 mg, 94%). Rf = 0.41 (5% MeOH/DCM); m.p. 
151-153 °C; λmax (EtOH)/nm 340.2, 259.6, 220.6; IR νmax/cm-1  3063, 3022, 2974, 2929, 2866, 
1712 (C=O), 1595 (C=O); 1H NMR (500 MHz, CD3OD) δH  1.26 (6H, s, 2×CH3), 3.02 (1H, s, 
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N-CH3), 5.04 (2H, s, CH2), 6.50 (1H, s, 1×Pyridone-H), 7.18 (1H, dd, J = 8.3 and 2.0 Hz, Ar-
H), 7.33 (1H, s, 1×Pyridone-H), 7.39 (1H, d, J = 8.3 Hz, Ar-H), 7.44 (1H, d, J = 2.0 Hz, Ar-H); 
13C NMR (125 MHz, CD3OD) δC 24.0 (2×CH3), 26.9 (N-CH3), 45.5 (C(CH3)2), 52.7 (NCH2Ar), 
115.1 (CH-Pyridone), 116.5 (CH-Pyridone), 128.9 (C-Ar), 129.1 (C-Ar), 131.1 (C-Ar), 131.8 
(C-Ar), 132.8 (C-Ar), 133.5 (C-Ar), 138.9 (C-Ar), 155.1 (C-Ar), 163.5 (C=O pyridone), 180.4 
(C=O pyrrolidinone); HRMS calcd for C17H17Cl2N2O2 [M(
35Cl2)+H]
+ 351.0662, found 
351.0661. 
 
3-Benzylidene-5-methoxy-1,3-dihydro-2H-pyrrolo[2,3-c]pyridin-2-one (231) 
 
Prepared according to general procedure C using compound 191 (250 mg, 0.95 mmol), 
benzaldehyde (0.10 mL, 1.04 mmol), piperidine (0.29 mL, 2.93 mmol) and THF (2 mL). 
Purification by MPLC on SiO2 (DCM:MeOH, 0-10%) gave an orange solid (210 mg, 88%, E:Z 
= 1:4 by 1H NMR). Rf = 0.36 (5% MeOH/DCM); m.p. 221-224 °C; λmax (EtOH)/nm 323.2, 
260.6; IR νmax/cm-1  3161, 2978, 2938, 2345, 1694 (C=O); 1H NMR (500 MHz, DMSO-d6) δH  
3.76 (3H, s, OCH3, Z-isomer), 3.83 (3H, s, OCH3, E-isomer), 6.84 (1H, s, 1×Pyridine-H, Z-
isomer), 7.26 (1H, s, 1×Pyridine-H, E-isomer),  7.50-7.59 (3H, m 3×Ar-H, E and Z-isomers), 
7.64 (1H, s, 1×Pyridine-H, E-isomer), 7.71-7.74 (3H, m, 2×Ar-H + 1×Pyridine-H, Z-isomer), 
7.90 (1H, s, CHAr, Z-isomer), 8.09 (1H, s, CHAr, E-isomer), 8.43-8.45 (2H, m, 2×Ar-H, E-
isomer), 10.67 (1H, s, NH, E and Z isomers); 13C NMR (125 MHz, DMSO-d6) δC 53.7 (OCH3, 
Z-isomer), 53.7 (OCH3, E-isomer), 101.8 (CH-Pyridine, E-isomer), 104.0 (CH-Pyridine, Z-
isomer), 125.5 (CH-Pyridine, E-isomer), 125.8 (C-Ar), 126.4 (CH-Pyridine, Z-isomer), 126.9 
(C-Ar), 128.8 (C-Ar), 129.4 (C-Ar), 130.0 (C-Ar), 131.1 (C-Ar), 132.0 (C-Ar), 132.4 (C-Ar), 
132.8 (C-Ar), 133.1 (C-Ar), 133.8 (C-Ar), 134.2 (C-Ar), 137.7 (C-Ar), 142.1 (CH-Ar, Z-
isomer), 142.3 (CHAr, E-isomer), 159.4 (C-Ar), 159.7 (C-Ar), 167.0 (C=O, E-isomer), 168.2 
(C=O, Z-isomer); HRMS calcd for C15H13N2O2 [M+H]
+ 551.1310, found 551.1297. 
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3-Benzyl-5-methoxy-1,3-dimethyl-1,3-dihydro-2H-pyrrolo[2,3-c]pyridin-2-one (235) 
 
Prepared according to general procedure D using compound 231 (122 mg, 0.483 mmol), 10% 
Pd/C (40 mg), THF (18 mL) and MeOH (9 mL) in step A and Cs2CO3 (315 mg, 0.97 mmol), 
MeI (55 μL, 0.88 mmol), DMF (7.5 mL) in Step B. Purification by MPLC on SiO2 
(DCM:MeOH, 0-5%) gave a colourless sticky solid (75 mg, 55%). Rf = 0.70 (5% MeOH/DCM); 
m.p. 73-76 °C; λmax (EtOH)/nm 305.0, 251.0; IR νmax/cm-1  2927, 2655, 1708 (C=O); 1H NMR 
(500 MHz, CD3Cl) δH  1.45 (3H, s, CH3), 2.97 (1H, d, J = 13.2 Hz, CH2Ar), 3.00 (3H, s, N-
CH3), 3.14 (1H, d, J = 13.2 Hz, CH2Ar), 3.89 (3H, s, OCH3), 6.55 (1H, d, J = 0.6 Hz, 
1×Pyridine-H), 6.88-6.90 (2H, m, 2×Ar-H), 7.09-6.10 (3H, m, 3×Ar-H), 7.41 (1H, d, J = 0.6 
Hz, 1×Pyridine-H); 13C NMR (125 MHz, CD3Cl) δC 22.6 (2×CH3), 26.2 (N-CH3), 44.0 
(CH2Ar), 50.3 (C(CH3)CH2Ar), 53.7 (OCH3), 106.8 (CH-Pyridine), 123.5 (CH-Pyridine), 126.8 
(C-Ar), 127.8 (2×C-Ar), 129.8 (2×C-Ar), 134.8 (C-Ar), 135.4 (C-Ar), 146.5 (C-Ar), 160.2 
(C=O pyridone), 178.4 (C=O pyrrolidinone); HRMS calcd for C17H18N2O2 [M+H]
+ 253.0972, 
found 253.0971. 
 
3-Benzyl-6-(4-chlorobenzyl)-1,3-dimethyl-1,6-dihydro-2H-pyrrolo[2,3-c]pyridine-
2,5(3H)-dione (237) 
 
Prepared according to general procedure B using compound 235 (60 mg, 0.21 mmol), 1-
(bromomethyl)-4-chlorobenzene (87 mg, 0.42 mmol) and MeCN (2 mL). Reaction time: 30 
min. Purification by MPLC on SiO2 (DCM:MeOH, 0-6%) gave a white solid (53 mg, 64%). Rf 
= 0.45 (5% MeOH/DCM); m.p. 175-178 °C; λmax (EtOH)/nm 340.4, 260.0; IR νmax/cm-1  3049, 
2971, 2926, 1718 (C=O), 1594 (C=O); 1H NMR (500 MHz, CD3Cl) δH  1.48 (3H, s, CH3), 2.81 
(3H, s, N-CH3), 2.90 (1H, d, J = 13.1 Hz, CH2Ar), 3.22 (1H, d, J = 13.1 Hz, CH2Ar), 5.01 (1H, 
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d, J = 14.9 Hz, 1×4-Chlorophenyl-CH2), 5.06 (1H, d, J = 14.9 Hz, 1×4-Chlorophenyl-CH2), 
6.33 (1H, s, 1×Pyridone-H), 6.58 (1H, s, 1×Pyridone-H), 6.95-6.96 (2H, m, 2×4-Chlorophenyl-
H), 7.09-7.12 (5H, m, 5×Ph-H), 7.29-7.31 (2H, m, 2×4-Chlorophenyl-H); 13C NMR (125 MHz, 
CD3Cl) δC 22.6 (2×CH3), 26.2 (N-CH3), 44.7 (CH2Ar), 50.3 (C(CH3)CH2Ar), 51.6 ( (4-
Chlorophenyl-CH2N), 112.4 (CH-Pyridone), 116.3 (CH-Pyridone), 127.1 (C-Ar), 127.6 (C-
Ar), 128.0 (2×C-Ar), 129.1 (2×C-Ar), 129.2 (2×C-Ar), 129.9 (2×C-Ar), 134.0 (C-Ar), 135.0 
(C-Ar), 135.4 (C-Ar), 150.5 (C-Ar), 161.3 (C=O pyridone), 177.0 (C=O pyrrolidinone); HRMS 
calcd for C23H22ClN2O2 [M(
35Cl)+H]+ 393.1364, found 393.1359. 
 
5-Methoxy-3-(pyridin-2-ylmethylene)-1,3-dihydro-2H-pyrrolo[2,3-c]pyridin-2-one (232) 
 
Prepared according to general procedure C using compound 191 (250 mg, 0.95 mmol), 
picolinaldehyde (99 μL, 1.04 mmol), piperidine (291 μL, 2.95 mmol) and THF (2 mL). 
Purification by MPLC on SiO2 (DCM:MeOH, 0-10%) gave an orange solid (120 mg, 50%). Rf 
= 0.39 (5% MeOH/DCM); m.p. 217-230 °C; λmax (EtOH)/nm 333.2, 263.6, 210.2; IR νmax/cm-
1  3163, 3105, 2992, 2943, 2851, 1717 (C=O); 1H NMR (500 MHz, DMSO-d6) δH  3.83 (3H, s, 
OCH3), 7.52-7.55 (1H, m, Pyridine-H), 7.71 (1H, s, 1×Methoxypyridine-H), 7.80 (1H, s, 
CHAr), 7.97-8.02 (2H, m, 2×Pyridine-H), 8.47 (1H, s, 1×Methoxypyridine-H),  8.93-8.95 (2H, 
m, 2×Ar-H), 10.68 (1H, s, NH); 13C NMR (125 MHz, DMSO-d6) δC 53.7 (OCH3), 109.6 (CH-
Methoxypyridine), 125.5 (CH-Methoxypyridine), 125.8 (C-Ar), 128.3 (C-Ar), 130.1 (C-Ar), 
133.1 (C=CH), 134.2 (C-Ar), 138.0 (C-Ar), 139.4 (C=CH), 150.3 (C-Ar), 152.9 (C-Ar), 160.0 
(C-Ar), 168.8 (C=O); HRMS calcd for C14H11N3O2 [M+H]
+ 254.0924, found 254.0927. 
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5-Methoxy-1,3-dimethyl-3-(pyridin-2-ylmethyl)-1,3-dihydro-2H-pyrrolo[2,3-c]pyridin-2-
one (236) 
 
Prepared according to general procedure D using compound 232 (95 mg, 0.37 mmol), 10% 
Pd/C (30 mg), THF (12 mL) and MeOH (6 mL) in step A and Cs2CO3 (257 mg, 0.79 mmol), 
MeI (47 μL, 0.75 mmol), DMF (4 mL) in Step B. Purification by MPLC on SiO2 (DCM:MeOH, 
0-5%) gave a beige solid (60 mg, 56%). Rf = 0.48 (5% MeOH/DCM); m.p. 105-108 °C; λmax 
(EtOH)/nm 306.2, 252.2, 205.0; IR νmax/cm-1  3005, 3009, 2976, 2937, 1700 (C=O); 1H NMR 
(500 MHz, CD3Cl) δH  1.46 (3H, s, CH3), 3.14 (3H, s, N-CH3), 3.22 (1H, d, J = 13.8 Hz, CH2Ar), 
3.41 (1H, d, J = 13.8 Hz, CH2Ar), 3.85 (3H, s, OCH3), 6.54 (1H, s, 1×Methoxypyridine-H), 
6.98-7.03 (2H, m, 2×Ar-H), 7.45-7.49 (2H, m, 2×Ar-H), 8.30-8.32 (2H, m, 2×Ar-H); 13C NMR 
(125 MHz, CD3Cl) δC 23.4 (2×CH3), 26.5 (N-CH3), 45.0 (CH2Ar), 48.9 (C(CH3)CH2Ar), 53.5 
(OCH3), 106.9 (CH-Methoxypyridine), 121.7 (C-Ar), 123.5 (CH-Methoxypyridine), 123.8 (C-
Ar), 134.9 (C-Ar), 136.1 (C-Ar), 146.4 (C-Ar), 148.7 (C-Ar), 156.3 (C-Ar), 160.3 (C-Ar), 178.8 
(C=O); HRMS calcd for C16H18N3O2 [M+H]
+ 284.1394, found 284.1393. 
 
6-(4-Chlorobenzyl)-1,3-dimethyl-3-(pyridin-2-ylmethyl)-1,6-dihydro-2H-pyrrolo[2,3-
c]pyridine-2,5(3H)-dione (238) 
 
Prepared according to general procedure B using compound 236 (46 mg, 0.16 mmol), 1-
(bromomethyl)-4-chlorobenzene (67 mg, 0.32 mmol) and MeCN (1 mL). Reaction time: 30 
min. Purification by MPLC on SiO2 (DCM:MeOH, 0-6%) gave a brown solid (32 mg, 50%). 
Rf = 0.30 (5% MeOH/DCM); m.p. 182-185 °C; λmax (EtOH)/nm 340.6, 260.8, 222.0; IR 
νmax/cm-1  3187, 3044, 2966, 2927, 1711 (C=O), 1586 (C=O); 1H NMR (500 MHz, CD3OD) δH  
1.48 (3H, s, CH3), 3.02 (3H, s, N-CH3), 3.26 (1H, d, J = 14.1 Hz, CH2-Pyridine), 3.41 (1H, d, 
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J = 14.1 Hz, CH2-Pyridine), 5.04 (1H, d, J = 14.8 Hz, 1×4-Chlorophenyl-CH2), 5.12 (1H, d, J 
= 14.8 Hz, 1×4-Chlorophenyl-CH2), 6.51 (1H, s, 1×Pyridone-H), 7.09-7.14 (2H, m, 2×Pyridine-
H), 7.16 (1H, s, 1×Pyridone-H), 7.18-7.19 (2H, m, 2×4-Chlorophenyl-H), 7.30-7.32 (2H, m, 
2×4-Chlorophenyl-H), 7.57 (1H, td, J = 11.5 and 1.9 Hz, 1×Pyridine-H), 8.22-8.23 (1H, m, 
1×Pyridine-H); 13C NMR (125 MHz, CD3OD) δC 23.5 (2×CH3), 26.8 (N-CH3), 45.8 (CH2-
Pyridine), 50.0 (C(CH3)CH2Ar), 52.8 (4-Chlorophenyl-CH2N), 116.0 (CH-Pyridone), 116.1 
(CH-Pyridone), 123.2 (C-Ar), 125.3 (C-Ar), 129.7 (C-Ar), 129.8 (2×C-Ar), 130.2 (2×C-Ar), 
134.7 (C-Ar), 137.0 (C-Ar), 137.8 (C-Ar), 149.6 (C-Ar), 152.6 (C-Ar), 157.5 (C-Ar), 163.2 
(C=O pyridone), 179.5 (C=O pyrrolidinone); HRMS calcd for C22H21ClN3O2 [M(
35Cl)+H]+ 
394.1311, found 394.1311. 
 
3-Methyloxetane-3-carbaldehyde (240) 
 
(3-methyloxetan-3-yl)methanol (0.49 mL, 4.89 mmol) was dissolved in DCM (15 mL) and 
cooled to 0 ˚C. Dess-Martin periodinane (3.11 g, 7.34 mmol) in DCM (30 mL) was added and 
the solution was stirred at 0 ˚C for 30 min and at r.t. for 3 h. The reaction mixture was poured 
into a solution of saturated aqueous Na2S2O3 (30 mL) and saturated aqueous NaHCO3 (30 mL) 
and stirred for 30 min. The aqueous layer was extracted with DCM (3×40 mL), the organic 
layers were combined, dried over MgSO4 and the solvent removed in vacuo to get a colourless 
oil (380 mg, 78%). 1H NMR (500 MHz, CD3Cl) δH  1.47 (3H, s, CH3), 4.49 (2H, d, J = 6.3 Hz, 
CH2), 4.86 (2H, d, J = 6.3 Hz, CH2), 9.94 (1H, s, CHO); 
13C NMR (125 MHz, CD3Cl) δC 17.5 
(CH3), 49.3 (Cq), 76.7 (2×CH2), 200.6 (C=O). 
 
5-Methoxy-3-((3-methyloxetan-3-yl)methylene)-1,3-dihydro-2H-pyrrolo[2,3-c]pyridin-2-
one (241) 
 
Prepared according to general procedure C using compound 191 (200 mg, 0.76 mmol), 
compound 240 (121 mg, 1.21 mmol), piperidine (150 μL, 1.51 mmol) and THF (0.7 mL). 
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Purification by MPLC on SiO2 (DCM:MeOH, 0-10%) gave an light-orange solid (120 mg, 
50%). Rf = 0.27 (5% MeOH/DCM); m.p. 154-156 °C; λmax (EtOH)/nm 255.8; IR νmax/cm-1  
3157, 3069, 3023, 2955, 2855, 1715 (C=O); Ratio of diatereoisomers by 1H NMR = 3:5; 1H 
NMR (500 MHz, DMSO-d6) δH 1.59 (3H, s, CH3-Oxetane, isomer 1), 1.60 (3H, s, CH3-Oxetane, 
isomer 2), 3.80 (3H, s, OCH3, isomer 1), 3.80 (3H, s, OCH3, isomer 2), 4.48 (1H, d, J = 6.1 Hz, 
2×Oxetane-H, isomer 1), 4.67-4.69 (4H, m, 2×Oxetane-H, isomer 1 and 2), 4.76 (1H, d, J = 5.8 
Hz, 1×Oxetane-H, isomer 2), 6.38 (1H, s, 1×Methoxypyridine-H, isomer 2), 7.06 (1H, s, 
1×Methoxypyridine-H, isomer 1), 7.34 (1H, s, CH=CCO, isomer 2), 7.60 (1H, s, CH=CCO, 
isomer 2), 7.63 (1H, s, 1×Methoxypyridine-H, isomer 1), 7.70 (1H, s, 1×Methoxypyridine-H, 
isomer 2), 10.53 (1H, s, NH, isomer 1), 10.62 (1H, s, NH, isomer 2); 13C-NMR was not be 
obtained; HRMS calcd for C13H14N3O2 [M+H]
+ 247.1077, found 247.1080. 
 
5-Methoxy-1,3-dimethyl-3-((3-methyloxetan-3-yl)methyl)-1,3-dihydro-2H-pyrrolo[2,3-
c]pyridin-2-one (243) 
 
Prepared according to general procedure D using compound 241 (58 mg, 0.24 mmol), 10% 
Pd/C (20 mg), THF (10 mL) and MeOH (5 mL) in step A and Cs2CO3 (176 mg, 0.54 mmol), 
MeI (30 μL, 0.48 mmol), DMF (4.7 mL) in Step B. Purification by MPLC on SiO2 
(DCM:MeOH, 0-5%) gave an off-white solid (30 mg, 42%). Rf = 0.40 (5% MeOH/DCM); m.p. 
98-101 °C; λmax (EtOH)/nm 305.6, 249.8, 205.2; IR νmax/cm-1  3060, 2931, 2866, 1715 (C=O); 
1H NMR (500 MHz, CD3Cl) δH  0.96 (3H, s, CH3-Oxetane), 1.34 (3H, s, CH3), 2.32 (1H, d, J = 
14.5 Hz, CH2-Oxetane), 2.39 (1H, d, J = 14.5 Hz, CH2-Oxetane), 3.20 (3H, s, N-CH3), 3.78 
(1H, d, J = 5.8 Hz, 1×Oxetane-H2),  3.90 (3H, s, OCH3), 4.05 (1H, d, J = 5.8 Hz, 1×Oxetane-
H2), 4.37 (1H, d, J = 5.8 Hz, 1×Oxetane-H2), 4.46 (1H, d, J = 5.8 Hz, 1×Oxetane-H2), 6.64 (1H, 
s, 1×Methoxypyridine-H), 7.65 (1H, s, 1×Methoxypyridine-H); 13C NMR (125 MHz, CD3Cl) 
δC 22.9 (CH3-Oxetane), 26.6 (N-CH3), 27.0 (CH3), 39.2 (C-Oxetane), 45.5 (Pyrrolidinone-CH2-
Oxetane), 47.3 (C(CH3)CH2Oxetane), 53.7 (OCH3), 83.5 (CH2-Oxetane), 83.8 (CH2-Oxetane), 
106.8 (CH-Methoxypyridine), 124.1  (CH-Methoxypyridine), 134.6 (C-Ar), 146.6 (C-Ar), 
160.4 (C-Ar), 178.7 (C=O); HRMS calcd for C15H21N2O3 [M+H]
+ 277.1547, found 277.1544. 
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6-(4-Chlorobenzyl)-1,3-dimethyl-3-((3-methyloxetan-3-yl)methyl)-1,6-dihydro-2H-
pyrrolo[2,3-c]pyridine-2,5(3H)-dione (244) 
 
Prepared according to general procedure B using compound 243 (18 mg, 0.065 mmol), 1-
(bromomethyl)-4-chlorobenzene (27 mg, 0.13 mmol) and MeCN (1 mL). Reaction time: 45 
min. Purification by MPLC on SiO2 (DCM:MeOH, 0-6%) gave an off-white solid (21 mg, 
83%). Rf = 0.32 (5% MeOH/DCM); m.p. 167-170 °C; IR νmax/cm-1  3049, 2964, 2923, 2863, 
1709 (C=O) 1598 (C=O); 1H NMR (500 MHz, CD3Cl) δH  1.05 (3H, s, CH3-Oxetane), 1.35 (3H, 
s, CH3), 2.22 (1H, d, J = 14.5 Hz, CH2-Oxetane), 2.40 (1H, d, J = 14.5 Hz, CH2-Oxetane), 3.04 
(3H, s, N-CH3), 3.93 (1H, d, J = 5.8 Hz, 1×Oxetane-H2),  4.05 (1H, d, J = 5.8 Hz, 1×Oxetane-
H2), 4.44 (1H, d, J = 5.8 Hz, 1×Oxetane-H2), 4.48 (1H, d, J = 5.8 Hz, 1×Oxetane-H2), 4.98 (1H, 
d, J = 14.6 Hz, 1×4-Chlorophenyl-CH2), 5.21 (1H, d, J = 14.6 Hz, 1×4-Chlorophenyl-CH2), 
6.54 (1H, s, 1×Pyridone-H), 6.64 (1H, s, 1×Pyridone-H), 7.23-7.24 (2H, m, 2×4-Chlorophenyl-
H2), 7.31-7.33 (2H, m, 2×4-Chlorophenyl-H2); 
13C NMR (125 MHz, CD3Cl) δC 23.4 (CH3-
Oxetane), 26.7 (N-CH3), 27.1 (CH3), 39.4 (C-Oxetane), 45.7 (Pyrrolidinone-CH2-Oxetane), 
46.9 (C(CH3)CH2Oxetane), 51.7 (NCH2-Ar), 83.6 (CH2-Oxetane), 83.6 (CH2-Oxetane), 113.0 
(CH-Methoxypyridine), 116.3 (CH-Methoxypyridine), 127.0 (C-Ar), 129.3 (2×C-Ar), 129.5 
(2×C-Ar), 134.3 (C-Ar), 135.0 (C-Ar), 150.6 (C-Ar), 161.1 (C-Ar), 177.3 (C=O); HRMS calcd 
for C21H24ClN2O3 [M(
35Cl)+H]+ 387.1470, found 387.1465. 
 
Tert-butyl 5'-methoxy-2'-oxospiro[cyclopropane-1,3'-pyrrolo[2,3-c]pyridine]-1'(2'H)-
carboxylate (260) 
 
Compound 191 (600 mg, 2.27 mmol) and Cs2CO3 (1.62 g, 4.99 mmol) were suspended in 
MeCN (15 mL). 1,2-dibromoethane (0.22 mL, 2.50 mmol) was added and the mixture was 
stirred at 40 ˚C for 3.5 h. The starting material was not completely consumed, therefore, 1,2-
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dibromoethane (50 μL, 0.57 mmol) was added and stirred at 40 ˚C for 1.5 h. The reaction 
mixture was filtered using EtOAc (3×30 mL) and the filtrate was evaporated in vacuo. Water 
(30 mL) was added to the residue and the aqueous layer was extracted with EtOAc (3×25 mL). 
The organic layers were combined, dried over MgSO4 and the solvent removed in vacuo. 
Purification by MPLC on SiO2 (Petrol:EtOAc, 0-10%) gave a white solid (360 mg, 55%). Rf = 
0.75 (5% MeOH/DCM); m.p. 146-149 °C; λmax (EtOH)/nm 293.8; IR νmax/cm-1 3085, 2977, 
1767 (C=O), 1720 (C=O); 1H NMR (500 MHz, CDCl3) δH 1.59 (2H, q, J = 4.2 Hz, CH2-
spirocyclopropane), 1.65 (9H, s, C(CH3)3), 1.92 (2H, q, J = 4.2 Hz, CH2-spirocyclopropane), 
3.92 (3H, s, OCH3), 6.23 (1H, d, J = 0.6 Hz, 1×Pyridine-H), 8.55 (1H, d, J = 0.6 Hz, 1×Pyridine-
H); 13C NMR (125 MHz, CDCl3) δC 22.5 (CH2-spirocyclopropane), 27.8 (C(CH2)3), 28.1 
(C(CH3)3), 53.7 (OCH3), 84.7 (C(CH3)3), 100.3 (CH-Pyridine), 131.5 (C-Pyridine), 131.6 (CH-
Pyridine), 143.1 (C-Pyridine),  148.7 (COOtBu), 160.8 (Pyridine-C-OMe), 174.3 (C=O 
pyrrolidinone); HRMS calcd for C15H19N2O4 [M+H]
+ 291.1339, found 291.1337. 
 
6'-(4-Chlorobenzyl)-1',6'-dihydrospiro[cyclopropane-1,3'-pyrrolo[2,3-c]pyridine]-2',5'-
dione (264) 
 
Prepared according to general procedure B using compound 260 (100 mg, 0.34 mmol), 1-
(bromomethyl)-4-chlorobenzene (141 mg, 0.69 mmol) and MeCN (3.4 mL). Reaction time: 45 
min. Purification by MPLC on SiO2 (DCM:MeOH, 0-10%) gave a white solid (70 mg, 68%). 
Rf = 0.24 (5% MeOH/DCM); m.p. 298 °C; λmax (EtOH)/nm 339.4, 230.6; IR νmax/cm-1  3073, 
3026, 2997, 2936, 2876, 2735, 1714 (C=O), 1554 (C=O); 1H NMR (500 MHz, DMSO-d6) δH  
1.53-1.61 (4H, m, 2×CH2), 5.06 (2H, s, CH2-Ar), 6.19 (1H, s, 1×Pyridone-H), 7.25 (1H, s, 
1×Pyridone-H), 7.28-7.30 (2H, m, 2×Ar-H), 7.39-7.41 (2H, m, 2×Ar-H), 10.42 (1H, s, NH); 
13C NMR (125 MHz, DMSO-d6) δC 20.5 (2×CH2), 27.1 (C(CH2)2), 50.7 (NCH2Ar), 109.8 (CH-
Pyridone), 115.7 (CH-Pyridone), 124.8 (C-Ar), 128.9 (2×C-Ar), 130.0 (2×C-Ar), 132.4 (C-Ar), 
137.4 (C-Ar), 150.1 (C-Ar), 160.3 (C=O pyridone), 176.0 (C=O pyrrolidinone); HRMS calcd 
for C16H14ClN2O2 [M(
35Cl)+H]+ 301.0738, found 301.0738. 
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6'-(4-Chlorobenzyl)-1'-methyl-1',6'-dihydrospiro[cyclopropane-1,3'-pyrrolo[2,3-
c]pyridine]-2',5'-dione (265) 
 
Prepared according to general procedure A using compound 264 (60 mg, 0.199 mmol), Cs2CO3 
(130 mg, 0.398 mmol), MeI (25 μL, 0.398 mmol) and DMF (4 mL). Purification by MPLC on 
SiO2 (DCM:MeOH, 0-5%) gave a white solid (50 mg, 80%). Rf = 0.32 (5% MeOH/DCM); m.p. 
155-157 °C; λmax (EtOH)/nm 339.4, 231.2; 1H NMR (500 MHz, CD3Cl) δH  1.51 (2H, q, J = 4.1 
Hz, CH2-spirocyclopropane), 1.83 (2H, q, J = 4.1 Hz, CH2-spirocyclopropane), 3.12 (1H, s, N-
CH3), 5.11 (2H, s, CH2-Ar), 6.13 (1H, s, 1×Pyridone-H), 6.67 (1H, s, 1×Pyridone-H), 7.23-7.25 
(2H, m, 2×Ar-H), 7.30-7.32 (2H, m, 2×Ar-H); 13C NMR (125 MHz, CD3Cl) δC 21.0 (2×CH2), 
26.9 (N-CH3), 51.6 (NCH2Ar), 109.9 (CH-Pyridone), 112.6 (CH-Pyridone), 128.0 (C-Ar), 
129.2 (2×C-Ar), 129.4 (2×C-Ar), 134.1 (C-Ar), 135.3 (C-Ar), 148.8 (C-Ar), 161.3 (C=O 
pyridone), 174.3 (C=O pyrrolidinone); HRMS calcd for C17H16ClN2O2 [M(
35Cl)+H]+ 315.0895, 
found 315.0893. 
 
6’-(4-Chlorobenzyl)-1,1’-dimethyl-1’,6’-dihydrospiro[pyrrolidine-3,3’-pyrrolo[2,3-
c]pyridine]-2’,5’-dione (271) 
 
Prepared according to general procedure E using Compound 265 (150 mg, 0.476 mmol), MgI2 
(13 mg, 0.047 mmol), 1,3,5-trimethyl-1,3,5-triazinane (0.17 mL, 1.19 mmol) and THF (1.6 
mL). Purification by MPLC on SiO2 (DCM:MeOH, 0-12%) gave a beige solid (92 mg, 53%). 
Rf = 0.27 (5% MeOH/DCM); m.p. 78-80 °C; λmax (EtOH)/nm 339.4, 259.8; IR νmax/cm-1  3047, 
2936, 2844, 2783, 1707 (C=O), 1588 (C=O); 1H NMR (500 MHz, CD3Cl) δH  2.00 (1H, dt, J = 
12.9, 7.5 Hz, CH-spiropyrrolidine), 2.35-2.40 (1H, m, CH-spiropyrrolidine), 2.40 (3H, s, N-
CH3), 2.65 (1H, dd, J = 16.3 and 8.4 Hz, CH-spiropyrrolidine), 2.78 (2H, s, CH2-
Spiropyrrolidine), 2.99-3.03 (1H, m, CH-spiropyrrolidine), 3.05 (3H, s, N-CH3), 5.09 (2H, s, 
CH2-Ar), 6.59 (1H, s, 1 × Pyridone-H), 6.81 (1H, s, 1×Pyridone-H), 7.25-7.27 (2H, m, 2 × Ar-
H), 7.30-7.33 (2H, m, 2 × Ar-H); 13C NMR (125 MHz, CD3Cl) δC 26.6 (N-CH3), 37.9 (CH2-
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Spiropyrrolidine), 41.4 (N-CH3), 51.5 (NCH2Ar), 53.0 (C-Spiropyrrolidine), 56.0 (CH2-
Spiropyrrolidine), 66.1 (CH2-Spiropyrrolidine), 112.1 (CH-Pyridone), 115.9 (CH-Pyridone), 
127.1 (C-Ar), 129.1 (2×C-Ar), 129.4 (2×C-Ar), 134.0 (C-Ar), 135.1 (C-Ar), 152.7 (C-Ar), 
161.7 (C=O pyridone), 177.0 (C=O pyrrolidinone); LRMS (ES+) m/z 358.3 [M(35Cl)+H]+, 
360.3 [M(37Cl)+H]+. 
 
Tert-butyl 3,3-diallyl-5-methoxy-2-oxo-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine-1-
carboxylate (255) 
 
Compound 191 (493 mg, 1.865 mmol) and Cs2CO3 (1.40 g, 4.289 mmol) were suspended in 
MeCN (12.5 mL). Allyl bromide (0.4 mL, 4.662 mmol) was added and the mixture was stirred 
at 40 ˚C for 2.5 h. The reaction mixture was filtered using EtOAc (3×30 mL) and the filtrate 
was evaporated in vacuo. Water (40 mL) was added to the residue and the aqueous layer was 
extracted with EtOAc (3×25 mL). The organic layers were combined, dried over MgSO4 and 
the solvent removed in vacuo. Purification by MPLC on SiO2 (Petrol:EtOAc, 0-20%) gave a 
white solid (350 mg, 55%). Rf = 0.56 (20% EtOAc/Petrol); m.p. 84-87 °C; λmax (EtOH)/nm 
295.2, 230.6; IR νmax/cm-1 3084, 2980, 2947, 2908, 1759 (C=O), 1719 (C=O); 1H NMR (500 
MHz, CD3Cl) δH  1.63 (9H, s, C(CH3)3), 2.49-2.53 (2H, m, CH2CH=CH2),  2.60-2.64 (2H, m, 
CH2CH=CH2),  3.93 (3H, s, OCH3), 4.98-5.05 (4H, m, 2×CH2CH=CH2), 5.40-5.49 (2H, m, 
2×CH2CH=CH2), 6.61 (1H, d, J = 0.7 Hz, 1×Pyridine-H), 8.51 (1H, d, J = 0.7 Hz, 1×Pyridine-
H); 13C NMR (125 MHz, CDCl3) δC 28.1 (C(CH3)3), 41.6 (2×CH2CH=CH2), 53.4 
(C(CH2CH=CH2)2), 53.7 (OCH3), 84.7 (C(CH3)3), 105.7 (CH-Pyridine), 120.2 (2×CH=CH2), 
130.9 (2×CH=CH2), 131.4 (C-Pyridine), 132.0 (CH-Pyridine), 143.2 (C-Pyridine), 148.5 
(COOtBu), 160.8 (Pyridine-C-OMe), 176.3 (C=O pyrrolidinone); HRMS calcd for C19H25N2O4 
[M+H]+ 345.1809, found 345.1804. 
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Tert-butyl 5'-methoxy-2'-oxospiro[cyclopentane-1,3'-pyrrolo[2,3-c]pyridin]-3-ene-
1'(2'H)-carboxylate (256) 
 
Compound 255 (329 mg, 0.955 mmol) was dissolved in DCM (19.5 mL). Grubbs catalyst 2nd 
generation (41 mg, 5 mol%) was added and the reaction mixture was stirred at 80 ˚C under 
microwave irradiation for 20 min. The solvent was removed in vacuo and the residue was 
purified by MPLC on SiO2 (Petrol:EtOAc, 0-20%) to get a white solid (272 mg, 90%). Rf = 0.48 
(20% EtOAc/Petrol); m.p. 163-166 °C; 1H NMR (500 MHz, CD3Cl) δH  1.65 (9H, s, C(CH3)3), 
2.60-2.63 (2H, m, CH2CH=CHCH2), 3.08-3.11 (2H, m, CH2CH=CHCH2), 3.91 (3H, s, OCH3), 
5.79 (2H, s, CH2CH=CHCH2), 6.68 (1H, d, J = 0.7 Hz, 1×Pyridine-H), 8.51 (1H, d, J = 0.7 Hz, 
1×Pyridine-H); 13C NMR (125 MHz, CDCl3) δC 28.1 (C(CH3)3), 46.2 (2×CH2CH=CHCH2), 
52.7 (CCH2CH=CH), 53.7 (OCH3), 84.8 (C(CH3)3), 103.8 (CH-Pyridine), 128.5 (2×CH=CH), 
130.1 (C-Pyridine), 131.9 (CH-Pyridine), 148.4 (C-Pyridine), 148.7 (COOtBu), 161.4 
(Pyridine-C-OMe), 178.7 (C=O pyrrolidinone); HRMS calcd for C17H21N2O4 [M+H]
+ 
317.1496, found 317.1493. 
 
6'-(4-Chlorobenzyl)-1',6'-dihydrospiro[cyclopentane-1,3'-pyrrolo[2,3-c]pyridin]-3-ene-
2',5'-dione (257) 
 
Prepared according to general procedure B using compound 256 (257 mg, 0.81 mmol), 1-
(bromomethyl)-4-chlorobenzene (334 mg, 1.63 mmol) and MeCN (5.4 mL). Reaction time: 45 
min. Purification by MPLC on SiO2 (DCM:MeOH, 0-10%) gave a white solid (237 mg, 89%). 
Rf = 0.29 (5% MeOH/DCM); m.p. 274-277 °C; λmax (EtOH)/nm 343.0, 258.4, 221.4; IR 
νmax/cm-1  3021, 2933, 2844, 2792, 2734, 1718 (C=O), 1588 (C=O); 1H NMR (500 MHz, 
DMSO-d6) δH  2.55-2.59 (2H, m, CH2CH=CHCH2), 2.79-2.82 (2H, m, CH2CH=CHCH2), 5.04 
(2H, s, CH2-Ar), 5.78 (2H, s, CH2CH=CHCH2), 6.29 (1H, s, 1×Pyridone-H), 7.21 (1H, s, 
1×Pyridone-H), 7.31-7.33 (2H, m, 2×Ar-H), 7.39-7.41 (2H, m, 2×Ar-H), 10.31 (1H, s, NH); 
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13C NMR (125 MHz, DMSO-d6) δC 45.2 (2×CH2CH=CHCH2), 50.7 (NCH2Ar), 51.9 
(CCH2CH=CH), 113.1 (CH-Pyridone), 115.7 (CH-Pyridone), 124.1 (C-Ar), 129.0 (2×C-Ar), 
129.1 (2×CH=CH),  130.2 (2×C-Ar), 132.6 (C-Ar), 137.2 (C-Ar), 155.5 (C-Ar), 160.8 (C=O 
pyridone), 180.1 (C=O pyrrolidinone); HRMS calcd for C18H16ClN2O2 [M(
35Cl)+H]+ 
327.0895, found 327.0895. 
 
6'-(4-Chlorobenzyl)-1'-methyl-1',6'-dihydrospiro[cyclopentane-1,3'-pyrrolo[2,3-
c]pyridin]-3-ene-2',5'-dione (258) 
 
Prepared according to general procedure A using compound 257 (225 mg, 0.69 mmol), Cs2CO3 
(673 mg, 2.07 mmol), MeI (110 μL, 1.72 mmol) and DMF (7 mL). Purification by MPLC on 
SiO2 (DCM:MeOH, 0-10%) gave an off-white solid (205 mg, 87%). Rf = 0.48 (5% 
MeOH/DCM); m.p. 56-58 °C; λmax (EtOH)/nm 339.6, 261.0, 221.6; IR νmax/cm-1  3058, 2918, 
2844, 1704 (C=O), 1582 (C=O); 1H NMR (500 MHz, CD3Cl) δH  2.56-2.62 (2H, m, 
CH2CH=CHCH2), 2.98-3.03 (2H, m, CH2CH=CHCH2), 3.06 (3H, s, N-CH3), 5.08 (2H, s, CH2-
Ar), 5.78 (2H, s, CH2CH=CHCH2), 6.60 (1H, s, 1×Pyridone-H), 6.62 (1H, s, 1×Pyridone-H), 
7.25-7.27 (2H, m, 2×Ar-H), 7.31-7.33 (2H, m, 2×Ar-H); 13C NMR (125 MHz, CD3Cl) δC 25.6 
(N-CH3), 44.0 (2×CH2CH=CHCH2), 50.5 (NCH2Ar), 50.9 (CCH2CH=CH), 111.3 (CH-
Pyridone), 113.1 (CH-Pyridone), 126.0 (C-Ar), 127.6 (2×CH=CH), 128.1 (2×C-Ar), 128.4 
(2×C-Ar), 133.0 (C-Ar), 134.0 (C-Ar), 152.7 (C-Ar), 160.8 (C=O pyridone), 177.2 (C=O 
pyrrolidinone); HRMS calcd for C19H18ClN2O2 [M(
35Cl)+H]+ 341.1051, found 341.1050. 
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(1s,3R,4S)-6’-(4-Chlorobenzyl)-3,4-dihydroxy-1’-methyl-1’,6’-
dihydrospiro[cyclopentane-1,3’-pyrrolo[2,3-c]pyridine]-2’,5’-dione (252) 
 
Compound 258 (25 mg, 0.073 mmol) was dissolved in THF:water (3:1, 2.4 mL) and cooled to 
0 ˚C. N-methylmorpholine (12 mg, 0.099 mmol) and 2.5 wt% OsO4 in tBuOH (30 μL, 4 mol%) 
were  added, respectively and the mixture was stirred at r.t. for 18 h. The starting material was 
not completely consumed, therefore, 2.5 wt% OsO4 in 
tBuOH (70 μL, 9.3 mol%) was added 
and the reaction was stirred at r.t. for 24 h. The mixture was quenched with saturated Na2SO3 
(30 mL) and stirred for 30 min. The aqueous layer was extracted with EtOAc (3×20 mL), the 
organic layers were combined, dried over MgSO4 and the solvent removed in vacuo. 
Purification by MPLC on SiO2 (DCM:MeOH, 0-10%) gave a white solid (16 mg, 59%) and 
other isomer 259 (5 mg, 18%). Rf = 0.18 (5% MeOH/DCM); m.p. 68-71 °C; λmax (EtOH)/nm 
339.4, 260.8, 221.6; IR νmax/cm-1  3355 (OH), 3049, 2925, 2853, 1698 (C=O), 1582 (C=O); 1H 
NMR (500 MHz, CD3Cl) δH  2.17-2.20 (4H, m, 2×CH2CHOH), 3.09 (3H, s, N-CH3), 3.81 (2H, 
d, J = 9.8 Hz, 2×OH), 4.28-4.33 (2H, m, 2×CHOH), 5.08 (2H, s, CH2-Ar), 6.52 (1H, s, 
1×Pyridone-H), 6.65 (1H, s, 1×Pyridone-H), 7.25-7.27 (2H, m, 2×Ar-H), 7.31-7.33 (2H, m, 
2×Ar-H); 13C NMR (125 MHz, CD3Cl) δC 26.5 (N-CH3), 42.2 (2×CH2CHOH), 51.1 (NCH2Ar), 
51.2 (CCH2CHOH), 74.4 (2×CHOH), 112.9 (CH-Pyridone), 114.8 (CH-Pyridone), 126.4 (C-
Ar), 128.7 (2×C-Ar), 129.0 (2×C-Ar), 133.8 (C-Ar), 134.2 (C-Ar), 151.0 (C-Ar), 160.9 (C=O 
pyridone), 179.9 (C=O pyrrolidinone); HRMS calcd for C19H20ClN2O4 [M(
35Cl)+H]+ 375.1106, 
found 375.1103. 
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(1r,3R,4S)-6'-(4-Chlorobenzyl)-3,4-dihydroxy-1'-methyl-1',6'-
dihydrospiro[cyclopentane-1,3'-pyrrolo[2,3-c]pyridine]-2',5'-dione (259) 
 
Obtained as a white solid from the reaction above (5 mg, 18%). Rf = 0.11 (5% MeOH/DCM); 
λmax (EtOH)/nm 339.4, 260.8, 221.8; IR νmax/cm-1  3374 (OH), 2924, 2853, 1700 (C=O), 1567 
(C=O); 1H NMR (500 MHz, CD3Cl) δH  2.00 (2H, dd, J = 13.7 and 5.2 Hz, CH2CHOH), 2.34 
(2H, dd, J = 13.7 and 6.0 Hz, CH2CHOH), 3.04 (3H, s, N-CH3), 3.31 (2H, br s, 2×OH), 4.43 
(2H, br s, 2×CHOH), 5.09 (2H, s, CH2-Ar), 6.58 (1H, s, 1×Pyridone-H), 7.03 (1H, s, 
1×Pyridone-H), 7.24-7.26 (2H, m, 2×Ar-H), 7.31-7.33 (2H, m, 2×Ar-H); 13C NMR (125 MHz, 
CD3Cl) δC 26.6 (N-CH3), 42.6 (2×CH2CHOH), 50.5 (NCH2Ar), 51.6 (CCH2CHOH), 74.2 
(2×CHOH), 112.1 (CH-Pyridone), 116.8 (CH-Pyridone), 127.9 (C-Ar), 129.2 (2×C-Ar), 129.5 
(2×C-Ar), 134.1 (C-Ar), 134.8 (C-Ar), 153.5 (C-Ar), 162.2 (C=O pyridone), 179.1 (C=O 
pyrrolidinone); HRMS calcd for C19H20ClN2O4 [M(
35Cl)+H]+ 375.1106, found 375.1102. 
 
3-Hydroxy-1-methyl-3-((trimethylsilyl)methyl)indolin-2-one (280) 
 
N-methylisatin (200 mg, 1.24 mmol) was dissolved in THF (6.2 mL) and cooled to -78 ˚C. 1 M 
(trimethylsilyl)methylmagnesium chloride in Et2O (2.5 mL, 2.5 mmol) was added dropwise and 
the solution was stirred at r.t. for 1.5 h. The solvent was removed in-vacuo and the residue was 
purified by MPLC on SiO2 (Petrol:EtOAc, 0-20%) to get a light yellow solid (220 mg, 71%). 
Rf = 0.31 (5% MeOH/DCM); m.p. 143-145 °C; λmax (EtOH)/nm 256.8, 209.4; IR νmax/cm-1 3352 
(OH), 3057, 2950, 2899, 2871, 1690 (C=O), 1609 (C=O); 1H NMR (500 MHz, CDCl3) δH -0.31 
(9H, s, 3×CH3), 1.53 (1H, d, J = 13.5 Hz, 1×CH2), 1.56 (1H, d, J = 13.5 Hz, 1×CH2), 2.80 (1H, 
s, OH), 3.18 (3H, s, NCH3), 6.83 (1H, d, J = 7.7 Hz, 1×Ar-H), 7.09 (1H, td, J = 7.5 and 0.9 Hz, 
1×Ar-H), 7.32 (1H, td, J = 7.7 and 1.3 Hz, 1×Ar-H), 7.36 (1H, dd, J = 7.5 and 0.9 Hz, 1×Ar-
H), 8.54 (1H, d, J = 0.6 Hz, 1×Pyridine-H); 13C NMR (125 MHz, CDCl3) δC 0.0 (3×CH3), 27.4 
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(N-CH3), 29.9 (CH2), 76.9 (COH), 109.7 (CH-Ar), 124.4 (CH-Ar), 125.4 (CH-Ar), 131.0 (CH-
Ar),  132.3 (C-Ar), 144.2 (C-Ar), 179.5 (C=O pyrrolidinone); HRMS calcd for C13H20NO2Si 
[M+H]+ 250.1258, found 250.1257. 
 
2-(1,3-Dimethyl-2-oxoindolin-3-yl)acetamide (277) 
 
To a solution of compound 282 (60 mg, 0.37 mmol) in DMF (4 mL), Cs2CO3 (182 mg, 0.55 
mmol) and 2-bromoacetamide (77 mg, 0.55 mmol) were added, respectively. The reaction 
mixture was stirred at 50 ˚C for 2 h. The reaction was quenched with water (20 mL) and the 
aqueous layer was extracted with EtOAc (3×20 mL). The organic layers were combined, dried 
over MgSO4 and the solvent removed in vacuo. Purification by MPLC on SiO2 (DCM:MeOH, 
0-7%) gave a white solid (10 mg, 12%). Rf = 0.28 (5% MeOH/DCM); m.p. 177-178 °C; λmax 
(EtOH)/nm 252.8, 205.6; IR νmax/cm-1 3371 (NH), 3189, 3052, 2920, 1674 (C=O), 1609 (C=O); 
1H NMR (500 MHz, CDCl3) δH 1.42 (3H, s, CH3), 2.66 (1H, d, J = 14.9 Hz, 1×CH2), 2.78 (1H, 
d, J = 14.9 Hz, 1×CH2), 3.21 (3H, s, NCH3), 5.30 (1H, br s, 1×NH2), 6.40 (1H, br s, 1×NH2), 
6.83 (1H, d, J = 7.7 Hz, 1×Ar-H), 7.05 (1H, td, J = 7.7 and 0.9 Hz, 1×Ar-H), 7.23-7.28 (2H, m, 
2×Ar-H); 13C NMR (125 MHz, CDCl3) δC 23.5 (CH3), 26.4 (N-CH3), 43.4 (CH2), 46.0 
(C(CH3)), 108.4 (CH-Ar), 122.7 (CH-Ar), 122.9 (CH-Ar), 128.3 (CH-Ar),  133.3 (C-Ar), 142.8 
(C-Ar), 171.3 (CONH2), 180.6 (C=O pyrrolidinone); HRMS calcd for C12H15N2O2 [M+H]
+ 
219.1128, found 219.1125. 
 
4-Formyl-N,N-dimethyl-1H-imidazole-1-sulfonamide (285) 
 
1H-imidazole-4-carbaldehyde (200 mg, 2.08 mmol) was suspended in DCM (7 mL), 
trimethylamine (0.32 mL, 2.29 mmol) and N,N-dimethylsulfamoyl chloride (0.25 mL, 2.29 
mmol) were added, respectively. The reaction mixture was stirred at r.t. for 24 h. N,N-
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dimethylsulfamoyl chloride (0.12 mL, 1.14 mmol) and the reaction mixture was stirred at 40 
˚C for 24 h. The reaction was quenched with water (30 mL) and the aqueous layer was extracted 
with EtOAc (3×30 mL). The organic layers were combined, dried over MgSO4 and the solvent 
removed in vacuo. Purification by MPLC on SiO2 (DCM:MeOH, 0-5%) gave colourless 
crystals (360 mg, 85%). Rf = 0.36 (5% MeOH/DCM); m.p. 99-101 °C; λmax (EtOH)/nm 245.8; 
IR νmax/cm-1 3134, 3092, 3032, 2951, 2838, 1692 (C=O), 1387 (SO), 1174 (SO); 1H NMR (500 
MHz, CDCl3) δH 2.91 (6H, s, 2×CH3), 7.88 (1H, d, J = 1.3 Hz, 1×Ar-H), 7.95 (1H, d, J = 1.3 
Hz, 1×Ar-H), 9.93 (1H, s, CHO); 13C NMR (125 MHz, CDCl3) δC 38.2 (2×CH3), 121.8 (CH-
Ar), 137.5 (CH-Ar), 142.3 (C-Ar), 185.8 (C=O pyrrolidinone); HRMS calcd for C6H10N3O3S 
[M+H]+ 204.0437, found 204.0433. 
 
Tert-butyl 3-((1-(N,N-dimethylsulfamoyl)-1H-imidazol-4-yl)methylene)-5-methoxy-2-
oxo-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate (286) 
 
Compound 191 (275 mg, 1.04 mmol) and compound 285 (275 mg, 1.35 mmol) were dissolved 
in THF (0.5 mL), piperidine (0.2 mL, 2.08 mmol) was added and the reaction mixture was 
stirred at 50 ˚C for 1 h. The reaction mixture was filtered using Et2O (5×20 mL) and water 
(2×10 mL) to get a yellow solid (140 mg, 30%). Rf = 0.63 (5% MeOH/DCM); m.p. 197-200 
°C; λmax (EtOH)/nm 339.4, 213.2; IR νmax/cm-1  3108, 3019, 2971, 2927, 1773 (C=O), 1636 
(C=O), 1118 (SO); 1H NMR (500 MHz, DMSO-d6) δH  1.60 (9H, s, C(CH3)3), 2.91 (6H, s, 
N(CH3)2), 3.88 (3H, s, OCH3), 7.81 (1H, s, Pyrrole-H), 8.51 (1H, s, 1×Pyridine-H), 8.63 (1H, 
s, Pyrrole-H), 8.65 (1H, s, C=CH), 8.87 (1H, s, 1×Pyridine-H); 13C NMR (125 MHz, DMSO-
d6) δC 28.2 (C(CH3)3), 38.3 (N(CH3)2), 53.9 (OCH3), 84.4 (C(CH3)3), 107.6 (C-Ar), 121.5 (C-
Ar), 128.8 (C-Ar), 130.5 (C-Ar), 131.3 (C-Ar), 132.2 (C-Ar), 133.0 (C-Ar), 138.2 (C=CH), 
139.6 (C=CH), 148.7 (COOtBu), 160.9 (C-OMe), 166.0 (C=O pyrrolidinone); HRMS calcd for 
C19H24N5O6S [M+H]
+ 450.1442, found 450.1430. 
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Tert-butyl 3-((1-(N,N-dimethylsulfamoyl)-1H-imidazol-4-yl)methyl)-5-methoxy-3-
methyl-2-oxo-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate (288) 
 
Prepared according to general procedure D using compound 286 (75 mg, 0.16 mmol), 10% 
Pd/C (20 mg), THF (12 mL) and MeOH (6 mL) in step A and Cs2CO3 (81 mg, 0.25 mmol), MeI 
(20 μL, 0.25 mmol), DMF (4.5 mL) in Step B. Purification by MPLC on SiO2 (DCM:MeOH, 
0-5%) gave a white solid (53 mg, 69%). Rf = 0.51 (5% MeOH/DCM); λmax (EtOH)/nm 229.4; 
IR νmax/cm-1  3112, 2972, 2935, 1792 (C=O), 1385 (SO), 1144 (SO); 1H NMR (500 MHz, 
CD3Cl) δH  1.52 (3H, s, CH3), 1.63 (9H, s, C(CH3)3), 2.67 (6H, s, N(CH3)2), 2.99 (1H, d, J = 
14.3 Hz, CH2),  3.21 (1H, d, J = 14.3 Hz, CH2),  3.88 (3H, s, OCH3), 6.54 (1H, d, J = 0.5 Hz, 
1×Pyridine-H), 6.78 (1H, s, 1×Pyrrole-H), 7.62 (1H, d, J = 1.2 Hz, 1×Pyrrole-H), 8.43 (1H, d, 
J = 0.5 Hz, 1×Pyridine-H); 13C NMR (125 MHz, CD3Cl) δC 23.6 (CH3), 28.1 (C(CH3)3), 36.9 
(CH2), 38.0 (N(CH3)2), 49.3 (C(CH3)), 53.6 (OCH3), 84.7 (C(CH3)3), 105.6 (C-Ar), 115.3 (C-
Ar), 130.9 (C-Ar), 131.8 (C-Ar), 136.1 (C-Ar), 138.5 (C-Ar), 145.0 (C-Ar), 148.8 (COOtBu), 
160.8 (C-OMe), 177.2 (C=O pyrrolidinone); HRMS calcd for C20H28N5O6S [M+H]
+ 466.1755, 
found 466.1743. 
 
1-((2-(Trimethylsilyl)ethoxy)methyl)-1H-pyrrole-3-carbaldehyde (292) 
 
1H-pyrrole-3-carbaldehyde (500 mg, 5.25 mmol) was dissolved in THF (21 mL) and cooled to 
0 ˚C. NaH (60% in mineral oil, 252 mg, 6.30 mmol) was added portion wise and the mixture 
was stirred at 0 ˚C for 30 min. 2-(chloromethoxy)ethyltrimethylsilane (1.02 mL, 5.78 mmol) 
was added and the reaction mixture was stirred at r.t. for 2.5 h. The reaction was quenched with 
saturated NH4Cl (30 mL) and the aqueous layer was extracted with EtOAc (3×50 mL). The 
organic layers were combined, dried over MgSO4 and the solvent removed in vacuo. 
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Purification by MPLC on SiO2 (Petrol:EtOAc, 0-20%) gave colourless oil (1 g, 85%). 
1H NMR 
(500 MHz, CD3Cl) δH  0.00 (9H, s, Si(CH3)3), 0.91-0.95 (2H, m, CH2), 3.56-3.59 (2H, m, CH2), 
5.74 (2H, s, NCH2O), 6.33 (1H, dd, J = 3.9 and 2.6 Hz, Ar-H), 7.01 (1H, dd, J = 3.9 and 1.7 
Hz, Ar-H), 7.17-7.18 (1H, m, 1×Ar-H), 9.62 (1H, d, J = 1.0 Hz, CHO); 13C NMR (125 MHz, 
CD3Cl) δC 0.0 (Si(CH3)3), 19.3 (CH2), 67.6 (CH2), 78.1 (NCH2O), 112.0 (C-Ar), 126.7 (C-Ar), 
132.5 (C-Ar), 133.3 (C-Ar), 181.1 (C=O). 
 
5-Methoxy-3-((1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrol-2-yl)methylene)-1,3-
dihydro-2H-pyrrolo[2,3-c]pyridin-2-one (293) 
 
Prepared according to general procedure C using compound 191 (335 mg, 1.26 mmol), 
compound 292 (343 mg, 1.52 mmol), piperidine (250 μL, 2.53 mmol) and THF (250 μL), except 
temperature was 60 ˚C. Purification by MPLC on SiO2 (DCM:MeOH, 0-5%) gave an orange 
solid (372 mg, 79%), ratio of diastereomers = 4:3; Rf = 0.32 (5% MeOH/DCM); m.p. 142-145 
°C; λmax (EtOH)/nm 399.8, 260.4, 209.0; IR νmax/cm-1  3137, 3085, 2946, 2888, 1688 (C=O); 
1H NMR (500 MHz, DMSO-d6) δH  -0.12 (9H, s, Si(CH3)3, isomer 1), -0.10 (9H, s, Si(CH3)3, 
isomer 2),   0.78-0.83 (2H, m, CH2, isomer 1 and 2), 3.43-3.47 (2H, m, CH2, isomer 1 and 2), 
3.80 (3H, s, OCH3, isomer 1), 3.81 (3H, s, OCH3, isomer 2),  5.50 (2H, s, NCH2O, isomer 1), 
5.67 (2H, s, NCH2O, isomer 2), 6.35 (1H, dd, J = 4.1 and 2.7 Hz, Ar-H, isomer 2), 6.42 (1H, 
dd, J = 3.7 and 2.7 Hz, Ar-H, isomer 1), 7.12 (1H, s, Ar-H, isomer 2), 7.15 (1H, d, J = 3.3 Hz, 
Ar-H, isomer 1), 7.29 (1H, s, Ar-H, isomer 1), 7.45 (1H, dd, J = 2.5 and 1.4 Hz, Ar-H, isomer 
1), 7.46 (1H, dd, J = 2.5 and 1.7 Hz, Ar-H, isomer 2), 7.60 (1H, s, Ar-H, isomer 2), 7.68 (1H, 
s, Ar-H, isomer 1), 7.79 (1H, s, Ar-H, isomer 1), 7.84 (1H, s, Ar-H, isomer 2), 8.42 (1H, dd, J 
= 4.0 and 1.5 Hz, Ar-H, isomer 2), 10.43 (1H, s, NH, isomer 2), 10.49 (1H, s, NH, isomer 2); 
13C NMR (125 MHz, DMSO-d6) δC -0.6 (Si(CH3)3, isomer 1),  -0.5 (Si(CH3)3, isomer 2), 17.9 
(CH2, isomer 1 and 2), 54.0 (OCH3, isomer 1 and 2), 65.9 (CH2, isomer 1), 66.0 (CH2, isomer 
2), 76.2 (NCH2O, isomer 1), 76.7 (NCH2O, isomer 2), 100.5, 103.5, 111.1, 111.2, 117.3, 119.2, 
120.5, 124.0, 125.3, 126.1, 127.5, 128.0, 128.9, 129.2, 130.8, 132.0, 132.1, 133.5, 133.8, 138.6, 
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159.7 (C-OMe, isomer 1), 160.0 (C-OMe, isomer 2), 167.8 (C=O, isomer 1), 169.6 (C=O, 
isomer 2); HRMS calcd for C19H26N3O3Si [M+H]
+ 372.1738, found 372.1732. 
 
5-Methoxy-1,3-dimethyl-3-((1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrol-2-
yl)methyl)-1,3-dihydro-2H-pyrrolo[2,3-c]pyridin-2-one (295) 
 
Prepared according to general procedure D using compound 293 (100 mg, 0.27 mmol), 10% 
Pd/C (20 mg), THF (15 mL) and MeOH (7.5 mL) in step A and Cs2CO3 (202 mg, 0.62 mmol), 
MeI (40 μL, 0.62 mmol), DMF (5 mL) in Step B; reaction done at r.t.. Purification by MPLC 
on SiO2 (DCM:MeOH, 0-5%) gave a beige sticky liquid (72 mg, 67%). Rf = 0.57 (5% 
MeOH/DCM); λmax (EtOH)/nm 305.4, 250.0; IR νmax/cm-1 2949, 2892, 1708 (C=O); 1H NMR 
(500 MHz, CD3Cl) δH  -0.047 (9H, s, SiC(CH3)3), 0.77-0.87 (2H, m, CH2), 1.43 (3H, s, CH3), 
3.11 (1H, d, J = 15.2 Hz, Pyrrolidinone-CH2-Pyrrole), 3.11 (3H, s, NCH3), 3.19 (1H, d, J = 15.2 
Hz, CH2-Pyrrole), 3.27-3.35 (2H, m, CH2), 3.88 (3H, s, OCH3), 4.90 (1H, d, J = 11.2 Hz, 
NCH2O), 5.10 (1H, d, J = 11.2 Hz, NCH2O), 5.59 (1H, dd, J = 3.4 and 1.6 Hz, Pyrrole-H), 5.89 
(1H, app t, Pyrrole-H), 6.44 (1H, d, J = 0.6 Hz, 1×Pyridine-H), 6.52 (1H, dd, J = 2.7 and 1.7 
Hz, Pyrrole-H), 7.54 (1H, d, J = 0.6 Hz, 1×Pyridine-H); 13C NMR (125 MHz, CD3Cl) δC 0.0 
(SiC(CH3)3), 19.1 (CH2), 24.4 (CH3), 27.9 (N(CH3)2), 34.5 (Pyrrolidinone-CH2-Pyrrole), 50.8 
(C(CH3)), 55.0 (OCH3), 66.7 (CH2), 77.4 (NCH2O), 108.0 (C-Ar), 108.7 (C-Ar), 111.0 (C-Ar), 
123.2 (C-Ar), 125.2 (C-Ar), 128.3 (C-Ar), 161.9 (C-OMe), 180.1 (C=O pyrrolidinone), 2 
aromatic carbons not observed due to dilute NMR sample; HRMS calcd for C21H32N3O3Si 
[M+H]+ 402.2207, found 402.2203. 
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3-((1H-Pyrrol-2-yl)methyl)-5-methoxy-1,3-dimethyl-1,3-dihydro-2H-pyrrolo[2,3-
c]pyridin-2-one (298) 
 
Compound 295 (55 mg, 0.13 mmol) was dissolved in THF (0.25 mL), 1 M TBAF in THF (0.7 
mL, 0.7 mmol) was added and the reaction mixture was stirred at 50 ˚C for 48 h. THF (20 mL) 
and TBAF scavenger (1 g) were added to the reaction and the mixture was stirred at r.t. for 48 
h. The reaction mixture was filtered and the filtrate was evaporated in vacuo to get an off-white 
solid (19 mg, 51%). Rf = 0.42 (5% MeOH/DCM); m.p. 146-149 °C; λmax (EtOH)/nm 249.4; IR 
νmax/cm-1  3348 (NH), 2976, 2928, 2863, 1706 (C=O); 1H NMR (500 MHz, CD3Cl) δH  1.30 
(3H, s, CH3), 2.91 (1H, d, J = 14.5 Hz, CH2), 3.03 (1H, d, J = 14.5 Hz, CH2), 3.06 (3H, s, N-
CH3), 3.79 (3H, s, OCH3), 5.40-5.42 (1H, m, Pyrrole-H), 5.77 (1H, dd, J = 5.6 and 2.6 Hz, 
Pyrrole-H), 6.44-6.46 (1H, m, Pyrrole-H), 6.59 (1H, d, J = 0.7 Hz, 1×Pyridone-H), 7.69 (1H, 
d, J = 0.7 Hz, 1×Pyridone-H), 10.3 (1H, s, NH); 13C NMR (125 MHz, CD3Cl) δC 23.0 (CH3), 
26.6 (N-CH3), 35.3 (CH2), 49.2 (C(CH3)), 53.6 (OCH3), 106.2 (C-Ar), 106.8 (C-Ar), 107.8 (C-
Ar), 116.7 (C-Ar), 124.3 (C-Ar), 126.3 (C-Ar), 135.4 (C-Ar), 147.1 (C-Ar), 159.9 (C-Ar), 178.5 
(C=O pyrrolidinone); HRMS calcd for C15H18N3O2 [M+H]
+ 272.1394, found 272.1394. 
 
1-Allyl-6’-(4-chlorobenzyl)-1’-methyl-1’,6’-dihydrospiro[pyrrolidine-3,3’-pyrrolo[2,3-
c]pyridine]-2’,5’-dione (273) 
 
Prepared according to general procedure E using Compound 265 (30 mg, 0.095 mmol), MgI2 
(5 mg), compound 276 (118 mg, 0.57 mmol) and THF (0.3 mL). The residue was purified by 
MPLC on SiO2 (DCM:MeOH, 0-7%) gave a sticky beige solid (16 mg). The compound was not 
pure enough by 1H-NMR. However, to avoid the loss of any material, the compound was taken 
forward without further purification and characterisation.  
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6'-(4-Chlorobenzyl)-1'-methyl-1',6'-dihydrospiro[pyrrolidine-3,3'-pyrrolo[2,3-
c]pyridine]-2',5'-dione (253) 
 
To a mixture of tetrakistriphenylphosphine palladium (2 mg, 4.4 mol%) and N,N-
dimethylbarbituric acid (15 mg , 0.097 mmol), a solution of compound 273 (15 mg, 0.039 
mmol) in DCM (1 mL) purged with N2 was added and the mixture was stirred at 35 ˚C for 16 
h. The solvent was removed in vacuo and the residue was treated with saturated NaHCO3 (10 
mL) and Et2O (10 mL) and the mixture was stirred for 30 min. The aqueous layer was collected 
and the residue was purified by eluting through a pad of amine silica (DCM:MeOH, 10%) to 
get  beige  sticky solid (7 mg, 22% over 2 steps).  Rf = 0.48 (15% MeOH/DCM); λmax (EtOH)/nm 
339.4, 221.2; IR νmax/cm-1  3415 (NH), 3045, 2921, 2851, 1705 (C=O), 1585 (C=O); 1H NMR 
(500 MHz, CD3Cl) δH  2.00-2.06 (1H, m, Pyrrolidine-H), 2.29-2.35 (1H, m, Pyrrolidine-H), 
2.92-2.96 (1H, m, Pyrrolidine-H), 3.06 (1H, s, N-CH3), 3.14-3.19 (1H, m, Pyrrolidine-H), 3.36-
3.39 (2H, m, Pyrrolidine-H), 5.09 (2H, s, CH2-Ar), 6.55 (1H, s, 1×Pyridone-H), 6.62 (1H, s, 
1×Pyridone-H), 7.25-7.27 (2H, m, 2×Ar-H), 7.31-7.33 (2H, m, 2×Ar-H); 13C NMR (125 MHz, 
CD3Cl) δC 26.5 (N-CH3), 39.6 (C-Pyrrolidine), 49.0 (C-Pyrrolidine), 51.5 (NCH2Ar), 54.2 (C), 
60.7 (C-Pyrrolidine), 112.4 (CH-Pyridone), 114.8 (CH-Pyridone), 127.4 (C-Ar), 129.1 (2×C-
Ar), 129.4 (2×C-Ar), 134.1 (C-Ar), 135.0 (C-Ar), 150.9 (C-Ar), 161.4 (C=O pyridone), 178.0 
(C=O pyrrolidinone); HRMS calcd for C18H19ClN3O2 [M(
35Cl)+H]+ 344.1160, found 344.1160. 
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Appendices 
 
Crystal data and structure refinement for RO2443 3. 
 
Identification code  rjg130001 
Chemical formula (moiety) C24H20ClF2N3O4 
Chemical formula (total) C24H20ClF2N3O4 
Formula weight  487.88 
Temperature  150(2) K 
Radiation, wavelength  MoK, 0.71073 Å 
Crystal system, space group  triclinic, P1 
Unit cell parameters a = 8.8755(5) Å  = 78.372(6)° 
 b = 10.4934(7) Å  = 81.700(5)° 
 c = 13.5493(9) Å  = 69.763(6)° 
Cell volume 1155.88(13) Å3 
Z 2 
Calculated density  1.402 g/cm3 
Absorption coefficient  0.218 mm1 
F(000) 504 
Crystal colour and size 0.40  0.02  0.02 mm3 
Reflections for cell refinement 2773 ( range 3.8 to 28.5°) 
Data collection method Xcalibur, Atlas, Gemini ultra 
 thick-slice  scans 
 range for data collection 3.0 to 26.0° 
Index ranges h 10 to 10, k 12 to 12, l 16 to 16 
Completeness to  = 25.0° 99.8 %  
Reflections collected 10284 
Independent reflections 4441 (Rint = 0.0335) 
Reflections with F2>2 3486 
Absorption correction semi-empirical from equivalents 
Min. and max. transmission 0.9180 and 0.9957 
Structure solution direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting parameters a, b 0.0624, 0.5323 
Data / restraints / parameters 4441 / 0 / 311 
Final R indices [F2>2] R1 = 0.0478, wR2 = 0.1155 
R indices (all data) R1 = 0.0669, wR2 = 0.1293 
Goodness-of-fit on F2 1.030 
Extinction coefficient 0.0031(16) 
Largest and mean shift/su 0.005 and 0.000 
Largest diff. peak and hole 0.77 and 0.26 e Å3  
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